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Summary
Acute myeloid leukaemia (AML) is a heterogeneous disorder 
characterised by the accumulation of immature haematopoietic cells 
blocked at various stages of differentiation. Despite improved survival 
rates over the past decade, relapse occurs in approximately 70% 
patients undergoing chemotherapy. A potential reason for this is that 
current clinical protocols do not take account of the level of residual 
disease present at remission. Therefore, one strategy to reduce relapse 
rates is to monitor minimal residual disease and continue to treat until 
the patient is minimal residual disease negative. Current minimal 
residual disease markers are available for patients with characterised 
fusion genes but approximately 50% of patients have no detectable 
chromosomal aberration and therefore are without markers. Gene 
expression profiling is a powerful tool for disease classification, 
prognosis and therapeutic predictions. This study aimed to investigate 
the use gene expression profiling to identify novel minimal residual 
disease markers for specific AML sub-groups. Patient diagnostic 
samples were profiled to identify genes specific to AML patients with a 
favourable translocation in order to establish the “proof-of-principle”. 
Several genes identified were followed in patient diagnostic and follow- 
up samples and compared to the markers currently used. Continuing 
with normal karyotype AML, genes were identified as specific to this 
sub-group. Several homeobox (HOX) genes and the Wilms’ tumour 
(WT1) gene were identified and their MRD levels followed in diagnostic 
and follow-up samples. Only WT1 identified as specific to normal 
karyotype AML met the necessary criteria to be an MRD marker. 
Although the majority of genes selected from the GEP in this study 
proved unsuitable as markers, the identification and validation of a 
marker already used for MRD monitoring, WT1, demonstrates the ability 
of gene expression profiling to identify potential minimal residual 
disease markers in normal karyotype AML.
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Chapter 1 
Introduction
1
1.1 Haematopoiesis
Mature blood cells incapable of further growth or that are damaged are 
replaced constantly through the tightly controlled process of 
haematopoiesis. All mature blood cells are derived from haematopoietic 
stem cells (HSC). Early studies of lethally irradiated adult mice 
transplanted with bone marrow cells demonstrated the existence of a 
cell population able to sustain haematopoiesis (Ford et al, 1956). HSCs 
have the capacity to self-renew in order to generate more HSCs and to 
differentiate into progenitor cells leading to the development of cells of 
all lineages; B- and T-cells, Natural killer (NK) cells, erythrocytes, 
granulocytes and monocytes (Sorrentino, 2004;Bellantuono, 2004).
1.1.1 Haematopoietic Hierarchy
The process of haematopoiesis is hierarchically organised. HSCs give 
rise to a series of progenitors that become progressively more restricted 
in their differentiation capacity and loose the ability to self-renew as they 
progress along one of two lineages. The common lymphoid progenitors 
(CLP) give rise to only the B-, T- and NK cells (lymphocytes) whereas 
the common myeloid progenitors (CMP) give rise to the bipotent 
megakaryocyte/erythrocyte progenitors (MEP) and
granulocyte/macrophage progenitors (GMP) (Kondo et al, 1997;Akashi 
et al, 2000). From in vitro culture assays of human bone marrow, 
multipotent progenitor cells termed colony-forming units (CFU) have 
been identified and characterised by their ability to form mixed
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haematopoietic colonies that give rise to blood cells of multiple 
lineages. The early multipotent progenitors CFU-GEMM (colony-forming 
units -  granulocyte-eyrthroid-macrophage-megakarocyte) give rise to 
the granulocytes, erythrocytes, megakaryocytes and monocytes 
(Fauser & Messner, 1978;Fauser& Messner, 1979) (Figure 1).
Haematopoietic Stem cell (HSC)
I
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I 1
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Figure 1. The production of multiple lineages from a single stem cell during 
normal haematopoiesis.
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The terminally differentiated lymphocytes play major roles in the body’s 
immune response system. B-cells develop in the bone marrow but 
reach their full maturity in peripheral blood organs. They provide a 
humoral immunity through the production of antibodies against 
extracellular pathogens (Larosa & Orange, 2008). T-cells develop from 
progenitors that have migrated to the thymus and received signals from 
the notch receptors. T-cells provide a cell-mediated immunity by 
producing cytokines to direct an immune response (La Motte-Mohs et 
al, 2005;Larosa & Orange, 2008). Natural killer (NK) cells are part of the 
innate immune system as their function is induced or inhibited by a 
variety of germ-line-encoded receptors (Orange & Balias, 2006;Larosa 
& Orange, 2008). Megakaryocytes and erythroblasts arise from the 
differentiation of MEPs. Megakaryocytes are responsible for the 
production of platelets (thrombocytes) necessary for normal blood 
clotting. Circulating thrombopoietin (TPO) induces a concentration- 
dependent maturation of megakaryocyte progenitors by causing 
megakaryocytes to undergo an increase in cell size and ploidy to form 
proplatelets before fragmenting in platelets (Deutsch & Tomer, 2006). 
Granulocytes and macrophages arise from the differentiation of GMPs. 
Neutrophils, eosinophils and basophils are collectively termed as 
granulocytes characterised by the presence of granules in their 
cytoplasm and cooperate to mount allergic and innate immune 
responses. Monocytes develop from GMPs and terminally differentiate 
into macrophages and dendritic cells.
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1.1.2 Bone Marrow Microenvironment
In the bone marrow, HSCs reside in a special microenvironment “niche” 
where they are supported by cell-cell interactions with non- 
haematological cells to maintain their cell functions of self-renewal and 
differentiation. Osteoblasts line the endosteal surface in the bone 
marrow and function as the endosteal niche to regulate and maintain 
HSC numbers. Several mechanisms of osteoblast control in vivo and in 
vitro have been identified. The activation of parathyroid 
hormone/parathyroid hormone-related peptide receptors (PPRs) 
stimulates the increase in the number of osteoblasts, which in turn 
produce high levels of the Notch ligand, jagged 1, that increases the 
number of HSCs (Calvi et al, 2003). Additionally, osteoblasts express 
bone morphogenic protein (BMP) receptor type IA through which the 
BMP signalling pathway acts and regulates the size of the endosteal 
niche to control the HSC numbers (Zhang et al, 2003). Angiopoietin 1 
(Ang-1) in osteoblasts contribute to the quiescent and anti-apoptotic 
state of HSCs by interacting with a tyrosine kinase receptor, Tie-2, 
expressed in HSCs in the bone marrow. Tie-2/Ang-1 signalling 
enhances the adhesion of HSCs and osteoblasts resulting in the 
promotion and maintenance of HSC quiescence (Arai et al, 2004).
However, not all HSCs associate with osteoblasts and the mobilisation 
of HSCs into peripheral circulation suggests an association with blood 
vessels. Immunohistochemical analysis of primitive cells identified a 
number of HSCs associated with sinusoidal endothelial cells of
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parafollicular areas of mobilised murine spleen and bone marrow (Kiel 
et al, 2005). The vascular endothelial cells of this “vascular niche” have 
been implicated in promoting the differentiation, proliferation and 
mobilisation of HSCs and their progenitor cells. Regions of vascular 
bone marrow endothelium cells (BMEC) are highlighted as areas of 
megakaryocyte regulation. In vivo, polyploid megakaryocytes localise to 
sinusoidal BMECs to form proplatelets and fragment into platelets that 
are released into the bone marrow vascular sinusoids (Zucker-Franklin 
& Philipp, 2000;Avecilla et al, 2004). The growth factor thrombopoietin 
(TPO) is suggested as the most effective cytokine supporting the 
proliferation and maturation of megakaryocyte progenitor cells. TPO is 
seen to stimulate the proliferation and differentiation of haematopoietic 
progenitors into megakaryocytes and platelets in vitro and in vivo 
(Kaushansky et al, 1994;Lok et al, 1994), but further in vivo evidence 
suggests TPO is not essential. An in vivo study of thrombopoietin 
(TPO)-deficient mice observed how the interaction of megakaryocytes 
with bone marrow endothelial cells (BMEC) mediated by 
megakaryocyte-active cytokines in TPO/_ mice promoted TPO- 
independent maturation of megakaryocytes and the production of 
platelets. The cytokine fibroblast growth factor 4 (FGF-4) supported the 
adhesion of megakaryocytes to sinusoidal BMECs to increase their 
survival and maturation whilst stromal-derived factor-1 (SDF-1) 
promoted the affinity and migration of platelets across the BMECs 
(Avecilla et al, 2004).This data suggests that TPO is not essential for 
the regulation of megakaryocytes and BMECs of the vascular niche are
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able to provide support for the differentiation and proliferation of HSCs 
through alternative factors.
1.1.3 Regulation of Haematopoiesis
a. Transcription Factors
Transcription factors contribute to the proliferation and differentiation 
signals required for haematopoiesis by regulating the expression of 
genes. The expression of each transcription factor involved in regulating 
haematopoiesis is not necessarily restricted to single cell lineage. For 
example, the development of erythrocytes and megakaryocytes are 
both under regulation of the zinc-finger transcription factor GATA-1. The 
expression of GATA-1 mRNA coding for GATA-1 is detected in 
multipotent progenitors and the erythroid, megakaryocyte, eosinophil 
and mast cell lineages (Tsai et al, 1989;Romeo et al, 1990;Zon et al,
1993). Disruption of the GATA-1 gene in mouse embryonic stem cells 
results in a block in the production of mature erythroid cells and whilst 
GATA-1' embryonic stem cells can generate erythroid colonies 
containing proerythroblasts, they are unable to mature properly and 
apoptose (Pevny et al, 1991;Weiss & Orkin, 1995). Shivdasani et al 
(1997) also demonstrated a development of megakaryocytes with 
reduced ploidy and a failure to generate platelets in mice lacking 
expression of GATA-1 (Shivdasani et al, 1997). Pu.1 (Purine rich box-1) 
belongs to the Ets (erythroblastosis)-family of transcription factors. 
Evidence of Pu.1 as a key regulator of haematopoiesis has been 
provided from mice knock-out studies. Pu.1-1- mice lacked cells from
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the myeloid and lymphoid lineages resulting in prenatal lethality (Scott 
et a/, 1994). Transcription factors also contribute towards the self­
renewal capacities of HSCs. For example, Homeobox (HOX) genes 
encode DNA-binding transcription factors. They are organised into four 
genomic clusters (A-D) and were first identified as regulators of 
positional identity along the anterior-posterior body axis in embryos (as 
reviewed by (Krumlauf, 1994). The majority of the A, B and C clusters 
are expressed in haematopoietic cells, and most of these HOX genes 
are preferentially expressed in HSCs and primitive progenitor cells, 
decreasing in expression as the cells differentiate and mature (Moretti 
et al, 1994;Sauvageau et al, 1994;Pineault et al, 2002). Southern blot 
analysis of cDNA identified HOX genes located at the 3' regions of the 
A and B clusters as enhanced in expression in primitive CD34* cells 
whereas those located at the 5* end were expressed at relatively equal 
levels in all the primitive CD34* sub-populations (Sauvageau et al,
1994). Mice knock-out studies have demonstrated the various effects of 
HOX genes on proliferation, differentiation and HSC-renewal. Knock-out 
studies revealed subtle reductions in the HSC and progenitor cell 
numbers without disrupting haematopoiesis in /-/OXB4-deficient mice 
and a more pronounced decrease in the proliferation capacity of these 
cells in HOXB3- and HOXB4-deficient mice (Bjomsson et al, 2003;Brun 
et al, 2004). HOXB3 and HOXB4 are both highly expressed in primitive 
CD34+ cells, but a decrease in their expression is observed as the cells 
differentiate and mature (Sauvageau et al, 1994). Despite their similar 
expression patterns and a decrease in HSC proliferation resulting from
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their underexpression, the overexpression of these two genes 
generates very different results. An overexpression of HOXB3 blocks 
the development of T- and B-cells whilst an overexpression of HOXB4 
results in the selective expansion of primitive haematopoietic cells 
(Sauvageau etal, 1995;Sauvageau et al, 1997).
b. Cytokines
Many of the regulatory pathways controlling the haematopoietic system 
are controlled by cytokines, a large family of extracellular ligands, 
binding to and activating a family of cytokine receptors. Cytokines are 
secreted from or presented on the surface of mesenchymal cells within 
the bone marrow, known as stromal cells, to promote the survival, 
proliferation and differentiation of haematopoietic stem cells and 
progenitors. Colony-stimulating factors (CSF) are synthesised locally by 
stromal cells and include macrophage-CSF (M-CSF), granulocyte-CSF 
(G-CSF) and granulocyte-macrophage-CSF (GM-CSF). M-CSF and G- 
CSF are relatively lineage-specific contributing to the differentiation and 
proliferation of macrophages and granulocytes. GM-CSF is produced by 
osteoblasts at relatively low levels and functions at earlier stages of 
lineage commitment, promoting the proliferation and maturation of 
granulocytes and macrophages and working with other cytokines as a 
growth factor for erythroid and megakaryocyte progenitors (Barreda et 
al, 2004). The multi-CSF is more commonly known as interleukin-3 (IL- 
3) contributing to the production of macrophages, neutrophils, 
eosinophils, basophils, mast cells, megakaryocytes, and erythrocytes
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(as reviewed by (Barreda et al, 2004). Several cytokines work in 
synergy with other cytokines to promote haematopoiesis. Stem cell 
factor (SCF) functions with G-CSF, GM-CSF, IL-3 and EPO 
(erythropoietin) to support the growth of colony-forming units (CFU) in 
semisolid media (Martin etal, 1990).
c. Cytokine Receptors
Cytokines interact with specific membrane receptors that transmit a 
series of intracellular signals to the target cell following the cytokine- 
receptor interaction. The receptors for M-CSF and SCF, M-CSFR (also 
known as c-fms) and c-kit respectively, belong to the class III receptor 
tyrosine kinase (RTK) family (Yarden et al, 1987). Class III receptor 
RTKs are characterised by an extracellular ligand-binding domain 
containing five immunoglobulin-like domains, a single transmembrane 
domain, a juxtamembrane domain, two intracellular domains and a C- 
terminal domain (Ullrich & Schlessinger, 1990). Binding of a ligand to a 
class III RTK results in the activation of intrinsic tyrosine kinase activity 
(Ullrich & Schlessinger, 1990;Weiss & Schlessinger, 1998). The 
receptors mediating the effects of G-CSF, GM-CF and IL-3 all belong to 
the type 1 cytokine receptor superfamily. Unlike M-CSF, G-CSFR, the 
receptor for G-CSF, has no intrinsic kinase activity. The GM-SCF 
receptor, GM-CSFR, and the IL-3 receptor are members of the gp140 
family of type 1 cytokine receptors composed of two distinct chains; a 
and p. The a-chain is the primary binding chain of the ligands whilst the 
P-chain is necessary for signal transduction (Chiba et al, 1990;Barreda
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et al, 2004). Binding of the ligands to their receptors results in the 
activation of kinases from the Janus kinase family (JAK) resulting in a 
cascade of phosphorylation events through the initiation of several 
pathways, for example the p21Ras (rat sarcoma)/MAP (mitogen- 
activated protein) kinase and PI-3 (phosphoinositol-3) kinase/PKB 
(protein kinase B) pathways, to promote cell survival, proliferation and 
differentiation (Ihle & Kerr, 1995).
d. Cell Cycle Regulation
An important characteristic of haematopoietic stem cells is their relative 
proliferative quiescent state. The clonal-succession model proposed by 
Kay et al (1965) hypothesised that only one or a few HSC clones from 
the large pool of HSCs gives rise to mature blood cells at any time 
whilst the remainder of HSC clones remain quiescent until they are 
needed due to the exhaustion of the proliferative capacity of the long­
term HSC (LT-HSC) clone (Kay, 1965). Studies by Abkowitz et al 
(1990) and Guttorp et al (1990) supported the clonal-succession model. 
Safari cats heterozygous for the X chromosome linked enzyme glucose- 
6-phosphate dehydrogenase (G6PD) received autologous marrow 
transplantations with limited numbers of cells following lethal doses of 
radiation. The data suggests that haematopoiesis resumed to the state 
observed before irradiation but fewer stem-cell clones were contributing 
(Abkowitz et al, 1990;Guttorp et al, 1990). A later in vivo model studying 
the bromodeoxyuridine (BrdU) incorporation by replicating cells did not 
support the model. Cheshier et al (1999) proposed that long term-HSCs
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enter the cell cycle in an asynchronous manner and that a few clones 
did not dominate proliferation. From their results they calculated that 
99% of long term-HSCs divided, on average, every 57 days (Cheshier 
et al, 1999). The self-renewal capacity of HSCs requires maintaining the 
coordination of HSC progression through the cell cycle and HSC-fate 
choices. A direct control of the HSC cycle is by the activation of a group 
of enzymes known as cyclin-dependent kinases (CDK). CDKs are 
positive regulators inducing cell cycle progression; their activity partly 
controlled by their association with cyclins to form a cyclin-dependent 
kinase complex. The activities of the complexes are further regulated by 
cyclin-dependent kinase inhibitors (CDKIs) acting as negative 
regulators inhibiting the progression of the cell cycle. CDKIs belong to 
one of two families depending on their targets; the Cip/Kip family, 
including p21 and p27, inhibit a number of cyclin-dependent kinases 
whilst the Ink4 (inhibitors of CDK4) family, including p15 and p16, 
inhibits CDK4 and CDK6 (Harper et al, 1995;Sherr & Roberts, 
1999;Attar & Scadden, 2004). The Cip/Kip family members inhibit the 
kinase activity of the cyclin/CDK2 complexes and over-expression of 
these inhibitors induces a cell cycle arrest in the Gi phase (Harper et al, 
1995;Lee & Yang, 2001). The p21 family member is under 
transcriptional control of p53 and appears to play a role in the inhibition 
of stem cell proliferation acting as a switch. Early studies with irradiated 
mice demonstrated the targeted disruption of the gene encoding p21 
impaired the ability of cells to achieve cell cycle arrest (Deng et al,
1995). Study of mice deficient in p21 demonstrated the number of
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primitive haematopoietic cells in the G0 phase was reduced yet the 
number of primitive cells that gave rise to long-term multipotent colonies 
in culture was increased indicating the role p21 in controlling the 
quiescence of HSCs (Cheng et al, 2000).
1.2 Disorders of Haematopoiesis
A characteristic hallmark of leukaemia is the inhibition of cell 
differentiation. Unable to terminally differentiate, these cells instead 
retain their proliferative capacity (Andreeff, 1986). Some cells may only 
display the phenotype of hyperproliferation (myeloproliferative 
disorders) or defective differentiation (myelodysplasia) and therefore 
are not true leukaemias but these disruptions in the haematopoietic 
process can result in the progression to several forms of leukaemia 
(Sawyers et al, 1991). Depending on the symptoms patients present 
with, and the cells involved, leukaemias can be sub-grouped into acute 
and chronic and further classified depending on the cell of origin into 
lymphoid and myeloid leukaemia (Sawyers et al, 1991).
1.2.1 Types of Leukaemia
a. Myeloproliferative Disorders
Myeloproliferative disorders encompass clonal haematopoietic 
syndromes of increased proliferation and accumulation of erythroblasts, 
granulocytes and megakaryocytes in the bone marrow and peripheral 
blood (Dameshek, 1951). Myeloproliferative neoplasms (MPN) include
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chronic myelogenous leukaemia (CML), polycythaemia vera (PV)t 
essential thrombocythaemia (ET), primary myelofibrosis (PMF), 
mastocytosis, chronic eosinophilic leukaemia-not otherwise specified, 
chronic neutrophilic leukaemia, and “MPN, unclassifiable” according to 
the 2008 World Health Organization (WHO) classification system 
(Vannucchi et al, 2009;Vardiman et al, 2009). A single point mutation in 
the JAK2 (Janus Kinase 2) gene, a valine to phenylalanine substitution 
at codon 617 (JAK2V617F), has been identified in a large proportion of 
patients with PV, ET and PMF (Baxter et al, 2005;Levine et al, 2005). 
The substitution results in the constitutive phosphorylation of JAK2. 
Mice transplanted with haematopoietic stem cells containing 
JAK2V617F rapidly develop an erthyrocytosis which has identified 
JAK2V617F as a primary molecular event in the development of PV 
(James et al, 2005b;James et al, 2005a).
b. Myelodysplastic Syndromes
The myelodysplastic syndromes (MDS) are clonal haematopoietic cell 
disorders characterised by bone marrow failure leading to cytopenia 
with defects in erythroid, myeloid, and megakaryocytic maturation 
(Janssen et al, 1989). MDS are susceptible to undergoing 
transformation to a more acute phase with an increased risk of patients 
developing acute myeloid leukaemia (AML) (Bennett et al, 
1982;Malcovati & Nimer, 2008). MDS is generally classified as “primary” 
MDS (de novo) or “therapy-related” MDS (t-MDS) in patients previously 
treated with chemotherapy and/or radiotherapy (Mijovic & Mufti, 1998).
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Due to the challenges associated with accurate diagnosis, the World 
Health Organisation (WHO) has refined the previous MDS classification 
to include 10 sub-classifications of MDS (Table 1) (Vardiman et al, 
2009). Each sub-classification is associated with an increasing risk in 
leukaemic transformation. MDS is thought to arise from abnormalities 
resulting in defective haematopoietic stem cell self-renewal and 
differentiation; chromosomal abnormalities have been detected in 
approximately 48% of patients presenting with MDS and in more than 
90% of patients with t-MDS. The most common abnormalities involve 
interstitial deletions of the long arm of chromosomes 5 (Mufti, 
1992;Malcovati & Nimer, 2008).
Myelodysplastic syndrome (MDS)
Refractory cytopenia with unilineage dysplasia 
Refractory anaemia (RA)
Refractory neutropenia 
Refractory thrombocytopenia 
Refractory anaemia with ring sideroblasts (RARS) 
Refractory cytopenia with multilineage dysplasia 
Refractory anaemia with excess blasts (RAEB) 
Myelodysplastic syndrome with isolated del(5q) 
Myelodysplastic syndrome, unclassifiable 
Childhood myelodysplastic syndrome
Table 1. 2008 WHO classification of myelodysplastic disorders
c. Chronic Leukaemia
Patients with chronic leukaemias usually present with symptoms of 
fatigue, weight loss and an enlarged spleen. Chronic lymphocytic
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leukaemia (CLL) is the most common form of adult leukaemia in 
western countries and mainly affects elderly individuals with a median 
age at diagnosis of 64 years (Dighiero & Binet, 2000;Montserrat & 
Moreno, 2008). CLL is characterised by the accumulation of mature 
monoclonal CD5* B-lymphocytes in the blood, bone marrow and 
lymphoid tissues. These cells also express CD19 and CD23 whilst 
weakly expressing the surface immunoglobulins (Ig) IgM, IgD and 
CD79b (Dighiero, 2005;Chiorazzi et al, 2005). Hairy cell leukaemia 
(HCL) is an uncommon chronic mature B-lymphocyte disorder named 
for its characteristic “hairy” appearance of the leukaemic lymphoid cells 
due to the mixture of fine hair-like villi and membrane ruffles on the cell 
surface (Polliack, 2002;Tiacci et al, 2006). Chronic myeloid leukaemia 
(CML) accounts for approximately 15-20% of adult leukaemias 
(Sessions, 2007). A clonal HSC disorder resulting in an increase in 
myeloid cells, erythroid cells and platelets in the peripheral blood, CML 
progresses from a chronic phase (CP) to a rapid blast crisis where cells 
fail to mature resembling cells found in acute leukaemia (Sawyers,
1999). CML is usually diagnosed from the detection of a translocation 
occurring between chromosomes 9 and 22, resulting in the Philadelphia 
(Ph) chromosome (Rowley, 1973).
d. Acute Leukaemia
Acute leukaemia is a heterogeneous group of malignant haematopoietic 
lymphoid and myeloid progenitor disorders. They are characterised by 
an increase in circulating cells that are unable to properly mature or
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function (Sawyers et al, 1991). Patients present with fatigue, bone and 
joint pain, haemorrhages and infection (Jabbour et al, 2005). Acute 
lymphoblastic leukaemia (ALL) is the commonest leukaemia affecting 
children, peaking between the ages of 2 and 5 years with an incidence 
of 4 to 5 cases per 100,000 persons. Also occurring in adults, the 
incidence of ALL cases gradually rises at approximately 50 years of age 
but accounts for only 20% of all cases of adult leukaemia (Jabbour et al, 
2005). Acute myeloid leukaemia (AML) is the commonest form of acute 
leukaemia affecting adults with an incidence of approximately 4 cases 
per 100,000 persons (Estey & Dohner, 2006;Teitell & Pandolfi, 2009). 
The median age of diagnosis of AML is approximately 65 years and 
above this age the incidence of cases increase to approximately 18 
cases per 100,000 persons (Estey & Dohner, 2006). AML is 
characterised by an accumulation of immature blasts incapable of 
differentiation. According to the 2008 WHO classification, de novo AML 
is diagnosed when 20% or more blasts are detected in the bone marrow 
or peripheral blood (Vardiman et al, 2009).
1.2.2 Process of Myeloid Leukaemogenesis
a. Multistep Process
The progression of a pre-malignant clone through intermediate steps to 
eventually becoming a malignant neoplasm is promoted by an initiating 
event. The majority of malignancies are thought to be initiated by 
spontaneous or induced somatic mutations but latency periods between 
the development of a mutation and the transformation into a malignancy
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suggests the need for more than one event (Knudson, 2001). Foulds 
(1954) described a step-wise development of neoplastic tumours of 
increasing autonomy due to changes in the cellular phenotype (Foulds, 
1954) In vitro models and in vivo mice models of virally-infected 
leukaemia have helped to observe the multi-step process involved in 
the transformation of leukaemia. Following a long latency period from 
infection with a helper-independent Friend Murine Leukemia Virus (F- 
MuLV), bone marrow cultures and mice developed myeloblastic 
leukaemia displaying several steps in the progression to malignant 
transformation. During a “pre-leukaemic” stage the cells in culture 
displayed an abnormal response to GM-CSF, a promotion in their 
proliferation of colonies containing both mature granulo-macrophagic 
and immature myeloblastic cells, and acquired growth autonomy before 
finally achieving an in vivo tumourigenicity (Heard et al, 1984).
b. Clonality
Normal haematopoiesis is a process of polyclonal expansion; several 
stem cells proliferating and differentiating to generate a mixed pool of 
terminally-differentiated end-cells. However, the majority of 
haematological disorders result from monoclonal expansions. A genetic 
event resulting in a growth advantage of one cell over others can lead 
to the development of a clone. The multistep nature of AML can result 
in the generation of a range of sub-clones differing in their acquired 
secondary abnormality. One clone will usually dominate and direct the 
course of the disease but the application of pressure, for example
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chemotherapy, can generate a clonal shift allowing a minor clone to 
dominate the disease. As relapsed leukaemia is often resistant to 
chemotherapy, it suggests that the event contributing to a leukaemic 
relapse is not always the original leukaemia present at diagnosis but 
instead a leukaemia resulting from a clonal shift and therefore relapse is 
accompanied by clonal evolution (Nakano et al, 1999). Monitoring of 
both the FLT3 (Fms-like tyrosine kinase 3) gene and the N-ras 
(neuroblastoma RAS viral (v-ras) oncogene homologue) gene in AML 
have demonstrated the instability of such aberrations and their role as 
secondary events with the observation of the acquisition or loss of 
mutations over the course of the disease in AML patients (Nakano et al, 
1999;Shih et al, 2004b;Chen et al, 2005).
Historically, methods used to identify clonality in haematological 
malignancies have adopted a system of genetic markers. Intrinsic 
markers, for example cellular markers or somatic cytogenetic 
aberrations, that have developed during normal cell processes or as 
part of the disease can act as useful intrinsic markers for clonality 
studies. The Philadelphia (Ph) chromosome is expressed in the majority 
of chronic myeloid leukaemic (CML) cells, but in almost no non-CML 
cells; the fusion product resulting from the translocation of 
chromosomes 9 and 22. This led to the suggestion that this leukaemia 
evolved from a single cell in which the aberrant chromosomal event 
occurred, therefore demonstrating the monoclonality of CML. However, 
the possibility of CML resulting from a polyclonal expansion can not be
19
ruled out based on this evidence alone and further analysis with 
extrinsic markers is required. Extrinsic markers take advantage of 
cellular mosaicism. The nature of mosaicism allows for markers 
completely independent of the disease of interest to be studied and to 
not be restricted to a particular cell lineage (Raskind et al, 1998). 
Mosaicism results from the inactivation of all but one X chromosome in 
cells containing two or more X chromosomes and occurs during the 
early stages of embryogenesis. The selection of either the maternal X 
chromosome or paternal X chromosome for inactivation is usually a 
random event and is stably transmitted during mitosis to daughter cells. 
Beutler et al (1962) demonstrated the mosaicism of cells in females 
using the X-linked enzyme G6PD as a marker (Beutler et al, 1962). 
Early studies of X-chromosome inactivation patterns (XCIPs), using 
isoforms of the G6PD enzyme resulting from a polymorphism, for 
determining the clonal origin of neoplastic cells were limited to small 
minority of the female population (Fialkow et al, 1967;Fialkow et al, 
1981). Vogelstein et al (1987) were able to extend the use of XCIPs to a 
wider population using restriction fragment length polymorphisms 
(RFLP) and methylation patterns of the inactive and active X 
chromosomes.
c. Target Cells
As previously mentioned, an early study by Fialkow et al (1981) 
demonstrated the clonality of acute non-lymphocytic leukaemia through 
chromosomal studies of the x-linked enzyme G6PD. The data indicated
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some cases of acute myeloid leukaemia (AML) originated from 
pleuripotent stem cells whilst others originated from cells already 
restricted to the granulocyte/monocyte pathway (Fialkow et al, 1981). 
Later studies by Griffin et al (1986) of surface marker analysis further 
supported the heterogeneity of AML showing AML clonal cells arose 
from various points in the haematopoietic hierarchy in different patients 
(Griffin & Lowenberg, 1986;Griffin et al, 1986). These models predicted 
that differences in phenotype of the leukaemic stem cells would be 
observed between AML patients depending on the origin of their 
disease (Fialkow et al, 1981;Griffin & Lowenberg, 1986). Alternatively, 
McCulloch et al (1983) proposed leukaemias originate from stem cells 
with the ability to differentiate or acquire surface markers from the 
influence of transformation agents resulting in little variability of stem 
cell phenotype between patients (McCulloch, 1983). Fluorescence In 
situ hybridisation (FISH) and flow cytometric analysis studies of MDS 
and AML samples identified characteristic cytogenetic aberrations in the 
CD34+/CD38' cell compartment providing evidence of primitive cell 
involvement in MDS and AML (Haase et al, 1995;Mehrotra et al, 1995). 
Lapidot et al (1994) identified SCID (severe combined 
immunodeficiency) leukaemia-initiating cells (SL-IC) as AML-initiating 
cells that could establish human leukaemia in SCID mice. The SL-ICs 
displayed an expression pattern of CD34+/CD38' similar to that 
observed in normal haematopoietic stem cells and when transplanted 
into SCID mice they initiated leukaemia, unlike the transplanted 
CD34+/CD38+ cells, an expression pattern observed in more
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differentiated cells, even when in the presence of AML-CFUs (Lapidot 
et al, 1994). Bonnet et al (1997) observed similar results when they 
transplanted SL-ICs into NOD/SCID (non-obese diabetic-severe 
combined immunodeficiency) mice. When transplanted, the 
CD34+/CD38* SL-ICs generated large numbers of AML-CFUs and 
leukaemic blasts expressing the irregular combinations of surface 
antigens observed in the patient samples from which the cells 
originated (Bonnet & Dick, 1997). However, In favour of the hypothesis 
of Fialkow et al (1981), recent studies of mouse bone marrow 
transduced with oncogenic fusion genes have demonstrated the ability 
of MLL-ENL (mixed-lineage leukaemia - eleven nineteen leukaemia) 
and MOZ-TIF2 (monocytic leukaemia zinc finger - TGF-beta induced 
factor-2) to transform not only HSCs but committed myeloid progenitors 
(Cozzio et al, 2003;Huntly et al, 2004). Kirstetter et al (2008) 
demonstrated the potential of leukaemic transformation to occur in 
progenitors with limited self-renewal capacity. Approximately 9% of de 
novo AML cases present with mutations of the C/EBPa 
(CCAAT/enhancer binding protein (C/EBP), alpha) gene. C/EBPa is 
produced of two polypeptides of 30 kDa (p30) and 42 kDa (p42), with 
most C/EBPa mutations in AML resulting in the loss of p42. Knock-in 
mice studies demonstrated that whilst GMPs were still generated, a loss 
of p42 resulted in myeloid progenitors with a vastly increased self­
renewal capacity and progression to AML and ultimately death from 
liver and bone marrow failure. These mouse models demonstrated the 
role of C/EBPa mutations as AML-initiating events that result in the
22
generation of leukaemia-initiating cells (LIC) displaying an 
immunophenotype observed in myeloid-committed cells that generate 
only myeloid cells in irradiated recipients (Kirstetter et al, 2008). 
Therefore mutations occurring in HSCs or more committed progenitors 
may both give rise to the leukaemic stem cell.
d. Leukaemic Stem Cell
Early in vitro colony assays observed only a minority of proliferative 
leukaemic blasts (AML-CFU) were able to give rise to colonies. Several 
studies also identified similar properties of active proliferation, self­
renewal and the ability to undergo differentiation of the normal 
haematopoietic progenitor cells in AML-CFUs in vitro. This led to the 
suggestion that a leukaemic clone exists in a hierarchy of proliferating 
progenitors differentiating into a population of non-cycling leukaemic 
blasts similar to that seen in normal haematopoiesis (Minden et al, 
1978;Buick et al, 1979;Pessano et al, 1984;Griffin & Lowenberg, 
1986;Bonnet, 2005). Evidence of a leukaemic stem cell (LSC) with the 
ability to initiate and sustain the growth of a leukaemic clone in vivo 
combined with their self-renewal capacity supports the concept of a 
hierarchical organisation of AML sustained by a small number of 
leukaemic stem cells transformed from normal haematopoietic cells. 
Their increased resistance to chemotherapeutic drugs have made it 
difficult to completely eradicate leukaemic stem cells and relapse often 
occurs. Similar to normal HSCs, a number of LSCs spend a large 
proportion of their time resting in the Go phase, unlike the AML-CFUs
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they generate. Whilst cell cycle-specific chemotherapeutic drugs 
targeting the leukaemic blasts are able to eradicate the majority of 
blasts, the LSCs quiescent state protects them allowing relapse to 
occur due to their self-renewal capacity and generation of new progeny 
(Guan et al, 2003;Ravandi & Estrov, 2006;Misaghian et al, 2009). 
Unfortunately the concept of a hierarchical organisation in leukaemia 
similar to that in normal haematopoiesis is still a very controversial area. 
Data supporting the hierarchical organisation hypothesis was obtained 
through studies performing xenografts. It is argued that cells with a 
potential to be tumourigenic may require extrinsic factors from the 
surrounding microenvironment to engraft. Therefore when performing a 
xenograft between mouse and human, there may be a lack of 
appropriate microenvironment factors required for engraftment due to 
species-differences. When assessing the capacity of the grafted cells to 
initiate the growth of tumours, what may appear non-tumourigenic in the 
host may actually be tumourigenic under the correct microenvironment 
conditions in the donor (Rosen & Jordan, 2009).
1.3 Acute Myeloid Leukaemia
Acute myeloid leukaemia (AML) is an extremely heterogeneous 
disorder characterised by an accumulation of immature haematopoietic 
cells that have lost the ability to differentiate. The classification of 
myeloid neoplasms provides useful information regarding a patient’s 
disease particularly with regard to prognosis and the approach to
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treatment required. As our knowledge of AML increases it is important 
to change and add to these classifications to reflect this (Arber, 2001).
1.3.1 French-American-British (FAB) Cooperative Group
The French-American-British (FAB) cooperative group established 
objective criteria for the classification of AML in 1976 to allow for 
comparisons between therapeutic trials and reduce discrepancies. This 
classification was entirely based on the morphological appearance of 
bone marrow and peripheral blood (Bennett et al, 1976). The 
classification can only be applied to samples from patients who have 
not received cytotoxic drug treatment and patients fall into one of nine 
groups (Table 2).
MO Minimally differentiated myeloblastic leukaemia
M1 Myeloblastic leukaemia without maturation
M2 Myeloblastic leukaemia with maturation
M3 Hypergranular promyelocytic leukaemia
M4 Myelomonocytic leukaemia
M4Eo Myelomonocytic leukaemia with eosinophils
M5 Monocytic leukaemia
M6 Erythroleukaemia
M7 Megakaryocytic leukaemia
Table 2 The FAB classification of acute myeloid leukaemia (Bennett et al, 1976)
25
1.3.2 Cytogenetics of AML
More than 200 structural and numerical aberrations have been detected 
through cytogenetic studies. The cytogenetic characteristics of patients 
at diagnosis have been widely recognised as a powerful diagnostic and 
prognostic tool for AML. Cytogenetics at diagnosis can classify patients 
into one of three prognostic sub-groups; favourable, intermediate or 
poor. Patients presenting with a full or partial deletion of chromosome 5, 
deletion of chromosome 7 or with a complex karyotype (three or more 
chromosomal aberrations) are placed into the poor prognosis group. 
Patients presenting with a t(15;17) or a t(8;21) translocation or an 
inversion of chromosome 16 are placed into the favourable risk group. 
The intermediate risk group contains patients presenting with any other 
cytogenetic abnormalities including a translocation involving the mixed 
lineage leukaemia (MLL) gene located on chromosome 11q23 or with 
an apparently normal karyotype (Grimwade et al, 1998;Slovak et al, 
2000).
a. t(15;17)
Based on the French-American-British (FAB) classification of AML, 
acute promyelocytic leukaemia (APL) is classified as FAB M3. Based 
on morphology, two subtypes of APL can be identified; hypergranular 
classical APL (M3) and hypogranular variant APL (M3v). In 
hypergranular APL hypergranular abnormal promyelocytes replace the 
bone marrow and patients often present with leukopenia. Less granular 
blasts are detected in hypogranular APL and patients typically present
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with an elevated leukocyte count. Both forms of AML are characterised 
by a granulocytic differentiation block and the presence of chromosomal 
translocation involving chromosome 17q21 on which the retinoic acid 
receptor alpha (RARa) gene is located (Puccetti & Ruthardt, 2004). 
RARa encodes for the RARa protein that belongs to the retinoic acid 
receptor (RAR) family of nuclear receptors. RARs form heterodimers 
with members of the retinoid X receptor (RXR) family of nuclear 
receptors in order to transduce retinoid signalling. The RXR-RAR 
heterodimer binds to specific DNA sequences of target genes, known 
as retinoic acid response elements (RARE), and activates their 
transcription by allowing the recruitment of co-activators and histone 
acetyltransferases (HAT). In the absence of the ligands the RXR-RAR 
heterodimer binds to DNA and recruits the co-repressors NCoR 
(nuclear receptor corepressor), SMRT (silencing mediator for retinoid or 
thyroid-hormone receptors) and histone deactetylase (HDAC) resulting 
in a repression of transcription (Vitoux et al, 2007). Physiological levels 
of retinoic acid (RA) (1x10‘9M) can release the corepressor complex 
from the heterodimer and allow the recruitment of co-activators resulting 
in transcriptional activation of the RARa-target genes (Lo et al, 1999). 
More than 95% of cases of APL display the fusion of the promyelocytic 
leukaemia (PML) gene with RARa resulting from the t(15;17)(q22;q21) 
translocation. The PML protein is localised in discrete nuclear structures 
named PML nuclear bodies (Dyck et al, 1994). Cell line and mice 
knock-out studies have identified functions of PML in growth control and 
as a tumour suppressor (Mu et al, 1994;Wang et al, 1998;Ruggero et al,
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2000). The PML-RARa fusion protein can also bind to RXR to form a 
heterodimer with an increased affinity for corepressors resulting in 
constitutive transcriptional repression. Only pharmacological levels of 
RA (1x1 O^M) can release the PML-RARa fusion protein to resume 
transcriptional activation (Grignani et al, 1998;Grignani et al, 
2000;Vitoux et al, 2007). In the remaining cases of APL various 
chromosomal aberrations have resulted in the RARa gene forming 
fusion gene products with other genes including promyelocytic 
leukaemia zinc finger (PLZF) gene, the nucleophosmin (NPM) gene, the 
nuclear mitotic apparatus (NuMA) gene and the signal transducer and 
activator of transcription 5b (STAT5b) gene (Mistry et al, 2003;Vitoux et 
al, 2007) (Table 3).
Chromosomal
Aberration Fusion product Frequency
t(15;17)(q22;q21) PML-RARa
RARa-PML
>95%
t(11 ;17)(q23;q21) PLZF-RARa
RARa-PLZF
0.80%
t(11 ;17)(q13;q21) NuMA-RARa Very rare
t(5;17)(q35;q21) NPM-RARa
RARa-NPM
<0.5%
der(17) STAT5b-RARa Very rare
Table 3. The chromosomal aberrations and their resultant fusion products present 
in APL. RARa, retinoic acid receptor alpha; PML, promyelocytic leukaemia; PLZF, 
promyelocytic leukaemia zinc finger; NuMA, nuclear mitotic apparatus protein; 
NPM, Nucleophosmin; STAT5b, signal transducer and activator of transcription 5B 
(Mistry et al, 2003)
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b. t(8;21)
Rowley et al (1973) first reported the t(8;21) translocation in a 
leukaemia patient sample in the early 1970s but AML1 and ETO were 
not idenitfied as the two genes located at the breakpoints until the early 
1990s (Gao et al, 1991;Miyoshi et al, 1991;Erickson et al, 
1992;Peterson & Zhang, 2004). Commonly associated with FAB group 
M2, the translocation of chromosomes 8 and 21 results in the formation 
of the fusion gene AML1-ETO. AML1 is located on the long arm of 
chromosome 21 and encodes for the AML1 protein. AML1, also known 
as CBFa2 (core binding factor alpha-2) and RUNX1 (runt-related 
transcription factor 1), is a subunit of the core binding factor (CBF) 
complex. As a RUNX protein, AML1 contains a runt homology DNA 
binding domain, a transactivation domain, a nuclear matrix attachment 
signal (NMTS) and two inhibitory domains. The runt domain of CBFa 
interacts with the beta CBF subunit, CBFp, to form a heterodimeric 
complex in order to increase its DNA-binding affinity and protect it from 
ubiquitin-mediated proteolysis. AML1 activates gene transcription 
through facilitating the assembly of transcriptional activation complexes 
(Kitabayashi et al, 1998). Dependant upon the target gene, AML1 can 
also function as a repressor of transcription through the recruitment of 
co-repressors (Yagi et al, 1999;Perry et al, 2002). The core binding 
factor (CBF) complex regulates the transcription of several 
haematopoietic-specific genes, including M-CSFR, IL-3 and GM-CSF 
(Cameron et al, 1994;Takahashi et al, 1995;Rhoades et al, 1996). The 
importance of AML1 to this complex and its regulation in
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haematopoiesis was demonstrated through mouse knock-out studies. 
A A/fLf-deficient embryos lacked definitive haematopoietic progenitors 
and failed to develop foetal liver haematopoiesis resulting in extensive 
haemorrhaging and mid-gestational lethality (Okuda et al, 1996;Wang 
et al, 1996a;Wang et al, 1996b). ETO is a nuclear protein containing 
regions characteristic to transcription factors; three 
proline/serine/threonine-rich regions, a leucine-rich region and two zinc- 
finger domains (Rhoades et al, 1996). ETO associates with the nuclear 
co-repressor NCoR, mSin3A and HDACs (Gelmetti et al, 
1998;Lutterbach et al, 1998). In the resultant AML1-ETO fusion protein 
the C-terminal sequences for transactivation of AML1 are replaced by 
the ETO protein. ETO retains its capacity to form stable complexes with 
co-repressors allowing the fusion protein to block the transactivation of 
haematopoietic-specific genes by associating with the co-repressor 
complex containing NCoR, mSin3A and HDACs, resulting in a block of 
myeloid differentiation (Gelmetti et al, 1998). The runt-binding domain is 
also retained in the fusion gene allowing the AML1-ETO protein to 
interfere in the activation and expression of genes normally associated 
with the AML1-CBFp complex (Meyers et al, 1996;Perry et al, 2002). 
Patients with a t(8;21) translocation are found to have a relatively 
favourable prognosis (Grimwade et al, 1998;Slovak et al, 2000).
c. inv(16)
Arthur and Bloomfield (1983) first detected a del(16)(q22) in five AML 
patients with bone marrow eosinophilia ranging between 8% to 54%
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(Arthur & Bloomfield, 1983). Further studies identified an association 
between an inversion of chromosome 16 and FAB M4 AML (Tantravahi 
et al, 1984) and the Fourth International Workshop on Chromosomes in 
Leukaemia: a Prospective Study of Acute Non-Lymphocytic Leukaemia 
confirmed an association between abnormal eosinophils, AML and 
structural rearrangements of chromosome 16 (Vardiman et al, 
1984;Reilly, 2005). A later study by Larson et al (1986) identified what is 
now widely recognised as the breakpoints occurring at both 16p13 and 
16q22 being most closely associated with M4Eo (Larson et al, 1986). 
An inversion of chromosome 16, inv(16)(p13q22), generates the fusion 
gene product core binding factor beta-smooth muscle myosin heavy 
chain (CBFP-MYH11). The core binding factor beta (CBFp) gene is 
situated at the chromosome locus 16q22 and encodes for the CBFp 
protein; a subunit of the core binding factor (CBF). Widely expressed, 
CBFp regulates transcription indirectly through interaction with the 
subunit CBFa2, otherwise known as AML1. Instead of binding directly to 
DNA, CBFP increases the affinity of AML1 for the consensus DNA 
sequence TGT/cGGT. This is achieved through the interaction of the 
CBFp core domain with the runt domain of AML1 (Wang et al, 1996b). 
CBFp-MYH11 knock-in mice studies have demonstrated the importance 
of the CBFp gene in haematopoiesis and the pathogenic consequences 
of the CBFP-MYH11 fusion gene. Embryonic haematopoiesis was 
impaired at stem-progenitor cell level and mice were unable to achieve 
definitive haematopoiesis resulting in mid-gestational lethality as the 
function of the AML1-CBFp heterodimer was suppressed (Wang et al,
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1996a;Wang et al, 1996b;Kundu et al, 2002). Castilla et al (1999) 
demonstrated that whilst the CBFP-MYH11 gene alone was not 
sufficient to induce AML in the mice, leukaemia characterised by the 
presence of myelomonocytic blasts and the occasional eosinophils 
developed approximately 4 months after treatment with A/-ethyl-A/- 
nitroso-urea (ENU) (Castilla et al, 1999). Patients presenting with an 
inversion of chromosome 16 are associated with a relatively favourable 
prognosis (Grimwade et al, 1998;Slovak et al, 2000).
d. 11q23
The mixed lineage leukaemia (MLL) gene is located at chromosome 
11q23 and is widely expressed during development in most tissues. 
MLL is required for haematopoiesis with many clustered HOX genes as 
targets (Ernst et al, 2004;Harper & Apian, 2008). Many chromosomal 
rearrangements involving the MLL gene are associated with myeloid, 
lymphoid and mixed lineage leukaemias (Ayton & Cleary, 2001). The 
commonest form of translocation involving the MLL gene results in the 
fusion of the C-terminus coding sequence of a partner gene and the N- 
terminus coding sequencing of the MLL gene. The resultant fusion 
genes encode for in-frame oncogenic proteins (Hess, 2004). Currently 
more than 51 fusion partners of MLL have been identified (Basecke et 
al, 2006). Translocations involving MLL occur in approximately <10% of 
AML cases and generate a similar prognosis to those AML cases with 
an intermediate prognosis. Common translocations detected in AML 
include the t(6;11)(q27;q23), t(9;11)(q22;q23) and t(10;11 )(q12;q23)
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translocations fusing MLL with AF6, AF9 and AF10 respectively 
(Martineau et al, 1998;Hess, 2004). In addition to the balanced 
chromosomal translocations, the partial tandem duplication (PTD) of 
exons encoding the N-terminal sequences of MLL has been recorded in 
approximately 10% of AML cases, predominantly in those cases with a 
normal karyotype or a trisomy 11, and confers a poor prognosis 
(Basecke et al, 2006).
e. Normal Karyotype
AML patients that are karyotypically normal following standard 
cytogenetic analysis at diagnosis constitute the largest cytogenetic sub­
group in AML, accounting for approximately 45% of all de novo AML 
cases. These patients are placed in the intermediate risk group with 
only 20-42% being long-term survivors (Grimwade et al, 1998;Slovak et 
al, 2000;Byrd et al, 2002). Despite the lack of chromosomal aberrations, 
this sub-group of AML is extremely heterogenous displaying many gene 
mutations. The FLT3 gene encodes for a class III receptor tyrosine 
kinase. An internal tandem duplication (ITD) in the juxtamembrane 
domain-coding sequence of the gene results in a constitutive 
autophosphorylation of the FLT3 protein. Normal karyotype AML 
patients with a FLT3 ITD differ clinically from those normal karyotype 
patients displaying a wild-type FLT3; an increased white blood count 
and increased percentages of peripheral blood and bone marrow blasts 
are observed in the FLT3 ITD patients. A poorer prognosis has been 
assigned to those normal karyotype patients displaying a FLT3 ITD
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compared to those normal karyotype patients without the mutation 
(Frohling et al, 2002;Bienz et al, 2005;Mrozek et al, 2007b). Conversely 
mutations detected in the nucleophosmin 1 (NPM1) gene or the 
CCAAT/enhancer-binding protein a (CEBPA) gene confer a more 
favourable prognosis in normal karyotype AML patients (Mrozek et al, 
2007b). As well as the various mutations detected, aberrant gene 
expressions are often detected in the normal karyotype AML patients. 
The over-expression of both the brain and acute leukemia, cytoplasmic 
(BAALC) gene and the meningioma 1 (MN1) gene are associated with 
an adverse prognosis in normal karyotype patients (Mrozek et al, 
2007a). The numerous genetic factors displayed in normal karyotype 
AML generating different clinical outcomes may be able to provide 
useful information in order to improve the treatment stratification by 
providing molecular-based treatments (Radmacher et al, 2006;Baldus 
et al, 2007).
1.3.3 Gene Mutations in AML
a. FMS-like Tyrosine Kinase 3 (FLT3)
FLT3, FMS-like tyrosine kinase 3, is a class III receptor tyrosine kinase, 
composed of an extracellular ligand-binding domain containing five 
immunoglobulin (Ig) loops, a transmembrane domain, a juxtamembrane 
dimerisation domain and an intracellular kinase domain. FLT3 exhibits 
strong sequence and structural similarities with class III receptor 
tyrosine kinase receptor family members c-fms and c-kit; the cytokine
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receptors for M-CSF and SCF (Yarden et al, 1987;Carow et al, 
1996;Gilliland & Griffin, 2002). The ligand for the FLT3 protein (FL) is a 
type I transmembrane protein and a growth factor for stem cells and 
immature myeloid cells (Rusten et al, 1996). FL activates the tyrosine 
kinase activity of FLT3 and stimulates the proliferation of primitive 
haematopoietic progenitor cells and more committed early myeloid and 
lymphoid precursors through synergy with other growth factors and 
interleukins (IL) (Veiby et al, 1996;Ebihara et al, 1997;Lyman & 
Jacobsen, 1998;Meshinchi & Appelbaum, 2009). Preferentially 
expressed on haematopoietic CD34+ stem cells in normal bone marrow 
and decreasing in expression as differentiation progresses, high 
expression levels of both the FLT3 gene and FLT3 protein have been 
observed in the majority of acute myeloid leukaemias (Birg et al, 
1992;Small et al, 1994;Carow et al, 1996;Gilliland & Griffin, 2002;Kiyoi 
et al, 2005). As well as the high levels of expression observed, two 
types of activating mutations of the FLT3 gene have been reported in 
haematological malignancies, and therefore the FLT3 gene is 
considered to play an important role in leukaemogenesis (Gilliland & 
Griffin, 2002). The first reported FLT3 gene mutation was internal 
tandem duplication (ITD) in the juxtamembrane domain-coding 
sequence; reported in approximately 20% of all cases of adult AML. 
The second type of FLT3 mutation is a point mutation in the activation 
loop of the tyrosine kinase domain (TKD)-coding sequence. The point 
mutation involving the aspartic acid 835 (D385) residue is the most 
frequently occurring point mutation and occurs in approximately 7% of
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adult AML patients (Thiede et al, 2002;Yamamoto et al, 2001) (Figure 
2). Both of these mutations result in constitutive autophosphorylation of 
the FLT3 protein and activation of downstream targets including the 
RAS/MAPK, STAT (signal transducer and activator of transcription) and 
the AKT/PI3 kinase pathways resulting in cytokine-dependent 
proliferation of cells (Mizuki et al, 2000;Hayakawa et al, 2000;Gilliland & 
Griffin, 2002). The presence of a FLT3 ITD is associated with an 
unfavourable prognosis whilst the prognostic relevance of a FLT3 TKD  
currently remains undefined (Abu-Duhier et al, 2000;Thiede et al, 
2002;Moreno et al, 2003;Mead et al, 2008;Whitman et al, 2008).
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Figure 2. The FLT3 protein and the locations affected by the activating gene 
mutations (Gilliland & Griffin, 2002;Small, 2006) ECD -  extracellular domain, TM -  
transmembrane domain, TK -  tyrosine kinase domain.
b. Nucleophosmin 1 (NPM 1)
Nucleophosmin (NPM 1), also known as B23, belongs to the 
nucleoplasmin family of nuclear chaperones. NPM1 is predominantly 
located in the nucleolus and is ubiquitously expressed. Driven by a 
bipartite nuclear localization signal (NLS), the protein shuttles between 
the nucleus and the cytoplasm stimulating the import of proteins into the
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nucleus (Szebeni et al, 1995;Hingorani et al, 2000;Falini et al, 2009). 
The NPM1 gene is located on chromosome 5q35 and three isoforms 
exist as a result of alternative splicing; B23.1, B23.2 and B23.3 (Falini et 
al, 2007). The NPM1 protein is seen to be aberrantly localised in the 
cytoplasm when a chromosomal translocation involving the NPM1 gene 
occurs or a mutation in the NPM1 gene is present (Falini et al, 2005). 
Chromosomal translocations disrupting the NPM1 gene have been 
observed in various haematopoietic malignancies generating fusion 
proteins that retain the N-terminus of NPM1. Approximately 85% of 
cases of anaplastic large cell lymphoma (ALCL) display the 
t(2;5)(p23;q35) translocation at diagnosis resulting in the fusion gene 
product nucleophosmin-anaplastic lymphoma kinase 1 (NPM-ALK) 
(Skinnider et al, 1999). A fusion between the NPM1 gene and myeloid 
leukaemia factor 1 (MLF1) gene results from the t(3;5)(q25.1;q34) 
observed in rare myelodysplasia/AML and the t(5;17)(q32;q21) results 
in the fusion of NPM1 and the retinoic acid receptor a (RARa) gene 
observed in APL patients (Redner et al, 1996;Yoneda-Kato et al, 
1999;Falini & Mason, 2002). Mutations involving the C-terminus of exon 
12 of the NPM1 gene have been identified in approximately 25-35% of 
adult AML cases, and approximately 50% of AML patients with a 
normal karyotype (Schnittger et al, 2005;Falini et al, 2007). The most 
common mutation seen to occur in NPM1 is called Type A, a TCTG 
insertion at position 596, and is observed in approximately 70-80% of 
normal karyotype AML cases with an NPM1 mutation (Schnittger et al, 
2005;Chen et al, 2006;Falini et al, 2007). The presence of an NPM1
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gene mutation is seen to confer to a favourable outcome in AML 
patients with a normal karyotype when in the absence of a FLT3 ITD 
(Dohner et al, 2005;Falini et al, 2009).
c. CCAAT/enhancer binding protein, alpha (CEBPA)
CEBPA is a member of the leucine zipper transcription factor family with 
an N-terminal trans-activation domain and a leucine-rich dimerisation 
domain termed “leucine-zipper” at its C-terminus to mediate DNA- 
binding and dimerisation (Johnson, 2005;Fuchs, 2007). Expressed in 
many tissues, CEBPA plays an important role in the regulation of cell 
proliferation and differentiation. CEBPA mediates the actions of cyclin- 
dependent kinases (CDK) and the CDK2-inhibitor p21, amongst other 
targets, to up-regulate lineage-specific gene products and cause a 
proliferation arrest due to exit from the cell cycle (Fuchs, 2007). In 
haematopoiesis, CEBPA regulates myeloid differentiation; an up- 
regulation of the CEBPA gene results in the development of 
granulocytes and an inhibition in the development of monocytes 
(Radomska et al, 1998). A distinct pattern of CEBPA expression in the 
haematopoietic system has been generated; low levels of CEBPA 
expression are detected in HSCs, an up-regulation of expression in 
GMPs and a down-regulation through differentiation to megakaryocyte 
and erythroid progenitors (Mueller & Pabst, 2006). A mutation in the 
CEPBA gene is reported in approximately 15% of AML patients; 
approximately 70% of these cases also present with a normal karyotype 
(Pabst et al, 2001;Preudhomme et al, 2002;Frohling et al, 2004;Mueller
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& Pabst, 2006). Mutations of the CEBPA gene result in disruptions to 
the leucine zipper affecting the binding of DNA and resulting in a loss of 
CEBPA function, or an induction of proliferation due to the premature 
termination of the normal 42 kDa form of CEBPA (Mueller & Pabst, 
2006;Fuchs, 2007). The presence of a CEBPA mutation in AML is 
associated with a favourable prognosis (Preudhomme et al, 2002;Bienz 
et al, 2006).
1.3.4 Aberrant Gene Expression in AML
a. Brain and acute leukaemia, cytoplasmic (BAALC) gene 
The brain and acute leukaemia cytoplasmic gene (BAALC) was 
identified from its over-expression in leukaemic blasts of AML with a 
trisomy 8 in comparison to normal karyotype AML. Located on 
chromosome 8q22.3, BAALC appears to have no sequence homology 
to other proteins or functional domains. BAALC is involved in 
neuroectodermal and haematopoietic development, expressed primarily 
in neuroectoderm-derived tissues and haematopoietic precursors 
(Tanner et al, 2001). High levels of BAALC expression have been 
detected in CD34+ progenitor cells but as the cells subsequently go 
through differentiation, the level of BAALC expression is seen to 
decrease (Langer et al, 2008;Baldus et al, 2003a;Tanner et al, 2001). 
High levels of BAALC have also been observed in cytogenetically 
normal AML in adults and is associated with an adverse clinical 
outcome (Baldus et al, 2003b;Bienz et al, 2005).
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b. Meningioma 1 (MN1)
MN1 is a 136kDa nuclear protein functioning as a transcriptional co­
activator. Transient transcription assays confirmed the transcriptional 
role of MN1 when the activation of transcription of the Moloney sarcoma 
virus long terminal repeat (MSV-LTR) in a murine fibroblast cell line was 
observed (Buijs et al, 2000). MN1 stimulates retinoic acid 
receptor/retinoid X receptor (RAR-RXR)-mediated transcription through 
the recruitment and co-expression of the protein co-activators p300 and 
RAC3 (retinoic acid receptor interacting protein 3) (Buijs et al, 2000;van 
Wely et al, 2003). Carella et al (2007) performed quantitative RT-PCR 
analysis of mouse bone marrow to identify which haematopoietic cells 
expressed the MN1 gene. Low levels of MN1 expression were detected 
in HSCs and high expression levels detected in GMPs but no
expression in the CMP, CLP or MEP fractions suggesting a role of MN1 
in GMP-derived myelopoiesis (Carella et al, 2007). The balanced 
chromosome translocation t(21;22)(p13;q12) is associated with 
haematological malignancies including acute myeloid leukaemia. The 
translocation results in the fusion of the MN1 gene with the ETS- 
transcription factor-encoding gene TEL. Studies of MN1-TEL knock-in 
mice displayed the oncogenic properties of the fusion gene in
haematopoiesis; expression of the gene in myeloid and lymphoid 
compartments resulted in the development of T-cell lymphoma and 
AML (Kawagoe & Grosveld, 2005a;Kawagoe & Grosveld, 2005b). An 
over-expression of the MN1 has also been associated with
haematological malignancies with an inv(16) (Carella et al, 2007). An
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over-expression of MN1 has also been detected in some patients 
presenting with a normal karyotype where it is associated with a poor 
prognosis (Heuser et al, 2006).
c. Ecotropic Viral Integration Site-1 (EVI1)
The EVI1 gene, located on chromosome 3q26 encodes for the nuclear 
transcription factor EVI1. Located in the nucleus, EVI1 consists of 
multiple zinc finger domains, a repression domain and an acidic region 
at the C-terminus. EVI1 plays important roles in both normal 
development and oncogenesis. Gene targeting mice studies have 
demonstrated a high expression of EVI1 in embryonic and adult bone 
marrow HSCs and a role of EVI1 in the maintenance of HSCs. EWf-/- 
embryos displayed a markedly decreased number of HSCs with 
defective self-renewal, proliferation and repopulating capacity (Yuasa et 
al, 2005). The EWf-/- embryos also displayed a reduced expression of 
the GATA-2 gene; the transcription factor encoded by GATA-2 is 
essential for the proliferation of HSCs (Yuasa et al, 2005). EVI1 was 
originally identified as the integration site of the ecotropic retrovirus 
leading to myeloid leukaemia in mouse models (Goyama & Kurokawa, 
2009). Chromosomal rearrangements involving the EVI1 gene locus, 
3q26, result in the formation of fusion genes involving EVI1 and are 
commonly found in myeloid malignancies. The translocation of 
chromosome 3q26 is found in cases approximately 1-2% of cases of 
MDS, AML and CML in blast crisis; the translocation t(3;3)(q21;q26) or 
inversion inv(3)(q21q26) occurring most frequently (Nucifora, 1997).
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The rearrangements involving 3q26 can result in the over-expression of 
EVI1 but high levels of EVI1 expression have also been detected in a 
group of AML cases without a 3q26 involvement. The cause of this 
over-expression of EVI1 is unknown but it has been shown to be 
associated with a poor prognosis in de novo AML cases (Barjesteh van 
Waalwijk van Doom-Khosrovani et al, 2003;Wieser, 2007).
1.3.5 WHO
As part of the 3rd edition of the series, WHO Classification of Tumours, 
a collaboration of the World Health Organization (WHO), the Society for 
Haematopathology and the European Association of Haematopathology 
published a “Classification of Tumours of the Hematopoietic and 
Lymphoid Tissues”. Although the FAB classification of AML took into 
account the morphological heterogeneity, it did not reflect the genetic or 
clinical diversity of AML now recognised to be important (Vardiman et 
al, 2002). The WHO classification of tumours makes use of all available 
diagnostic information; genetic, immunophenotypic, biological, clinical 
and morphological, to define specific disease entities. In 2008, a 
revised classification was published as part of the 4th edition to 
incorporate the scientific and clinical information gathered over the 7 
years between editions in order to define the diagnostic criteria of 
haematopoietic neoplasms (Vardiman, 2009). In the WHO 
classification, “Myeloid” includes all cells belonging to the granulocytic, 
monocytic/macrophage, erythroid, megakaryocytic and mast cell 
lineages. As with previous classifications, the blast percentage detected
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in samples is used as a means of categorising the myeloid neoplasms 
and making decisions in regards to their progression; a myeloid 
neoplasm with more than 20% blasts detectable in the bone marrow or 
peripheral blood is considered to be AML when it occurs de novo 
(Vardiman et al, 2009). Based on the level of maturation, myeloid 
neoplasms are split into several groups. Those neoplasms comprised 
mainly of blasts with minimal, if any, maturation (AML) are placed 
together in one group. If any maturation of the blasts is detectable, the 
neoplasms are further split into one of three classes; those with 
effective maturation (MPN), those with ineffective maturation with 
dysplastic features (MDS) or those with both ineffective and effective 
maturation (MDS/MPN) (Vardiman, 2009). Since the 3rd edition, a 
number of gene mutations have been accepted as contributing to the 
leukaemic process and the morphologic and clinical characteristics of 
the disease; the mutational status of the NPM1 and CEBPA genes have 
been incorporated as provisional entities (Vardiman et al, 2009). 
Despite incorporating the mutational status of several genes into the 
new classification, it is still necessary to use a “multiparameter” 
approach when classifying neoplasms; the blast count remains an 
important criteria factor in the classification process (Vardiman, 2009) 
(Table 4).
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Myeloproliferative neoplasms (MPN)
Myeloid and lymphoid neoplasms associated with eosinophilia 
and abnormalities of PDGFRA, PDGFRB, or FGFR1 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
Myelodysplastic syndrome (MDS)
Acute myeloid leukaemia and related neoplasms 
Acute myeloid leukaemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1 -RUNX1T1 
AML with inv( 16)(p 13.1 q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t( 15; 17)(q22;q 12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21 q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Pure erythroid leukaemia 
Erythroleukaemia, erythroid/myeloid 
Acute megakaryoblastic leukaemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemias of ambiguous lineage 
B lymphoblastic leukaemia/lymphoma 
T lymphoblastic leukaemia/lymphoma
Table 4. The WHO classification of myeloid neoplasms focusing on the acute 
myeloid leukaemia and related neoplasms (Vardiman et al, 2009).
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1.3.6 Current and Potential AML Therapies
More than two decades ago the application of prolonged-duration multi­
agent chemotherapy programmes generated disappointing results in 
AML despite the successful cure rates in childhood acute lymphoid 
leukaemia (ALL) (Vaughan & Karp, 2008). As the supportive care in 
transfusion and infectious disease management improved, investigators 
turned to researching more intensive remission induction regimes for 
the role of maintenance therapy and improving cure rates. Studies in 
timed-sequential chemotherapy to further intensify remission induction 
therapy or for consolidation therapy using a combination of two agents, 
anthracycline and cytarabine, were performed in clinical trials leading to 
a regime similar to that used today (Vaughan & Karp, 2008). As a 
consequence of increased knowledge about the molecular basis of 
leukaemogenesis more target-specific therapies are now being 
investigated to improve current regimes. Coordinated management of 
the treatment of AML has been the focus the Medical Research Council 
(MRC) trials throughout the UK; treatment improvements were made 
based on the results from previous trials. The current MRC AML 16 trial 
focuses on older patients (>60 years) diagnosed with AML or high-risk 
myelodysplastic syndrome (MDS) and not considered suitable for the 
MRC AML 15 trial for younger patients; patients are entered into one of 
two randomised treatment arms based on the consideration of their 
fitness for intensive treatment. The development of the next trial, MRC 
AML 17, has resulted from the recognition of the importance of 
cytogenetics and gene aberrations in AML; patients are randomised
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based on t(15;17) translocations, core binding factor translocations or 
the presence of FLT3 mutations.
a. Chemotherapy
Currently patients diagnosed with AML aged 18-60 years go through 
several treatment phases. The initial therapy consists of induction 
chemotherapy; the removal of all haematopoietic elements from the 
bone marrow to allow re-population with normal cells. This often results 
in less than 5% leukaemic blasts in the bone marrow and therefore 
patients are deemed to be in remission. A regime commonly known as 
“3+7” is used; patients receive an anthracycline (daunorubicin or 
idarubicin) for 3 days followed by the cell cycle-specific cytarabine (ara- 
C) for 7 days (Stone et al, 2004;Estey, 2009). Approximately 50% to 
75% of AML adults receiving this treatment regime will achieve 
complete remission (CR) (Tallman et al, 2005). To improve complete 
remission rates higher doses of the agents used have been tested in 
combination with other agents, for example etoposide; an inhibitor of 
microtubular assembly in dividing cells (Tallman et al, 2005). Following 
remission it is necessary that patients receive further therapy in an 
attempt to reduce the remaining undetectable leukaemic burden. 
Autologous and allogeneic bone marrow transplantation following 
remission provides a long-term disease-free survival but is 
accompanied by a high mortality and long-term morbidity rate. Post­
remission therapy strategies include intensive consolidation therapies of 
either high-dose chemotherapy or chemo-radiotherapy with
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allogeneic/autologous haematopoietic stem-cell transplantation (HSCT), 
or a low-dose maintenance therapy (Tallman et al, 2005). The vast 
heterogeneity of AML patients and their different response to standard 
treatments has provided a rationale for exploring more targeted 
therapies based on chromosomal aberrations and gene mutations and 
the expression of cell surface markers. Compared to the progress made 
in the treatment of younger patients, the treatment of AML in patients 
older than 60 years has not improved significantly. Following standard 
induction therapy, 43% to 57% of patients over the age of 60 years 
achieve a complete remission, long term survival ranges between 10% 
and 15% (Hiddemann et al, 1999;Goldstone et al, 2001). Elderly 
patients display differences in the biological and clinical behaviour of 
AML to their younger counterparts that often result in a poorer 
prognosis, for example chromosomal aberrations. The presence of co- 
morbid illnesses and poor performance status also affects their eligibility 
to receive standard induction therapy (Goldstone et al, 2001;Mulford, 
2008).
b. Differentiation agents
The induction of terminal differentiation by retinoids in leukaemic cell 
lines and short-term culture APL cells was observed in the early 1980s. 
An in vitro study by Breitman et al (1980) demonstrated the 
differentiation of HL-60 cells induced by 10'6M all trans retinoic acid 
(ATRA), resulting in terminal differentiation in 90% of the cells (Breitman 
et al, 1980). Further investigation into ATRA-induced differentiation in
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APL cells exhibiting the t(15;17) translocation led to the development of 
ATRA as a therapy for APL (Breitman et al, 1981). As previously 
discussed in section 1.3.2, retinoic acid receptors (RARs) are a family 
of transcription factors that regulates granulocytic differentiation. The 
fusion product PML-RARa is a negative regulator of transcription 
through the formation of homodimers with RARs, recruiting a co­
repressor complex containing HDACs and inhibiting transcription of 
haematopoietic lineage-specific genes. Pharmacological concentrations 
of ATRA (10-6 M) induce a conformational change releasing the co­
repressor complex and activating transcription (Grignani et al, 
1998;Vitoux et al, 2007). ATRA was first used to treat APL patients in 
Shanghai, and later in France, with promising results (Huang et al, 
1988;Castaigne et al, 1990). A progressive change in malignant cells in 
the bone marrow and signs of terminal differentiation was observed. 
Clonal cells exhibiting a t(15;17) were replaced by polyclonal 
haematopoietic cells and no primary resistance occurred. However, in 
some patients an increase in white blood count due to an activation of 
leukocytes during the first two weeks of treatment was observed in 
several patients, often accompanied by “retinoic acid syndrome” 
characterised by fever, weight gain, difficulty in breathing and pleural 
effusion, and occasionally resulting in death (Castaigne et al, 1990;De 
Botton S. et al, 1998;Fenaux et al, 2001). Following treatment with 
ATRA, a relapse within months is often observed when receiving ATRA 
alone or with mild chemotherapy due to a resistance to the drug. 
Following treatment with ATRA with intensive anthracycline-AraC
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chemotherapy has been seen to successfully reduce relapse rates in 
APL cases (Fenaux et al, 1993;Fenaux et al, 1994).
c. Signal transduction inhibition
Now there is a better understanding into the molecular biology of 
leukaemogenesis, and in particular AML, treatment regimes can be 
improved with the development of targeted therapies. Receptor tyrosine 
kinase (RTK) signalling is essential for many cellular processes, 
including cell proliferation and survival and the control of the cell cycle. 
Many RTKs are constitutively activated in AML, for example FLT3 
(Section 1.3.2a), as a result of molecular aberrations and therefore 
investigation into new targeted therapies has been directed towards the 
inhibition of tyrosine kinase activity. Various inhibitors have been used 
in clinical trials for the inhibition of the tyrosine kinase activity of FLT3. 
The indolinone compounds SU5416 and SU5614 designed to target the 
tyrosine kinase activity of FLT3 have been seen to decrease cell 
proliferation and increase cell apoptosis in AML. The compounds inhibit 
the activity of both wild-type FLT3 and FLT3 ITD isoforms resulting in 
the inhibition of downstream signalling via the MAPK and STAT 
pathway (Yee et al, 2002). In leukaemic cell lines and mouse models, 
Gi cell cycle arrest and apoptosis in AML cells expressing mutant FLT3 
was seen to be selectively induced through the small molecule FLT3 
inhibitor PKC412 directly inhibiting the tyrosine kinase activity of FLT3 
(Weisberg et al, 2002). Levis et al (2002) observed the inhibitory effects 
of the indolocarbazole derivative CEP-701 in AML cell lines and AML
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primary blasts. CEP-701 was seen to be effective against cells 
expressing the wild-type, ITD and TKD isoforms of FLT3. By inhibiting 
the downstream targets ERK (extracellular signal-regulated kinases) 
and STAT5, a varying cytotoxic effect dependant upon the FLT3- 
expressing cell was observed (Levis et al, 2002).
d. Monoclonal antibodies
During the search for new therapies in AML attention has been focused 
on the use of monoclonal antibodies (mAbs) targeting antigens 
specifically expressed on myeloid cells. Monoclonal antibodies can 
provide a more specific and a less toxic means of treating AML 
compared to conventional chemotherapy (Mulford, 2008).
/. CD33
Currently the most successful mAb agent used in the battle against 
AML is the immunoconjugate known as gemtuzumab ozogamicin (GO), 
also known as Mylotarg, that binds to the CD33 antigen. CD33 is a 
transmembrane glycoprotein found specifically on myeloid cells but not 
expressed on normal CD34+ pleuripotent haematopoietic and non- 
haematopoietic tissues (Andrews et al, 1983;Stasi et al, 2008). As the 
CD33 molecule is also expressed on more than 80% of myeloid 
leukaemia cells, an anti-CD33 immunoconjugate would allow for the 
selection and elimination of malignant myeloid cells whilst sparing 
immature haematopoietic progenitors (Mulford, 2008). GO is a 
humanised lgG4 anti-CD33 monoclonal antibody conjugated to a
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hydrazide derivative of calicheamicin, a naturally occurring hydrophobic 
enediyne antibiotic (Figure 3). GO rapidly targets CD33+ cells and is 
internalised resulting in the release of the calicheamicin derivative by 
acid hydrolysis. Calicheamicin interferes with biological processes by 
cleaving free DNA and displacing a DNA-binding protein through 
competition or altering DNA structure leading to apoptosis (Stasi et al, 
2008).
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Figure 3. The schematic structure of gemtuzumab ozogamicin (Stasi et al, 
2008)_____________________________________________________________
//. CD44
The cell surface antigen CD44 is a highly glycosylated type 1 
transmembrane receptor involved in survival, migration, proliferation, 
differentiation and apoptosis. CD44 is encoded by a single gene 
consisting of 20 exons. Whilst 10 of the exons are constitutively 
expressed in all CD44+ cells generating a standard isoform of the CD44 
molecule, the other 10 exons are alternatively spliced. Various
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combinations of expression of the variant exons generates CD44 
variant isoforms (CD44v) characterised by additional sequences 
inserted into the extracellular domain of the molecule. The expression 
of the standard CD44 isoform in haematopoiesis is dependant upon the 
cell lineage and stage of differentiation. Expressed on all types of 
mature blood cells and the majority of mononuclear bone marrow 
precursors, a high level of CD44 expression can be detected on 
monocytic cells and CD34+ HSCs and lower levels on erythroid cells 
and platelets. Some of the CD44 variant isoforms have been detected 
on monocytes, macrophages, lymphocytes, and dendritic cells (Mackay 
et al, 1994;Ghaffari et al, 1995;Legras et al, 1998;Gadhoum et al, 
2004). An increased expression of several of the variant isoforms has 
been detected on malignant haematopoietic cells; an up-regulation of 
CD44v-6 and CD44v-10 has been detected on AML cells and a strong 
expression of CD44v-6 in AML has been shown to be an indicator of 
poor prognosis (Ghaffari et al, 1995;Legras et al, 1998). Charrad et al 
(1999) were the first group to demonstrate the potential use of anti- 
CD44 monoclonal antibodies (mAbs) as a therapy for AML. In primary 
AML blast cultures the addition of an anti-CD44 mAb could induce 
terminal differentiation and block proliferation of the AML blasts in FAB 
groups M1 to M5 (Charrad etal, 1999).
Treatment Failure
Treatment failures resulting in reduced complete remission rates and an 
increase in the number of relapse cases arise from a number of factors.
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As previously discussed, age plays an important role in the success of 
AML treatment. Elderly patients may present with co-morbid illness or 
biological influences reducing the success of treatment they receive. 
The elderly are often unable to tolerate the intensive therapy required to 
eliminate AML, often developing life-threatening infections during the 
course of treatment (Estey et al, 1982). Secondary AML is associated 
with a resistance to standard chemotherapy and as a result, a poorer 
prognosis and treatment failure. Patients with a history of 
myelodysplastic syndrome (MDS) or a chronic myeloproliferative 
disorder often develop secondary AML (Larson, 2007). Alternatively, 
secondary AML is therapy-related (t-AML) arising from treatment with 
alkylating agents, topoisomerase II inhibitors, radiation therapy, or 
immunosuppressive agents (Leone et al, 1999;Larson, 2007). 
Importantly, a large number of AML cases do achieve complete 
remission but unfortunately relapse ultimately occurs. Induction therapy 
is designed to remove all the haematopoietic cells from the bone 
marrow to allow for repopulation of normal cells. As the cut-off for 
remission is less than 5% leukaemic blasts remaining, residual disease 
may confer a growth advantage and repopulate at a later date. The 
hypothesis of the leukaemic stem cell discussed previously (Section 
1.2.2d) would suggest that only a few leukaemic stem cells remaining in 
the residual disease would be necessary for the development of a 
haematological relapse.
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1.4 Minimal residual disease (MRD)
When a patient is diagnosed with AML, the number of leukaemic cells 
present may exceed 1012. Defining a patient as being in complete 
remission (CR) depends on the identification of leukaemic cells based 
on their morphology and immunophenotype. A patient’s bone marrow is 
classed as “normal” when the number of morphologically identifiable 
blasts calculated is less than 5%, which can equate to as many as 1010 
leukaemic cells still present in the marrow (Campana & Pui, 1995). 
Following remission patients undergo post-remission treatment to 
further reduce the tumour load with the aim of eliminating the leukaemic 
clone. The patients receive treatment at the same intensity regardless 
of their individual residual tumour load and the decision to stop post­
remission treatment is also decided without the knowledge of any 
residual disease present (Campana & Pui, 1995;Liu Yin, 2002f). Whilst 
survival rates have increased in adult patients, relapse occurs in up to 
70% of the patients undergoing chemotherapy alone presumably due to 
residual leukaemic cells still present after treatment (Liu Yin, 2002e). 
Therefore, the study of MRD in patients with AML could produce 
information that could be used as a powerful tool for the prognosis of 
patients and therefore determining a treatment approach for patients 
(Grimwade & Lo Coco, 2002). Being aware of the level of leukaemic 
cells remaining following treatment would allow for therapy regimes to 
be altered and the risk of relapse reduced (Grimwade & Lo Coco, 
2002;Liu Yin, 2002d;Chung et al, 2006). The various methods available
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for the detection of MRD rely on the morphological, cytochemical, 
immunophenotypic and genetic properties of the leukaemic cells.
1.4.1 Detection of MRD
MRD detection methods require a sensitivity of detection of at least one 
leukaemic cell in 103 cells. To avoid false-positives techniques 
employed also require the ability to distinguish leukaemic cells from 
healthy normal cells. Over the years several techniques have been 
developed and evaluated that vary in sensitivity and specificity.
a. Conventional cytogenetics
Karyotyping is an essential tool routinely carried out at diagnosis. Clonal 
abnormalities including structural and numerical changes specific to the 
leukaemic cells can be detected and used to monitor the progression of 
the disease as they disappear during remission and reappear during 
relapse (Yin & Tobal, 1999;Liu Yin, 2002c). In a very early study by 
Testa et al (1979), chromosomal aberrations detected at diagnosis 
through karyotyping were seen to disappear when patients achieved 
complete remission and re-appear with the onset of relapse (Testa et al, 
1979). MRD detection by cytogenetics also has the advantage of being 
able to detect new aberrations arising during the progression of the 
disease. However, karyotyping is quite insensitive and relies on the 
analysis of small numbers of metaphase cells (Liu Yin, 2002b).
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b. Fluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) has the advantage over 
conventional karyotyping of being able to detect chromosomal 
abnormalities in both metaphase and interphase cells, increasing the 
chance of detecting abnormalities previously missed due to low 
proliferative rates. DNA probes specific to a region of a chromosomal 
breakpoint or to a whole chromosome are used to detect chromosomal 
abnormalities throughout a patient’s disease. Structural rearrangements 
that would have previously been missed during traditional karyotyping 
can be detected by FISH (Yin & Tobal, 1999). To improve the accuracy 
of results, FISH analysis is often combined with morphologic or 
immunohistochemical analysis (Campana & Pui, 1995). Unfortunately 
FISH has a detection limit of only one abnormal cell per 100 cells (1%) 
due to aneuploid cells and other artefacts. The co-localisation of two 
signals can also generate false-positives further reducing the sensitivity 
of FISH as a means of MRD detection (Yin & Tobal, 1999;Liu Yin, 
2002a).
c. Flow Cytometry
Despite a lack of leukaemia-specific antigens, the immunophenotype of 
some leukaemic cells differ enough from those of “normal” 
haematopoietic cells that immunophenotyping can be used for 
monitoring disease progression (Campana & Coustan-Smith, 1999;Liu 
Yin, 2002g). Staining with a number of fluorochrome-labelled antibodies 
can identify leukaemia-associated aberrant immunophenotypes (LAIP)
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of leukaemic cells, which can alter between diagnosis and relapse 
(Kern et al, 2008). Multi-parameter flow cytometry can detect antigen 
co-expression in leukaemic cells and has been used for the detection of 
MRD and predicting relapse in AML patients in several studies (San 
Miguel et al, 1997;Sievers et al, 1996). Unique to this method, size and 
granularity of the cells can also be measured by flow cytometry 
(Campana & Coustan-Smith, 2002). A major advantage of the use of 
multi-parameter flow cytometry for the detection of MRD is its sensitivity 
(one leukaemic cell in 103-104 normal cells) and the speed of analysis 
over other methods (Liu Yin, 2002h). However, there are several 
problems existing with the use of flow cytometry for the detection of 
MRD, which contribute to reducing the sensitivity of this particular 
method. A lack of specificity or the use of inappropriate markers can 
result in false-positives due to background levels of “normar cells with a 
similar immunophenotype to the leukaemic clones. False-negatives can 
also occur from a phenotypic-switch occurring at relapse (Campana & 
Coustan-Smith, 2002)
d. Reverse transcription-polymerase chain reaction and Polymerase 
chain reaction (RT-PCR/PCR)
DNA-amplification PCR methods are used to detect mutations, 
translocations, polymorphisms and aberrant changes in gene 
expression that can be used to follow the progression of a disease. RT- 
PCR and PCR methods are very sensitive capable of detecting one 
leukaemic cell in 103-106 normal cells, dependant upon many variables,
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and so useful for the monitoring of MRD (Yin & Grimwade, 
2002;Campana, 2003). Many studies have demonstrated the prognostic 
significance of the presence of disease-specific markers detected by 
PCR in AML (Trka et al, 2002;Krauter et al, 2003;Leroy et al, 
2005;Perea et al, 2006).
Qualitative Reverse Transcriptase-PCR
Qualitative RT-PCR can be used to amplify target gene transcripts for 
the detection of gene rearrangements, for example fusion gene 
transcripts generated from chromosomal translocations including 
breakpoints spread over a large area (Yin & Tobal, 1999;Gabert et al, 
2003). Complementary DNA (cDNA) generated in the first step of RT- 
PCR is amplified by PCR in the second step. The qualitative data 
generated, negative or positive expression, is dependant on the 
sensitivity of the assay. Inefficiency of the first step generating cDNA 
and degradation of the starting material can reduce the sensitivity of the 
process greatly. The sensitivity and the qualitative nature are major 
disadvantages for RT-PCR and its contribution to MRD detection. A 
negative result generated for a patient does not automatically imply 
there is no residual disease remaining; simply there is no residual 
disease that can be detected by the assay. In a similar manner, a 
positive result may not imply a potential relapse. Several studies have 
detected a persistence of cells bearing the t(8;21) translocation in AML 
patients in long-term remission after receiving chemotherapy or an 
autologous bone marrow transplant (Nucifora et al, 1993;Saunders et
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al, 1994). As a result quantitative PCR methods for MRD detection have 
been developed.
Nested RT-PCR
Nested PCR is used to reduce contamination in the amplification 
process by using two sets of primers; an external primer set and an 
internal primer set. The amplified product generated from the first PCR 
run is amplified in a second PCR using internal oligonucleotide primers 
(Cross, 1995). A two-step nested RT-PCR can reach a minimal target 
sensitivity of 10-4, and is reported to be more sensitive than real-time 
PCR techniques but as a qualitative method it can provide only limited 
information in regards to MRD kinetics (Takenokuchi et al, 2004;Schuler 
& Dolken, 2006). As a result, Takenokuchi et al (2004) developed a 
quantitative nested RT-PCR (QN-RT-PCR) technique. Compared to 
real-time PCR, QN-RT-PCR was 10 times more sensitive for the 
detection of plasmid DNA containing AML1-ETO fusion cDNA 
(Takenokuchi et al, 2004).
Competitive PCR
Competitive PCR has been shown to be useful in predicting relapse in 
CML and AML t(8;21) patients (Cross et al, 1993;Tobal & Yin, 1996). 
Serial dilutions of a known amount of internal standard, known as a 
“competitor”, are amplified using the same primers as the target gene of 
interest. The competitor produces different sized products to the gene 
target, which can be visualised by gel electrophoresis. As the amount of
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competitor added initially to the PCR reaction is known, the amount of 
target gene transcript produced can be estimated (Cross, 1995;Yin & 
Tobal, 1999). A disadvantage of this form of quantitative PCR reaction 
is that it is time consuming and labour intensive (Gabert et al, 2003).
Quantitative Real-time PCR (RQ-PCR)
Quantitative real-time PCR (RQ-PCR) allows for a rapid and sensitive 
measurement of mRNA expression levels of AML-specific genes 
relative to a control/reference gene. The level of PCR product is 
measured as it accumulates throughout the amplification process rather 
than measuring end-point amount of product (Liu Yin, 2002i). RQ-PCR 
can be used to follow the progression of a patient’s disease by 
detecting gene mutations, fusion-gene transcripts resulting from 
translocations and aberrantly expressed.
RQ-PCR Techniques. The hybridisation probe method utilises two 
juxtaposed sequence-specific probes; one labelled at the 3' end with a 
donor fluorochrome and one labelled at the 5' end with an acceptor 
fluorochrome. During the annealing phase, both probes hybridise to the 
target sequence. Light with a longer wavelength is emitted from the 
donor fluorochrome upon excitement, which in turn excites the acceptor 
fluorochrome. The SYBR green dye method is simpler than the 
hybridisation probe method. As DNA is generated, the SYBR green dye 
is incorporated into the molecule and its fluorescence increases; further 
increases are detected as the amount of DNA exponentially increases.
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Compared to the hybridisation probe method, the SYBR green method 
has a reduced specificity and non-specific DNA products and primer 
dimmers can be detected (Kern et al, 2005).
Sensitivity & Specificity. Despite studies demonstrating RQ-PCR as less 
sensitive by 10 times than nested PCR, it is a technique of choice. 
Unfortunately the high sensitivity of this method makes it vulnerable to 
the generation of false-positives from contamination (Schuler & Dolken, 
2006). The definition of the sensitivity of a method in most MRD studies 
applies to lowest proportion of leukaemic cells that can be measured, 
although it is debated that sensitivity applies to the lowest proportion of 
leukaemic cells that can be distinguished from healthy or leukaemia- 
free, regenerating bone marrow (Steinbach & Debatin, 2008). The 
sensitivity of RQ-PCR assays can be affected by a number of variables. 
Similar to qualitative RT-PCR, factors occurring both pre- and during- 
PCR can greatly influence the sensitivity of detection (See Quality 
Control and Standardisation below). Important effectors of sensitivity to 
be aware of and control include the amount of RNA or DNA used, the 
quality of each sample and the number of replicates performed (Ross et 
al, 2009). The sensitivity of an assay can be determined through an 
experiment of serial dilutions of leukaemic cells in a healthy bone 
marrow sample; the lowest amount of leukaemic cells that can generate 
a positive result is deemed the sensitivity (Steinbach & Debatin, 2008). 
The specificity of an RQ-PCR assay can be influenced by the choice of 
SYBR green or probes. Hybridisation probes specifically targets the
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sequence of interest whereas non-specific PCR products and primer- 
dimers can be amplified with SYBR green. When performing SYBR 
green assays, melting curves can be generated to assess the level of 
specificity; a single curve generated for each sample suggests the 
amplification of a single product (Kem et al, 2005).
Quality Control and Standardisation. The level of mRNA expression of 
an AML-specific gene is compared to the level of mRNA expression 
level of a control gene to account for and control the variability between 
samples that may arise. House-keeping genes are selected on the 
basis of them being expressed at similar levels in different cell types 
(Kem et al, 2008). Variability can arise during the pre-PCR stage due 
the choice of methods utilised by laboratories, for example the type of 
sample used, the method of mononuclear cell isolation, method of RNA 
extraction, method of cDNA synthesis. Even during the PCR process 
variability can arise. Results can be affected by the selection of 
reagents used, whether primers or probes are used and the PCR 
machine used, and even by the method of data analysis selected. A 
joint project between 25 university laboratories in ten European 
countries was designed via the “Europe Against Cancer” (EAC) 
programme to develop standardisation and quality control. The primary 
aim was to establish a standardised protocol to allow for comparison of 
MRD data for leukaemia bearing an appropriate molecular marker 
(Gabert et al, 2003).
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Fusion Genes as Markers of MRD. The most common fusion genes 
used as MRD markers for detection by PCR are PML-RARa, AML1- 
ETO, and CBFf5-MYH11\ the fusion genes generated from 
translocations associated with favourable AML. Using fusion gene 
products as markers allows for highly sensitive and specific MRD 
detection but due to their low incidence, detection of MRD in this 
manner only accounts for approximately 25% of adult de novo AML 
cases (Kern et al, 2008).
Gene Mutations as Markers of MRD. PCR detection of fusion genes 
limits the number of cases of AML that can be monitored; patients with 
a normal karyotype display no fusion gene products resulting from 
balanced chromosomal translocations. As a result, mutations detected 
in genes are being increasingly used for MRD monitoring. Assessing 
the behaviour of specific gene mutations allows for up to approximately 
75% of normal karyotype AML cases to be monitored (Kern et al, 2008). 
Commonly monitored gene mutations include; FLT3, NPM1 and 
CEBPA.
Aberrant Gene Expression as a Marker of MRD. As for gene mutations, 
monitoring the over-expression of genes provides a means of 
monitoring MRD in patients without a chromosomal translocation 
resulting in the generation of a fusion gene product. A disadvantage to 
the use of aberrant gene expression is its limited sensitivity compared 
to other markers; the genes monitored are rarely “undetected” in normal
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healthy cells but instead display a low level background expression 
(Kern et al, 2008). The WT1 gene has been demonstrated to be useful 
in monitoring the behaviour of MRD in normal karyotype AML patients.
1.4.2 Current MRD markers
As previously discussed, several sub-clones can exist in AML with a 
dominating clone directing the disease. Chemotherapy can result in the 
elimination of one sub-clone allowing complete remission to be 
achieved but may result in the domination of a minor sub-clone leading 
to the re-initiation of the disease and relapse through an alternative 
initiating event. Markers of MRD need to be stable events that are 
present at both diagnosis and remission, for example a primary event 
such as a chromosomal marker or a secondary event that is essential to 
the clone. Secondary abnormalities, for example FLT3, are not always 
present at relapse when previously observed at diagnosis and vice 
versa, and therefore are not as useful as MRD markers (Shih et al, 
2004a).
a. PML-RARa
With the advent of ATRA, APL is now one of most prognostically 
favourable subsets of AML (Grimwade et al, 1998;Grimwade, 2002). 
Despite the high cure rates, a small subgroup of patients with a poorer 
prognosis will ultimately relapse. With attempts to further improve cure 
rates, early studies suggested the monitoring of the PML-RARa fusion 
gene product. An RT-PCR assay was developed to detect PML-RARa
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fusion gene transcripts in leukaemic samples with a greater detection 
sensitivity than conventional cytogenetics or Northern blot analysis 
(Castaigne et al, 1992;Miller, Jr. et al, 1992). Several groups observed 
a disappearance of the fusion gene following therapy but those patients 
remaining PML-RARa positive following consolidation therapy or who 
became PML-RARa positive after achieving a negative PCR result 
eventually relapsed (Biondi et al, 1992;Lo Coco et al, 1992;Miller, Jr. et 
al, 1992). Diverio et al (1993) went on to confirm an absence of the 
fusion gene in long-term remission APL patients (Diverio et al, 1993). 
Monitoring of MRD in APL patients is now mainly performed using 
quantitative RT-PCR, providing reliable prognostic indexes for APL 
following diagnosis and after consolidation therapy (Gallagher et al, 
2003;Schnittger et al, 2003;Cassinat et al, 2009).
b. CBF fusion products
Patients exhibiting a t(8;21) translocation or an inv(16) at diagnosis are 
given a favourable prognosis and generally a high complete remission 
rate is achieved following standard induction chemotherapy (Byrd et al, 
2002). Invariably though, some patients will relapse despite receiving 
intensive consolidation therapies or an autologous stem-cell 
transplantation. Studies into the usefulness of MRD monitoring in the 
CBF leukaemias by qualitative RT-PCR have generated conflicting 
data; AML1-ETO transcripts were detected in several long-term 
remission patients (Nucifora et al, 1993;Saunders et al, 1994;Miyamoto 
et al, 1996). As a result, quantitative competitor and real-time PCR
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methods have been applied to CBF leukaemias for the monitoring of 
MRD. Several studies have demonstrated the prognostic value of 
monitoring MRD in these patients using quantitative methods (Tobal et 
al, 2000;Marcucci et al, 2001 ;Krauter et al, 2003)
c. Wilms’ tumour (WT1)
Wilms’ tumour 1 (WT1) was originally identified as a tumour-suppressor 
gene involved in the pathogenesis of Wilms’ tumour, a kidney neoplasm 
(Haber et al, 1990). The WT1 gene is found on chromosome 11 p13 and 
spans approximately 50Kb of DNA (Coppes et al, 1993). WT1 is 
expressed in a variety of tissues including the kidneys, gonads and 
those involved in haematopoiesis (Call et al, 1990) but an increase in 
expression is observed in Wilms’ tumours (Bergmann et al, 1997). 
Many groups have detected low levels of WT1 expression in normal 
bone marrow and peripheral blood samples yet high levels in AML 
samples and other leukaemic samples (Inoue et al, 1994) leading to the 
suggestion of WT1 as a candidate for MRD monitoring in AML (Inoue et 
al, 1994). An advantage to WT1 being used as a MRD marker is that it 
is expressed in 75-80% of patients compared other chromosomal 
aberrations that occur in only a small number of AML patients. In 
addition, PCR methods for the detection of WT1 have a sensitivity of 
one cell of 104-105 cells (Bergmann et al, 1997). Despite these 
advantages, the use of WT1 as an MRD marker and its clinical 
significance has been associated with some controversy. Schmid et al 
(1997) reported WT1 expression in leukaemic blasts but found no
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significant correlation between WT1 expression and disease-free 
survival or overall survival. Their data was also too limited to come to a 
conclusion about the usefulness of WT1 as a marker of MRD (Schmid 
et al, 1997). Using qualitative RT-PCR, Gaiger et al (1998) detected 
levels of WT1 expression in AML patients following chemotherapy and 
marrow transplantation indicating WT1 had no prognostic significance 
and could not reliably predict relapse (Gaiger et al, 1998). However, 
results from qualitative PCR methods need to be approached with 
caution as previously discussed. A low level of WT1 expression 
preceding a relapse may not be detected whilst a positive result 
generated from low levels of WT1 expression in a healthy normal cell 
will not always result in a relapse. More recent studies using 
quantitative PCR methods have demonstrated a positive prognostic 
value of WT1 and its ability to predict relapse in AML following both 
conventional chemotherapy and allogeneic hematopoietic stem cell 
transplant (HSCT) (Cilloni et al, 2003;0gawa et al, 2003;Candoni et al, 
2009).
d. Preferentially Expressed Antigen of Melanoma (PRAME) 
Overexpression of the PRAME gene in tumours encodes for a HLA- 
A24-restricted antigenic peptide (van Baren et al, 1998). PRAME is 
expressed at low levels in normal tissue cells but is predominantly 
expressed in acute leukaemia, in particular t(8;21) AML (Ikeda et al, 
1997;van Baren et al, 1998). Using real-time RT-PCR, Tajeddine et al 
(2006) demonstrated that PRAME was a good marker of MRD in
67
PRAME* AML displaying no other genetic markers. More recently Qin 
et al (2009) detected low levels of both PRAME and WT1 in normal 
bone marrow and an increased expression of both genes in normal 
karyotype AML by RQ-PCR. They confirmed that the simultaneous 
monitoring of PRAME and WT1 provides a more sensitive detection in 
MRD and may help to avoid false-positives (Qin et al, 2009).
1.5 Gene Expression Profiling
1.5.1 Early microarray studies
The identification of unique gene expression profiles has the potential to 
identify sub-groups within diseases with differing prognostic and 
therapeutic significance. Golub et al (1999) first approached the use of 
microarrays for disease classification. Using class discovery and a class 
prediction, previously unrecognisable subtypes were defined and “class 
predictors” were generated capable of assigning unknown samples to 
one of two classes. To validate the class prediction approach, Golub et 
al (1999) used 50 gene-predictors previously identified as most closely 
correlated with ALL-AML distinction in known samples to distinguish 
between 38 acute leukaemic samples (Figure 4) (Golub et al, 1999).
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Figure 4. The 50 “predictor” genes used to distinguish between 38 acute 
leukaemia samples. Each row corresponds to a gene and each column 
corresponds to a sample. Expression levels greater than the mean are coloured 
red and those below are coloured blue. Adapted from Golub et al (1999) (Golub 
et al, 1999).
1.5.2 Identification of AML-specific sub-groups
Following on from the work by Golub et al (1999) many groups 
investigated the potential of gene expression profiling analysis to 
identify specific gene-expression signatures that could distinguish 
between the AML sub-groups and their cytogenetic aberrations, and 
identify new potential prognostic markers and targets for therapy.
a. Favourable translocations
To determine whether a favourable leukaemia-specific genotype is 
associated with a distinct gene expression profile, Schoch et al (2002) 
performed gene expression profiling analysis on 37 AML patient 
samples exhibiting one of the three favourable chromosomal 
translocations. They confirmed a correlation between AML-specific
Genes more highly expressed in AML 
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chromosomal aberrations and gene expression. Using principal 
component analysis (PCA), AML patient samples exhibiting either a 
t(15;17), t(8;21) or an inv(16) were clearly separated into three distinct 
groups (Schoch et al, 2002). In agreement with these findings, AML 
patient samples were seen to group according to their favourable 
cytogenetic group in an unsupervised cluster carried out by Debernardi 
et al (2003). A hierarchical cluster of a set of genes identified with 
statistically significant differences in expression between the five groups 
analysed in this study (t(15;17), t(8;21), inv(16), 11q23 and normal 
karyotype) grouped the patient samples according to their cytogenetics 
(Debernardi et al, 2003). However, a more recent study by Bullinger et 
al (2007) demonstrated the molecular heterogeneity within the core 
binding factor (CBF) leukaemias. Rather than a distinct clustering of 
t(8;21) patient samples and inv(16) patient samples as previously seen, 
an unsupervised hierarchical cluster saw CBF AML samples segregate 
between two heterogeneous clusters. The larger of the two clusters 
displayed a separation of the t(8;21) patient samples and inv(16) 
patient samples into two distinct groups whilst the t(8;21) and inv(16) 
patient samples in the smaller cluster were mixed together (Bullinger et 
al, 2007). More recently, Verhaak et al (2009) used PAM (predictive 
analysis for microarrays) analysis to predict the cytogenetic status of 
AML patient samples with a favourable karyotype (t(15;17, t(8;21) or 
inv(16)) with 100% accuracy (Verhaak et al, 2009). These studies 
demonstrated a strong association between the three favourable 
chromosomal aberrations and their patterns of gene expression. The
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distinct gene expression profiles observed within the CBF leukaemia 
may be a result of other clinical and genomic characteristics of the CBF 
patients that contribute to their disease and prognosis.
b. Normal Karyotype
Patients with a normal karyotype make up the largest sub-group in AML 
and are not homogenous in respect to their molecular genetics and 
therefore their clinical outcome (Marcucci et al, 2005). Gene expression 
profiling has been applied to normal karyotype AML patients to explore 
the heterogeneity amongst these patients and recognise distinct 
expression signatures (Radmacher et al, 2006). As previously 
discussed, in the study by Debernardi et al (2003), unsupervised 
clustering of 28 AML patient samples saw the clustering of samples 
based on their cytogenetics; with the exception of two samples 
clustering with the inv(16) patients, normal karyotype samples formed a 
distinct separate cluster (Debernardi et al, 2003). From the application 
of a statistical group comparison restriction filter to identify genes with 
statistically significant differences in expression among the cytogenetic 
groups, an increased expression of a number of homeobox (HOX) 
genes were seen in the normal karyotype group. Further unsupervised 
hierarchical clustering of 87 HOX genes saw the separation of samples 
into two distinct clusters; favourable AML with low HOX expression 
separating into one cluster and normal karyotype and 11q23 samples 
grouping together in the second cluster displaying a high expression of 
the HOX genes. Further analysis identified ten HOX genes specifically
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over-expressed in normal karyotype AML; HOXA4, HOXA5, HOXA9, 
HOXB2, HOXB3, HOXB5, HOXB6, HOXB7, MEISI (myeloid ecotropic 
viral integration site 1 homolog) and PBX3 (pre-B-cell leukemia 
transcription factor 3) (Debernardi et al, 2003). Bullinger et al (2004) 
observed a grouping of normal karyotype patients into two distinct 
clusters; a prevalence of FLT3 aberrations and FAB M1 and M2 
samples were observed in cluster 1 whilst FAB M4 and M5 samples 
were common to cluster 2. Later studies into expression profiles of AML 
patients observed the clustering of normal karyotypes was also 
associated with other molecular aberrations. Valk et al (2004) observed 
a clustering of normal karyotype patients between 3 out of 16 clusters. 
The majority of the patients grouped into two of these clusters displayed 
a normal karyotype and an internal tandem duplication of the FLT3 
gene. The third cluster containing mostly patients with a normal 
karyotype presented with no consistent extra abnormalities (Valk et al, 
2004). In determining whether or not gene expression profiling could 
improve outcome prediction and risk classification, Wilson et al (2006) 
identified one out of six clusters of AML patients with the best rate of 
overall survival; 25% at 5 years. This particular cluster contained a high 
number of NPM1 mutations (78%), an unequal number of females 
(67%) and the majority of normal karyotype patients (75%) in the study 
(Wilson et al, 2006). These studies indicated that gene expression 
profiling might be useful for risk classification and prediction of outcome 
but further profiling work was required with the inclusion of other 
molecular aberrations and the influence they have on prognosis.
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c. Gene mutations and aberrant gene expression 
AML exhibiting mutations and/or aberrant expressions of FLT3, NPM1, 
CEBPA and EVI1 have been associated with specific gene expression 
signatures and several investigations have been carried out to 
determine whether these signatures have the ability to predict the 
presence or absence of these mutations and determine risk and 
prognosis of the patients. In a study by Alcalay et al (2005) 
unsupervised hierarchical clustering of de novo AML displaying no 
AML-associated chromosomal translocations demonstrated the 
strongest clustering of patients based on their NPM1 mutation status; 
FL 73 mutations had no influence on the clustering (Alcalay et al, 2005). 
Within the cluster of samples displaying aberrant cytoplasmic NPM1 
localisation due to a mutation of the NPM1 gene, a number of HOX 
genes were seen to be up-regulated in the gene expression signature 
(Alcalay et al, 2005). Similar to Alcalay et al (2005), Verhaak et al 
(2005) also identified a HOX-specific gene signature associated with 
mutant NPM1 AML patients. Through PAM analysis, they were also 
able demonstrate the positive predictive power for NPM1 mutations in 
both their training and independent data sets (Verhaak et al, 2005). 
Investigation into FL 73-specific gene expression profiles has generated 
some contradictory results. Several studies of normal karyotype 
samples have demonstrated the positive accuracy of specific gene 
signatures to separate AML samples based on the presence of a FLT3- 
TKD or a FLT3-ITD and of the presence of a FL 73-TKD or wild-type 
FLT3 (Neben et al, 2005;Whitman et al, 2008). However, in an analysis
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of paediatric AML, Lacayo et al (2004) observed a separation between 
wild-type FLT3 samples and FLT3-ITD samples but several wild-type 
samples were seen to cluster with the FLT3-ITD samples, reducing the 
predictive power of FL 73-specififc gene signatures (Lacayo et al, 2004).
In a gene expression analysis previously discussed, Valk et al (2004) 
identified two clusters of AML patients displaying a high frequency of 
CEBPA mutations, which are associated with a favourable outcome. 
The two clusters differed from each other by the genes that were up- or 
down-regulated in the samples (Valk et al, 2004). Combining the two 
clusters containing patients with a CEBPA mutation and using PAM 
analysis to identify genes capable of predicting karyotype, the presence 
of a CEBPA mutation was detected with 98% accuracy. The same 
group also observed an over-expression of the EVI1 gene in 11 of 22 
patients and in 5 of 14 patients in two clusters. The patients differed 
between the two clusters in the chromosomal abnormality they 
displayed; 60% of the EVI1 over-expressing patients in the first cluster 
also displayed a chromosome 7 abnormality whilst the patients in the 
second cluster exhibited an 11q23 aberration (Valk et al, 2004). From 
their investigation, Verhaak et al (2009) concluded that gene expression 
profiling was capable of accurate prediction of the favourable AML sub- 
types but not for other mutations and molecular aberrations (Verhaak et 
al, 2009).
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1.5.3 Risk Classification and therapeutic targeting
Microarray analysis began as a disease classification tool for identifying 
sub-group specific signatures and class prediction but gene expression 
profiling is now being directed towards the possibility of it being useful in 
risk classification and therapeutic targeting. Wilson et al (2006) 
identified six distinct groups based on gene expression with 
unsupervised hierarchical clustering on a cohort of 170 patients. A 
cluster dominated by patients with NPM1 mutations was identified with 
having the best overall and disease-free survival (Wilson et al, 2006). A 
gene expression profiling study was carried out to identify novel gene 
signatures and markers to predict patient response to the 
farnesyltransferase inhibitor tipifamib (Zarnestra). The analysis 
identified eight genes as potential markers for response to treatment 
predictors and whilst the overall accuracies were only around 60%, the 
concept of gene expression profiling for identifying patients who 
respond to various therapies has been highlighted (Raponi et al, 2007).
1.6 Project aims and objectives
Complete remission rates of AML have greatly increased over the last 
50 years but some patients still relapse within months of achieving 
complete remission. One approach to improving treatment outcomes is 
the development of sub-group specific therapies rather than the 
standardised management currently being employed. In addition, the 
effective and accurate monitoring of MRD within these sub-groups has 
the potential to improve patient outcomes. The aim of this study was to
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utilise gene expression profiling as a tool to help provide a better clinical 
management for specific AML sub-groups.
Aims:
■ Establish a “proof-of-principle” by using gene expression profiling 
to identify genes specific to t(15;17) AML.
■ Use gene expression profiling to identify genes specific to CBF 
AML patients.
■ Investigate the potential of the identified genes as markers of 
minimal residual disease within the favourable prognosis AML 
sub-groups and compare with markers currently used.
■ Use gene expression profiling to identify genes specific to normal 
karyotype AML patients.
■ Validate the expression of these genes and their ability to act as 
markers of minimal residual disease.
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Chapter 2 
Materials and Methods
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2.1 Materials
2.1.1 Primer sequences
Gene Direction of primer Primer sequence (5' - 3')
Control genes S14 Forward ggcagaccgagatgaactct
Reverse ccaggtccaggggtcttggt
ABL Forward cccaaccttttcgttgcactgt
Reverse cggctctcggaggagacgtaga
t(15;17) IGFBP2 Forward agcatggcctgtacaacctc
Reverse aagcctcctgctgctcatt
HGF Forward acctgcaatggggagagtta
Reverse gggtgtgagggtcaagagta
t(8;21) FRAME Forward tcagggagttgctgtgtgag
Reverse tgcacatcctggctttagtg
POU4F1 Forward tgctgagctttctccttggt
Reverse caggacctggcccagtataa
IL5RA Forward ccctgaggacacgcagtatt
Reverse tgatcaaagggcctgatagc
ETO Forward ccccttccaccatagagaca
Reverse cgttactggccctctgtgtt
inv(16) ST18 Forward tttgagcaggatgttttgtga
Reverse gcatacatcattgcctttttg
MYH11 Forward cagttcgaaagggatctcca
Reverse gtagctgcttgatggcttcc
MN1 Forward acgaccccagaatgaaacag
Reverse ggattgcctaacacacagca
Normal HOXA5 Forward agatctacccctggatgcgc
Reverse ccttctccagctccagggtc
HOXA9 Forward gagtggagcgcgcatgaag
Reverse ggtgactgtcccacgcttgac
HOXB6 Forward aggacaagagcgtgttcggc
Reverse ggcccaaaggaggaactgttg
WT1 Forward caggctgcaataagagatattttaagct
Reverse gaagtcacactggtatggtttctca
COL4A5 Forward ttaagaccatatgccccctg
Reverse gaggccacaggaggattctt
cDNA synthesis Affy_T7 ggccagtgaattgtaatacgactcactatagggaggcggtttttttttttttttttttttttt
siRNA PRAME Sense gaggcuugccuaucugcau99
FRAME Antisense augcagauaggcaagccuc99
MN1 Sense gcguugagucaucaacacu99
MN1 Antisense aguguugaugacucaacgc99
HOXA1 Sense gagcagaguuuacgggucu99
HOXA1 Antisense agacccguaaacucugcuc99
Table 1. The 5-3 '  oligonucleotide sequences used for the study.
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All oligonucleotide primer sets for RQ-PCR and siRNA transfection 
were supplied by Eurogentec Ltd, Southampton, Hampshire, UK.
2.1.2 Suppliers
Reagents used were supplied by Affymetrix UK Limited (High 
Wycombe, UK), Agilent Technologies UK Ltd (Stockport, Cheshire, UK), 
Alexis Biochemicals (Bingham, Nottingham, UK), Ambion Inc (Applied 
Biosystems, Warrington, UK), Applied Biosystems (Warrington, UK), 
Beckman Coulter UK Ltd (High Wycombe, Buckinghamshire, UK), 
Qiagen (Crawley, West Sussex, UK), DAKO Ltd, Ely, Cambridgeshire, 
UK, Invitrogen Ltd (Paisley, UK), R&D Systems Europe Ltd (Abingdon, 
Oxfordshire, UK), Roche Diagnostics Ltd (West Sussex, UK) and 
Sigma-Aldrich Company Ltd (Dorset, UK).
2.1.3 Enzymes and PCR reagents
The buffers (1st strand and 2nd strand), DNA ligase, DNA polymerase 1, 
RNase H and Superscript 11 reverse transcriptase used for the gene 
chip arrays were supplied by Invitrogen Ltd (Paisley, UK),
Deoxynucleotide triphosphates (dNTPs), DNA polymerase, RNase 
inhibitor, MuLV (Murine Leukaemia Virus) reverse transcriptase, 
AmpliTaq gold DNA polymerase, MgCh and buffers for PCR and 
reverse transcription PCR were supplied by Applied Biosystems Limited 
(Warrington, UK).
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LightCycler FastStart enzyme, LightCycler FastStart reaction mix, 
MgCI2 and PCR grade water used for the real-time quantitative PCR 
(RQ-PCR) were supplied by Roche Diagnostics Ltd (West Sussex, UK).
2.1.4 Commercial Kits
The precise compositions of some of the solutions provided with 
commercial kits were not supplied by the manufacturer.
RNeasy mini kit and RNase-free DNase Set were supplied by Qiagen, 
Crawley, West Sussex, UK. Buffers included in the RNeasy mini kit are 
as follows;
- RW1 (Wash buffer 1): used to wash away all components other
than RNA bound to the column (i.e. DNA and proteins)
- RLT (Lysis buffer): contains a chaotropic guanidine salt to allow
for the binding of RNA to the silica membrane of the column
- RPE: used to wash the RNA and removes the chaotropic 
guanidine salt left over from buffer RLT and RW1 and prepares 
the RNA for the final elution.
LightCycler FastStart DNA Master SYBR Green 1 was supplied by 
Roche Diagnostics Ltd, West Sussex, UK.
GeneChip® Sample Cleanup Module and Enzo BioArray HighYield 
RNA transcript Labelling kit were supplied by Affymetrix UK Limited, 
High Wycombe, UK.
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Human hepatocyte growth factor (HGF) Quantikine enzyme-linked 
immunosorbent assay (ELISA) kit supplied by R&D Systems Europe 
Ltd, Abingdon, Oxfordshire, UK. Buffers included in the HGF ELISA kit 
are as follows;
- Calibrator diluent RD5P concentrate (5X): a concentrated 
buffered protein base with preservatives
- HGF standard: a recombinant human pro-HGF in a buffered 
protein base with preservatives
- Colour A reagent: a stabilised hydrogen peroxide
- Colour B reagent: a stabilised chromogen (tetramethylbenzidine)
- Assay diluent RD1W: a buffered protein base with preservatives
- HGF conjugate: a polyclonal antibody against HGF conjugated to 
horseradish peroxidase with preservatives
- Stop solution: 2 N sulphuric acid
Silencer siRNA Starter kit and Silencer siRNA Labelling kit supplied by 
Ambion Inc. (Applied Biosystems), Warrington, UK.
2.1.5 Composition of Solutions
1x siRNA annealing buffer; 50mM Tris, pH7.5-8.0, 100mM NaCI in 
DEPC (diethylpyrocarbonate)-treated water.
2.1.6 Antibodies
CD11b and CD38 mouse anti-human antibodies were supplied by 
DAKO Ltd, Ely, Cambridgeshire, UK.
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2.1.7 Laboratory Equipment
Additional laboratory and tissue culture consumables were supplied by 
Bioquote Ltd (York, UK), Eppendorf UK limited (Histon, Cambridge, UK) 
Fisher Scientific UK Ltd (Loughborough, Leicestershire, UK), Immune 
Systems Ltd (Paignton, UK) and Thermo Life Sciences (Basingstoke, 
Hampshire, UK).
2.1.8 Cell Lines
The cell lines were originally obtained from their specific source and 
maintained within the department.
Cell Line Cell type Translocations Source Cultureconditions
NB4 Humanpromyelocytic t(15;17)
Beatson Institute 
for Cancer 
Research, 
Glasgow, UK
RPMI 1640, 
10% FBS, 
37 C, 5% COz
HL-60 Human None*
Dr Chris Bunce, 
Dept Medicine, 
University of 
Birmingham, UK
RPMI 1640, 
10% FBS, 1% 
Pen/strep, 
37 C, 6% C 02
Me-1 Human lnv(16)
DSMZ,
Braunschweig,
Germany
RPMI 1640, 
20% FBS, 1% 
Pen/strep, 
37°C, 6% C 02
Dr. George 
Follows, Dept RPMI 1640,
Kasumi-1 Human t(8;21) Molecular 
Medicine, Leeds 
University, UK
20% FBS, 
37 C, 5% C 02
Table 2. The source and culture conditions of the cell lines used. *Whilst HL-60 
cells have no specific translocations, they do have a complex karyotype. (FBS - 
foetal bovine serum)
2.2 Patient Database and Gene Expression Profiling
2.2.1 Patient and Donor Samples
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2.2 Patient Database and Gene Expression Profiling
2.2.1 Patient and Donor Samples
Gene expression microarrays were used to profile the diagnostic 
samples of 290 AML patients and 10 normal healthy donors. Duplicate 
microarray chips were performed for five of the AML patients, resulting 
in a total of 295 AML patient samples used in this study. The patients’ 
clinical and molecular characteristics are presented in Table 3. The 
samples were obtained from the School of Medicine, Cardiff University, 
University Hospital Wales or from University Hospital, London, and 
processed by the School of Medicine, Cardiff University, University 
Hospital Wales. Patient confidentiality and permission to use excess 
biological material for research was been approved by the Multicentre 
Research Ethics Committee (MREC) (Appendix I).
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Characteristic Value
Sex - no. (%)
Male 144 (49.7) (*3rep.)
Female 132 (45.5) (*2rep.)
Not determined 14 (4.2)
Age group -  no. (%)
<30 years 29 (10.0)
30-60 years 130 (44.8)
>60 years 119 (41.0)
Not determined 12 (4.2)
Age -  years
Median* 56
Range* 16-87
French-American British Classification -  no. (%)
M0 14 (4.8)
M1 53 (18.3)
M2 66 (22.8) C1rep.)
M3 30 (10.3) ("2 rep.)
M4 51 (17.6)
M5 33 (11.4) (*2rep.)
M6 3 (1.0)
M7 2 (0.7)
Bi 1 (0.3)
Not determined 37 (12.8)
Cytogenetic Abnormalities -  no. (%)
t(15; 17) 26 (9.0) (*2rep.)
t(8;21) 15 (5.2)
inv(16)/t(16;16) 18 (6.2) H  rep.)
+8 6 (2.1)
+11 4 (1.4)
+21 0 (0)
-5 0 (0)
-5(q) 0 (0)
-7 5 (1.7)
3q 1 (0.3)
t(6;9) 3 (1.0)
t(9;22) 1 (0.3)
t(11q23) 4 (1.4)
Complex karyotype 20 (6.9)
Other abnormal 21 (7.2)
karyotypes
Normal karyotype 119 (41.0) ('2 rep.)
Not determined 47 (16.3)
Molecular Abnormalities -  no. (%) 
Mutation
FLT3 Internal tandem 63 (21.7) ("2 rep.)
duplication
FLT3 Tyrosine kinase 34 (11.7) (*1 rep.)
domain
Table 3. The frequencies and percentages of the clinical and molecular 
characteristics of the 290 patients diagnosed with AML used in this study. *The 
characteristics of the 5 replicate patient samples are indicated in italics.
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2.2.2 Microarray Chips
The microarray chips used to analyse the patient and donor samples 
were the Affymetrix human genome U133A microarray chips. On a 
single chip over 14,500 genes are represented by 22,283 
oligonucleotides, referred to as probes, complementary to a 
corresponding region of a gene. The probe sets on each chip were 
selected from sequences in GenBank, dbEST and RefSeq; databases 
containing publicly available genomic DNA, transcripts and protein 
sequences. Each gene is represented by many probes evenly 
distributed to allow for an accurate reading of the hybridisation signals 
and to allow for the normalisation of any signals generated from mis- 
priming. Control probes are also present on the chip in the form of mis­
matched probes, differing from the matched probes by one nucleotide. 
The mis-matched probes are able to hybridise to non-specific 
sequences in order to measure background ‘noise’ caused by non­
specific interactions occurring on the chip. An intensity level is then 
generated based on the amount of gene transcript present in the 
sample taking into account the intensity levels obtained from the 
matched and mismatched probe sets.
2.2.3 From Patient to Chip
2.2.3a Isolation of Total RNA
The RNA used for the gene expression profiling analysis was extracted 
from patient mononuclear cells using TRIzol reagent as described in
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section 2.4.1 d. The extracted RNA was quantified using the Nanodrop 
1000 spectrophotometer (Nanodrop products, Thermo Scientific, 
Wilmington, USA) and visualised on the Agilent Bioanalyser (Agilent 
Technologies UK Ltd, Stockport, Cheshire, UK) for quality control as 
described in section 2.4.2. If the RNA concentration was too low for 
efficient and reliable cDNA synthesis, the RNA was ethanol precipitated 
or two 1st strand synthesis reactions were run for the sample to be 
combined at the 2nd strand synthesis step. For ethanol precipitation of 
RNA, 1710th volume of 3M Sodium Acetate (pH 5.2), 2.5 volumes of 
100% ethanol and 1 pi glycogen (5 mg/ml) were added to the RNA and 
allowed to precipitate at -20°C for at least 1 hour. The sample was then 
centrifuged at 12,000 x g for 20 minutes at 4°C. The RNA pellet was 
washed twice with 80% ethanol and centrifuged at 12,000 x g for 10 
minutes at 4°C after each wash. The pellet was air-dried and 
resuspended in an appropriate volume of RNase-free water (10pl for 8- 
16pg total RNA/reaction).
2.2.3b cDNA Synthesis
The cDNA synthesis was carried out in microfuge tubes as an Applied 
Biosystems GeneAmp® PCR System 9700 thermal cycler was required 
for the 1st and 2nd strand synthesis step. Components for the cDNA 
synthesis were bought individually from Invitrogen Ltd (Paisley, UK).
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/. First Strand Synthesis
A volume of 10 jliI for 5-8pg total RNA was mixed with 2pJ of 50pmol/pl 
T7 primer. The mix was incubated at 70°C for 10 minutes, put on ice 
and then briefly centrifuged down to collect the mix at the bottom of the 
tube. The following mixture was added to the RNA and T7 primer 
mixture, mixed well and briefly centrifuged down to collect the mix at the 
bottom of the tube (Table 4);
5 x 1st Strand Buffer 4pl
DTT (0.1 M) 2pl
dNTP mix (10mM) 1 pi!
Table 4. The reaction mixture used for the 1st strand cDNA synthesis. All reagents 
used were supplied by Invitrogen Ltd (Paisley, UK). DTT, Dithiothreitol.
The mix was then incubated at 42°C for 2 minutes before adding 1 pi of 
Superscript II reverse transcriptase enzyme, mixed well and incubated 
at 42°C for 1 hour.
ii. Second Strand Synthesis
The 1st strand synthesis reaction was placed on ice and briefly 
centrifuged down to collect the mix at the bottom of the tube. The 
following mixture was added to the 1st strand synthesis reaction, mixed 
well and briefly centrifuged down to collect the mix at the bottom of the 
tube (Table 5).
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RNase-free water 91 pi
5 x 2nd Strand Buffer 30pl
dNTP mix (10mM) 3pl
DNA Ligase 1 pi
DNA Polymerase I 4pl
RNase H 1pl
Table 5. The reaction mixture used for the 2nd strand cDNA synthesis. *71 pi of 
RNase-free water was used if two separate 181 strand reactions had been carried 
out. All reagents used were supplied by Invitrogen Ltd (Paisley, UK).
The mix was incubated at 16°C for 2 hours until 10pJ of 0.5 M EDTA 
(ethylenediaminetetraacetic acid) was added to stop the reaction.
The cDNA was cleaned up using the GeneChip Sample Cleanup 
Module (Affymetrix UK Limited, High Wycombe, UK). A volume of 24ml 
of ethanol (96-100%) was added to the cDNA wash buffer, as indicated 
on the bottle, to obtain a working solution. All steps were performed at 
room temperature. The cDNA reaction mixture was transferred into a 
1.5ml microfuge tube. A volume of 600pl of cDNA Binding Buffer was 
added to the final double-stranded cDNA synthesis reaction mixture 
(162pl) and vortexed for 3 seconds. The colour of the reaction mixture 
was checked; the mixture should be yellow, similar to the cDNA Binding 
Buffer without the cDNA synthesis reaction. If the colour of the mixture 
was orange or violet, 10ml of 3M sodium acetate (pH 5.0) was added 
and mixed to turn the colour of the mixture yellow. 500pl of the sample 
was applied to the cDNA Cleanup Spin column sitting in a 2ml collection 
tube and centrifuged for one minute at 8000 x g; the flow-through was
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discarded. The remaining mixture was added to the column and 
centrifuged as before, discarding the flow-through and collection tube. 
The spin column was transferred into a new 2ml collection tube and 
750pl cDNA wash buffer was pipetted onto the column. The column 
was centrifuged for one minute at 8000 x g and the flow-through 
discarded. The cap of the spin column was opened and the column 
centrifuged for five minutes at maximum speed. The flow-through and 
collection tube were discarded. The spin column was transferred to a 
1.5ml collection tube and 14pl of cDNA elution buffer was pipetted 
directly onto the spin column membrane. The column was incubated for 
one minute at room temperature and centrifuged for one minute at 
maximum speed to elute.
2.2.3c IVT Reaction
The IVT (in vitro transcription) reaction was carried out in an Eppendorf 
Mixer Comfort Mixer (Eppendorf UK limited, Histon, Cambridge, UK), 
programmed to incubate at 37°C for 6 hours with 15 seconds of mixing 
every 30 minutes. The IVT was performed using the cDNA prepared 
above and the Enzo BioArray High Yield RNA Transcript Labelling Kit, 
supplied by Affymetrix UK Limited (High Wycombe, UK).
The 12pl cDNA synthesis reaction mixture was added to a 1.5 ml 
microfuge tube. All solutions, except the enzymes, were brought to 
room temperature. The following mixture was added to the cDNA 
synthesis reaction, mixed well and briefly centrifuged down to collect 
the mix at the bottom of the tube to give a final volume of 40pl (Table 6).
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RNase-free water 10pl
10 X HY buffer* 4pl
10 x Biotin-labelled Ribonucleotides 4pl
10 x DTT** 4pl
RNAse Inhibitor mix 4pl
T7 RNA Polymerase 2(jl
Table 6. The reaction mixture used for the IVT reaction. *HY -  HighYield. **The 
DTT was mixed well to remove any precipitate. All reagents used were from the 
Enzo BioArray High Yield RNA Transcript Labelling Kit, supplied by Affymetrix UK 
Limited, High Wycombe, UK
The mix was incubated in the Eppendorf Mixer Comfort mixer for six 
hours. The cRNA was cleaned up using the GeneChip Sample Cleanup 
Module (Affymetrix UK Limited, High Wycombe, UK). The IVT reaction 
mixture was made up to 100pl by the addition of 60pJ of RNase-free 
water and vortexed for 3 seconds. IVT cRNA Binding Buffer (350pl) was 
added to the sample and mixed by vortexing for 3 seconds. 250jjJ of 
ethanol (96-100%) was added to the lysate and mixed well by pipetting. 
The sample was applied to an IVT cRNA Cleanup spin column sitting in 
a 2ml collection tube and centrifuged for 15 seconds at 8000 x g; the 
flow-through and collection tube was discarded. The spin column was 
transferred to a new 2 ml collection tube and 500|il of IVT cRNA wash 
buffer was applied and centrifuged for 15 seconds at 8000 x g to wash; 
the flow-through was discarded. 500}il of 80% ethanol was pipetted 
onto the spin column and centrifuged for 15 seconds; the flow-through 
was discarded. The cap of the spin-column was opened and the column 
centrifuged for 5 minutes at maximum speed; the flow-through and the 
collection tube were discarded. The spin-column was transferred to a
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1.5ml collection tube and 11pl of RNase-free water was pipetted directly 
onto the RNeasy membrane. After one minute, the column was 
centrifuged for one minute at 8000 x g to elute. A further 10pJ of RNase- 
free water was pipetted onto the spin membrane and after one minute 
the column was centrifuged for one minute at 8000 x g. A further 15|il of 
RNase-free water was pipetted onto the spin membrane and after one 
minute the column was centrifuged for one minute at 8000 x g.
2.2.2d cRNA Fragmentation 
/. cRNA Quantification
The adjusted cRNA yield was calculated using the following equation to 
reflect the carryover of unlabelled total RNA;
Adjusted Yield = (amount of cRNA measured after IVT, in ng) -  (amount of total 
RNA used in cDNA synthesis reaction) x (fraction of cDNA synthesis reaction 
used in IVT)
The fragmentation and hybridisation of cRNA was only continued if 
there was a calculated adjusted cRNA volume of ~15|ig.
//. cRNA Fragmentation
The fragmentation reaction was performed in microfuge tubes and then 
these tubes were used directly to make up the hybridisation cocktail 
later. The following mix was used for the fragmentation mix (Table 7)
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cRNA (15pg)
5 x Fragmentation buffer 
RNase-free water
1-32(jl
8|jl
Make up to a volume of 40pl
Table 7. The reaction mixture used for the cRNA fragmentation reaction. All 
reagents were supplied by Affymetrix UK Limited, High Wycombe, UK.
The reaction mixture was incubated at 94°C for 35 minutes and then 
placed on ice and stored at -20°C until required for the hybridisation.
//'/. Gel Analysis
The cRNA and fragmented cRNA were visualised on an Agilent RNA 
nano chip RNA for quality control as described in section 2.4.2.
2.2.3f Test3 Chip Hybridisation
Test3 chips were routinely run to check the integrity and quality of the 
cRNA before proceeding to the more expensive full chips. The protocol 
was set up in such a way that when the hybridisation cocktail was made 
for a full chip, there was automatically enough to run on a Test3 chip 
without needing to process more sample. A 1 x and 2 x hybridisation 
buffer was initially made up. The 20 x GeneChip Eukaryotic Control and 
B2 Oligo tubes were heated to 65°C for 5 minutes to ensure that the 
cRNA is completely resuspended. The array chips were removed from 
the bags and left to equilibrate to room temperature. The rotisserie oven 
(GeneChip® Hybridisation oven, Affymetrix UK Limited, High Wycombe,
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UK) was switched on to warm up. The following mix was used for the 
hybridisation cocktail (Table 8).
Fragmented cRNA (15jig)
Control Oligo B2
20 x Eukaryotic Hybridisation Controls 
Herring Sperm DNA (10 mg/ml) 
Acetylated BSA (50 mg/ml)
2 x Hybridisation Buffer 
RNase-free water Final volume of 300pl
40pl* 
5pl 
15 pi 
3pl 
3pl 
150pl
Table 8. The reaction mixture used for the hybridisation reaction. 'Fragmentation 
reaction mixture. BSA - Bovine Serum Albumin. All reagents used were supplied 
by Affymetrix UK Limited, High Wycombe, UK
The hybridisation cocktail was heated to 99°C for 5 minutes, followed by 
45°C for 5 minutes in a PCR thermal cycler machine. Whilst the 
hybridisation cocktail was denaturing, the Test3 chip was filled with 
1OOpI of 1 x Hybridisation Buffer. The chip was turned upside down and 
a venting tip was placed in the septum at the bottom of the chip and 
filled via the other one, to reduce leakage. The Test3 chip was pre­
hybridised in the rotisserie oven for 10 minutes at 45°C, rotating at 60 
rpm. The hybridisation cocktail was spun down at maximum speed in a 
microfuge for 5 minutes to remove any insoluble material from the 
hybridisation mixture. When the hybridisation cocktail was ready, and 
the chip was finished pre-hybridising, the chips were removed from the 
oven. The pre-hybridisation solution was removed from the Test3 chips 
and replaced with 80 pi of hybridisation cocktail. The chips were then
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hybridised in the rotisserie oven for 16 hours at 45°C, rotating at 60 
rpm. The remaining hybridisation cocktail was stored at -20°C.
2.2.3g Washing, Staining and Scanning of Test3 Chips 
Buffer A and buffer B were filter sterilised before use and used to prime 
the fluidics station before use. The array chips were removed from the 
rotisserie oven and the hybridisation cocktail was removed from the 
chip and replaced in the tube with the remainder of the hybridisation 
cocktail and stored at -20°C. The chip was filled with 10Ojxl of Wash 
Buffer A and placed in the fluidics station. A volume of 1200pJ of stain 
solution was made up in an eppendorf, and split between two 
eppendorfs, each with 600pl, and 600pl of antibody solution was made 
up in a separate eppendorf (Table 9).
Stain Solution
2 x Stain Buffer 160pl
Water 540pl
Acetylated BSA (50mg/ml) 48 pi
SAPE (1 mg/ml) 12pl
Antibody Solution
2 x Stain Buffer 300pi
Water 266.4pl
Acetylated BSA (50mg/ml) 24pl
Normal Goat IgG (10mg/ml) 12pl
Biotinylated antibody (0.5 mg/ml) 3.6pl
Table 9. The mixtures used for the stain solution and the antibody solution. BSA - 
Bovine serum albumin. SAPE - Streptavidin-phycoerythin dye. All reagents used 
were supplied by Affymetrix UK Limited, High Wycombe, UK
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The required protocol was then run, adding the stain solution tubes and 
the antibody stain tube when required. When the protocol was finished, 
the Test3 chip was ejected and checked for bubbles. If bubbles were 
present the chip was replaced into the fluidics station and refilled with 
wash buffer A. When there were no bubbles visible on the chip, the chip 
was checked for leaks and then scanned in the scanner.
2.2.3h Full Chip Hybridisation
The array chips were removed from their bags and left to equilibrate to 
room temperature. The pooled hybridisation cocktail from the Test3 
chips was thawed and heated to 99°C for 5 minutes, followed by 45°C 
for 5 minutes in a PCR thermal cycler. The hybridisation cocktail was 
then centrifuged at maximum speed in a microfuge for 5 minutes. Whilst 
the hybridisation cocktail was denaturing, the full chip was filled with 
250|il of 1 x Hybridisation Buffer as described previously in section 
2.2.3f. The full chips were pre-hybridised in the rotisserie oven for 10 
minutes at 45°C, rotating at 60 rpm. When the hybridisation cocktail 
was ready, and the chip had finished pre-hybridising, the chip was 
removed from the oven. The pre-hybridisation solution was removed 
from the full chip and replaced with 200pJ of hybridisation cocktail. The 
full chip was hybridised in the rotisserie oven for 16 hours at 45°C, 
rotating at 60 rpm, secured into the oven racks.
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2.2.3i Washing, Staining and Scanning of Full Chips 
The full chip was washed and stained as described previously in section 
2.2.3g but with 250pl of Wash Buffer A pipetted into the full chip. The 
chip was placed in the fluidics station and the required protocol was
selected. Following the completion of the protocol, the full chip was
scanned in the scanner.
2.2.4 Data Normalisation
The gene expression data generated from the 305 Affymetrix human 
genome U133A microarray chips was analysed using GeneSpring GX 
7.0 (Silicon Genetics, Agilent Technologies, Wokingham, Berkshire, 
UK). To allow for a comparison of gene expression changes between 
experiments and between experiments performed by other centres, the 
gene expression data was initially normalised by applying a target 
(TGT) normalisation value. The overall average intensity of every chip
was scaled to 100 by multiplying the average intensity by a scaling
factor. The data was also normalised using the GeneSpring software to 
standardise the data further with a per-chip normalisation and a per- 
gene normalisation. A per-chip normalisation is used to control 
variations in signal intensity across the chips due to experimental error. 
The expression value of each data point for a gene is normalised to the 
50th percentile of all the data points. The per-gene normalisation allows 
for differences in detection efficiency between genes, enabling relative 
changes in gene expression to be compared. The normalisation is
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achieved by dividing each signal value for a gene by the median of all 
the signals involved in the experiment (Silicon Genetics Tech notes).
Details of the probe sets identified, including name and nucleotide 
sequence was obtained from the Affymetrix NetAffx analysis centre 
(Affymetrix, http://www.affymetrix.com/analysis/index.affx).
2.3 Tissue Culture
2.3.1 Cell counts and viability
2.3.1a Fast Read Disposable Counting Chamber 
Cells were counted using a Fast Read Disposable counting chamber. 
An aliquot of 10pl of cell culture was removed from the flask and mixed 
with 10pl 0.4% trypan blue. A 10pl aliquot of cells/trypan blue was 
placed on the counting chamber and analysed by a light microscope. 
The number of cells was calculated as:
Cell count (16 squares) x dilution factor x 1000 = number cells/ml
Cell viability was assessed using the trypan blue. Live cells excluded 
the dye whilst dead cells were stained blue. The number of live cells 
was expressed as a percentage of the total number of cells.
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2.3.1b Vi-CELL™ XR Cell Viability Analyser
Cell growth and viability were assessed using a Vi-CELL™ XR cell 
viability analyser (Beckman Coulter, High Wycombe, UK), which uses 
the trypan blue exclusion method for calculating cell viability. An aliquot 
of 500pl of cell culture was used for growth and viability measurements.
2.3.2 Cryopreserving of lines
For long term storage, cultured cells were stored in liquid nitrogen. Cells 
(5 x 106) were centrifuged at 300 x g for 5 minutes and resuspended in 
1 ml IMDM (Iscove's Modified Dulbecco's Medium) medium containing 
20% foetal bovine serum (FBS) and 10% dimethyl sulphoxide (DMSO). 
The cells were aliquoted into 1.8ml cryopreservation vials and placed in 
a freezing box half filled with isopropan-1-ol to ensure slow freezing 
when placed at -80°C.
When required for use, cells were rapidly thawed at 37°C and 1 ml of 
pre-warmed media was added drop-wise to the cryopreservation tube. 
The cells were transferred to a universal container and slowly made up 
to a volume of 5ml with pre-warmed media. The cells were then 
centrifuged at 300 x g for 5 minutes to harvest and resuspended in their 
appropriate culture medium.
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2.3.3 Extraction of Mononuclear Cells from Bone Marrow Aspirates 
and Peripheral Blood Samples
An initial baseline count of the samples was performed using a Vi- 
CELL™ XR cell viability analyser (Beckman Coulter, High Wycombe, 
UK). A dilution medium was prepared using MEM (Minimum Essential 
Media) with 1% Pen/Strep (1 ml/100ml) and 300U Heparin per 20ml. 
The sample was diluted with the MEM dilution medium to ensure there 
were no more than 100 x 106 cells per ficoll tube. If a significant 
dilution was required, the mixture included FCS (foetal calf serum) as 
a thickening agent. A volume of 6-7mls of Ficoll (histopaque) was 
aliquoted into a universal container. The same volume of diluted blood 
as Ficoll used was carefully run down the side of the universal 
container to form a layer on top of the Ficoll. The ficoll tube was 
centrifuged at 400 x g for 30 minutes with the brake off. The 
mononuclear cell (MNC) interface layer was carefully removed from 
the ficoll tube using a syringe and quill. The quill tip was placed just 
above the interface layer and suction applied while gently moving the 
quill tip around horizontally. Care was taken not to disturb the red cell 
pellet. The interface layer was placed into a fresh universal container 
and diluted with MEM dilution medium to even out volumes if multiple 
ficoll tubes were used. The tube was centrifuged again at 400 x g for 
10 minutes. The supernatant was removed to leave a pellet of MNC's 
at the bottom of the tube. The cells were resuspended in an 
appropriate volume of MEM dilution medium and pooled into one 
container if more than one Ficoll tube was used. To calculate the
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volume to add It was assumed there would be a 25% loss from the 
initial total cell count and enough was added to give 100 x 106 per ml. 
The number of MNC's was again counted using the coulter counter to 
give the number of cells/ml of cell preparation. The cells were either 
cryo-preserved for use later (Section 2.3.2) or continued onto RNA 
extraction (Section 2.4.1).
2.4 RNA: From Extraction to cDNA
2.4.1 RNA Extraction
2.4.1a Donated Patient and Normal Healthy Donor Material 
The AML patient and healthy donor samples used for gene expression 
microarray analysis were obtained and processed by the School of 
Medicine, Cardiff University. The RNA was extracted from mononuclear 
cell of bone marrow aspirates using TRIzol reagent. The patient and 
normal healthy donor RNA and cell lysates used for real-time 
quantitative-PCR analysis were donated by the School of Medicine, 
Cardiff University and the Department of Clinical Haematology, 
Manchester Royal Infirmary. The centres extracted RNA from 
mononuclear cells of bone marrow aspirates or peripheral blood 
samples using either TRIzol reagent (Cardiff and Manchester) or the 
Qiagen RNeasy Mini kit (Cardiff). The cell lysates donated by the 
School of Medicine, Cardiff University, were patient or normal healthy 
donor mononuclear cells from bone marrow aspirates resuspended in
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Qiagen RLT buffer and P-mercaptoethanol ready for RNA extraction 
using the Qiagen RNA extraction protocol.
2.4.1b Leukaemic Cell lines and Normal Healthy Donor Samples 
Cells from leukaemic cell lines cultured within the department (1x107 
cells) or from normal healthy donor mononuclear cells from bone 
marrow aspirates (5x106) were harvested by centrifugation at 300 x g 
for 5 minutes. The supernatant was removed and the cell pellet was 
disrupted through the addition of 600pl or 350pl, respectively, of Qiagen 
RLT buffer and P-mercaptoethanol and passing the cell lysate through a 
20-gauge needle fitted to an RNase-free syringe at least 5 times. The 
cell lysates were either stored at -80°C until required or continued 
through the extraction protocol.
2.4.1c Qiagen RNeasy Mini Protocol
A mononuclear cell pellet of 1x107 or of less than 5x106 cells were 
loosened and disrupted by the addition of 600pl or 350pl, respectively, 
of RLT buffer and the cell lysate passed through a 20-gauge needle 
fitted to an RNase-free syringe at least 5 times. A 1x volume of 70% 
ethanol was added to the homogenised sample and mixed by pipetting 
the sample up and down. Up to 700pl of the sample was applied to an 
RNeasy mini spin column and centrifuged for 15 seconds at 8000 x g. 
The flow-through from the column was discarded following 
centrifugation. Any remaining sample was added to the column and 
centrifuged for 15 seconds at 8000 x g. The flow-through from the
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column was discarded following centrifugation. An on-column digestion 
of DNA was performed by adding a volume of 350pl of buffer RW1 to 
the column and centrifuging the column for 15 seconds at 8000 x g and 
discarding the flow-through. 10pl of DNase I stock solution was added 
to 70pl RDD buffer and mixed gently by inversion of the tube. The 
incubation mix was applied directly to the spin column membrane and 
left at 20-30°C for 15 minutes. A volume of 350pl of buffer RW1 was 
added to the column and the column was centrifuged for 15 seconds at 
8000 x g and the flow-through was discarded. Following the DNA 
digestion, the RNeasy column was transferred to a clean collection tube 
and 500pl of RPE buffer was added to the column. The column was 
centrifuged at 8,000 x g for 15 seconds and the flow-through was 
discarded. 500pl RPE buffer was again added to the column and the 
column was centrifuged at 8000 x g for 2 minutes. The column was 
transferred to a new collection tube and centrifuged at a speed of 16000 
x g for 1 minute to remove last traces of buffer. The column was then 
placed in a 1.5ml collection tube and 30pl of RNase-free water was 
added directly to the membrane at the base of the column. The column 
was spun at 8000 x g for 1 minute to elute the RNA. The RNA was 
stored at -80°C until required.
p-Mercaptoethanol was added to the RLT buffer and 100% ethanol was 
added to the RPE buffer before use.
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2.4.1 d TRIzol RNA Extraction Protocol
A cells pellet of 0.5-1 x107 cells was homogenised by the addition of 1ml 
TRIzol reagent. The cell pellet was resuspended by pipetting to lyse the 
cells. A pre-dispensed Phase Lock Gel-Heavy tube was centrifuged at 
1500 x g for 30 seconds to collect the gel to the bottom of the tube. The 
cell lysate was then added to the tube and incubated at 15-30°C for 5 
minutes. A volume of 0.2ml of chloroform was added to the lysate in the 
Phase Lock Gel-Heavy tube and shaken vigorously for 15 seconds. The 
tube was centrifuged at no more than 12000 x g for 10 minutes at 2- 
8°C. After centrifugation a clear, aqueous phase should be entirely atop 
the Phase Lock Gel and a red phenol chloroform phase and cloudy 
interphase should be below the Phase Lock Gel layer. The addition of 
chloroform and centrifugation was repeated if this was not the case. 
The aqueous phase containing the RNA was transferred to a new tube 
and the RNA was precipitated by the addition of 0.5ml isopropyl alcohol 
per 1ml TRIzol Reagent used initially. The sample was mixed by 
repeated inversion and allowed to incubate at 15-30°C for 10 minutes 
and then centrifuged for 10 minutes at no more than 12000 x g at 2- 
8°C. The RNA pellet was visible on the side and the bottom of the tube. 
The supernatant was decanted and 1 ml of 75% ethanol per 1 ml TRIzol 
reagent used initially was added to wash the RNA pellet. The sample 
was mixed to dislodge the pellet; a vortex was used if necessary, and 
centrifuged at no more than 7500 x g for 5 minutes at 2-8°C. The 
supernatant was carefully decanted and the RNA pellet was left to air- 
dry for 5-10 minutes to remove any residual ethanol. The RNA pellet
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was dissolved in 30pl RNAse-free water and incubated at 55-60*C for 
10 minutes to facilitate dissolution.
2.4.2 RNA quantification and visualisation
Extracted RNA was quantitated using the Nanodrop 1000 
spectrophotometer (Nanodrop products, Thermo Scientific, Wilmington, 
USA). The instrument was blanked using 1.5pl of RNase-free water 
before applying 1.5pl of the extracted RNA to the spectrophotometer. 
The absorbance of the RNA was measured at 230nm, 260nm and 
280nm to determine purity and concentration of the RNA.
The Agilent Bioanalyser (Agilent Technologies UK Ltd, Stockport, 
Cheshire, UK) produces profiles of RNA and DNA that can give an 
indication of their quality. Samples are mixed with a dye that specifically 
binds to either RNA or DNA and travels from the sample wells through 
microchannels. Each sample is injected into a separation channel 
where it is separated based on its size. At the detection point the 
fluorescence generated from the sample as it passes through a laser is 
detected before moving onto the waste/buffer well. Samples are 
visualised either as a graph of fluorescence against time or as a 
conventional electrophoresis gel showing bands of different sizes.
The extracted RNA was visualised on an Agilent RNA nano chip. All 
reagents required were left at room temperature for 30 minutes before 
use. A gel-dye mix was prepared by the addition of 550pl of RNA 6000
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nano gel to a spin filter and centrifuged at 1500 x g for 10 minutes. RNA 
6000 nano dye concentrate was vortexed and 1pl added to a 65pl 
aliquot of the filtered RNA 6000 nano gel. The mix was thoroughly 
vortexed for proper mixing before being centrifuged at 13000 x g for 10 
minutes. 9pl of gel-dye mix was loaded into the gel well of a RNA nano 
chip and pressurised into the capillaries of the chip using a chip priming 
station. A further 9pl of gel-dye mix was added to the remaining 2 gel 
wells. A volume of 5pl of RNA 6000 nano marker was added to the 12 
sample wells and to the ladder well. 1 pi of RNA ladder previously heat 
denatured at 70°C for 2 minutes to minimise secondary structures was 
thawed and added to the ladder well. 1pl of RNA was added to the 
sample wells; the RNA sample added must be less than 500ng/pl. To 
any wells without RNA samples, 1pl of RNA nano 6000 marker was 
added. The RNA nano chip containing the RNA was vortexed for 1 
minute at a speed of 2400 rpm using the IKA vortex mixer (IKA® Werke 
GmbH & Co. KG, Staufen, Germany) and inserted into the Agilent 2100 
Bioanalyser.
2.4.3 Reverse Transcription (RT) of RNA
RNA from patient samples and cell lines was reverse transcribed into 
complementary DNA (cDNA) using the following reaction mixture and 
cycling conditions (Table 10 and Table 11);
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RNA (3pl total volume made up with water) 1M9
MgCI2 (25mM) 4pl
10 x Buffer II 2pl
dATP (10mM) 2pl
dTTP (10mM) 2pl
dCTP (10mM) 2pl
dGTP (10mM) 2pl
Random hexamers (50pM) 1 pi
RNase inhibitor (20U/pl) 1 pi
MuLV reverse transcriptase (50U/pl) 1|j|
Table 10. The reaction mixture used for reverse-transcription of RNA. All 
reagents used were supplied by Applied Biosystems Limited (Warrington, UK).
Temperature (°C) Time (minutes) Cycles
25 10 1
42 30 1
95 5 1
4 Soak 1
Table 11. The cycling conditions used for reverse-transcription of RNA. An initial 
priming step is performed at 25 C followed by the cDNA synthesis at 42°C. Finally 
a deactivation step is performed at 95°C. The reverse-transcriptase reaction was 
performed in an Applied Biosystems GeneAmp® PCR System 9700 thermal 
cycler.
A “no-RNA” control sample was included. The samples were stored at - 
20°C until required.
2.5 Real-Time Quantitative-PCR (RQ-PCR)
RQ-PCR was used to quantitate the level of gene expression in the 
AML patient samples and normal healthy donor samples. The 
LightCycler PCR system uses air to achieve temperature cycling
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resulting in a faster process than conventional thermal blocks. The high 
surface-to-volume ratio of the reaction capillaries allows a rapid 
equilibration between the air and the reaction mixture. The optical unit 
of the LightCycler detects fluorescence from the tip of the capillary 
allowing a more sensitive method of detection. The fluorescence 
detected in the reaction corresponds to the amount of PCR product 
generated. As DNA is produced, more double strand-specific SYBR 
green dye is incorporated into the molecule and the levels of 
fluorescence increases, generating an amplification curve (Figure 1). At 
the end of the reaction the temperature of the thermal chamber is raised 
causing the double stranded (ds) DNA to denature and release the 
SYBR green dye. As each dsDNA has its own specific melting 
temperature (Tm) an analysis of the melting curve generated is useful 
for determining that the PCR products generated in each reaction are 
the same; a single peak should be generated for each gene (Figure 2). 
The Tm of DNA is the temperature at which half the DNA strands are 
present as double strands and half are present as single strands.
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Figure 1. The amplification curves generated as double-stranded (ds) DNA is 
produced, incorporating more double strand-specific SYBR green dye, 
resulting in an increase in levels of fluorescence. As no dsDNA will be 
generated in water controls and RNA-negative samples, there should be no 
increase in the levels of fluorescence.
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Figure 2. The melting curves (a) and melting peaks (b) generated in the final 
reaction step as the temperature is increased and the double-stranded (ds) 
DNA is degraded, releasing the double strand-specific SYBR green dye. A 
single peak for each gene indicates the PCR product generated in each 
reaction is the same. As no dsDNA will be generated in water controls and 
RNA-negative samples, there should be no increase in the levels of 
fluorescence.
2.5.1 Primer design
Primers were designed to produce PCR products of approximately 150- 
200 base pairs for each gene of interest. The gene sequences used to 
design the primers were the sequences of the identified probe sets as 
supplied by the Affymetrix NetAffx analysis centre and primer 
sequences were generated using Primer 3 select software.
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2.5.2 Magnesium Chloride (MgCI2) Concentration and Annealing 
Temperature Optimisation
The MgCh concentration for each set of primers was optimised on the 
LightCycler using cDNA reverse-transcribed from leukaemic cell-line 
RNA. The following reaction mixture for MgCl2 concentrations of 3mM, 
4mM and 5mM and cycling conditions were used (Table 12 and Table
13).
MgCI2 (25mM) 3mM/4mM/5mM
Primer Forward (10pM) 0.5pl
Primer Reverse (10pM) 0.5pl
SYBR Green reaction mixture 1pl
RT reaction 1pl
Water make up to 10pl
Table 12. The reaction mixture used for real-time quantitative-PCR. All reagents 
used were supplied by Roche Diagnostics Ltd (West Sussex, UK).
Programme Temperature (°C) Time (Seconds) Cycles
Denaturation 95 600 1
Amplification 95 3 45
60 5
72 15
Melting 95 0 1
70 15
95 0
Cooling 40 30 1
Table 13. The cycling conditions used for real-time quantitative-PCR. The RQ- 
PCR reaction was performed in the Roche Applied Sciences LightCycler® 
Carousel-Based thermal cycler.
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The samples were repeated in duplicates. A duplicate “no-cDNA” 
control sample was included in every LightCycler run to ensure the 
primers were RNA-specific. The accumulation of PCR product was 
measured by the acquisition of one fluorescent measurement per 
72°C extension period. The melting curve data was obtained by 
continuous measurements during the melting stage at the end of the 
run. The MgCh concentration that produced a melting curve most 
reproducible between replicates was used. The annealing 
temperature was increased or decreased as necessary to also 
generate reproducible results. The optimised MgCfe concentration and 
annealing temperature used for each set of primers were as follows 
(Table 14).
Primers Temperature (°C) MgCh Cone. (mM)
HGF2 60 4
ILGFBP2 60 4
ETO 60 5
IL5RA 60 5
PRAME 60 3
POU4F1 60 5
ST18 62 5
MYH11 60 5
MN1 60 4
HOXA5 60 4
HOXA9 60 4
HOXB6 60 4
COL45A 60 4
WT1 60 4
Table 14. The optimised magnesium chloride concentrations and annealing 
temperatures used for each primer set for Q-PCR.
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2.5.3 Optimised LightCycler PCR
The optimised MgCfe concentration and annealing temperature for each 
set of primers was run on the LightCycler using the cycling conditions 
optimised as described above (Table 14). Per LightCycler run, every 
sample was run in duplicate for a test gene (TG) and for a 
control/housekeeping gene (CG). Duplicate “no-cDNA” samples were 
also included for both the TG and CG. Crossing point (Cp/Ct) values 
are generated using the second derivative maximum method of 
analysis; the point at which the rate of change of fluorescence is the 
fastest is usually where the sample fluorescence can be distinguished 
from the background fluorescence and the LightCycler software 
calculates the baseline value by subtracting the mean of the five lowest 
measured data points from each reading point in the sample. The Cp 
value generated is the number of cycles at the point where PCR 
amplification is clearly positive above the background phase. The 
crossing points are determined during the exponential phase of the 
PCR reaction (Technical note no. LC 10/update 2003, Roche Applied 
Science). The mean Cp value for the test genes of duplicate samples 
was normalised to the mean Cp value of the control genes of the 
corresponding duplicates. Samples with Cp values greater than 40 
cycles were deemed as having an expression of a test gene as “not 
determined”; i.e. “negative”.
112
2.6 Treatment of cell lines with NK4 and ATRA
2.6.1 Treatment of cells with ATRA
An All-frans retinoic acid (ATRA) solution was made to a concentration 
of 3.3x10'3M by dissolving 1pg ATRA in 1pl DMSO. 30pl of the 1pg/1pl 
ATRA was added to 970pl of RPMI + 10% FBS to give a final 
concentration of lO^M. The lO^M ATRA was used at 1 pl/1 ml of cell 
culture to treat the cells at a concentration of 10‘7M. The cells to be 
treated with ATRA were seeded to the required density and 1 |jl of 10'4M 
ATRA was added per 1 ml of cell culture. A set of the same type of cells 
were left untreated to act as a control. The cells’ growth, viability and 
gene expression were assessed at time points throughout the 
experiment.
2.6.2 Determination of HGF protein concentration
The level of hepatocyte growth factor (HGF) protein present in the NB4 
cell cultures was determined using the Quantikine® HGF ELISA kit. 
NB4 cells were grown overnight and volumes of cell culture at a density 
of 1x105 and 1x106 cells/ml were centrifuged at 300 x g for 5 minutes to 
separate the cells and the supernatant. The supernatant was removed 
and stored at -80°C until required.
A volume of 250ml of wash buffer was initially prepared from 10ml of 
wash buffer concentrate diluted with distilled water. A volume of 100ml 
of calibrator diluent (1X) was prepared from 20ml of calibrator diluent
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RD5P concentrate (5X) diluted with distilled water. The HGF standard 
was reconstituted with 5ml of the calibrator diluent (1X) solution to 
produce a final concentration of 8000pg/ml. A volume of 500pl of 
calibrator diluent (1X) was pipetted into six eppendorfs (1.5ml) for a 
serial dilution of the reconstituted HGF standard; a concentration range 
of 125 pg/ml-8000pg/ml was generated and the calibrator diluent (1X) 
served as a Opg/ml standard. The substrate solution was made up by 
the addition of 4ml of colour reagent A to 4ml of colour reagent B. The 
resultant substrate mixture was light sensitive and needed to be used 
within 15 minutes of its production. When required the cell culture 
supernatants were defrosted in a 37°C water bath. A volume of 150pl of 
assay diluent RD1W, followed by the addition of 50pl of standard, 
control or sample was added to each well and mixed by gentle tapping 
of the plate; the plate was covered with an adhesive strip. After an 
incubation of 2 hours at room temperature each well was aspirated and 
washed with 400pl with a multi-channel pipette for a total of 4 times. To 
ensure complete removal of wash buffer the plate was blotted against 
paper towels after the final wash. A volume of 200pl of HGF conjugate 
was then added to each well, the plate was covered with an adhesive 
strip and incubated at room temperature for 1.75 hours. After this time 
the process of washing each well with 400jil of wash buffer and 
aspirating was repeated 4 times. A volume of 200jnl of substrate 
solution was added to each well and the plate was left to incubate at 
room temperature, protected from the light. After 30 minutes 50pl of 
stop solution was added to each well causing a colour change from blue
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to yellow. Gently tapping the plate ensured mixing of the reagents. The 
optical density of each well was determined using a microplate reader 
set to 450nm and to 540nm for correction.
2.6.3 Treatment of cells with NK4
NK4 is an antagonist of HGF and contains the N-terminal domain and 
the 4 kringle domains of HGF. NB4 cells seeded to the required density 
were treated with 0.8pl of 10pl/ml NK4 per 1ml of cell culture over a 
period of 72 hours. Cells were either treated at day 0 only or at day 0 
and day 1. A set of the same type of cells were left untreated to act as a 
control. The cells’ growth, viability and cell surface marker expression 
were assessed at time points throughout the experiment.
2.7 siRNA
2.7.1 siRNA design and production
The siRNA oligonucleotides were designed and synthesised by 
Eurogentec Ltd, Southampton, Hampshire, UK. Eurogentec were 
supplied with the identified probe set sequences from the Affymetrix 
NetAffx analysis centre.
2.7.2 siRNA annealing
Oligonucleotides were centrifuged briefly, resuspended to 100pM using 
RNase-free water and stored at -70°C until required. The
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oligonucleotides were diluted to 50|jM aliquots for annealing. The 
following reaction mixture was used (Table 15);
Oligonucleotide sense 30pl
Oligonucleotide antisense 30 pi
5x annealing buffer 10pl
Table 15. The reaction mixture used for annealing the sense and antisense 
oligonucleotides used for siRNA transfection.
The solution was incubated for 1 minute at 95°C and then allowed to 
cool to room temperature over 60 minutes. The tube containing the 
reaction mixture was briefly centrifuged to collect the mix to the bottom 
of the tube and stored at 4°C until required.
2.7.3 siRNA labelling
The dry fluorescein (FAM) labelling reagent was resuspended with 
100pl reconstitution solution, vortexed and left at room temperature for 
5 minutes before vortexing again to ensure proper resuspension. The 
following mixture for was used for the labelling reaction (Table 16);
RNase-free water 18.3pl
10x labelling buffer 5 pi
siRNA duplex (5pg) 19.2pl
FAM labelling reagent 7.5pl
Table 16. The reaction mixture used to label the annealed siRNA oligonucleotides 
with the FAM dye.
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The reagents were added in this order and mixed by vortexing whilst 
limiting the amount of time the reaction mixture was exposed to light. 
The reaction mix was incubated at 37°C for 1 hour in the dark. The 
labelled siRNA was retrieved by ethanol precipitation. For a 50pl 
reaction mix, 5pl of 5M NaCI and 125pl cold 100% ethanol was added 
and mixed well. The mixture was then placed at -20°C for 60 minutes. 
The labelled siRNA was pelleted by centrifugation at 8,000 x g for 20 
minutes. The supernatant was aspirated off and 175pl of 70% ethanol 
was added to the pellet. The mix was centrifuged at 8,000 x g for 5 
minutes and the supernatant was aspirated off. The siRNA was dried 
for 10 minutes at room temperature and resuspended in 19.2pl RNase- 
free water.
2.7.4 Transfection of siRNA
When warmed to room temperature, 10pl of siPORT NeoFX 
transfection agent was added to 90pl Opti-MEM (Gibco, Invitrogen Ltd) 
per reaction and incubated at room temperature for 10 minutes. 
Labelled siRNA was added to the transfection mixtures to achieve a 
final siRNA concentration of 50nM and 100nM and mixed by pipetting. 
The siRNA/transfection mixes were incubated at room temperature for 
10 minutes. Cells set to the required density were added to the reaction 
mix and gently mixed by swirling. Following 24 hours, 3mls of fresh 
medium was added to the cells to reduce toxicity and after 48 hours 
following transfection the effect of siRNA transfection was determined 
by RQ-PCR (Section 2.5). A transfection reaction was carried out for
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each gene at 50nM and 100nM, and for a scrambled siRNA at 50nM 
and 100nM and one without siRNA as negative controls.
2.7.5 Determination of siRNA transfection efficiency
The efficiency level of siRNA transfection into the cells was determined 
by flow cytometry on day 2 following transfection on a FACScan flow 
cytometer (Becton Dickinson, NJ, USA) using CellQuest software.
2.8 Immunophenotyping
To assess the expression of cell surface markers in the treated cell 
lines, fluorescently labelled antibodies were bound to the cell surface 
markers of interest. Cells were pelted by centrifugation at 120 x g for 3 
minutes. The pellet was washed 3 timed with 1x PBS, 1% BSA and 
then resuspended in 10pl 1x PBS, 1% BSA. The resuspended cells 
were incubated in the dark at 4°C for 1 hour with 2.5pl of the labelled 
antibody. 50pl of FACSFlow was added to stop the binding reaction. 
The cell were pelleted by centrifugation and resuspended in 50pl 
FACSFlow before being transferred to a Luckham LP2 tube. The cells 
were analysed on a FACS Calibur flow cytometer (Becton Dickinson, 
NJ, USA) using CellQuest software.
2.8.1 Markers for NB4 cell lines
The antibodies used to assess the effect of NK4 on NB4 cells were 
mouse anti-human CD11b and mouse anti-human CD38. IgG was used
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as a control to show the level of background or irrelevant binding of the 
antibody.
2.8.2 Flow analysis
A FACS Calibur was used to collect the flow cytometry data and the 
data was analysed using Summit 4.0 (DAKO, Ely, UK). The data was 
gated to exclude debris and background staining was determined using 
the data generated for the cells stained with the IgG control antibody. 
The level of antibody staining was expressed as the mean fluorescence 
intensity.
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Chapter 3
Using gene expression profiling to identify novel minimal 
residual disease markers specific for t(15;17) acute 
myeloid leukaemia - a “proof of principle”
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3.1 Introduction
3.1.1 Acute Promyelocytic Leukaemia (APL)
A reciprocal balanced translocation between chromosomes 15 and 17, 
resulting in the fusion of the promyelocytic (PML) gene on chromosome 
15 and the retinoic acid receptor-a (RARa) gene on chromosome 17, is 
the genetic hallmark of acute promyelocytic leukaemia (APL). The 
resulting fusion genes, PML-RARa and RARa-PML, are detected in 
more than 95% of APL patients (Lo-Coco & Ammatuna, 2006). The 
PML protein, encoded by the PML gene, co-localises with other proteins 
in discrete nuclear speckles to form complexes called nuclear PML 
bodies or PODs (PML oncogenic domains) (Jensen et al, 2001). The 
PML protein contains a RING-finger domain, two B-box domains and an 
a-helical coiled-coil domain, which form the RBCC domain; responsible 
for the homodimerisation, localisation and PML-protein interactions of 
PML (Zhong et al, 2000). Accumulating evidence suggests an important 
role for PML in the regulation of transcription; the conformation of the 
protein and its interactions with other proteins controlling the direction of 
its transcriptional regulation (Ahn et al, 1998;Zhong et al, 2000). The 
RARa gene on chromosome 17 encodes for the RARa protein; a 
member of a nuclear hormone receptor superfamily. RARa acts as a 
ligand-inducible transcription factor by binding to specific response 
elements (RARE) of target genes. In the absence of ligand, RARa acts 
as a transcriptional repressor by forming a heterodimeric complex with 
retinoid X receptor (RXR); the heterodimer recruits a repression 
complex consisting of histone deacetylases (HDACs) and nuclear
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receptor co-repressors. In the presence of retinoic acid (RA), the 
repression complex is dissociated in favour of the recruitment of a co­
activator complex consisting of histone acetylases (HAT) leading to the 
activation of gene transcription. The fusion protein PML-RARa can bind 
to retinoic acid response elements (RAREs) as a homodimer unlike the 
wild-type RARa (Perez et al, 1993). The fusion protein is also able to 
heterodimerise to retinoid receptors (RXR) with an increased affinity for 
the HDACs and nuclear receptor co-repressors compared to wild-type 
RARa, resulting in an aberrant retinoid receptor leading to constitutive 
transcriptional repression and, thus, an increase in cell growth and a 
block in cell differentiation (Perez et al, 1993;Melnick & Licht, 
1999;Pandolfi, 2001). The transcription repression resulting from the 
PML-RARa protein can be released with pharmacological levels of 
retinoic acid (10'6M) (Grignani et al, 1998;Mozziconacci et al, 1998).
3.1.2 Minimal Residual Disease and APL
Reverse-transcription polymerase chain reaction (RT-PCR) is an 
established method for the rapid and sensitive identification of the 
fusion gene product resulting from the rearrangement of the PML gene 
and the RARa gene in APL cells. Three different breakpoints in the PML 
gene have been recorded, resulting in the generation of three possible 
PML-RARa transcripts (Pandolfi et al, 1992). RT-PCR for the 
amplification of the PML-RARa transcript has also become a valuable 
method for MRD detection in APL patients; RT-PCR positivity has been 
used to predict haematological relapse following consolidation therapy
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whilst persistent RT-PCR negativity has been associated with a lower 
relapse rate (RR) and long-term survival (Chang et al, 1992;Huang et 
al, 1993;Millert Jr. et al, 1992;Diverio et al, 1998;Jurcic et al, 2001). 
Unfortunately a number of studies have shown that despite achieving 
PCR negativity at the end of consolidation therapy, a number of patients 
go on to relapse suggesting more time-points and a longer follow-up are 
required for the monitoring of MRD. Furthermore, a method with greater 
sensitivity than RT-PCR (1 in 104) is required to correctly predict relapse 
or long-term survival (Devaraj et al, 1996;Mandelli et al, 1997;Burnett et 
al, 1999;Gameiro et al, 2001). An alternative to RT-PCR is real-time 
RT-PCR; the level of PCR product is quantified as it accumulates (Liu 
Yin, 2002). Subsequent studies have considered the use of real-time 
quantitative PCR (RQ-PCR) as a more sensitive method of MRD 
monitoring. RQ-PCR can achieve sensitivities of 1 leukaemic cell in 106 
cells and serial MRD monitoring on a 3-monthly basis can prove 
informative in identifying APL patients at a high risk of relapse (Tobal et 
al, 2001 ;Gallagher et al, 2003;Lee et al, 2006).
The aim of this chapter was to use t(15;17) AML as a “proof of principle” 
to determine whether gene expression profiling can identify new MRD 
markers that are specific for leukaemic sub-groups. Genes specific to 
the t(15;17) sub-group were identified by gene expression profiling in 
order to identify potential candidate markers of minimal disease. Their 
levels of expression were tracked over time in t(15;17) AML patient 
samples using RQ-PCR and correlated with corresponding transcription
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data for markers currently used for monitoring MRD in these patients 
(PML-RARa and RARa-PML).
3.2 Methods
3.2.1 Patient and donor samples
The sample dataset used for analysis in this section contained gene 
expression data from 295 patient samples (including 5 patient replicate 
samples) and 10 healthy normal donor samples processed by the 
School of Medicine, Cardiff University as described in section 2.2.1 
(Chapter 2). The patient cohort used contained 26 AML patients 
presenting with a t(15;17) including two t(15;17) patient replicate 
samples (Chapter 2, Table 3).
The t(15;17) AML patient and normal healthy donor RNA was 
processed from bone marrow aspirates and supplied from within the 
Department of Haematology, School of Medicine, Cardiff University.
3.2.2 Gene Expression Data Analysis 
3.2.2a Expression summarisation
Image files (CEL files) were analysed using the statistical algorithms in 
MAS 5.0 using target intensity (TGT) of 100. The resultant data matrix 
of expression levels for each probe set was taken forward for further 
analysis (see accompanying CD for CEL files).
124
3.2.2b Quality Control of probe Sets
Before starting the gene expression analysis process, probes 
representing genes that were not expressed in any of the samples were 
removed. Retaining such probe sets could affect the analysis by 
generating false-positives in a statistical analysis or grouping dissimilar 
expression profiles in a cluster analysis. A method of “filtering on flags” 
was used to remove such probe sets. Probe sets were assigned a “flag” 
of either present, marginal or absent based on the reliability of the 
intensity of certain features, for example level of intensity compared to 
the level of saturation or whether the feature is a population outlier 
(Agilent GeneSpring GX9 Tutorial). Further, more stringent, quality 
controls were applied by identifying probes sets flagged as present in at 
least 2 samples. From this set, probe sets that did not increase or 
decrease in expression level by more than 2 fold, between 0.5 and 2, 
(an accepted level of change) across the 305 samples were classed as 
non-changing and were removed to leave a list of probe sets called 
“present and changing”.
3.2.2c Fold Change Calculation
A fold change calculation is a simple way of identifying differentially 
expressed genes between two states. Using mean expression values, a 
gene is said to be differentially expressed if its mean expression value 
varies by more than a set factor between the control state and the test 
state. To identify genes differentially expressed between the t(15;17) 
AML patients, the non-t(15;17) AML patients and the healthy normal
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donors, the probe sets were filtered on a change of 2-, 3-, 4- and 5-fold. 
The fold change filtering process was applied to both the list of probe 
sets classified as “present in at least 1 sample” and the set classified as 
“present and changing”.
3.2.2d Significance Analysis of Microarrays (SAM)
Significance Analysis of Microarrays (SAM) was used as another 
method for analysing the microarray data. SAM identifies changes in 
gene expression that are statistically significant by using gene-specific 
f-tests. A false discovery rate (FDR) threshold is applied to the data to 
control the expected proportion of false-positives identified. Adjusting 
the threshold alters the number of gene identified (Tusher et al, 2001). 
An FDR of 0.05 was used as a 5% probability of identifying false- 
positives is an established significance level; an FDR of 0.01 was used 
for more stringent testing.
3.2.2e Analysis of Variance (ANOVA)
Analysis of Variance (ANOVA) is a statistical test used to assess 
significant differences between the means of datasets. The variances of 
the datasets of interest are compared in order to test for the differences 
between the means. ANOVA was used to analyse the microarray data 
in this study by identifying genes with a statistically significant difference 
in their expression between the t(15;17) AML patients and the normal 
healthy donors.
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3.2.3 Diagnostic Screening of Candidate Genes
The genes identified from the gene expression profiling analysis were 
screened in a group of diagnostic t(15;17) AML patient bone marrow 
samples (n=9) and normal healthy donor bone marrow samples (n=16). 
Real-time quantitative PCR (RQ-PCR) was used as described in 
section 2.5 (Chapter 2) to measure the expression levels of the 
candidate gene transcripts. Each sample was run in duplicate and a 
duplicate “no-RNA” cDNA control sample and “no-cDNA” control 
sample was included as negative-controls. The expression data 
generated from the real-time PCR was normalised to a house-keeping 
gene, S14 (gene encoding for the 40S ribosomal subunit protein S14) 
(Rhoads et al, 1986), as recommended by Roche for relative gene 
expression studies on their LightCycler® Real-Time PCR System and 
optimised and published from in the Department to allow for 
comparisons with other on-going projects within the laboratory (Guinn et 
al, 2005;Walsby et al, 2008).
3.2.4 Validation of Candidate Genes as MRD Markers
The candidate genes screened in diagnostic patient samples were 
validated as markers of MRD using RQ-PCR as previously described. 
Duplicate samples and negative controls were used and all gene 
expressions were normalised to the transcript expression of S14. 
Diagnostic (DX) and follow-up (FUP) patient bone marrow samples 
were used for quantitative PCR analysis of the genes of interest. A 
normalised fold change in expression value was calculated for every
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gene expression value for each patient sample using the following 
equation;
Fold change = 2^ Control9eneCtvalue"Test9eneCtvalue)
A minimal residual disease value (MRDv) was calculated for every 
gene expression value and compared to MRDv data for the markers 
currently used. The MRDv was calculated using the AACt method as 
described by Beillard et al (2003) in the “Europe Against Cancer” 
programme based on the assumption that the intercept and slope 
values between the control gene and the gene of interest are identical, 
using the following calculation
MRD value = 10 «*ct(FUP)-ACt<DX))/-3.4)
Where ACt(FUP) is the normalised crossing point for the gene of 
interest in a patient follow-up sample, ACt(DX) is the normalised 
crossing point for the gene of interest in the patient diagnostic sample 
and -3.4 is the average slope value from plasmid standard curves 
(Beillard et al, 2003;Gabert et al, 2003). Data for the markers currently 
used, PML-RARa and RARa-PML, was supplied by Professor D. 
Grimwade, Guy’s Hospital, London.
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3.2.5 Statistical Analysis of Diagnostic Screening and MRD 
Analyses
The gene expression data generated from the diagnostic patient and 
normal healthy donor samples was analysed using an unpaired student 
f-test. All MRD data was analysed using a two-tailed Pearson’s 
correlation. A Pearson’s correlation was used to visualise the degree of 
linear relationship between the MRD data generated for the candidate 
genes and for markers currently used.
3.3 Results
3.3.1 Identification of genes expressed specifically in t(15;17) AML 
samples
Using filtering tools based on present/absent calls and fold change, 
22,283 probe sets in 295 AML diagnostic patient samples (representing 
290 patients) and 10 donor samples were analysed to identify genes 
specific to those patients with a t(15;17) translocation.
3.3.1a Quality Control of Probe sets
From 22,283 probe sets, 17,844 probe sets (probe set list 3.1) were 
flagged as “present”, i.e. assigned a call of present, in at least one 
sample of the patient and donor cohort. Further filtering through flag 
assignment with an increased stringency identified 16,988 probes sets 
(probe set list 3.5) assigned a call of present in at least two samples in 
the cohort. From this group of probe sets, eleven probe sets did not
129
increase or decrease in expression by at least 2 fold (probe set list 3.6) 
and so were removed for being “non-changing”. This left a group of 
16,977 probe sets classified as “present and changing” (probe set list 
3.7).
Gene expression profiling was performed on both the group of “present 
in at least 1 sample” probe sets and the group of “present and 
changing” probe sets to compare the robustness and reliability of the 
analysis.
3.3.1b Identification of Differentially Expressed Genes by Fold 
change
The “present in at least 1 sample” probe sets were filtered on a 2-, 3-, 4- 
and 5-fold change in expression level between the t(15;17) patients and 
non-t(15;17) patients and between the t(15;17) patients and the normal 
healthy donor patients (Table 1). By using a >3 fold change as the 
threshold for significance, the group of 27 probe sets identified as 
having a greater expression in the t(15;17) patients than in the non- 
t(15;17) patients (probe set list 3.2) was combined with the group of 204 
probe sets identified as having a greater expression in the t(15;17) 
patients than in the normal healthy donors (probe set list 3.3) to 
generate a group of 18 probe sets with a greater level of expression in 
t(15;17) AML patients when compared with other AML patient sub­
groups or normal healthy donors (Probe set list 3.3) (Figure 1; Table 2).
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The “present and changing” probe sets were filtered on a 2-, 3-, 4- and 
5-fold change in expression level between the t(15;17) patients and 
non-t(15;17) patients and between the t(15;17) patients and the normal 
healthy donor patients (Table 1). By using a £3 fold change as the 
threshold for significance, the group of 26 probe sets identified as 
having a greater expression in the t(15;17) patients than the non- 
t(15;17) patients (probe set list 3.8) was combined with the group of 202 
probe sets having a greater expression in the t(15;17) patients than the 
normal healthy donors (probe set list 3.9) to generate a group of 17 
probe sets with a greater level of expression in t(15;17) AML patients 
than in any other AML patient sub-group or the normal healthy donor 
group (Probe set list 3.10) (Figure 2; Table 2).
Probe set group FoldChange
t(15;17) > non- 
t(15;17) t(15;17) > Donors
Present in at least 1 sample 2 140 873
3 27 204
4 6 43
5 5 26
Present and changing 2 139 833
3 26 202
4 6 43
5 5 26
Table 1. The number of probe sets identified as having a greater expression in 
t(15;17) AML patients than in non-t(15;17) patients or normal healthy donors.
Fold change filtering was applied to both probe set lists generated for quality 
control purposes as described in section 3.3.1a.
The group of 18 “present in at least 1 sample” probe sets and the group 
of 17 “present and changing” probe sets contained identical probe sets
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bar one; probe set 204879_at relating to the podoplanin (PDPN) gene 
was not identified during the filtering of probe sets classified as “present 
and changing”. The 17 probe sets represented 12 genes. Furthermore, 
the 7 probe sets showing the highest fold change in expression in both 
groups of probe sets represented 3 genes; hepatocyte growth factor 
(HGF), insulin-like growth factor binding protein 2 (IGFBP2) and 
prostaglandin D2 synthase (PGD2) (Table 2).
Performing the filtering analysis on both probe set groups allowed for 
the reliability and robustness of the filtering process to be confirmed. 
The identification of the same 17 probe sets specific to both groups 
suggests filtering on fold change is a robust and reliable method of 
analysis and that probe sets identified really were specififc to t(15;17) 
AML and were not false-positives. The identification of the 18th probe 
set, 204879_at, may be a false-positive due to the reduced stringency 
of the filtering on flags method originally applied to the probe set 
(present in only 1 sample rather than present in 2 and samples 
changing and changing in expression), or whilst it may be more specific 
to t(15;17) AML rather than non-t(15;17) AML it is not specififc enough 
to be detected with more stringent analysis and therefore would not 
make a suitable MRD marker.
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Probe Set GeneSymbol Gene Title
Fold
Change
1 210794_s_at MEG3 Maternally expressed 3 (non-protein coding) 3.002
2 208581_x_at MT1X Metallothionein 1X 3.149
3 209686_at SIOOB S100 calcium binding protein B 3.184
4 203074_at ANXA8 Annexin A8 3.387
5 221898_at* PDPN Podoplanin 3.689
6 205047_s_at ASNS Asparagine synthetase 3.706
7 *204879_at PDPN Podoplanin 3.739
8 219837_s_at CYTL1 Cytokine-like 1 3.838
9 207076_s_at ASS1 Argininosuccinate synthetase 1 3.874
10 211663_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 3.961
11 203068_at KLHL21 Kelch-like 21 (Drosophila) 3.970
12 209960_at HGF Hepatocyte growth factor 4.796
13 202718_at IGFBP2 Insulin-like growth factor binding protein 2 4.800
14 210755_at HGF Hepatocyte growth factor 5.263
15 212187_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 6.344
16 211748_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 6.950
17 210998_s_at HGF Hepatocyte growth factor 7.367
18 210997_at HGF Hepatocyte growth factor 8.958
Table 2. The 18 “present in at least 1 sample" probe sets and the 17 “present and 
changing” probe sets identified from the 305 sample dataset as upregulated in 
t(15;17) AML patients samples when compared to non-t(15-17) patients and to 
healthy donor samples by fold change (FC>3). The fold change value displayed is 
the mean fold change value of the probe sets across the t(15;17) samples. The 
group of 17 “present and changing” probe sets were identical to the group of 18 
“present in at least 1 sample” probe sets bar probe set 204879_at relating to the 
podoplanin gene*.
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Figure 1. The relative mean expression levels of the 18 probe sets identified, from 
probe sets that were classified as present in at least 1 sample, as being more 
significantly expressed in t(15;17) samples than non-t(15;17) samples and in donor 
samples by £3 fold. The probe sets are coloured according to their expression 
levels in their respective sub-group relative to their expression level in the donor 
samples. The numbers on each block correspond to the probe set it represents - 
see Table 2.
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Figure 2. The relative mean expression levels of the 17 probe sets identified, 
from probe sets that were classified as present in at least 2 samples and 
changing in expression, as being more significantly expressed in t(15;17) 
samples than non-t(15;17) samples and in donor samples by £3 fold. The probe 
sets are coloured according to their expression levels in their respective sub­
group relative to their expression level in the donor samples. The numbers on 
each block correspond to the probe set it represents - see Table 2.
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3.3.2 Identification of Genes Differentially Expressed in t(15;17) 
AML Samples using Statistical Tools.
To further support the use of gene expression profiling as a means of 
identifying genes specific to AML sub-groups, a statistical analysis was 
applied to the probe sets to corroborate the results of the initial t(15;17) 
analysis (Section 3.3.1).
3.3.2a Identification of Differentially Expressed Genes by 
Statistical Analysis of Microarrays (SAM)
SAM was used to identify differentially expressed genes through a 
series of gene-specific f-tests. Applied to the original group of 22,283 
probe sets, SAM identified 285 probe sets as differentially expressed 
with an FDR of 0.05 (Probe set list 3.11) and 159 probe sets with an 
FDR of 0.01 (Probe set list 3.12) (Table 3).
3.3.2b Identification of Differentially Expressed Genes by Analysis 
of Variance (ANOVA)
ANOVA was applied to the group of probe sets classified as “present 
and changing” (n=16,977) to identify differences in gene expression 
levels between the t(15;17) patients and the non-t(15;17) patients and 
normal healthy donors by comparing the variances of the test groups. 
Using an FDR of 0.05 7,680 probe sets (probe set list 3.13) were 
identified, while 5,501 probe sets (probe set 3.14) were identified with 
an FDR of 0.01 (Table 3).
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FDR SAM ANOVA
0.05 285 7,680
0.01 159 5,501
Table 3. The number of probe sets identified as having a greater expression in 
t(15;17) AML patients than in non-t(15;17) patients or normal healthy donors 
through SAM and ANOVA analysis.
3.3.2c Identification of Differentially Expressed Genes by Fold 
Change and Statistical Tools
Combining the differentially expressed probe sets identified by SAM 
and ANOVA analysis with an FDR of 0.05 (n=285 and n=7,680 
respectively) with the probe sets identified as “present and changing” 
with a greater expression in t(15;17) AML patients than in any other 
AML sub-group or the normal healthy donor group by £3 fold, a set of 
17 probe sets was generated; this set was identical to the original list 
identified in section 3.3.1b (Figure 3; Figure 2; Table 2).
Combining statistical and filtering tools generates a far more stringent 
method of identification of probe sets specific to t(15;17) by increasing 
the thresholds the probe sets are required to acheive for selection. The 
combination of statistical tools and fold change filtering identifying the 
same probe sets as unique to t(15; 17) AML as filtering alone indicates 
that, for t(15;17) AML, the initial analysis of filtering alone was robust
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and reliable enough to identify potential markers of MRD for this sub­
group and that the probe sets identified are not false-positives.
Figure 3. A combination of the probe sets identified from SAM (FDR=0.05), 
ANOVA testing (FDR=0.05) and having a greater level of expression in t(15;17) 
samples than in non-t(15;17) samples and in donor samples by >3 fold change 
filtering. Seventeen probe sets were identified as being specifically expressed in 
t(15;17) samples.
3.3.3 Validation of Identified Genes by Real-Time Quantitative PCR
Elevated levels of the HGF protein have been previously noted in 
leukaemic cell line populations and AML patient samples suggesting a 
role for HGF in AML (Nakamura et al, 1994;Hino et al, 1996). Weimar et 
al (1998) observed that HGF-induced colony formation and proliferation 
in leukaemic cells; an effect not observed in normal haematopoietic
t(1 5; 17)>n on -t(15; 17) and  
donors (3 fold change) A N O VA  (F D R  = 0.05)
SAM (FD R  = 0.05)
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cells. Given the potential importance of the HGF protein in AML and the 
high expression levels of the probes sets representing the HGF gene 
identified in the gene expression analysis, HGF was selected for further 
investigation to assess its potential as an MRD marker in AML.
Many studies have observed high serum levels of IGFBP2 in paediatric 
acute lymphoblastic leukaemia (ALL) (Dawczynski et al, 2003;Vorwerk 
et al, 2005). Whilst it has been debated that it is not strong enough to 
act as a prognostic marker alone, a negative correlation of IGFBP2 
serum levels at diagnosis and event free survival (EFS) rates has been 
observed (Vorwerk et al, 2005). Combining this evidence with the 
identification of the IGFBP2 gene as being highly expressed in t(15;17) 
AML patients through gene expression profiling, IGFBP2 was also 
selected for further investigation as a potential MRD marker in AML.
3.3.3a Diagnostic Screening of Candidate Genes
Transcript expression levels of HGF and IGFBP2 were measured in 
diagnostic t(15;17) AML patient samples and compared to levels 
measured in healthy normal donor samples. Initially primer sets were 
designed for the amplification of HGF and IGFBP2 as described in the 
Materials and Methods section 2.5.1 (Chapter 2) and using serial 
dilutions of cDNA, their amplification efficiency was compared to that of 
the house-keeping gene, S14. Both HGF and IGFBP2 produced similar 
amplification efficiencies to that produced by S14. Therefore S14 was 
considered suitable as the normalising control gene (Figure 4).
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Figure 4. The amplification curves of the primer sets used for HGF  and 
IGFBP2 and of the house-keeping gene, S14, to compare their amplification 
efficiencies.
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The levels of expression of HGF and IGFBP2 were measured in 8 and 
9 diagnostic AML patient samples (respectively) presenting with a 
t(15;17) and were compared to the levels of expression in 16 normal 
healthy bone marrow donor samples (Figure 5). A mean normalised Ct 
value of HGF of 0.634 (range -7.67 to 4.71) and a mean normalised Ct 
value of IGFBP2 of 1.247 (range -6.57 to 4.76) was detected at 
diagnosis in the t(15;17) AML patients samples. A mean normalised Ct 
value of HGF of -3.718 (range -7.13 to -1.20) and a mean normalised Ct 
value of IGFBP2 of -3.142 (range -6.19 to -0.32) was detected in the 
healthy normal donor samples (Figure 5). Using f-tests, a strong 
significant difference was observed between the mean normalised Ct 
values of the candidate genes in the diagnostic t(15;17) AML patient 
samples and the mean normalised Ct values of the candidate genes in 
the healthy normal donor samples (Table 4).
HGF IGFBP2
P Value
Are the means significantly 
different (p<0.05)
Donors mean value (n=16)
Donors 95% Cl
Donors Expression Range
t(15;17) mean value (n=8,9)
t(15;17) 95% Cl
t(15;17) Expression Range
0.0005
Yes
-3.718 
-4.51 to -2.93 
-7.13 to -1.20 
0.634 
-2.57 to 3.84 
-7.67 to 4.71
0.0001
Yes
-3.142 
-4.03 to -2.25 
-6.19 to -0.32 
1.247 
-1.10 to 3.59 
-5.57 to 4.76
Table 4. The statistical significance of the mean Ct values of the candidate 
genes measured in the t(15;17) AML diagnostic patient samples and the 
healthy normal donor samples normalised to the Ct values of S14. Cl = 
confidence interval.
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Figure 5. Scatter plots of the spread of the normalised Ct values of the 
candidate genes measured in the t(15;17) AML diagnostic patient samples 
and the healthy normal donor samples. Mean value ± 95% confidence 
interval plotted.
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As both HGF and IGFBP2 were more highly expressed in diagnostic 
samples from t(15;17) AML patients compared to normal healthy 
donors, both genes were followed through the progression of the 
disease of t(15;17) AML patients to validate their potential as markers of 
MRD
3.3.3b Hepatocyte Growth Factor (H G F) as an MRD Marker
The transcript levels and MRD values for the HGF gene were followed 
in the diagnostic and follow-up samples of three t(15;17) patients as 
described in section 2.5 and 3.2. The level of MRD in the first follow-up 
sample for the first two t(15;17) patients was two logs lower than the 
level of transcription observed at diagnosis (Figure 7a, 7b), and nearly 
three logs lower in the third t(15;17) patient (Figure 7c). The level of 
HGF MRD remained constant at these levels for the remainder of the 
follow-up period. Over the course of their disease, the levels of HGF 
MRD in the three t(15;17) patients displayed a similar pattern to the 
corresponding MRD values of the t(15;17) fusion gene products, PML- 
RARa and RARa-PML. A strong positive correlation was seen between 
the fusion gene product expression data of PML-RARa and RARa-PML 
and the expression data for HGF (r2 = 0.9947, p<0.0001 and r2 = 
0.9982, p<0.0001 respectively).
The expression of HGF detected in the three t(15;17) patients was 
above the upper threshold of expression detected in the healthy normal 
donor samples at diagnosis by at least 1 log. Following the start of
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induction therapy the expression of the candidate gene decreased 
below the upper threshold detected in the healthy normal donors by at 
least 1 log and remained so for the duration of the patients’ disease 
(Figure 6).
3.3.3c Insulin-like Growth Factor Binding Protein 2 (IG F B P 2 ) as an 
MRD Marker
The transcript levels and MRD values of IGFBP2 were followed in 
diagnostic and follow-up samples from three t(15; 17) patients. The level 
of IGFBP2 MRD in the first follow-up sample of the first two t(15;17) 
patients was two logs lower than the normalised level of transcripts 
observed at diagnosis (Figure 7at 7b)t and nearly three logs lower in the 
third t(15;17) patient (Figure 7c). The level of IGFBP2 MRD remained 
constant at these levels for the remainder of the follow-up period. The 
IGFBP2 transcript levels and MRD values of the 3 t(15;17) patients 
through the course of the disease displayed a similar pattern to the 
transcript levels and MRD values of the fusion gene products, PML- 
RARa and RARa-PML. A strong positive correlation was seen between 
the fusion gene product expression data of PML-RARa and RARa-PML 
and the expression data for IGFBP2 (r2 = 0.9993, p<0.0001 and r2 = 
0.9990, p<0.0001 respectively).
The expression of IGFBP2 detected in the three t(15;17) patients was 
above the upper threshold of expression detected in the healthy normal 
donor samples at diagnosis by at least 1 log. Following the start of
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induction therapy the expression of the candidate gene decreased 
below the upper threshold detected in the healthy normal donors by at 
least 1 log and remained so for the duration of the patients’ disease 
(Figure 6).
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Figure 6. The fold changes in expression of HGF, IGFBP2, PML-RARa and RARa-PML in the diagnostic and follow-up samples of 3 1(15;17) patients (a- 
c), calculated as described in section 3.2. The dashed lines indicate the upper level of fold changes in expression of HGF and IGFBP2 observed in the 
healthy normal donor samples.
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List Probe Sets
3.1 Probe sets present in at least 1 sample (n=17,844)
3.2 Probe sets present in at least sample with greater expression in t(15;17) than in non-t(15;17) samples by £3 fold (n=27)
3.3 Probe sets present in at least sample with greater expression in t(15;17) than in donor samples by £3 fold (n=204)
3.4
Probe sets present in at least Sample with greater expression in 
t(15;17) than in non-t(15;17) samples and in donor samples by 
£3 fold (n=18)
3.5 Probe sets present in at least 2 samples (n=16,988)
3.6 Probe sets present in at least 2 samples and not changing in expression by more than 2-fold across the 305 samples (n=11)
3.7 Probe sets that are present and changing (n=16,977)
3.8 Probe sets present and changing with greater expression in t(15;17) than in non-t(15;17) samples by £3 fold (n=26)
3.9 Probe sets present and changing with greater expression in t(15;17) than in donor samples by >3 fold (n=202)
3.10
Probe sets present and changing with greater expression in 
t(15;17) than in non-t(15;17) samples and in donor samples by 
>3 fold (n=17)
3.11 SAM analysis of all genes, FDR=0.05 (n=285)
3.12 SAM analysis of all genes, FDR=0.01 (n=159)
3.13 ANOVA analysis of present and changing probe sets, FDR=0.05 (n=7,680)
3.14 ANOVA analysis of present and changing probe sets, FDR=0.01 (n=5,501)
3.15
Probe sets common to probe sets present and changing with 
greater expression in t(15;17) than in non-t(15;17) samples and 
in donor samples by £3 fold, SAM analysis of all probe sets 
using an FDR of 0.05 and ANOVA analysis of probe sets 
present and changing using an FDR of 0.05 (n=17)
Table 5. The probe set lists identified from the gene expression profiling analysis 
(Section 3.3.1 and 3.3.2).
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3.4 Discussion
Gene expression profiling has been used to identify leukaemic 
populations based on their clinical subtypes and karyotypes and has 
identified genes specific for those groups (Andersson et al, 2005;Valk et 
al, 2004;Bullinger et al, 2004). Using this information, it may be possible 
to identify genes that can be used as markers of MRD for specific AML 
sub-groups. As a “proof of principle”, gene expression profiling was 
performed on AML patients to identify genes specific to t(15;17) AML 
patients; patients for which an MRD marker is already available. This 
approach allowed the selection of potential MRD marker candidates 
that were then compared with the markers currently used for MRD 
monitoring in t(15;17) AML patients i.e. the PML-RARa and RARa -  
PML fusion genes.
By profiling 295 diagnostic AML samples and 10 donor samples, a list 
of 18 probe sets, present in at least 1 sample, was identified as being 
specific for AML patients with a t(15;17). Further analysis identified 
17/18 of these probe sets as present and changing in at least 1 sample 
and as being specific for those AML patients with a t(15;17). The probe 
set filtered out when the analysis was performed on present and 
changing probe sets related to the podoplanin (PDPN) gene. PDPN is a 
small mucin-like transmembrane protein. Whilst its physiological 
function is unknown, its expression is upregulated in many human 
cancers, including squamous cell carcinomas of the oral cavity and 
larynx (Martin-Villar et al, 2005). Various studies by Wicki et al (2006)
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and Martin-Villar et al (2006) have shown the expression of PDPN in 
human cancers promotes the migration and invasion of cancer cells 
(Martin-Villar et al, 2006;Wicki et al, 2006). The identification of this 
gene from the less stringently filtered group of probe sets may be due to 
one of several reasons. The probe set may be false-positive identified 
as specific to t(15;17) AML because the original filtering to identify 
probe sets assigned a call of “present “ in at least 1 sample” was not 
stringent enough and did not take into account a lack of change in 
expression across the test sets, or the probe set may be specific to 
t(15;17) AML but not enough to act reliably as a marker of MRD for this 
sub-group and may be specific to AML as a whole rather than to an 
individual sub-group.
The 17 probe sets identified as specific for t(15;17) patients related to 
12 genes. Hepatocyte growth factor (HGF) was represented by 4 of the 
identified probes. HGF was also identified by Gutierrez et al (2005) as 
being the second most significantly over expressed gene in APL 
patients compared to non-APL patients by gene expression profiling. 
This finding was supported by Valk et al (2004) identifying HGF as 
being specific to the AML t(15;17) sub-group (Gutierrez et al, 2005;Valk 
et al, 2004). HGF is a pleiotropic cytokine that promotes the growth and 
motility of epithelial cells in several organs (Borset et al, 1996) 
(Bussolino et al, 1992). The ability of HGF to promote cell proliferation, 
invasion and motility has encouraged the proposal that the HGF gene 
plays a role in cancer growth and metastasis (Bussolino et al, 1992).
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However, a role in leukaemogenesis does not necessarily translate to a 
potential MRD marker; some genes displaying an increase in 
expression with the onset of malignancy may play no role in the 
pathogenesis. Many groups have reported increased concentrations of 
the HGF protein in AML patients’ serum samples at diagnosis 
compared to normal controls in haematological malignancies, including 
AML; Verstovsek et al (2001) measured significantly higher 
concentrations of plasma HGF in diagnostic AML and MDS 
(Myelodysplastic Syndrome) samples compared to healthy normal 
samples (p<0.0001) and Gwang et al (2005) found significantly higher 
HGF serum concentrations in patients with CML (Chronic Myeloid 
Leukaemia) and patients with AML than in healthy normal donors 
(P<0.0001, P<0.001 respectively) (Verstovsek et al, 2001;Gwang et al, 
2005). In this study, the level of HGF expression was screened in 8 
t(15;17) AML patient samples and 10 healthy normal donor samples. 
Whilst Verstovsek et al (2001) and Gwang et al (2005) screened the 
levels of the HGF protein; here HGF transcript levels were measured. 
Similar to the two protein studies, the levels of HGF transcript 
expression were significantly increased in the AML diagnostic samples 
compared to the healthy normal samples (P<0.0005) (Verstovsek et al, 
2001 ;Gwang et al, 2005). An obvious next step would be to compare 
the protein levels and transcript levels of HGF in the same samples. 
However, the circumstantial evidence from these unrelated studies 
suggests that there is probably a positive correlation between the level
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of expression of HGF transcript in t(15;17) AML and the amount of HGF 
protein translated.
The levels of HGF mRNA were screened in three t(15;17) AML patient 
diagnostic and follow-up samples. In all three patients the normalised 
expression of HGF decreased in the follow-up samples when compared 
to the diagnostic samples. A very strong correlation between HGF and 
PML-RARa and RARa-PML (p<0.0001) was also observed. The only 
comparable patient study of a haematological malignancy to relate 
these results to is a myeloma study by the Nordic Myeloma Study 
Group (1998). Seidel et al (1998) observed that HGF serum levels were 
raised in diagnostic samples of multiple myeloma patients compared to 
normal samples, decreased after treatment response and increased 
during relapse, and therefore suggested HGF as a candidate disease 
marker (Seidel et al, 1998).
Another probe set, related to insulin-like growth factor binding protein 2 
(IGFBP2) gene, was identified as being specific for AML patients with 
t(15;17). In agreement with these findings, Gutierrez et al (2005) also 
identified IGFBP2 as being highly expressed in APL patients (Gutierrez 
et al, 2005). A previous study by Vorwerk et al (2005) found highly 
elevated serum levels of IGFBP2 in acute lymphoblastic leukaemia 
(ALL) patients at diagnosis (Vorwerk et al, 2005). Insulin-like growth 
factor binding proteins (IGFBPs) bind to insulin-like growth factors 
(IGFs) and mediate the actions of IGFs through transport to specific
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cells (Rodriguez et al, 2007;Hettmer et al, 2005;Rodriguez et al, 2007). 
IGFBP2 has also been found to act as a regulatory carrier for IGF in 
childhood leukaemia (Vorwerk et al, 2002). The level of IGFBP2 
expression was screened in 9 t(15;17) AML diagnostic patient samples 
and 10 healthy normal donor samples. Similar to the findings of 
Vorwerk et al (2005), the levels of IGFBP2 expression were significantly 
higher in the t(15;17) AML diagnostic patients samples compared to the 
healthy normal donor samples (P<0.0001). The levels of IGFBP2 MRD 
were screened in three t(15;17) AML patient diagnostic and follow-up 
samples. In all three patients the expression of IGFBP2 decreased 
following diagnosis and the commencement of induction therapy and 
remained at these lower levels for the remainder of the disease. As with 
HGF, a very strong correlation between IGFBP2 and PML-RARa and 
RARa-PML (p<0.0001) was observed. To date IGFBP2 has not been 
investigated as a marker of MRD but another study by Vorwerk et al 
(2002) observed relapse of children with ALL was restricted to those 
with raised serum IGFBP2 concentrations at diagnosis and a difference 
was seen in the serum IGFBP2 concentration at diagnosis of those 
children who remained in continuous remission (Vorwerk et al, 2002).
Combining the gene expression data generated from this study with the 
findings of various studies by other groups supports the potential role of 
gene expression profiling for the identification of markers of MRD for 
AML sub-types, in particular those currently without markers. Further 
gene profiling analysis using statistical tools (ANOVA, SAM) combined
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with fold change thresholds identified a set of probe sets identical to the 
previous list identified in section 3.3.1b. These findings validate the 
strength of the results generated from the gene expression profiling 
analysis of fold change calculations alone, and the potential of gene 
expression profiling for identifying MRD markers. The diagnostic 
screening of two of the identified genes, HGF and IGFBP2, compared 
to healthy normal donors and the longitudinal monitoring their levels of 
expression in patient follow-up samples indicated that both genes may 
have the potential to act as markers of MRD in t(15;17) AML. Further 
investigations are now clearly warranted in which transcript and protein 
levels of HGF and IGFBP2 are serially monitored in order to establish 
the potential utility of these genes in MRD monitoring and the role they 
play in leukaemogenesis.
Whilst the two candidate genes, HGF and IGFBP, displayed expression 
patterns that would be expected of an ideal MRD marker in patients that 
achieved and remained in complete remission, it was unfortunate that 
longitudinal monitoring was not performed in any t(15;17) APL patients 
that subsequently relapsed to observe an increase in expression with 
the onset of or prior to relapse to confirm their potential as MRD 
markers. However, due to the improved treatment strategies and 
remission rates achieved for APL a relapse in APL is not commonly 
seen.
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A limitation to the study could have resulted from the sensitivity of the 
technique used. The sensitivity of the RQ-PCR technique used can be 
defined as the lowest dilution of cDNA still able to generate specific 
amplification (Papadaki et al, 2009). AML cell line cDNA was serially 
diluted to maximum of 1 in 10,000. At a sensitivity level of 10-4 specific 
amplification of the cDNA using the HGF and IGFBP2 primers was 
observed for all samples; samples generated a Cp value of less than 40 
cycles and were deemed as “positive” (Section 2.5.3). If a sample had 
generated a Cp value of greater than 40 it would have been deemed 
“negative” and all residual disease presumed to be absent. However, a 
more sensitive RQ-PCR (10'5-10-6) might detect some residual disease 
proving its absence in this current study as a “false-negative”. 
Fortunately specific amplification of all samples in this section was 
detected with 40 cycles and issues of “false-negative” MRD presence 
were avoided.
To summarise, gene expression profiling was able to identify a list of 
genes specific to t(15;17) AML patients. Selecting two of these genes 
and following the levels of expression in three t(15;17) patients, a strong 
correlation was seen between the expression of these genes and the 
expression of the two markers currently used for MRD monitoring, PML- 
RARa and RARa-PML. This suggests that gene expression profiling 
can identify genes specific to t(15;17) AML and therefore has the 
potential to identify minimal residual disease markers for monitoring in 
other subgroups of AML.
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Chapter 4
Using gene expression profiling to identify novel 
minimal residual disease markers specific to 
CBF leukaemias
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4.1 Introduction
4.1.1 Core Binding factors (CBF)
Core binding factors (CBF) are a group of transcriptional regulators that 
contain a beta (CBFp) subunit and one of three alpha (CBFa) subunits. 
Both subunits are required for normal haematopoietic development 
(Speck & Gilliland, 2002). The CBF members are common targets for 
gene mutations and rearrangements, and CBF acute leukaemia results 
from translocations involving either a CBFa subunit or a CBFP subunit 
(Appelbaum et al, 2006).
4.1.2 CBF Leukaemia
CBF leukaemia account for approximately 15% of AML cases under the 
age of 55 years (Slovak et al, 2000;Grimwade et al, 1998).
4.1.2a t(8;21)
Acute myeloid leukaemia 1 (AML1), the CBF alpha subunit, is involved 
in many chromosomal translocations in several haematological 
malignancies (Burel et al, 2001). The t(8;21) chromosomal translocation 
is commonly associated with the AML FAB group M2. The t(8;21) 
involves a translocation between the AML1 gene on chromosome 21 
and the eight twenty-one oncoprotein (ETO) gene located on 
chromosome 8 , resulting in the fusion gene product AML1-ETO 
(Peterson & Zhang, 2004). The role AML1-ETO plays in 
leukaemogenesis is to block cell differentiation and down-regulate the
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expression of CCAAT/enhancer binding protein, alpha (CEBPa), a 
transcription factor involved in the commitment and differentiation of 
myeloid cells (Burel et al, 2001).
4.1.2b inv(16)
The beta subunit, CBFp, is involved in the inv(16) commonly associated 
with the AML FAB group M4Eo (Delaunay et al, 2003). An inversion of 
chromosome 16 results in an inversion of CBFf$ and the smooth muscle 
myosin heavy chain (MYH11) gene located on chromosome 16, 
resulting in the fusion gene product CBFfi-MYH11. The CBFp unit is 
able to regulate transcription by interacting with the AML1 DNA-binding 
transcription factor. Disruption to CBFp through chromosome 16 
inversion leads to a disruption of AML1 and transcription is negatively 
regulated (Lutterbach et al, 1999;Wang et al, 1993).
4.1.3 CBF Leukaemia and Gene Expression Profiling
Gene expression studies with microarrays have revealed distinct 
transcriptional differences between the two CBF leukaemias (Mrozek & 
Bloomfield, 2006) (Bullinger et al, 2007). Several groups have 
performed unsupervised hierarchical clustering analyses on sets of 
AML patient samples and found that despite both belonging to the 
collective group of CBF leukaemias, the t(8;21) patients and the inv(16) 
patients cluster into two distinct groups with different gene expression
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patterns (Bullinger et al, 2004;Bullinger et al, 2007;lchikawa et al, 
2006).
4.1.4 CBF Leukaemia and MRD
Minimal residual disease (MRD) in patients with a CBF leukaemia can 
be monitored by quantitative real-time PCR (RQ-PCR) of their resultant 
fusion gene products, AML1-ETO and CBFP-MYH11. However, various 
studies have shown that the t(8 ;2 1 ) fusion transcript can still be 
detected in some t(8 ;2 1 ) following complete remission and throughout 
long-term remission (Kwong et al, 1996;Nucifora et al, 1993;Downing et 
al, 1993).
4.1.5 Wilms’ Tumour (W T 1) as an MRD Marker
Wilms’ tumour 1 (WT1) was originally identified as a tumour suppressor 
gene involved in the pathogenesis of Wilms’ tumour, a kidney neoplasm 
(Haber et al, 1990). Expression of WT1 is found in a variety of tissues, 
including those involved in haematopoiesis and the kidney (Call et al, 
1990). Several studies have detected low levels of WT1 expression in 
normal bone marrow and peripheral blood samples yet high levels in 
AML samples and other leukaemic samples (Inoue et al, 1996;lnoue et 
al, 1994). Whilst it is unknown why WT1 expression has been found to 
be increased, WT1 has been suggested as a candidate for MRD 
monitoring in AML and has the potential to predict relapse (Inoue et al, 
1994). However, some controversy surrounds the clinical significance of
159
WT1 expression and data generated by reverse transcriptase-PCR. 
Schmid et al (1997) found that while WT1 was expressed in leukaemic 
blasts, the data was too limited to come to a conclusion about the 
usefulness of WT1 as a marker of MRD (Schmid et al, 1997), whilst 
Gaiger et al (1998) still detected WT1 expression in patients following 
complete remission (Gaiger et al, 1998). Elmaagacli et al (2 0 0 0 ) also 
detected WT1 expression in patients following transplantation 
(Elmaagacli et at, 2000).
Due to the persistence of t(8;21) gene transcripts following remission in 
t(8;21) patients and the need for further validation for the use of WT1 as 
an MRD marker, other potential markers may provide more reliable 
information about CBF leukaemia. Building on previous gene 
expression profiling studies performed on CBF leukaemias and the 
methods used in the previous chapter for acute promyelocytic 
leukaemia, the aim of this chapter was to identify potential MRD 
markers for t(8;21) AML patients and inv(16) AML patients and compare 
their ability to monitor CBF AML with AML1-ETO, CBF/5-MYH11 and 
WT1 transcript data from these patients.
4.2 Methods
4.2.1 Patient and donor samples
The sample dataset used for analysis in this section contained gene 
expression data for 295 patient samples (5 patient replicate samples)
160
and 10 healthy normal donor samples processed within the School of 
Medicine, Cardiff University as described in section 2.2.1 (Chapter 2). 
The patient cohort used contained 15 AML patients presenting with a 
t(8;21) and 18 AML patients presenting with an inv(16) (1 inv(16) patient 
replicate sample) (Chapter 2, Table 3).
The t(8;21) and inv(16) AML patient RNA for RQ-PCR was processed 
from bone marrow aspirates and supplied from the Department of 
Clinical Haematology, Manchester Royal Infirmary. The normal healthy 
donor RNA was processed from bone marrow aspirates and supplied 
from within the Department of Haematology, School of Medicine.
4.2.2 Gene Expression Data Analysis
The gene expression profiling analysis to determine genes differentially 
expressed in t(8;21) AML patients and in inv(16) AML patients was 
performed in an identical manner to the analysis of t(15;17) patients as 
described in chapter 3, section 3.2.2. As previously seen, a quality 
control test was applied to the probes sets before applying fold change 
and statistical analyses.
4.2.3 Diagnostic Screening of Candidate Genes
The genes identified from the t(8;21) gene expression profiling analysis 
were screened in a group of diagnostic t(8;21) AML patient bone 
marrow samples (n=1 0 ) and normal healthy donor bone marrow
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samples (n=16). The genes identified from the inv(16) gene expression 
profiling analysis were screened in a group of diagnostic inv(16) AML 
patient bone marrow samples (n=13) and normal healthy donor bone 
marrow samples (n=16). Real-time quantitative PCR (RQ-PCR) was 
used as previously described in section 2.5 and section 3.2.3 (Chapter 
2 & Chapter 3) to measure the expression levels of the candidate 
genes.
4.2.4 Validation of Candidate Genes as MRD Markers
The candidate genes screened in diagnostic patient samples were 
validated as markers of MRD using RQ-PCR in the same manner as 
described in chapter 3 (Section 3.2.4). Data for the markers currently 
used, AML1-ETO, MYH11-CBFP and WT1, was supplied by Professor J 
L Yin, Department of Clinical Haematology, Manchester Royal 
Infirmary. The data were displayed in the form of normalised copy 
number using the following calculation:
Normalised copy = (number of copies/number of ABL copies) x 100
4.2.5 Statistical Analysis of Diagnostic Screening and MRD 
Analyses
The gene expression data generated from the diagnostic patient and 
normal healthy donor samples was analysed using an unpaired student 
Mest. All MRD data was analysed using a two-tailed Pearson’s 
correlation. A Pearson’s correlation is used to visualise the degree of
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linear relationship between the MRD data generated for the candidate 
genes and for markers currently used.
4.3 Results 
A. t(8;21) AML
4.3.1 Identification of genes expressed specifically in t(8;21) 
AML samples
Using filtering tools based on present/absent calls and fold change and 
statistical analysis tools, 22,283 probe sets in 295 AML diagnostic 
patient samples (representing 290 patients) and 1 0 donor samples were 
analysed to identify genes specific to those patients with a t(8 ;2 1 ) 
translocation.
4.3.1a Identification of Differentially Expressed Genes by Fold 
change
The fold change calculation used was applied to the two probe set 
groups previously identified as “present in at least 1 sample” and 
“present and changing” through filtering on flags (Chapter 3, Section 
3.3.1a) to remove any inconsistent data. Filtering was applied to both 
groups of probe sets to assess the robustness and reliability of the 
analysis.
The group of “present in at least 1 sample” probe sets were filtered on a 
2-, 3-, 4- and 5-fold change in expression level between the t(8;21)
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patients and non-t(8 ;2 1 ) patients and between the t(8 ;2 1 ) patients and 
the normal healthy donor patients (Table 1). By using a £3 fold change 
as the threshold for significance, the group of 94 probe sets identified 
as having a greater expression in the t(8 ;2 1 ) patients than in the non- 
t(8;21) patients (probe set list 4.1) was combined with the group of 272 
probes sets identified as having a greater expression in the t(8 ;2 1 ) 
patients than in the normal healthy donors (probe set list 4.2) to 
generate a group of 60 probe sets with a greater level of expression in 
t(8;21) AML patients when compared to other AML patient sub-groups 
or normal healthy donors (Probe set list 4.3) (Figure 1; Table 2).
The “present and changing” probe sets were filtered on a 2-, 3-, 4- and 
5-fold change in expression level between the t(8;21) patients and non- 
t(8 ;2 1 ) patients and between the t(8 ;2 1 ) patients and the normal healthy 
donors (Table 1). By using a £3 fold change as the threshold for 
significance the group of 94 probe sets identified as having greater 
expression in the t(8 ;2 1 ) patients than in the non-t(8 ;2 1 ) patients (probe 
set list 4.4) was combined with the group of 272 probe sets identified as 
having a greater expression in t(8 ;2 1 ) patients than in the normal 
healthy donors (probe set list 4.5) to generate a group of 60 probe sets 
with a greater level of expression in t(8;21) AML patients when 
compared to other AML patient sub-groups or normal healthy donor 
(Probe set list 4.6) (Figure 1; Table 2).
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The group of 60 probe sets identified from the “present in at least 1 
sample” probe sets (Probe set list 4.3) and the group of 60 probe sets 
identified from the “present and changing" probe sets (Probe set list 4.6) 
were identical confirming the robustness of the filtering analysis and the 
unlikelihood that the probe sets identified as specific to t(8;21) AML 
were false-positives.
Probe set group FoldChange t(8;21)>non-t(8;21) t(8;21)>Donors
Present in at least 1 sample 2 318 930
3 94 272
4 31 95
5 23 64
Present and changing 2 313 930
3 94 272
4 31 75
5 23 23
Table 1. The number of probe sets identified as having a greater expression in 
t(8;21) AML patients than in non-t(8;21) patients or normal healthy donors. Fold 
change filtering was applied to both sets of probe sets generated for quality 
control purposes as described in section 3.3.1a (Chapter 3).
The 60 probe sets represented 46 genes. Furthermore amongst the 16 
probe sets with the highest fold changes (greater than 8  fold) 7 probe 
sets identified the tryptase alpha 1 and beta 1 genes (TPSAB1) and 
tryptase beta 2 (TPSB2) gene involved in proteolysis.
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Probe Set Gene Gene Title FoldSymbol Change
31 203913_s_at HPGD Tydroxyprostaglandin dehydrogenase 15-(NAD) 4.220
32 203065_s_at CAV1 Caveolin 1, caveolae protein, 22kDa 4.439
33 204468_s_at TIE1
Tyrosine kinase with immunoglobulin-like and EGF-like 
domains 1 4.551
34 219686_at STK32B Serine/threonine kinase 32B 4.716
35 204885_s_at MSLN Mesothelin 5.182
36 209170_s_at GPM6B Glycoprotein M6B 5.236
37 218876_at TPPP3 Tubulin polymerization-promoting protein family member 3 5.312
38 208534_s_at RASA4 RAS p21 protein activator 4 5.353
39 209010_s_at TRIO Triple functional domain (PTPRF interacting) 5.453
40 209167_at GPM6B Glycoprotein M6B 6.328
41 206726_at PGDS Prostaglandin D2 synthase, hematopoietic 6.844
42 206940_s_at POU4F1 POU class 4 homeobox 1 7.522
43 212097_at CAV1 Caveolin 1, caveolae protein, 22kDa 8.016
44 213194_at ROBOI
Roundabout, axon guidance receptor, homolog 1 
(Drosophila 8.209
45 207741_x_at TBSAB1 Tryptase alpha/beta 1 8.355
46 204086_at PRAME Preferentially expressed antigen in melanoma 8.990
47 207134_x_at TPSB2 Tryptase beta 2 9.150
48 201655_s_at HSPG2 Heparan sulfate proteoglycan 2 9.649
49 205683_x_at TPSAB1 Tryptase alpha/beta 1 10.01
50 216474_x_at TPSAB1 Tryptase alpha/beta 1 12.06
51 216831_s_at RUNX1T1* Runt-related transcription factor 1 13.09
52 205529_s_at RUNX1T1* Runt-related transcription factor 1 13.25
53 215382 x at TPSAB1 Tryptase alpha/beta 1 13.61
54 217023_x_at TPSB2 Tryptase alpha/beta 1 14.81
55 210744_s_at IL5RA Interleukin 5 receptor, alpha 16.56
56 205528_s_at RUNX1T1* Runt-related transcription factor 1 18.12
57 210084_x_at TPSAB1 Tryptase alpha/beta 1 21.71
58 211517_s_at IL5RA Interleukin 5 receptor, alpha 25.35
59 211341_at POU4F1 POU class 4 homeobox 1 39.08
60 206622_at TRH Thyrotropin-releasing hormone 39.27
Table 2. The top 30 “present in at least 1 sample” and “present and changing "probe sets 
identified from the 305 sample dataset as upregulated in t(8;21) AML patients samples 
when compared to non-t(8;21) patients and to healthy donor samples by fold change 
(FC>3). The fold change value displayed is the mean fold change value of the probe sets 
across the t(8;21) samples. The numbers assigned to the probe sets correspond to their 
location in figure 1. For a complete list of the 60 probe sets see appendix \\.*RUNX1T1 is 
also known as £70, the gene previously mentioned as involved in the t(8;21) (Section 
4.2.1a).
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Figure 1. The relative mean expression levels of the 60 probe sets identified, from 
probe sets that were classified as present in at least 1 sample and as present and 
changing, as being more significantly expressed in t(8;21) samples than non-t(8;21) 
samples and in donor samples by £3 fold. The probe sets are coloured according to 
their mean expression levels in their respective sub-group relative to their mean 
expression level in the donor samples. The numbers on each block correspond to 
the probe set it is representing - see table 2 (only top 20 probe sets numbered).
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4.3.1b Identification of genes differentially expressed in t(8;21) 
AML samples with statistical tools
As with the t(15;17) gene profiling analysis, a number of different statistical 
analysis tools were applied to the probe sets to corroborate the results of 
the initial t(8;21) fold change analysis (Section 4.3.1) and to apply more 
stringent filtering methodologies to the datasets.
/. Identification of Differentially Expressed Genes Statistical Analysis 
of Microarrays (SAM)
SAM was used to identify differentially expressed genes through a series 
of gene-specific t-tests. Applied to the original group of 22,283 probe sets, 
SAM identified 200 probe sets as differentially expressed with an FDR of 
0.05 (Probe set list 4.7); 75 probe sets with an FDR of 0.01 (Probe set list 
4.8) (Table 3).
ii. Identification of Differentially Expressed Genes by Analysis of 
Variance (ANOVA)
ANOVA was applied to the group of probe sets classified as “present and 
changing” (n=16,977) to identify differences in gene expression levels 
between the t(8 ;2 1 ) patients and the non-t(8 ;2 1 ) patients and normal 
healthy donors by comparing the variances of the test groups. Using an 
FDR of 0.05, 7,271 probe sets (probe set list 4.9) were identified, while
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4,957 probe sets (probe set 4.10) were identified with an FDR of 0.01 
(Table 3).
FDR SAM ANOVA
0.05 200 7,271
0.01 75 4,957
Table 3. The number of probe sets identified as having a greater expression in t(8;21) 
AML patients than in non-t(8;21) patients or normal healthy donors through SAM and 
ANOVA analysis.
4.3.1c Identification of Differentially Expressed Genes by Fold change 
and Statistical tools
Combining the differentially expressed probe sets identified by SAM and 
ANOVA analysis with an FDR of 0.05 (n=200, n=7,271) with the probe sets 
identified as “present and changing” with a greater expression in t(8 ;2 1 ) 
AML patients than in any other AML sub-group or normal healthy donors 
(n=60), a set of 41 common probe sets was generated as being specific for 
t(8;21) samples (Probe set list 4.11;Figure 2; Table 4; Figure 3).
Unlike the analysis performed for the t(15; 17) sub-group (Chapter 3), 
statistical tools used for the identification of probe sets specific to t(8 ;2 1 ) 
AML filtered out many probe sets identified as specific from the original fold 
change filtering. This could be due to a result of a greater variance in the 
expression levels of the probe sets amongst the t(8 ;2 1 ) samples compared
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to the t(15;17) samples resulting in less probe sets originally identified 
achieving the required threshold expression levels of SAM and ANOVA 
analysis to be identified as specific to t(8;21) AML.
t(8;21)>non-t(8;21) and 
donors (3 fold change) ANOVA (FDR = 0.05)
Figure 2. A combination of the probe sets identified from SAM (FDR=0.05), ANOVA testing 
(FDR=0.05) and having a greater level of expression in t(8;21) samples than in non-t(8;21) 
samples and in donor samples by 3 fold change filtering. Forty-one probe sets were identified 
as being specifically expressed in t(8;21) samples.
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Probe Set Gene Gene Title FoldSymbol Change
3 202242_at TSPAN7 Tetraspanin 7 3.010
5 208178_x_at TRIO Triple functional domain (PTPRF interacting) 3.033
6 206187_at PTGIR Prostaglandin 12 (prostacyclin) receptor (IP) 3.082
9 207030_s_at CSRP2 Cysteine and glycine-rich protein 2 3.229
12 211140_s_at CASP2 Caspase 2, apoptosis-related cysteine peptidase 3.247
14 207496_at MS4A2 Membrane-spanning 4-domains, subfamily A, member 2 3.293
16 211549_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 3.439
19 209543_s_at CD34 CD34 molecule 3.542
20 219090_at SLC24A3 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 3.590
21 204990_s_at ITGB4 Integrin, beta 4 3.614
22 202760_s_at PALM2-AKAP2 PALM2-AKAP2 readthrough transcript 3.653
23 209013_x_at TRIO Triple functional domain (PTPRF interacting) 3.671
25 204811_s_at CACNA2D2 Calcium channel, voltage-dependent, alpha 2/delta subunit 2 3.787
26 204073_s_at C11orf9 Chromosome 11 open reading frame 9 3.843
27 201015_s_at JUP Junction plakoglobin 3.932
29 201621_at NBL1 Neuroblastoma, suppression of tumorigenicity 1 3.986
31 203913_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 4.220
32 203065_s_at CAV1 Caveolin 1, caveolae protein, 22kDa 4.439
34 219686_at STK32B Serine/threonine kinase 32B 4.716
38 208534_s_at RASA4 RAS p21 protein activator 4 5.353
39 209010_s_at TRIO Triple functional domain (PTPRF interacting) 5.453
40 209167_at GPM6B Glycoprotein M6B 6.328
41 206726_at PGDS Prostaglandin D2 synthase, hematopoietic 6.844
42 206940_s_at POU4F1 POU class 4 homeobox 1 7.522
43 212097_at CAV1 Caveolin 1, caveolae protein, 22kDa 8.016
44 213194_at ROBOI Roundabout, axon guidance receptor, homolog 1 8.209
45 207741_x_at TBSAB1 Tryptase alpha/beta 1 8.355
46 204086_at PRAME Preferentially expressed antigen in melanoma 8.99
47 207134_x_at TPSB2 Tryptase beta 2 9.15
48 201655_s_at HSPG2 Heparan sulfate proteoglycan 2 9.649
49 205683_x_at TPSAB1 Tryptase alpha/beta 1 10.01
50 216474_x_at TPSAB1 Tryptase alpha/beta 1 12.06
51 216831_s_at RUNX1T1 Runt-related transcription factor 1 13.09
52 205529_s_at RUNX1T1 Runt-related transcription factor 1 13.25
53 215382_x_at TPSAB1 Tryptase alpha/beta 1 13.61
54 217023_x_at TPSB2 Tryptase alpha/beta 1 14.81
55 210744_s_at IL5RA Interleukin 5 receptor, alpha 16.56
56 205528_s_at RUNX1T1 Runt-related transcription factor 1 18.12
57 210084_x_at TPSAB1 Tryptase alpha/beta 1 21.71
58 211517_s_at IL5RA Interleukin 5 receptor, alpha 25.35
59 211341 at POU4F1 POU class 4 homeobox 1 39.08
60 206622_at TRH Thyrotropin-releasing hormone 39.27
Table 4. The 41 probe sets identified from the 305 sample dataset as upregulated in t(8;21) 
AML patients samples when compared to non-t(8;21) patients and to healthy donor 
samples by fold change (FC>3) and by SAM analysis and ANOVA analysis with a FDR of 
0.05. The numbers assigned to the probe sets correspond to their location in figure 1 and 3.
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Figure 3. The relative mean expression levels of the 41 “present and changing” probe 
sets identified as being more significantly expressed in t(8;21) samples than non- 
t(8;21) samples and in donor samples by £3 fold and through SAM and ANOVA 
analysis with an FDR of 0.05. The probe sets are coloured according to their 
expression levels in their respective sub-group relative to their expression level in the 
donor samples. The numbers on each block correspond to the probe set it is 
representing - see Table 2 (only top 20 genes numbered).
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The identified probe sets (n=41) corresponded to 29 genes. ETO, part of 
the fusion gene product AML1-ETO resulting from the t(8;21) translocation, 
was represented by 3 sets of probes all exhibiting an expression greater in 
t(8 ;2 1 ) samples than non-t(8 ;2 1 ) samples and in donor samples by more 
than 13 fold. Seven sets of probes with an expression greater in t(8;21) 
samples than in the non-t(8 ;2 1 ) samples and donor samples by more than 
8  fold corresponded to the tryptase alpha 1 and beta 1 and tryptase beta 2  
(TPSAB1, TPSB2) genes. These genes are involved in proteolysis and 
were previously identified in the analysis of the probe sets flagged as 
present in at least 1 sample and flagged as present and changing (section 
4.3.1a). Thyrotropin-releasing hormone (TRH) was represented by the 
most highly expressed probe set specific to t(8;21) AML (fold change of 
37.3). The second and third most highly expressed probe sets represented 
the IL5RA (interleukin 5 receptor, alpha) gene with a fold change of 26.4 
and the POU4F1 (POU domain, class 4, transcription factor 1) gene with a 
fold change of 39.1; both genes were represented by two probe sets. The 
ETO gene, involved in the t(8;21) translocation, was represented by three 
probes sets in the top 1 0  most highly expressed probe sets identified as 
having a greater expression in t(8;21) AML than non-t(8;21) AML or donors 
by more than 13 fold.
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4.3.2 Validation of Candidate Genes as MRD Markers
The ETO, P0U4F1, IL5RA and PRAME genes were selected for further 
investigation as potential markers of MRD in t(8;21) AML. The ETO gene 
was selected as it plays a major role in leukaemogenesis, being part of the 
AML1-ETO fusion gene product detected in t(8;21) patients (Nucifora et al, 
1993). Several studies has detected high levels of PRAME in AML and it 
has already been suggested as a potential MRD marker (Paydas et al, 
2005;Matsushita et al, 2001). The IL5RA gene encoders a cytokine 
receptor involved in the regulation of haematopoietic cells (Pierce et al, 
1998). The POU4F1 genes was selected for further investigation from the 
observation that over-expression of POU4F1 is associated with a 
protection of cells from apoptosis (Latchman, 1998;Smith et al, 1998). All 
four genes were also represented by probe sets identified as more highly 
expressed in t(8;21) AML than non-t(8;21) AML and donors by more than
7.5 fold.
4.3.2a Diagnostic Screening of Candidate Genes
Expression levels of the four genes (PRAME, POU4F, ETO and IL5RA) 
were measured in diagnostic t(8;21) AML patient samples and compared 
to expression levels measured in healthy normal donor samples.
Initially primer sets were designed for the amplification of the four genes as 
described in the Materials and Methods section 2.5.1 (Chapter 2) and
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using serial dilutions of cDNA, their amplification efficiencies were 
compared to that of the house-keeping gene, S14. All four genes produced 
similar amplification efficiencies to that produced by S14. Therefore S14 
was considered suitable as the normalising control gene (Figure 4).
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Figure 4. The amplification curves of the primer sets used for PRAME, POU4F, ETO 
and IL5RA and of the house-keeping gene, S14, to compare their amplification 
efficiencies.
The levels of expression of PRAME, POU4F, ETO and IL5RA were 
measured in AML diagnostic patient samples (n=11, 11 12 and 12, 
respectively) presenting with a t(8;21) and compared to the levels of 
expression in normal healthy bone marrow donor samples (n=15, 14, 16 
and 16, respectively) (Figure 5).
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Figure 5. Scatter plots of the spread of the normalised Ct values of the candidate 
genes measured in the t(8;21) AML diagnostic patient samples and the healthy 
normal donor samples. Mean value ± 95% confidence interval plotted.
Using t-tests, highly significant differences were observed between the 
mean normalised Ct values of the candidate genes in the diagnostic t(8;21) 
AML patient samples and mean normalised Ct Values of the candidate 
genes in the healthy normal donor samples (Table 5).
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PRAME POU4F1 ETO IL5RA
P Value <0 .0 0 0 1 <0 .0 0 0 1 <0 .0 0 0 1 0 .0 0 0 2
Are the means
significantly Yes Yes Yes Yes
different (p<0.05)
Number of donors 11 11 12 12
Donors mean value -8.401 -8.165 -5.619 -6.442
Donors 95% Cl -9.41 to - -8.87 to - -6.13 to - -7.31 to -7.39 7.46 5.11 5.58
Donors expression -11.34 to -9.12 to - -6.83 to - -9.22 to -
range -5.65 5.89 3.95 3.95
Number of t(8;21) 15 14 16 16
t(8;21) mean value -1.742 -1.470 0.285 -3.094
t(8;21) 95% Cl -3.13 to - 0.35
-2.58 to - 
0.36
-0 .8 6  to 
1.43
-4.66 to - 
1.53
t(8;21) expression range -7.02 to -5.74 to -3.18 to -7.94 to -0.30 0.17 2 .0 2 0.62
Table 5. The statistical significance of the mean Ct values of the candidate genes 
measured in the t(8;21) AML diagnostic patient samples and the healthy normal donor 
samples normalised to the Ct values of S14. Cl = confidence interval.
Based on these findings it was agreed to continue following the expression 
levels of these genes in AML patient diagnostic and follow-up samples to 
establish whether any had the potential to act as a marker of MRD for 
t(8;21) AML.
4.3.2b Candidate Genes as MRD Markers
The transcript expression levels of the four genes were monitored in the 
diagnostic sample and follow-up samples of three AML patients with a 
t(8 ;2 1 ).
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The fold change of the genes’ transcript expression levels relative to S14 
were calculated as described in Chapter 3 and compared to the upper fold 
change in expression relative to S14 observed in the healthy normal donor 
samples (Figure 5). The MRD values (MRDv) of the genes in the patient 
samples were calculated as described in Chapter 3 and compared to the 
level of transcript detected at diagnosis (Figure 6 ).
Normalised copy number data for the fusion gene AML1-ETO and the WT1 
gene was supplied from the Department of Clinical Haematology, 
Manchester Royal Infirmary for comparison with the fold change data 
generated for the candidate genes:
/'. Patient 1
The fold change in expression of PRAME and ETO decreased by 
approximately 1 log over the first 9 months of the disease following 
induction therapy; increasing by approximately 1 log over the following 2.5 
months. The level of expression detected of both PRAME and ETO 
remained above the upper level detected in healthy normal donor samples, 
dipping below this level by approximately half a log between 8  and 11 
months following diagnosis. The fold change in expression of POU4F1 and 
IL5RA increased by approximately 2 logs and 1 log, respectively, over the 
first 3 months of the disease following diagnosis. By 11.5 months post 
diagnosis, the fold change in expression of POU4F1 and IL5RA had
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decreased to a level similar to that detected at diagnosis. The fold change 
in expression of IL5RA remained below the upper level detected in healthy 
normal donors for the entirety of the monitoring period. This patient 
relapsed at 11.5 months following diagnosis (Figure 7).
//. Patient 2
The fold change in expression of PRAME, POU4F1, ETO and IL5RA 
decreased by approximately 4 logs, 3 logs, 3 logs, and 1 log over the first
4.5 months of the disease following induction therapy. By 13.5 months 
following diagnosis, the fold change in expression of the four genes had 
increased by approximately 3 logs. Following the initial decrease after 
diagnosis and induction therapy, the level of expression of PRAME and 
ETO detected remained below the upper level detected in healthy normal 
donors until approximately 11 months following diagnosis. The level of 
expression of POU4F1 and IL5RA increased to above the upper level 
detected in healthy normal donors at approximately 9 and 13 months, 
respectively, following diagnosis. This patient relapsed at 13.5 months 
following diagnosis (Figure 7).
///. Patient 3
The fold change in expression of the four genes in patient 3 decreased by 
approximately 2 logs following diagnosis. The level of fold change in 
expression of the genes fluctuated for the remainder of the monitoring
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period, remaining at least 1 log lower than that detected at diagnosis. 
Following an initial decrease after diagnosis and induction therapy, the 
levels of expression detected of the four genes consistently remained 
below the upper level detected in healthy normal donors. This patient 
achieved complete remission (CR) (Figure 7)
The largest decrease in MRD from the level of transcript detected at 
diagnosis was detected in patient 2. PRAME, POU4F1 and ETO 
decreased by approximately 3 logs but the patient relapsed at 13.5 
months. The corresponding normalised number of AML1-ETO transcripts 
detected for this patient also displayed a decrease following diagnosis and 
induction therapy but by approximately 4 logs. By 13.5 months when the 
patient relapsed, the MRD levels of PRAME, POU4F1 and ETO had 
increased by at least 2 logs whilst the normalised number of AML1-ETO 
transcripts had increased by approximately 4 logs. The levels of MRD of 
PRAME, POU4F1 and IL5RA for patient 1 fluctuated by a maximum of 1 
log from the level of transcript detected at diagnosis for the duration of 
monitoring; the corresponding normalised number of AML1-ETO 
transcripts displayed a decrease by approximately 4 logs from diagnosis 
and increased by approximately 4 logs between 6  months and 13 months 
following diagnosis. The MRD levels of all four genes decreased following 
diagnosis and induction therapy in patient 3, the patient that achieved CR, 
reaching a minimum MRD value of approximately 3 logs lower than the
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level of transcript detected at diagnosis; the normalised copy number of 
AML1-ETO  transcripts displayed the same pattern of behaviour but 
decreased from the number detected at diagnosis by 6 logs. (Figures 6 
and 8)
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Figure 6. Longitudinal monitoring of the t(8;21) fusion gene in three t(8;21) AML 
patients, and of WT1 in one t(8;21) AML patient (no data available for patients 1 and 
2). The graphs show the normalised copy numbers of the genes in each patient, 
relative to the ABL gene. Red lines - normalised number of AML1-ETO transcripts in 
patients who relapsed. Green lines - normalised number of AML1-ETO transcripts in 
patient remaining in complete remission (CR). Green dashed line - WT1 normalised 
copy numbers in patient remaining in complete remission (CR). The numbers in the 
circles indicate the patient number.
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Figure 7. Longitudinal monitoring of PRAME (a), POU4F1 (b), ETO (c) and IL5RA (d) in three t(8;21) AML patients. The graphs show the fold 
change values generated for respective genes in each sample, relative to the S14 gene. Red lines - patients known to relapse. Green lines - 
patients remaining in complete remission (CR). The blue dashed line represents the upper limit of gene expression in the healthy normal donor 
samples. The numbers in the circles indicate the patient number.
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Figure 8. Longitudinal monitoring of PRAME (a), POU4F1 (b), ETO (c) and IL5RA (d) in three t(8;21) AML patients. The graphs show the 
MRD values calculated for the genes in each sample. Red lines - patients known to relapse. Green lines - patients remaining in complete 
remission (CR). The numbers in the circles indicate the patient number.
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4.3.2c Correlation between Candidate Markers and Current 
Markers
The MRD data for PRAME, P0U4F1, ETO and IL5RA was analysed for 
statistically significant associations with the fusion gene t(8;21) data and 
the WT1 gene data supplied by the Department of Clinical Haematology, 
Manchester Royal Infirmary.
As seen in Table 4.1, a positive correlation was observed between the 
t(8;21) copy number data and the MRD for PRAME, POU4F1, ETO and 
IL5RA. WT1 was only seen to correlate with the ETO data.
r
Value
t(8;21) 
p Value Significant rValue
WT1* 
p Value Significant
PRAME 0.766 0.0005 Yes 0.739 0.0663 No
POU4F1 0.652 0.0062 Yes 0.595 0.1667 No
ETO 0.676 0.0040 Yes 0.775 0.0480 Yes
IL5RA 0.639 0.0140 Yes 0.564 0.2000 No
Table 6. A summary of the correlations between the PRAME, POU4F1, ETO and 
IL5RA MRD data and the t(8;21) fusion gene and WT1 normalised copy number data. 
*No WT1 data was available for patient 1 and only one WT1 data point was available 
for patient 2.
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List Probe Sets
4.1 Probe sets present in at least sample with greater expression in t(8;21) than in non-t(8;21) samples by £3 fold (n=94)
4.2 Probe sets present in at least sample with greater expression in t(8;21) than in donor samples by >3 fold (n=272)
4.3
Probe sets present in at least sample with greater expression in 
t(8;21) than in non-t(8;21) samples and in donor samples by £3 
fold (n=60)
4.4 Probe sets present and changing with greater expression in t(8;21) than in non-t(8;21) samples by >3 fold (n=94)
4.5 Probe sets present and changing with greater expression in t(8;21) than in donor samples by £3 fold (n=272)
4.6
Probe sets present and changing with greater expression in 
t(8;21) than in non-t(8;21) samples and in donor samples by £3 
fold (n=60)
4.7 SAM analysis of all genes, FDR=0.05 (n=200)
4.8 SAM analysis of all genes, FDR=0.01 (n=75)
4.9 ANOVA analysis of present and changing probe sets, FDR=0.05 (n=7,271)
4.10 ANOVA analysis of present and changing probe sets, FDR=0.01 (n=4,957)
4.11
Probe sets common to present and changing probe sets with 
greater expression in t(8;21) than in non-t(8;21) samples and in 
donor samples by £3 fold, SAM analysis of all probe sets using 
an FDR of 0.05 and ANOVA analysis of probe sets present and 
changing using an FDR of 0.05 (n=41)
Table 7. The probe set lists identified from the gene expression profiling analysis 
(Section 4.3.1).
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B. inv(16) AML
4.3.3 Identification of genes expressed specifically in inv(16) 
AML samples
As previously shown with the t(8;21) AML gene expression profiling, 
filtering tools based on present/absent calls and fold change and statistical 
analysis tools were used to analysis 22,283 probe sets in 295 AML 
diagnostic patient samples (representing 290 patients) and 10 donor 
samples to identify genes specific to those patients with a inv(16).
4.3.3a Identification of Differentially Expressed Genes by Fold change
The fold change calculation used was applied to the two probe set groups 
previously identified as “present in at least 1 sample” and “present and 
changing” through filtering on flags (Chapter 3, Section 3.3.1a) to remove 
any inconsistent data.
The group of “present in at least 1 sample” probe sets were filtered on a 2-, 
3-, 4- and 5-fold change in expression level between the inv(16) patients 
and non-lnv(16) patients and between the inv(16) patients and the normal 
healthy donor patients (Table 8). By using a >3 fold change as the 
threshold for significance, the group of 131 probe sets identified as having 
a greater expression in the inv(16) patients than in the non-inv(16) patients 
(probe set list 4.12) was combined with the group of 453 probes sets 
identified as having a greater expression in the inv(16) patients than in the
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normal healthy donors (probe set list 4.13) to generate a group of 100 
probe sets with a greater level of expression in inv(16) AML patients when 
compared to other AML patient sub-groups or normal healthy donor (Probe 
set list 4.14) (Figure 9; Table 9).
The “present and changing” probe sets were filtered on a 2-, 3-, 4- and 5- 
fold change in expression level between inv(16) patients and non-inv(16) 
patients and between the inv(16) patients and the normal healthy donor 
patients (Table 8). By using a £3 fold change as the threshold for 
significance, the group of 130 probe sets identified as having a greater 
expression in the inv(16) patients than in the non-inv(16) patients (probe 
set list 4.15) was combined with the group of 446 probes sets identified as 
having a greater expression in the inv(16) patients than in the normal 
healthy donors (probe set list 4.16) to generate a group of 99 probe sets 
with a greater level of expression in inv(16) AML patients when compared 
to other AML patient sub-groups or normal healthy donor (Probe set list 
4.17) (Figure 9; Table 9).
The 99 probe sets identified from the “present and changing” group of 
probe sets were all identified in the list of 100 probe sets previously 
identified from the “present in at least 1 sample” group of probe sets. The 
extra probe set identified represented the activity-regulated cytoskeleton- 
associated protein (ARC) gene.
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The identification of the same 99 probe sets as specific to inv(16) AML 
from both probe set groups re-affirms the reliability and robustness of fold 
change filtering as a mean of identifying disease-specific genes. The extra 
probe set identified from the “present in at least 1 sample” may be a false 
positive due to less stringent filtering methods or specific to AML but not 
enough to reach the threshold limits of the more stringent filtering methods 
and therefore, not a suitable marker for MRD.
Probe set group FoldChange lnv(16)>non-inv(16) lnv(16)>Donors
Present in at least 1 sample 2 433 1352
3 131 453
4 32 158
5 18 107
Present and changing 2 424 1283
3 130 446
4 32 158
5 18 107
Table 8. The number of probe sets identified as having a greater expression in inv(16) 
AML patients than in non-inv(16) patients or normal healthy donors. Fold change 
filtering was applied to both sets of probe sets generated for quality control purposes 
as described in section 3.3.1a (Chapter 3).
The 100 probe sets represented 81 genes and the 99 probe sets identified 
represented 80 genes.
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Probe Set GeneSymbol Gene Title
Fold
Change
71* 208450_at LGALS2 Lectin, galactoside-binding, soluble, 2 5.059
72 204163_at EMILIN1 Elastin microfibril interfacer 1 5.240
73 210139_s_at PMP22 Peripheral myelin protein 22 5.296
74* 215382_x_at TPSAB1 Tryptase alpha/beta 1 5.322
75 214390_s_at BCAT1 Branched chain aminotransferase 1, cytosolic 5.524
76* 215666_at HLA-DRB4 Major histocompatibility complex, class II, DR beta 4 5.615
77* 206622_at TRH Thyrotropin-releasing hormone 5.722
78 201005_at CD9 CD9 molecule 5.828
79 205239_at AREG Amphiregulin 5.858«o00 210495_x_at FN1 Fibronectin 1 5.859
81 200665_s_at SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 5.889«CM00 210084_x_at TPSAB1 Tryptase alpha/beta 1 5.904
83 204661_at CD52 CD52 molecule 5.964
84 221914_at SYN1 Synapsin I 6.055
85 208978_at CRIP2 Cysteine-rich protein 2 6.491
86 213479_at NPTX2 Neuronal pentraxin II 6.530
87 203036_s_at MTSS1 Metastasis suppressor 1 6.634
88 209387_s_at TM4SF1 Transmembrane 4 L six family member 1 6.767
89 201324_at EMP1 Epithelial membrane protein 1 6.792
90 205987_at CD1C CD1c molecule 7.030
91 205330_at MN1 Meningioma (disrupted in balanced translocation) 1 7.947
92 203939_at NT5E 5'-nucleotidase, ecto (CD73) 8.023
93 208789_at PTRF Polymerase I and transcript release factor 8.230
94 201325_s_at EMP1 Epithelial membrane protein 1 8.544
95 209488_s_at RBPMS RNA binding protein with multiple splicing 8.791
96 212358_at CLIP3 CAP-GLY domain containing linker protein 3 9.902
97 201497_x_at MYH11 Myosin, heavy chain 11, smooth muscle 10.32
98 218876_at TPPP3 Tubulin polymerization-promoting protein family member3 10.81
99* 204885_s_at MSLN Mesothelin 15.47
100 206135_at ST18 Suppression of tumorigenicity 18 (breast carcinoma) 26.59
Table 9. The top 30 “present in at least 1 sample” and “present and changing "probe sets 
identified from the 305 sample dataset as upregulated in inv(16) AML patients samples 
when compared to non-inv( 16) patients and to healthy donor samples by fold change 
(FC>3). The fold change value displayed is the mean fold change value of the probe sets 
across the inv(16) samples. The numbers assigned to the probe sets correspond to their 
location in figure 9. For the complete list of probe sets see appendix II. *Probe sets not 
identified from the “present and changing” probe sets.
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Figure 9. The relative mean expression levels of the probe sets identified, from probe 
sets that were classified as present in at least 1 sample (n=100) and as present and 
changing (n=99), as being more significantly expressed in inv(16) samples than non- 
inv(16) samples and in donor samples by £3 fold. The probe sets are coloured 
according to their expression levels in their respective sub-group relative to their 
expression level in the donor samples. The numbers on each block correspond to the 
probe set it is representing - see Table 5 (only top 20 probe sets numbered).
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4.3.3b Identification of genes differentially expressed in inv(16) 
AML samples with statistical tools
As with the original t(15;17) gene profiling analysis and the previous t(8;21) 
analysis, statistical analysis was applied to the probe sets to corroborate 
the results of the initial inv(16) fold change analysis (Section 4.3.3a) and to 
apply more stringent filtering methodologies to the datasets.
/. Identification of Differentially Expressed Genes Statistical Analysis 
of Microarrays (SAM)
SAM was used to identify differentially expressed genes through a series 
of gene-specific t-tests. Applied to the original group of 22,283 probe sets, 
SAM identified 300 probe sets as differentially expressed with an FDR of 
0.05 (Probe set list 4.18); 147 probe sets with an FDR of 0.01 (Probe set 
list 4.19) (Table 6).
//. Identification of Differentially Expressed Genes by Analysis of 
Variance (ANOVA)
ANOVA was applied to the group of probe sets classified as “present and 
changing” (n=16,977) to identify differences in gene expression levels 
between the inv(16) patients and the non-inv(16) patients and normal 
healthy donors by comparing the variances of the test groups. Using an 
FDR of 0.05, 7,654 probe sets (probe set list 4.20) were identified, while
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5,405 probe sets (probe set 4.21) were identified with an FDR of 0.01 
(Table 10).
FDR SAM ANOVA
0.05 300 7,654
0.01 147 5,405
Table 10. The number of probe sets identified as having a greater expression in 
inv(16) AML patients than in non-inv(16) patients or normal healthy donors through 
SAM and ANOVA analysis.
4.3.3c Identification of Differentially Expressed Genes by Fold change 
and Statistical tools
Combining the differentially expressed probe sets identified by SAM and 
ANOVA analysis with an FDR of 0.05 (n=300, n=7,654, respectively) with 
the probe sets identified as “present and changing” with a greater 
expression in t(8;21) AML patients then in any other AML sub-group or 
normal healthy donors (n=99), a set of 66 probe sets was generated as 
being specific to inv(16) samples (Probe set list 4.22; Figure 10; Table 11; 
Figure 11).
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lnv(16)>non-inv(16) and 
donors (3 fold change) ANOVA (FDR = 0.05)
Figure 10. A combination of the probe sets identified from SAM (FDR=0.05), ANOVA testing 
(FDR=0.05) and having a greater level of expression in t(8;21) samples than in non-t(8;21) 
samples and in donor samples by 3 fold change filtering. Forty-one probe sets were identified 
as being specifically expressed in t(8;21) samples.
Similar to the t(8;21) AML analysis, statistical tools combined with filtering 
methods filtered out many probe sets identified as specific from the original 
fold change filtering. This could be due to a result of a greater variance in 
the expression levels of the probe sets amongst the inv(16) samples 
resulting in less probe sets originally identified achieving the required 
threshold expression levels of the SAM and ANOVA analysis to be 
identified as specific to inv(16) AML.
193
Probe Set GeneSymbol Gene Title
Fold
Change
61 210202_s_at BIN1 Bridging integrator 1 4.630
62 214020_x_at ITGB5 Integrin, beta 5 4.640
63 216474_x_at TPSAB1 Tryptase alpha/beta 1 4.712
64 206682_at CLEC10A C-type lectin domain family 10, member A 4.764
65 202747_s_at ITM2A Integral membrane protein 2A 4.771
69 201496_x_at MYH11 Myosin, heavy chain 11, smooth muscle 4.967
70 34210_at CD52 CD52 molecule 4.977
72 204163_at EMILIN1 Elastin microfibril interfacer 1 5.240
73 210139 s at PMP22 Peripheral myelin protein 22 5.296
75 214390 s at BCAT1 Branched chain aminotransferase 1, cytosolic 5.524
78 201005_at CD9 CD9 molecule 5.828
79 205239_at AREG Amphiregulin 5.858
81 200665_s_at SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 5.889
83 204661_at CD52 CD52 molecule 5.964
84 221914_at SYN1 Synapsin I 6.055
85 208978_at CRIP2 Cysteine-rich protein 2 6.491
86 213479_at NPTX2 Neuronal pentraxin II 6.530
87 203036_s_at MTSS1 Metastasis suppressor 1 6.634
88 209387_s_at TM4SF1 Transmembrane 4 L six family member 1 6.767
89 201324_at EMP1 Epithelial membrane protein 1 6.792
90 205987_at CD1C CD1c molecule 7.030
91 205330_at MN1 Meningioma (disrupted in balanced translocation) 1 7.947
92 203939_at NT5E 5-nucleotidase, ecto (CD73) 8.023
93 208789_at PTRF Polymerase I and transcript release factor 8.230
94 201325_s_at EMP1 Epithelial membrane protein 1 8.544
95 209488_s_at RBPMS RNA binding protein with multiple splicing 8.791
96 212358_at CLIP3 CAP-GLY domain containing linker protein 3 9.902
97 201497_x_at MYH11 Myosin, heavy chain 11, smooth muscle 10.32
98 218876_at TPPP3 Tubulin polymerization-promoting protein family member 3 10.81
100 206135_at ST18 Suppression of tumorigenicity 18 (breast carcinoma) 26.59
Table 11. The 66 probe sets identified from the 305 sample dataset as upregulated in 
inv(16) AML patients samples when compared to non-inv(16) patients and to healthy 
donor samples by fold change (FC>3) and by SAM analysis and ANOVA analysis with a 
FDR of 0.05. The fold change value displayed is the mean fold change value of the 
probe sets across the inv(16) samples. The numbers assigned to the probe sets 
correspond to their location in figure 11 and to their identification number in table 8.
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Figure 11. The relative mean expression levels of the 66 probe sets identified, from 
probe sets that were classified as present and changing, as being more significantly 
expressed in inv(16) samples than non-inv(16) samples and in donor samples by >3 
fold and through SAM and ANOVA analysis with an FDR of 0.05. The probe sets 
are coloured according to their expression levels in their respective sub-group 
relative to their expression level in the donor samples. The numbers on each block 
correspond to the probe set it is representing - see table 7 (only top 20 genes 
numbered).
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The identified probe sets (n=66) corresponded to 55 genes. MYH11, part 
of the fusion gene product CBFfi-MYHH resulting from the inv(16) 
translocation, was represented by two sets of probes, both exhibiting an 
expression greater in inv(16) samples than non-inv(16) samples and in 
donor samples by more than 4.97 fold. Three sets of probes with an 
expression greater in inv(16) samples than in the non-inv(16) samples and 
donor samples by more than 4.14 fold corresponded to the tryptase alpha 
1 and beta 1 (TPSAB1), genes previously identified in the analysis of the 
probe sets specifically expressed in t(8;21) AML patients (section 4.3.2c). 
The ST18 (suppression of tumourigenicity 18 (breast carcinoma)) gene 
was represented by the most highly expressed probe set specific to inv(16) 
AML patients by 26.6 fold.
4.3.4 Validation of Candidate Genes as MRD Markers
The MYH11, MN1, and ST18 genes were selected for further investigation 
as potential markers of MRD in inv(16) AML. The ST18 gene was selected 
as it was identified as the most highly expressed gene in inv(16) AML in 
this study and was previously identified through gene expression profiling 
as having a greater expression by 50 times in a pool of 10 AML patient 
samples compared to pools of healthy bone marrow samples in an earlier 
study by Steinbach et al (2006) (Steinbach et al, 2006). The MYH11 gene 
was selected for further analysis due to it’s representation by two probe 
sets identified as being more highly expressed in inv(16) AML than in non-
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inv(16) AML and healthy normal donors (by 4.97 fold and 10.32 fold) and 
the important role it plays in inv(16) AML. MYH11 is part of the fusion gene 
product CBF/5-MYH11 resulting from the inversion of chromosome 16.
4.3.4a Diagnostic Screening of Candidate Genes
Expression levels of the three genes (MYH11, MN1, and ST18) were 
measured in diagnostic inv(16) AML patient samples and compared to 
expression levels measured in healthy normal donor samples. Initially 
primer sets were designed for the amplification of the three genes as 
described in the Materials and Methods section 2.5.1 (Chapter 2) and 
using serial dilutions of cDNA, their amplification efficiency was compared 
to that of the house-keeping gene, S14. All three genes were seen to 
generate similar amplification efficiencies to that produced by S14. 
Therefore S14 was considered suitable as the normalising control gene 
(Figure 12).
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Figure 12. The amplification curves of the primer sets used for MYH11, MN1 and 
ST18 and of the house-keeping gene, S14, to compare their amplification efficiencies.
The levels of expression of MYH11, MN1 and ST18 were measured in 
AML diagnostic patient samples presenting with a inv(16) (n=13, 13 and 
10, respectively) and compared to the levels of expression in normal 
healthy bone marrow donor samples (n=12, 12 and 5, respectively) 
(Figure13).
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Figure 13. Scatter plots of the spread of the normalised Ct values of the candidate 
genes measured in the inv(16) AML diagnostic patient samples and the healthy 
normal donor samples. Mean value ± 95% confidence interval plotted.
Using f-tests, highly significant differences were observed between the 
mean normalised Ct values of MYH11 and MN1 in the diagnostic inv(16) 
AML patient samples and mean normalised Ct values of the two genes in 
the healthy normal donor samples The mean normalised Ct values of ST18
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was not found to be significantly from its mean normalised Ct values in the 
healthy normal donors (Table 12).
MYH11 MN1 ST18
P Value 
Are the means
<0.0001 <0.0001 0.0808
significantly 
different (p<0.05)
Yes Yes No
Number of donors 12 12 5
Donors mean value -7.628 -7.050 -7.490
Donors 95% Cl -8.63 to -6.63 -8.10 to -6.00 -10.3 to -4.68
Donors expression 
range
Number of inv(16)
-10.56 to -5.37 -9.93 to -4.33 -9.54 to -548
13 13 10
inv(16) mean value -1.039 -1.769 -4.441
inv(16) 95% Cl -2.29 to 0.21 -3.59 to 0.06 -6.73 to -2.16
inv(16) expression 
range -4.71 to 2.53 -4.68 to 3.51 -8.76 to 0.66
Table 12. The statistical significance of the mean Ct values of the candidate genes 
measured in the inv(16) AML diagnostic patient samples and the healthy normal donor 
samples normalised to the Ct values of S14. Cl = confidence interval.
4.3.4b Candidate Genes as MRD Markers
Based on findings in Section 4.3B, the expression levels of MYH11 and 
MN1 were monitored in AML patient diagnostic and follow-up samples of 
five inv(16) AML patients to identify the potential for either gene to act as a 
marker of MRD for inv(16) AML.
The fold change of the genes’ transcript expression levels relative to S14 
were calculated as described in Chapter 3 and compared to the upper fold
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change in expression observed in the healthy normal donor samples 
(Figure 5). The MRD values (MRDv) of the genes in the patient samples 
were calculated as described in Chapter 3 and compared to the level of 
transcript detected at diagnosis (Figure 6).
Normalised copy number data for the fusion gene CBFfi-MYHH and the 
WT1 gene was supplied from the Department of Clinical Haematology, 
Manchester Royal Infirmary for comparison with the fold change data 
generated for the candidate genes:
/. Patient 1
The fold change in expression of MYH11 and MN1 decreased by 
approximately 1.5 logs in patient 1 following diagnosis and induction therapy. 
The fold changes in expression remained at this lower level until 9.5 months 
following diagnosis when they began to increase, reaching a fold change in 
expression level of approximately 1 log higher by 12.75 months following 
diagnosis. Following the initial decrease after diagnosis, the levels of 
expression of both MYH11 and MN1 detected remained lower than the 
upper levels detected in healthy normal donors. This patient relapsed at 13 
months following diagnosis (Figure 14).
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//. Patient 2
The fold change in expression of MYH11 and MN1 decreased by 
approximately 3 logs in patient 2 following diagnosis and induction therapy. 
The fold changes in expression of these genes remained at this lower level 
until 8 months following diagnosis when the fold change in expression of 
MN1 began to increase, reaching a fold change in expression level of 
approximately 1.5 logs higher by 12 months following diagnosis. Following 
the initial decrease after diagnosis, the levels of expression of both MYH11 
and MN1 detected remained lower than the upper levels detected in healthy 
normal donors until approximately 10 months following diagnosis when the 
level of MN1 expression was higher than the upper level detected in healthy 
donors. This patient relapsed at 11 months following diagnosis (Figure 14).
///. Patient 3
The fold change in expression of MYH11 and MN1 decreased by 
approximately 2 logs and 1 log, respectively, in patient 3 following diagnosis 
and remained between 0.5 logs and 1 log lower than the upper level 
detected in healthy normal donors for the duration of the disease. This 
patient achieved and remained in complete remission (Figure 14).
/V. Patient 4
The fold change in expression of MYH11 and MN1 decreased by 
approximately 5 logs and 2.5 logs, respectively, in patient 4 following
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diagnosis. By 16.5 months following diagnosis the fold change in expression 
of both genes had increased to a level of approximately 1 log lower than that 
detected at diagnosis (Figure 14).
v. Patient 5
The fold change in expression of MYH11 and MN1 fluctuated throughout the 
disease of patient 5; both genes within 2 logs of the level of fold change 
detected at diagnosis. For the duration of the disease, the levels of 
expression of MYH11 and MN1 detected fluctuated within approximately 1.5 
logs of the upper level detected in healthy normal donors (Figure 14).
The MRD levels of MYH11 and MN1 decreased between 1.5 logs and 3 logs 
from the level of transcript detected at diagnosis in the inv(16) patients that 
relapsed; the corresponding normalised number of WT1 and CBFfi-MYH11 
transcripts decreased by between 2.5 logs and 5 logs following diagnosis. 
An increase in the MRD level of MYH11 and MN1 were detected at least 3 
months prior to haematological relapse in the two patients; by the time of 
relapse the MRD levels of both genes had increased between 1 and 2 logs. 
The normalised number of WT1 and CBFfi-MYHH transcripts also began to 
increase 3 months prior to haematological relapse in patient 2 but an 
increase was detected in patient 1 8 months prior to the haematological 
relapse; by the time of haematological relapse the normalised number of
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WT1 and CBF/S-MYH11 transcripts had increased by between 2 and 5 logs 
(Figures 15 and 16).
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Figure 14. Longitudinal monitoring of MYH11 (a) and MN1 (b) in five inv(16) AML 
patients. The graphs show the fold change values generated for respective genes in 
each sample, relative to the S14 gene. Red lines - patients who relapsed. Green 
lines - patients who remained in complete remission (CR). The blue dashed line 
represents the upper limit of gene expression in the healthy normal donor samples. 
The numbers in the circles indicate the patient number.
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Figure 15. Longitudinal monitoring of MYH11 (a) and MN1 (b) in five in(16) AML 
patients. The graphs show the MRD values calculated for the genes in each sample. 
Red lines - patients who relapsed. Green lines -  patients who remained in complete 
remission (CR). The numbers in the circles indicate the patient number.
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Figure 16. Longitudinal monitoring of the inv(16) fusion gene CBF(3-MYH11 (a) and 
WT1 (b) in five in(16) AML patients. The graphs show the normalised transcript 
numbers calculated for the genes in each sample. Red lines - patients who relapsed. 
Green lines - patients who remained in complete remission (CR). The numbers in the 
circles indicate the patient number.
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4.3.5 Correlation between Candidate Markers and Current Markers
The MRD data for MYH11 and MN1 was analysed for statistically 
significant associations with the inv(16) fusion gene and WT1 data 
generated for these patients.
As shown in Table 13, a positive correlation was seen between inv(16) 
and MYH11 and MN1, and between WT1 and MYH11 and MN1.
lnv(16)
r Value p Value Sigmfica
WT1*
r Value p Value Significant
MYH11
MN1
0.3087 0.0309 Yes 
0.3693 0.0077 Yes
0.4692 0.0007 Yes 
0.4229 0.0020 Yes
Table 13. A summary of the correlations between the MYH11 and MN1 MRD data 
and the inv(16) fusion gene and WT1 normalised copy number data.
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List Probe Sets
4.12 Probe sets present in at least sample with greater expression in inv(16) than in non-inv(16) samples by £3 fold (n=131)
4.13 Probe sets present in at least sample with greater expression in inv(16) than in donor samples by £3 fold (n=453)
4.14
Probe sets present in at least sample with greater expression in 
inv(16) than in non-inv(16) samples and in donor samples by £3 
fold (n=100)
4.15 Probe sets present and changing with greater expression in inv(16) than in non-inv(16) samples by >3 fold (n=94)
4.16 Probe sets present and changing with greater expression in inv(16) than in donor samples by £3 fold (n=446)
4.17
Probe sets present and changing with greater expression in 
inv(16) than in non-inv(16) samples and in donor samples by >3 
fold (n=99)
4.18 SAM analysis of all genes, FDR=0.05 (n=300)
4.19 SAM analysis of all genes, FDR=0.01 (n=147)
4.20 ANOVA analysis of present and changing probe sets, FDR=0.05 (n=7,654)
4.21 ANOVA analysis of present and changing probe sets, FDR=0.01 (n=5,405)
4.22
Probe sets common to present and changing probe sets with 
greater expression in inv(16) than in non-inv(16) samples and in 
donor samples by £3 fold, SAM analysis of all probe sets using 
an FDR of 0.05 and ANOVA analysis of probe sets present and 
changing using an FDR of 0.05 (n=66)
Table 14. The probe set lists identified from the gene expression profiling analysis 
(Section 4.3.3).
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4.4 Discussion
Core binding factor (CBF) leukaemia results from chromosomal 
aberrations involving either the CBFa subunit or the CBFp subunit 
(Appelbaum et al, 2006). Patients present with either a t(8;21) or an inv(16) 
translocation and are seen to have a relatively favourable prognosis 
(Grimwade et al, 1998). The resulting fusion gene products from these 
translocations, the AML1-ETO gene product generated from t(8;21) 
translocation and the CBF/5-MYH11 gene product generated from the 
inv(16), have been suggested as markers to monitor minimal residual 
disease (MRD) in the t(8;21) and inv(16) patients (Claxton et al, 1994). 
However, controversy has surrounded the use of these fusion genes 
products with conflicting results about the detection of these fusion 
products in some patients. Several groups were able to detect AML1-ETO 
and CBF/3-MYH11 transcripts using highly sensitive RT-PCR methods in 
some patients in long-term remission (Guerrasio et al, 1995;Tobal et al, 
1995;Jurlander et al, 1996). The Wilms’ tumour 1 (WT1) gene is often used 
as an MRD marker in AML patients but similar conflicting results regarding 
its expression in patients in remission has clouded the significance of its 
clinical use (Gaiger et al, 1998;Elmaagacli et al, 2000). Therefore gene 
expression profiling was applied to a cohort of diagnostic AML patient 
samples and donor samples to identify potential MRD markers specific to 
t(8;21) patients and to inv(16) AML patients.
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4.4.1. t(8;21) ANIL
Gene expression profiling was applied to the expression data of 290 
patients, 15 (5.2%) of which presented with a t(8;21) at diagnosis. By 
applying fold change calculations and statistical tools to the probe sets in 
the dataset identified as present in at least two samples and changing in 
expression in expression by more than two fold, 41 probe sets were 
identified as being highly expressed in t(8;21) patients compared to healthy 
normal donors. The ten most highly expressed probe sets were more 
highly expressed in t(8;21) AML than in non-t(8;21) AML and healthy 
donors by a fold of between 13.25 and 39.27 and represented six genes; 
TRH (thyrotropin-releasing hormone), POU4F1 (POU class 4 homeobox
1), IL5RA (interleukin 5 receptor, alpha), TPSAB1 (tryptase alpha/beta 1), 
ETO (runt-related transcription factor 1) and TPSB2 (tryptase alpha/beta
2). The identification of several of these genes as t(8;21)-specific is 
supported by the analysis of gene expression data from several other 
studies: Ichikawa et al (2006) analysed the gene expression profiles of 
leukaemic cells in 50 paediatric AML patients using microarrays and 
identified genes that were up- and down-regulated in the CBF sub-groups. 
As with the current study, the ETO gene and the POU4F1 gene were 
identified as highly expressed t(8;21)-specific genes. The TRH gene and 
the TPSAB1 gene were also identified as highly expressed genes but 
specific to both t(8;21) and inv(16) AML (Ichikawa et al, 2006). Using SAM 
analysis on 93 CBF AML samples, Bullinger et al (2007) identified more
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than 1000 genes that significantly correlated with the t(8;21) and inv(16) 
CBF groups. Genes defining the t(8;21) sub-group included POU4F1 and 
TRH (Bullinger et al, 2007). Steinbach et al (2006) also used microarrays 
to compare gene expressions profiles of healthy bone marrow CD34+ 
haematopoietic stem cells and 52 paediatric AML patients. Whilst this 
study was not limited to CBF AML, 23% presented with a CBF 
translocation at diagnosis. The analysis identified 158 genes as potential 
MRD markers, including PRAME, POU4F1 and TRH\ genes identified as 
t(8;21)-specific in this present study (Steinbach et al, 2006). Bullinger et al 
(2004) and Valk et al (2004) both identified ETO as discriminative to t(8;21) 
AML in studies using gene expression profiling to identify prognostically 
useful AML sub-groups (Bullinger et al, 2004;Valk et al, 2004). A study by 
Ross et al (2004) explored the concept of gene expression profiling to 
identify prognostically useful sub-groups specifically in paediatric AML as 
previously seen for adult AML. Using SAM analysis they also identified 
genes discriminative to t(8;21) AML. From their list of top 100 probe sets, 
18 were identified in this current study as t(8;21)-specific. Several of these 
probe sets represented the genes PRAME, POU4F1, ETO and IL5RA 
(Ross et al, 2004).
Based on their level of expression from the microarray analysis and 
previous associations with AML, four genes were selected for validation as 
MRD markers; PRAME, POU4F1, ETO and IL5RA. Using RQ-PCR, the
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normalised expression of the four genes relative to a house-keeping gene 
S14 were measured in a group of diagnostic t(8;21) AML patients and a 
group of healthy normal donors. Student f-tests identified a significant 
difference in the expression of the genes between the two test groups. The 
work previously mentioned by Steinbach et al (2006) further supports these 
findings with their RQ-PCR analysis of 65 of the 200 genes they previously 
identified through microarray analysis. They identified 12 genes that were 
more highly expressed by more than 50 times in one of three diagnostic 
AML groups (myelocytic AML (FAB M1/2), myelomonocytic AML (FAB M4) 
or monocytic AML (FAB M5)) compared to in healthy bone marrow CD34+ 
haematopoietic stem cells. Included in this group of genes were PRAME 
and POU4F1 (Steinbach et al, 2006). Similarly Paydas et al (2005) 
detected significant levels of PRAME expression in AML patient samples 
compared to the very low levels detected in healthy individuals (2 
copies/10,000 cells) through RQ-PCR of peripheral blood samples (Paydas 
et al, 2005). Van Baren et al (1998) observed preferential expression of 
PRAME in AML-M2 and AML-M3 patients, the AML FAB groups 
associated with the t(8;21) and t(15;17), respectively, compared to healthy 
normal donors and other FAB groups (van Baren et al, 1998). Qin et al 
(2009) investigated the expression levels of both WT1 and PRAME in 204 
diagnostic AML samples. They detected the highest levels of PRAME 
expression in FAB M2 AML patients with AML1-ETO and the second 
highest levels in APL patients with PML-RARa compared to other FAB
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group patients. Minimal levels of PRAME expression were detected in 
normal bone barrow and peripheral blood samples (Qin et al, 2009). A very 
early study by Nishii et al (1995) used Northern-blot hybridisation and 
reverse transcriptase PCR (RT-PCR) to detect the expression of IL5RA in 
a cohort of 35 AML patients. Within this sample group, IL5RA was detected 
in 17 patients; all nine FAB M2 AML patients with a t(8;21) were positive 
for IL5RA expression, as were two patients with structural abnormalities of 
chromosome 16. Only one of five M2 patients without a t(8;21) and six of 
24 patients lacking a t(8;21) or structural abnormalities of chromosome 16 
were also positive for IL5RA (Nishii et al, 1995). Whilst no healthy normal 
samples were included in this study to compare the expression of IL5RA 
with, it does highlight the specificity of IL5RA expression to CBF AML, in 
particular t(8;21), and supports the significant expression of IL5RA 
detected in the diagnostic t(8;21) samples compared to the healthy normal 
donors in this current study.
The fold change in expression and the MRD values of the four genes were 
followed in the diagnostic and several follow-up samples of three t(8;21) 
AML patients. The MRD levels of all four genes decreased by at least one 
log from the level of transcript detected at diagnosed and remained at this 
lower level in the t(8;21) patient that achieved CR and one t(8;21) patient 
that relapsed. An increase in MRD level of more than 1 log over serial 
samples was observed for PRAME, POU4F1 and ETO several months
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prior to haematological relapse for this relapsing patient; an increase in 
IL5RA was not detected till a haematological relapse occurred. The MRD 
levels of the four genes provided little information for the other relapsing 
t(8;21) patient; an increase in MRD of PRAME and ETO of less than one 
log was observed one month prior to haematological relapse. Whilst a 
positive correlation was observed between this data and the normalised 
transcript data of the t(8;21) fusion gene, it was apparent the t(8;21) fusion 
gene provided more useful information regarding the progression of the 
patient’s disease than the four candidate genes. A significant increase in 
the normalised number of AML1-ETO transcripts was observed in both 
relapsing patients; a three log increase from the level detected at least four 
months prior to when the haematological relapse occurred. Unlike the 
prognostic value of the candidate genes displayed in this current study, 
other groups have shown there to be more potential in the PRAME gene 
acting as an MRD marker. Paydas et al (2005) previously monitored 
PRAME in 15 cases of AML and detected decreased level of PRAME at 
remission and increased levels at relapses (Paydas et al, 2005). When 
monitoring PRAME in 84 serial samples collected from 14 t(8;21) M2 AML 
patients, Qin et al (2009) observed a good correlation between PRAME 
and AML1-ETO transcript levels in patients expressing AML1-ETO (Qin et 
al, 2009). The POU4F1 gene was identified by gene expression 
microarrays and validated by RQ-PCR in a previous study by Steinbach et 
a! (2006) but further analysis to identify candidate MRD markers removed
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POU4F1 from the selection and the use of POU4F1 as an MRD marker 
has not as yet been investigated by other groups. As the ETO gene forms 
one half of the fusion gene resulting from t(8;21), the potential of ETO as 
an MRD marker has not yet been investigated; instead the use of AML1- 
ETO as an MRD marker has been explored. The primers used in the 
current study for the amplification of ETO did not cover the breakpoint 
region of the ETO gene involved in the translocation of chromosomes 8 
and 21. Therefore the ETO transcripts detected may have actually been 
from AML1-ETO transcripts and therefore do not properly represent the 
behaviour of the ETO gene in t(8;21) AML patients. This problem could be 
solved by designing primers to cover the region involved in the 
translocation so only ETO transcripts are detected rather than AML1-ETO 
transcripts.
Gene expression profiling was able to identify genes specifically expressed 
in t(8;21) AML that have previously been identified in other gene 
expression profiling studies. Further investigation of the four genes 
PRAME, POU4F1, ETO and IL5RA by RQ-PCR corroborated the 
microarray results by detecting significantly high levels of expression of 
these genes in diagnostic t(8;21) AML compared to healthy normal donors. 
Unfortunately the detection of these genes in patient follow-up samples 
displayed their limitations to act as markers of MRD. Whilst some degree 
of prognostic information was obtained by the monitoring of these genes,
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the monitoring of the markers currently used, WT1 and AML1-ETO, 
provided more sensitive and reliable information. However, this could be a 
result of the lack of standardisation and optimisation of the assays used in 
this current study compared to the assays used by the Department of 
Clinical Haematology, Manchester Royal Infirmary. Further standardisation 
and optimisation of assays for the detection of the genes may provide 
more insightful results into the true potential of the genes. Various studies 
have already shown the strong potential of PRAME gene to act as a 
marker for t(8;21) AML. The investigation in ETO as a marker was limited 
by the design of primers for also allowing the potential detection of AML1- 
ETO transcripts. It would be insightful to see where the sequences of the 
probe sets representing ETO identified in the microarray analysis were 
located in relation to the translocation breakpoint to know whether they 
were detecting the expression of ETO or AML1-ETO in the t(8;21) patients 
and if the monitoring of ETO alone could help foresee haematological 
relapses. If so, ETO may also act as a useful marker for AML patients not 
expressing AML1-ETO.
4.4.2. inv(16) AML
Gene expression profiling was applied to the expression data of 290 
patients, 18 (6.2%) of which presented with an inversion of chromosome 
16 at diagnosis. By applying the fold change calculations and statistical 
tools described for the t(8;21) patients, 66 probe sets were identified as
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being highly expressed in inv(16) patients at diagnosis compared to 
healthy normal donors. The five most highly expressed probe sets were 
more highly expressed in inv(16) AML than in healthy donors by a fold of 
between 8.79 and 26.59 and represented five genes; ST18 (Suppression 
of tumourigenicity 18), TPPP3 (Tubulin polymerization-promoting protein 
family member 3), MYH11 (Myosin, heavy chain 11, smooth muscle), 
CLIP3 (CAP-GLY domain containing linker protein 3) and RBPMS (RNA 
binding protein with multiple splicing). Both Bullinger et al (2004) and Valk 
et al (2004) were able to identify specific gene signatures for the AML 
cytogenetic sub-classes, including the inv(16) sub-group, using gene 
expression microarrays. Within the gene signatures/clusters generated for 
AML patients exhibiting an inv(16), MYH11, a gene involved in the fusion 
gene created from the inversion of chromosome 16, was identified as 
discriminative to that particular sub-group (Bullinger et al, 2004;Valk et al, 
2004). As mentioned previously, Ichikawa et al (2006) identified common 
gene expression signatures in paediatric CBF leukaemic samples. 
Ichikawa et al (2006) also identified MYH11 as a highly expressed inv(16)- 
specific gene (Ichikawa et al, 2006). In agreement with a later study by 
Bullinger et al (2007), the SPARC (secreted protein, acidic, cysteine-rich) 
gene was among the genes identified as being more highly expressed in 
inv(16) AML than in healthy donors by 5.9 fold. Bullinger et al (2007) used 
SAM analysis to identify genes significantly correlated with CBF leukaemia; 
high-level expression of SPARC was found in cases with inv(16) (Bullinger
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et al, 2007). In this current study the MN1 (Meningioma 1) gene was 
identified as the 9th most highly expressed gene in inv(16) AML by a fold of 
7.95. Ichikawa et al (2006) also found a high expression of this gene in 
their gene expression profiling study but they identified it as common to 
both t(8;21) and inv(16) AML (Ichikawa et al, 2006). Whilst not a study 
restricted to CBF leukaemia, Steinbach et al (2006) identified ST18 as a 
potential MRD marker for AML patients using Affymetrix human U133A 
chips (Steinbach et al, 2006). In the study previously mentioned by Ross et 
al (2004), SAM analysis was used to identify genes discriminative to the 
paediatric AML sub-groups. From the list of probe sets identified for inv(16) 
AML, 12 were identified in this current study also as specific to inv(16) 
AML; MYH11, MN1 and ST18 were represented by several of the probe 
sets identified (Ross et al, 2004).
Based on their level of expression from the microarray analysis and 
previous associations with AML, three genes were selected for validation 
as MRD markers; MYH11, MN1, and ST18. As previously seen with the 
t(8;21) genes, RQ-PCR was used to detect the levels of these three genes 
in diagnostic inv(16) AML patients and normal healthy donors. A significant 
difference in the mean expressions of MYH11 and MN1 in the inv(16) AML 
patient group and the healthy normal donor group was observed 
(p<0.0001) but not for ST18 (p=0.0808). In disagreement with the results 
for ST18, Steinbach et al (2006) followed up on the identification of ST18
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through microarray by validating its expression in two pools of AML 
samples and two pools of healthy bone marrow samples by RQ-PCR. 
ST18 expression was detected in the AML pools at a level 50 times greater 
than in the healthy bone marrow pools (Steinbach et al, 2006). However 
these findings would be influenced by the mix of cytogenetics within the 
AML pools tested whereas the AML samples study in this study were 
known to all exhibit an inv(16) and arrayed separately. Carella et al (2007) 
detected levels of MN1 in inv(16) M4 AML samples at significantly higher 
level than in normal bone marrow samples by QRT-PCR. They also 
observed the levels of MN1 mRNA detected were far greater than 
determined by microarray analysis (Carella et al, 2007).
The fold change in expression and the MRD values of MYH11 and MN1 
were followed in the diagnostic and several follow-up samples of five 
inv(16) AML patients. Both genes displayed a decrease in expression fold 
change following diagnosis to levels lower than the upper limit detected in 
healthy normal donors in the five patients. The levels of MRD remained 
fairly consistent during the disease of the patients that achieved a 
complete remission but began to rise in the two patients that relapsed 
approximately three months prior to a haematological relapse and a 
positive correlation was seen between the MRD data for MYH11 and MN1 
and the WT1 and CBF/5-MYH11 transcript data. In some of the patients the 
decrease and increase in WT1 and CBF/5-MYH11 transcripts was greater
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by several logs than that detected for the MYH11 and MN1 MRD level 
suggesting the markers currently used are more sensitive and provide 
more reliable information in regards to the patient’s disease. There are 
currently no studies into the use of MYH11 as an MRD marker in inv(16) 
AML. As it forms one half of the resulting fusion gene CBFfi-MYHH 
studies have understandably concentrated on the inv(16) fusion gene as 
an MRD marker instead (Marcucci et al, 2001;Guerrasio et al, 2002;Perea 
et al, 2006;Lane et al, 2008). The inversion of chromosome 16 results in 
the fusion of the majority of the CBFfi gene and the tail domain of the 
MYH11 gene; Liu et al (1993) identified a single breakpoint located close to 
the 3’ end of the coding region and 3 breakpoints in the MYH11 gene (Liu 
et al, 1993). The primers used in the current study for MYH11 did not cover 
any of the three breakpoints previously identified. As a result the MYH11 
transcript supposedly detected by RQ-PCR had the potential to be a result 
of the detection of CBF/5-MYH11 mRNA rather than MYH11 mRNA alone. 
Therefore, as with the analysis of ETO in the t(8;21) patients, the analysis 
of MYH11 may not be a true representation of the potential of MYH11 to 
act as an MRD marker. To overcome this problem the primers designed for 
the amplification of MYH11 need to stretch across the region disrupted 
through the inversion of chromosome 16; a potential problem due to the 
option of three breakpoints.
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Gene expression profiling was able to identify genes specifically expressed 
in inv(16) AML that have previously been identified in other gene 
expression profiling studies, as for t(8;21) AML. Further investigation in the 
three genes MYH11, MN1 and ST18 by RQ-PCR identified MYH11 and 
MN1 displaying a significant level of expression in diagnostic inv(16) 
patients compared to healthy normal donors but ST18 did not despite 
being represented by the probe set identified in the initial microarray 
analysis as the most highly expressed probe set in inv(16) AML compared 
to healthy normal donors by a fold of 26.59. As with the markers currently 
used for t(8;21) monitoring, the inv(16) fusion gene and WT1 provided 
more sensitive and reliable information in some of the patients. Further 
standardisation and optimisation of assays for the detection of the genes 
may also prove to be more insightful results in this AML sub-group also.
As for ETO, the investigation in MYH11 as a marker was limited by the 
design of primers allowing for the detection of CBF/5-MYH11 transcripts 
also. Further investigation involving primers covering the MYH11 
breakpoints would help solve this problem but with multiple breakpoints it 
may be necessary to generate multiple primers for individual cases. Finally 
a much larger patient cohort is required to conclusively determine how well 
these genes monitor MRD and the clinical significance of their behaviour 
during the disease.
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Chapter 5 
Gene Expression profiling of 
Normal Karyotype AML
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5.1 Introduction
5.1.1 Cytogenetics
Cytogenetic aberration is recognised as a very important factor in the 
prognosis of acute myeloid leukaemia (AML) and is used routinely in 
clinical practice to predict a patient's outcome (Grimwade et al, 
1998;Mrozek et al, 2004). Newly diagnosed AML patients exhibiting a 
translocation between chromosome 8 and chromosome 21, a 
translocation between chromosome 15 and chromosome 17 or an 
inversion of chromosome 16 are classified as having a favourable 
prognosis. Various studies have identified patients bearing these 
translocations to have low rates of primary drug resistance, greater 
complete remission (CR) rates compared to those with normal 
cytogenetics and greater overall survival (OS) associated with a 
reduced relapse risk (RR) (Grimwade et al, 1998;Byrd et al, 2002). AML 
patients with a normal karyotype belong to the largest cytogenetic 
group, accounting for approximately 45% of newly diagnosed de novo 
AML patients (Baldus et al, 2007). These patients are placed in the 
intermediate risk group because their CR rates and survival 
probabilities are lower than those with a t(8;21), t(15;17) or an inv(16) 
(Grimwade et al, 1998;Byrd et al, 2002). Despite having no detectable 
chromosomal abnormality following standard metaphase analysis, this 
subset of patients is extremely heterogeneous at the molecular level; 
several gene mutations and changes in gene expression have been 
identified in normal karyotype AML patients that have been shown to 
have an effect on the prognosis and clinical outcome of the patient’s
223
disease (Mrozek et al, 2007b). An internal tandem duplication (ITD) of 
the fms-like tyrosine kinase 3 (FLT3) gene is a commonly seen genetic 
alteration in AML, occurring in -30% of AML cases (Kiyoi et at, 
1999;Thiede et al, 2002;Mrozek et al, 2007b). In addition to the ITD, 
point mutations in the activation loop of the tyrosine kinase domain 
(TKD) of the FLT3 gene have been reported in -7% of AML patients 
(Yamamoto et al, 2001;Thiede et al, 2002). Resulting in constitutive 
activation of the FLT3 kinase, an ITD of the FLT3 gene is associated 
with a decreased overall survival (OS) in normal karyotype patients 
(Kottaridis et al, 2001;Whitman et al, 2001;Bienz et al, 2005). To 
summarise, AML patients under the age of 60 years presenting with 
FLT3-ITD confer a poorer prognosis (Abu-Duhier et al, 2000). A 
mutation in exon 12 of the nucleophosmin (NPM1) gene results in the 
abnormal localisation of the nucleophosmin protein in the cytoplasm 
(Falini et al, 2005;Suzuki et al, 2005). The incidence of NPM1 mutations 
in normal karyotype patients is approximately 40-50% and they are 
associated with significantly higher complete remission (CR) rates 
(Falini et al, 2005;Suzuki et al, 2005;Schnittger et al, 2005;Mrozek et al, 
2007a). Approximately 40% of normal karyotype AML patients 
harbouring an NPM1 mutation also harbour a FLT3-ITD; in this context 
the favourable prognosis of the NPM1 mutation is lost (Schnittger et al, 
2005;Dohner et al, 2005;Thiede et al, 2006).
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5.1.2 Minimal Residual Disease Markers
Many studies have assessed the usefulness of monitoring minimal 
residual disease (MRD) in AML patients to improve their treatment 
regimes but these are limited to the fusion gene products resulting from 
the favourable translocations detected through RQ-PCR in those 
“favourable risk” patients (Grimwade & Lo Coco, 2002;Guerrasio et al, 
2002). Those patients with a “normal” karyotype currently lack a 
cytogenetic lesion that can be monitored for the purpose of MRD. 
Despite this, some genes are currently being investigated for and are 
currently used for the monitoring of MRD in patients with a favourable 
prognosis and those that are cytogenetically normal but controversy 
surrounds their use as markers. One such gene is Wilms’ Tumour 1 
(WT1), a tumour-suppressor located on chromosome 11 that was 
originally identified for its role in Wilms’ tumour, a tumour of the kidneys 
(Call et al, 1990). In normal haematopoietic cells WT1 has been shown 
to have a significantly lower level of expression compared to that 
observed in leukaemic cells at diagnosis. Furthermore, an increase in 
WT1 expression following treatment has been associated with relapse 
leading WT1 to be suggested as a good candidate for MRD monitoring 
(Inoue et al, 1997) (Cilloni et al, 2002). Despite many studies agreeing 
that WT1 has the potential to act as an MRD marker, others disagree. 
Gaiger et al (1998) observed no difference in disease-free survival 
(DFS) and survival from remission in WT1-positive and WT1-negative 
AML patients in CR following treatment whilst Elmaagacli et al (2000) 
observed that following allogenic bone marrow (BM) or peripheral blood
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stem cell (PBSC) transplant, WT1 was not reliable as an MRD marker 
or as a predictor of relapse (Gaiger et al, 1998) (Elmaagacli et al, 2000). 
Mutations in exon 12 of the NPM1 gene have been reported as the 
most common genetic abnormality occurring in de novo normal 
karyotype AML patients at diagnosis (Boissel et al, 2005;Falini et al, 
2007). As a result of these findings many groups have investigated the 
potential of the NPM1 gene as a marker of MRD for long-term 
monitoring. Sensitive RQ-PCR assays have been developed that have 
demonstrated the reliability of NPM1 gene mutations as MRD markers 
during long-term follow-up periods in the majority of normal karyotype 
AML patients (Gorello et al, 2006;Chou et al, 2007). However, other 
studies have reported a loss of NPM1 mutations in relapsed AML 
patients and an AML patient presenting with clonal evolution at relapse 
questioning the long-term stability and reliability of NPM1 as a marker of 
MRD (Suzuki et al, 2005;Papadaki et al, 2009).
5.1.3 Gene Expression Profiling
Transcriptomics is a widely used molecular approach allowing the 
simultaneous analysis of thousands of genes and allowing for the 
identification of changes in mRNA level between experimental 
conditions. Various methods are used by researchers for the selection 
of differentially expressed genes to establish different behaviours 
between control and diseased/treatment situations (Baldi & Long, 
2001;Mutch et al, 2002). Microarray gene expression profiling is 
commonplace in AML for identifying specific gene signatures that can
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help provide important information regarding diagnosis, prognosis and 
relevant therapies of patients. An early study by Golub et al (1999) 
suggested roles of gene expression profiling for class discovery (the 
identification of new subgroups), class prediction (using genes to 
predict already defined subgroups) and finally for class comparison (the 
identification of deregulated genes that may be responsible for certain 
biological properties) (Golub et al, 1999). Later studies demonstrated 
the association of the disease-specific favourable gene translocations; 
t(8;21), t(15;17) and inv(16), with distinct gene expression profiles 
(Schoch et al, 2002;Valk et al, 2004). The uses of gene expression 
profiling has developed further as various studies have shown its role in 
risk classification and subset identification for therapeutic targeting 
(Wilson et al, 2006;Raponi et al, 2007).
The aim of this chapter was to use gene expression profiling on a 
cohort of normal karyotype diagnostic AML patients and normal healthy 
donors to identify genes that may have the potential to monitor MRD in 
AML patients due to their specific expression patterns and significant 
levels of expression compared to those in normal healthy donors.
5.2 Materials and Methods
5.2.1 Patient and donor samples
Three gene expression datasets were used for the gene expression 
analysis to identify differentially expressed genes between normal 
karyotype AML patients and healthy donors.
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5.2.1a Core Dataset
The core dataset contained gene expression data from 72 normal 
karyotype AML diagnostic patient samples, obtained from 69 patients, 
and 10 healthy donor samples. The samples were obtained at the time 
of diagnosis and processed for microarray analysis by either the School 
of Medicine, Cardiff University or the University College Hospital, 
London (duplicate samples, processed on both sites, were available for 
three of the normal karyotype AML patients) (Table 1).
5.2.1b Expanded (with extra donors) dataset
The expanded (with extra donors) dataset contained data for the 82 
samples in the core dataset (described in 5.2.1a) plus expression data 
for an extra 44 healthy donor samples generated by other research 
groups; 19 samples from a second study by the School of Medicine, 
Cardiff University, 5 healthy donor samples from a Dutch-Belgium study 
(GEO accession: GSE 1159) (Valk et al, 2004) and 20 healthy donor 
samples from an American study (GEO accession number: GSE 9476) 
(Stirewalt et al, 2008) (Table 1).
5.2.1c Expanded (with public data) dataset
The expanded (with public data) dataset included the gene expression 
data for the extra 54 healthy donor samples previously mentioned for 
the expanded (with extra donors) dataset (5.2.1b) plus gene expression 
data for 124 normal karyotype AML diagnostic patient samples 
generated by two other research groups; 115 normal karyotype AML
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diagnostic samples from the Dutch-Belgium study (GEO accession: 
GSE 1159) (Valk et al, 2004) and 9 normal karyotype AML diagnostic 
samples from the American study (GEO accession number: GSE 9476) 
(Stirewalt et al, 2008) (Table 2).
The patient and donor RNA was extracted from bone marrow aspirates 
and peripheral blood using guanidinium thiocyanate (GSE 1159), 
TRIzol® reagent (GSE 9476, Cardiff samples) or the RNeasy® kit 
(Cardiff samples). The effect of total RNA isolation techniques on the 
precision and reproducibility of gene expression data has been 
investigated in a study by Campo Dell’Orto at al (2007). By comparing 
different total RNA isolation methods they concluded that the underlying 
biological characteristics of paediatric acute leukaemia classes largely 
surpassed any variations generated between the different protocols 
used and did not impair the overall distribution of the probe set signal 
intensity (Campo Dell'Orto et al, 2007). The samples were hybridised to 
Affymetrix human U133A or U133Plus2.0 Genechips.
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Characteristic Value
Sex - no. (%)
Male 32 (46.4)
Female 36 (52.2)
Not determined 1 (1.4)
Age group -  no. (%)
<30 years 4 (5.8)
30-60 years 22 (31.9)
>60 years 43 (62.3)
Age -  years
Median 64
Range 17-87
French-American British Classification - no. (%)
M0 4 (5.8)
M1 18 (26.1)
M2 16 (23.2)
M3 0 (0)
M4 15 (21.7)
M5 7 (10.1)
M6 2 (2.9)
M7 1 (1.4)
Bi 1 (1.4)
Not determined 5 (7.4)
Molecular Abnormalities -  no. (%)
Mutation
FLT3 Internal tandem 27 (39.1)
duplication (ITD)
FLT3 Tyrosine kinase 8 (11.6)
domain (TKD)
NPM1 24 (34.8)
ITD+/NPM1 + 11 (15.9)
ITD+/NPM1- 6 (8.7)
ITD"/NPM1 + 13 (18.8)
ITD7NPMT 13 (18.8)
Table 1. The frequencies and percentages of the clinical and molecular 
characteristics of the 69 patients diagnosed with normal karyotype AML in the 
core dataset and the expanded (with extra donors) dataset. Duplicate 
samples were available for 3 of the patients.
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Characteristic Value
Sex - no. (%)
Male 5 (4.0)
Female 4 (3.2)
Not determined 115 (92.8)
Age group -  no. (%)
<30 years 0 (0)
30-60 years 5 (4.0)
>60 years 4 (3.2)
Not determined 115 (92.8)
Age -  years
Median* 58
Range* 38-79
French-American British Classification - no. (%)
MO 0 (0)
M1 40 (32.3)
M2 24 (19.4)
M3 0 (0)
M4 21 (16.9)
M5 32 (25.8)
M6 2 (1.6)
M7 0 (0)
MDS/AML 1 (0.8)
Not determined 4 (3.2)
Molecular Abnormalities -  no. (%) 
Mutation
FLT3 Internal tandem 57 (46.0)
duplication
FLT3 Tyrosine kinase 9 (8.1)
domain
Table 2. The frequencies and percentages of the clinical and molecular 
characteristics of the 124 patients diagnosed with normal karyotype AML in 
the expanded (with public data) dataset from the GEO database (GSE9476 
and GSE1159) (*data not available for GSE1159). No NPM1 data was 
available for either dataset.
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5.2.2 Data Analysis
5.2.2a Expression summarisation
Image files (CEL files) were analysed using the statistical algorithms in 
MAS 5.0 using target intensity (TGT) of 100. The resultant data matrix 
of expression levels for each probe set was taken forward for further 
analysis (see accompanying DVD for CEL files).
5.2.2b Fold Change Calculation
A simple method for identifying differentially expressed genes between 
test groups is that of fold change. A gene is said to have significantly 
changed in expression if its mean expression value varies by more than 
a set factor between the control group and the test group. As a fold 
change calculation only takes into account the mean of the expression 
values, outlier values can greatly affect the mean expression value such 
that genes may be identified as significantly under or over expressed 
when in fact they are not in the majority of samples.
5.2.2c Improved Fold Change Calculation
As described above, the process of identifying differentially expressed 
genes on a global scale can easily be marred by the odd erroneous 
gene expression level present in some samples that underplay (or 
overplay) the true difference in fold change of the genes between the 
sample groups. To overcome this problem, and calculate a more 
accurate fold change value for the genes, the process of outlier 
detection and removal can be applied. A programme designed to
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identify and remove data outliers initially calculates the median and the 
median absolute deviation value (MAD) for the whole data set. The 
MAD is the median of the absolute values of the differences between 
values and is a more robust measurement of variance than standard 
deviation; the standard deviation is more sensitive to outliers whereas 
the MAD value is not altered by their presence. Data values of more 
than 3 MAD away from the median value are identified as outliers and 
removed from the data set. The median and the MAD are then re­
calculated for the remaining data and again data values of more than 3 
MAD away from the median value are identified as outliers and 
removed from the data set. This process is continued until all the data 
values sit within 3 MAD of the current median value of the data set 
(Figure 1).
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Figure 1. Schematic of the method used by the outlier programme to identify and 
remove outliers from the data set. The median value of the data set is calculated 
and values more than 3 MAD away are identified as outliers and removed (1). 
The median value is re-calculated and values more than 3 MAD away from the 
median value are identified as outliers and removed (2). The process is repeated 
(3) until all values lie within 3 MAD of the median value (4).
5.2.2d Detecting Differential Gene Expression
A simple fold-change approach for gene expression profiling is unlikely 
to yield optimal results as it only looks at the mean of the expression 
values. A Mest approach can provide information of greater significance 
by looking at the spread of the data (variance) as well as the location 
(mean) to give a statistical score of any “true” differences observed 
between two test sets. Disadvantages of a basic Mest include low 
repetition numbers leading to an underestimation of variance. A 
Bayesian Mest combines the use of prior distributions and likelihood to
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provide all relevant information regarding mean and variance allowing 
for the detection of potentially significant changes in gene expression 
between groups that would otherwise be missed by fold-change or 
simple Mest calculations (Baldi & Long, 2001).
5.2.2e Batch Correction
Non-biological differences between samples can occur when combining 
gene expression data generated by several different groups or 
platforms. When data is initially analysed, samples are seen to cluster 
based on which experiment they belong to rather than any informative 
biological differences occurring between the samples. This “batch- 
effect” can be adjusted using several methods. Unfortunately many 
methods may remove real biological variation from the data and require 
large numbers of samples for optimum results. The Empirical Bayes 
(EB) method is a robust method suitable for small batch sizes 
commonly used to adjust batch effects seen in microarray data. This 
method assumes that phenomena resulting in a batch effect will affect 
many genes in a similar way and uses this idea to make better 
estimates and adjustments across genes in an experiment (Johnson et 
al, 2007).
5.2.2f Biological Pathways and Networks
PathwayArchitect® (Stratagene) uses a repository of over 2 million 
biological findings derived from interaction databases and current 
literature. Using manual curation and text mining algorithms, it identifies
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the relationships, or interactions, between proteins and small 
molecules, also known as entities. A collection of entities and 
interactions are visualised through biological interaction networks (BIN). 
To identify more statistically relevant interactions, relevance interaction 
networks (RIN) are generated -  advanced statistical models are used to 
maximise the biological relevance of the genes/proteins and their 
interactions (Stratagene Software Solutions). MetaCore™ (GeneGO) is 
a manually curated database of protein-protein and protein-DNA 
interactions, and metabolic and signalling pathways that can also 
analyse microarray data for the identification of statistically significant 
pathways and networks.
5.3 Results
5.3.1 Expression profiling to identify MRD markers in normal 
karyotype AML patients.
Gene expression profiling is a useful and powerful tool to help identify 
specific gene expression patterns across different disease states. To 
identify potential markers of minimal residual disease for AML patients 
with a normal karyotype, gene expression profiling was used to identify 
genes differentially expressed between normal karyotype AML patients 
and normal healthy donors. The initial analysis was performed on a 
core dataset consisting of 72 normal karyotype AML samples and 10 
healthy bone marrow samples.
236
5.3.2 Improving the estimate of fold change and its importance in 
MRD marker identification
To act as a reliable marker of MRD, the expression levels of a particular 
gene need to be significantly differentially expressed between the 
disease state and the normal healthy state. Ideally a candidate gene 
should be highly expressed in the normal karyotype AML patients but 
have much lower, if not absent, levels of expression in healthy normal 
donors. To begin the analysis, a simple fold change calculation was 
applied to the core dataset to identify genes differentially expressed 
between the normal karyotype AML samples and the healthy donor 
samples by more than 4 fold and compared to genes similarly identified 
from the core dataset with any outliers removed. To remove the outliers, 
expression values more than 3 median absolute deviation values (MAD) 
away from the median expression value were identified as “outliers” and 
removed resulting in the median value being recalculated and the 
process repeated (see materials and methods) (Figure 2). With the 
removal of outliers and more accurate mean expression values 
calculated, a more accurate list of differentially expressed genes was 
generated.
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Figure 2. Dot plot of the relationship between the gene expression values from 
the original core dataset and from the “outlier free” core dataset.
5.3.3 Identification of MRD markers in the core dataset
Continuing with the “outlier-free” core dataset, a fold change calculation 
was applied to identify fold change differences between the normal 
karyotype AML diagnostic patient sample and the healthy donor 
samples. A Bayesian f-test was also applied to the core dataset, without 
the outliers removed, to improve the identification of genes with 
differences in expression between the two test groups by looking at the 
spread of the data (variance) as well as the mean of the data. 
Combining the genes identified through the Bayesian f-test (p<0.05) 
with the “outlier-free” genes identified as being differently expressed 
between the two test groups by more than 4 fold, 552 probe sets were
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identified as being differentially expressed between normal karyotype 
AML patient samples and healthy donor samples. A cluster analysis of 
these genes in the core dataset revealed a distinct formation of two 
clusters; the healthy donor samples and the normal karyotype AML 
diagnostic patient samples (Figure 3).
From these identified genes, 92 probe sets were shown to be 
upregulated in the normal karyotype AML samples compared to in the 
normal healthy donors and 460 probe sets were downregulated 
compared to the healthy donors.
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Figure 3. Heatmap of the 552 probe sets identified as being differentially 
expressed between the normal karyotype AML patient samples (light blue) and 
the healthy donor samples (dark blue) by Bayesian Mest (p<0.05) and a fold 
change calculation (FC>4) in the core dataset. The colours relate to the 
expression level of the genes to indicate either a high level of expression (red) 
or a low level of expression (green). The genes are displayed on the vertical 
axis and the samples are displayed on the horizontal axis.
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5.3.4 Improved identification of MRD markers using an expanded 
donor dataset
To improve the strength of the analysis, the core dataset was expanded 
with the addition of the expression data for another 44 healthy donor 
samples derived from two other studies (GEO accession: GSE 1159, 
GSE 9476). An analysis to identify the 1000 most variable genes was 
performed on the newly expanded (with extra donors) dataset and an 
unsupervised cluster analysis of these genes identified a problem with 
the donor samples; the cluster analysis identified 3 distinct clusters 
defined by the specific experiment they came from rather than their 
gene expressions. An EB-method of batch correction was applied to 
adjust the data and remove any distinct experimental-source problems. 
After the batch correction had been applied to the data no specific 
gene-expression-sample origin pattern was observed with an 
unsupervised cluster analysis (Figure 4).
A further cluster analysis of the 552 probe sets previously identified 
from the core dataset in the expanded (with extra donors) dataset of 
126 samples demonstrated the formation of two distinct clusters based 
on their levels of gene expression between the healthy donor samples 
and the normal karyotype AML patient samples, with the exception of 3 
healthy donor samples originating from two Cardiff studies that 
clustered in with the normal karyotype AML patient samples (Figure 5).
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Figure 4. An unsupervised cluster analysis of the 1000 most variable genes identified from the expanded (with extra donors) dataset in the 54 
healthy donor samples before batch correction (A) and after a batch correction (B) was applied. The colours of the heatmaps relate to the 
expression level of the genes to indicate either a high level of expression (red) or a low level of expression (green). The genes are displayed 
on the vertical axis and the samples are displayed on the horizontal axis. (Maroon = GEO samples, sea green = Cardiff samples HU133A, 
Lilac = Cardiff samples HU133Plus2.0)
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Figure 5. Heatmap of the 552 probe sets previously identified from the core dataset 
as having differences in expression between the normal karyotype AML patient 
samples (light blue) and the healthy donor samples (dark blue) by Bayesian Mest 
(p<0.05) and a fold change calculation (FC>4) applied to the batch-corrected 
expanded (with extra donors) dataset. The colours relate to the expression level of the 
genes to indicate either a high level of expression (red) or a low level of expression 
(green). The genes are displayed on the vertical axis and the samples are displayed 
on the horizontal axis. Light blue indicate normal karyotype AML, dark blue indicate 
healthy donor samples.
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To validate the identification of the significant genes and improve on the 
strength of the initial analysis applied to the core dataset further, the same 
process was applied to the dataset expanded with extra donors to identify 
a new list of genes differentially expressed between the healthy donor 
samples and the normal karyotype patient AML diagnostic samples. The 
same outlier programme was applied to the expanded (with extra donors) 
dataset to identify and remove any outlier values as before and provide 
more “accurate” fold change values. The fold change calculation (FC>4) 
was applied to the “outlier-free” data and the Bayesian Mest (P<0.05) was 
applied to whole data set to identify genes with differences in expression. 
When the two sets of identified genes were combined 1577 probe sets 
were identified as being common to both analyses. Cluster analysis of 
these genes in the 126 sample dataset demonstrated a distinct clustering 
of the healthy donor samples and of the normal karyotype AML diagnostic 
patient samples, with the same 3 healthy donor samples seen previously 
clustered with normal karyotype AML samples (Figure 6).
From these identified genes, 25 probe sets were shown to be upregulated 
in the normal karyotype AML samples compared to in the donor healthy 
normal donors (Table 3, Figure 7) and 1552 probe sets were 
downregulated. From the new list of probe sets identified, 13/25 (52%) 
were previously identified in the initial analysis of the core dataset and 6/7
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(85.7%) of the new probe sets with a fold change of more than 10 were 
also previously identified in the initial analysis.
Figure 6. Heatmap of the 1577 probe sets identified as being differentially expressed 
between the normal karyotype AML patient samples (light blue) and the healthy donor 
samples (dark blue) through a Bayesian f-test (p<0.05) and a fold change calculation 
(FC>4) in the expanded (with extra donors) dataset. The colours relate to the 
expression level of the genes to indicate either a high level of expression (red) or a 
low level of expression (green). The genes are displayed on the vertical axis and the 
samples are displayed on the horizontal axis.
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Probe set GeneSymbol Gene Title
Fold
Change
213147 at HOXA10 Homeobox A10 4.030
218000 s at PHLDA1 Pleckstrin homology-like domain, family A, member 1 4.084
212803 at NAB2 NGFI-A binding protein 2 4.141
214488 at RAP2B RAP2B, member of RAS oncogene family 4.171
209983 s at NRXN2 Neurexin 2 4.195
201243 s at ATP1B1 ATPase, Na+/K+ 4.252
206532 at - Human Ini1 mRNA, complete cds 4.296
204069 at MEIS1 Meis homeobox 1 4.446
206674 at FLT3* fms-related tyrosine kinase 3 4.584
205453_at HOXB2 Homeobox B2 4.621
214880 x at CALD1 Caldesmon 1 4.988
211039 at CHRNA1 Cholinergic receptor, nicotinic, alpha 1 5.538
219908 at DKK2 Dickkopf homolog 2 (Xenopus laevis 5.705
213150 at HOXA10 Homeobox A10 5.736
211125 x at GRIN1 Glutamate receptor 6.637
215441 at - Human clone 23842 mRNA sequence 7.490
216011 at SLC39A9 Solute carrier family 39 7.594
206310 at SPINK2 Serine peptidase inhibitor 8.030
213110 s at COL4A5 Collagen, type IV, alpha 5 10.593
214651 s at HOXA9 Homeobox A9 11.044
213844 at HOXA5 Homeobox A5 11.274
206067 s at WT1 Wilms’ tumour 1 14.051
217698 at - /DB_XREF=AV651668/CLONE=GLCCSC04 16.936
209905_at HOXA9 Homeobox A9 17.454
205366_s_at HOXB6 Homeobox B6 36.732
Table 3. The 25 probe sets identified from the expanded (with extra donors) dataset as 
upregulated in normal karyotype AML patients samples when compared to healthy 
donor samples by fold change (FC>4) and a Bayesian Mest (P>0.05). *39.1% of 
patients presented with a FLT3-ITD and 11.3% of patients presented with a FLT3-TKD.
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Figure 7. Heatmap of the 25 probe sets identified as being up regulated in the normal 
karyotype AML patient samples (light blue) compared to the healthy donor samples 
(dark blue) through a Bayesian Mest (p<0.05) and a fold change calculation (FC>4) in 
the expanded (with extra donors) dataset. The colours relate to the expression level of 
the genes to indicate either a high level of expression (red) or a low level of 
expression (green). The genes are displayed on the vertical axis and the samples are
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5.3.5 Validation of identified MRD markers using publicly available 
datasets
in order to validate the findings of the initial and second analyses and 
confirm the potential application of the identified genes as markers of 
MRD, the 25 up-regulated probe sets were applied to a new dataset 
containing the 54 healthy donor samples previously used and a new set of 
124 normal karyotype diagnostic AML samples obtained from the two 
independent studies used previously for their healthy donor samples (GEO 
accession: GSE 1159, GSE 9476). Looking at the expression levels of 
these 25 probe sets only in healthy normal samples and normal karyotype 
AML diagnostic samples, the two conditions separated into two distinct 
clusters; the normal karyotype AML diagnostic samples and the healthy 
normal samples (Figure 8). The 3 normal donor samples, previously seen 
to cluster with the normal karyotype diagnostic AML samples (Figures 5 
and 6) clustered with the other healthy donor samples in the new 
expanded dataset.
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Figure 8. A heatmap of the 25 probe sets identified as being up regulated in the 
normal karyotype AML patient applied to a new expanded dataset containing the 54 
previously used healthy donor samples (dark blue) and 124 new AML normal 
karyotype samples from two independent studies (light blue) (GEO accession: GSE 
1159, GSE 9476). The colours relate to the expression level of the genes to indicate 
either a high level of expression (red) or a low level of expression (green). The genes 
are displayed on the vertical axis and the samples are displayed on the horizontal 
axis.
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5.3.6 Pathway analysis of identified genes
The 25 probe sets identified as up-regulated were analysed in 
PathwayArchitect® to identify statistically relevant interactions between the 
proteins coded by the genes and the networks containing these 
interactions. A “relevance binding Interaction” network can be generated 
for proteins that physically interact with each other. From the 25 identified 
probe sets, proteins encoded by 13 genes, including the 3 homeobox A 
family members (HOXA) and the homeobox gene MEIS1 (myeloid 
ecotropic viral integration site 1 homolog), were identified as physically 
interacting with each other and forming a biologically relevant network. 
Within the pathways the HOXA9 protein appears to have central role 
interacting with the proteins MEIS1, HOXA5, HOXA10, WT1 (Wilms’ 
tumour), NAB2 (NGFI-A binding protein 2) and COL4A5 (collagen, type IV, 
alpha 5) through other intermediate proteins. Nine genes, including the 
homeobox B family member HOXB6, from the original list of 25 probe-sets 
were not found to code for proteins involved in a binding interaction 
network (Figure 9). A “relevance transcription regulation” network is 
generated from interactions occurring between proteins and small 
molecules involved in the regulation of transcription. From the original list 
of 25 probe sets, proteins encoded by 4 genes were identified as 
interacting in the regulation of transcription and forming a biologically 
statistically relevant network for this regulation; WT1, glutamate receptor, 
ionotropic, N-methyl D-aspartate 1 (GRIN1), HOXA10 and NAB2 (Figure
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10). All of these 4 genes were identified as coding for proteins with a 
statistically significant role in the relevance binding network also. The 
smallest binding network consisted of two identified proteins; SLC39A9 
(solute carrier family 39 (zinc transporter), member 9) and PHLDA1 
(pleckstrin homology-like domain, family A, member 1), connected by an 
intermediate protein, TCF (transcription factor). The third pathway 
contained 4 proteins encoded by the list of upregulated genes; GRIN1 
(glutamate receptor, ionotropic, N-methyl D-aspartate 1), CALD1 
(caldesmon 1), AP3S1 (adaptor-related protein complex 3, sigma 1 
subunit) and FLT3 (fms-like tyrosine kinase 3). The FLT3 gene is 
preferentially expressed in early haematopoietic progenitors and 
expressed at high levels in approximately 90-100% of AML cases (Birg et 
al, 1992;Carow et al, 1996)
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Figure 9. A relevance interaction network (RIN) showing the proteins coded by the 
genes identified as up-regulated in the normal karyotype AML diagnostic samples 
compared to the healthy donor samples from the expanded (with donors) dataset and 
their involvement in binding interactions i.e. they physically interact with each other. 
Only 13 genes were found to code for a protein with a binding interaction (circled with 
dark blue) and 3 networks were identified. Ca = Calcium
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Figure 10. A relevance interaction network (RIN) showing the proteins encoded by 
the genes identified as up-regulated in the normal karyotype AML diagnostic samples 
compared to the healthy donor samples from the expanded (with donors) dataset and 
their interactions in the regulation of transcription and the network they form. Only 4 
genes were found to code for proteins with a transcription regulation interaction 
(circled with dark blue). Estra = Estrace, Sust = Sustanon.
The 25 probe sets identified from the gene expression analysis was also 
applied to the GeneGO MetaCore® software to identify statistically 
significant pathways and diseases associated with the genes. A set of 10 
pathways was generated (p<0.05); pathways associated with cell adhesion 
(n=5, 50%), cytoskeleton remodelling (n=3, 30%), development (n=1, 10%) 
and G-protein signalling (n=1, 10%) (Table 4, Figure 11). The upregulated 
genes were also identified as having a statistically significant association 
with 50 diseases (p<0.005); 19/50 (38%) were haematological diseases, 
12/50 (24%) were development of kidney and gonad-related diseases 
(Table 5, Figure 11).
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Pathway Map pValue Networkobjects
Cell adhesion, Endothelial cell contacts 
by non-junctional mechanisms 
Cell adhesion, Plasmin signalling
8.76E-03
1.28E-02
1/24
1/35
Development,Flt3 signalling 1.60E-02 1/44
Cell adhesion, Integrin-mediated cell 
adhesion and migration 
Cytoskeleton remodeling, Integrin 
outside-in signalling
G-protein signalling, Proinsulin C-peptide 
signalling
Cell adhesion, ECM remodeling
1.75E-02
1.78E-02
1.89E-02
1.89E-02
1/48
1/49
1/52
1/52
Cell adhesion Chemokines and adhesion 3.62E-02 1/100
Cytoskeleton remodeling, Cytoskeleton 
remodeling
Cytoskeleton remodeling, TGF, WNT and 
cytoskeletal remodeling
3.69E-02 
4.01 E-02
1/102
1/111
Table 4. The pathway maps that the genes from the 25 up-regulated probe set list were 
identified as having a statistically significant association with by GeneGO MetaCore.
Disease p Value Networkobjects
Leukemia, Myeloid 
Myelodysplastic Syndromes 
Bone Marrow Diseases 
Leukemia
Leukemia, Myelocytic, Acute 
Proteinuria
Denys-Drash Syndrome 
Hematologic Neoplasms 
Leukemia, Non-lymphocytic, Acute 
Neoplasm, Residual
4.52E-09
9.73E-09
4.86E-08
3.29E-07
8.75E-07
2.76E-06
3.24E-06
5.04E-06
5.20E-06
7.94E-06
10/535
10/579
10/684
11/1098
7/325
4/56
2/2
4/65
7/424
3/22
Table 5. The statistically significant top 10 diseases that the genes from the 25 up- 
regulated probe set list were identified as having a statistically significant association 
with bv GeneGO MetaCore.
254
67
8
9
10 
Maps
-log(pValue)
1. Cell adhesion, Endothelial cell contacts by
non-junctional mechanisms
2. Cell adhesion, Plasmin signalling
3. Development, FLT3 signalling
4. Cell adhesion, Integrin-mediated cell 
adhesion and migration
5. Cytoskeleton remodelling, Integrin outside-in 
signalling
6. G-protein signalling, Proinsulin C-peptide 
signalling
7. Cell adhesion, ECM remodelling
8. Cell adhesion, Chemokines and adhesion
9. Cytoskeleton remodelling, Cytoskeleton 
remodelling
10. Cytoskeleton remodelling, TGF, WNT and 
cytoskeletal remodelling
1 2 3 4 5 6 7 8
-*• -log(pValue)
1. Leukaemia, Myeloid
2. Myelodysplastic Syndromes
3. Bone Marrow Disease
4. leukaemia
5. Leukaemia, Myelocytic, Acute
6. Proteinuria
7. Denys-Drash Syndrome
8. Haematologic neoplasms
9. Leukaemia, Nonlymphocytic, 
Acute
10. Neoplasm, residual
Disease B
Figure 11. Schematics of the pathway maps (A) and diseases (B) identified by GeneGO MetaCore and the statistical significance of the 
association of the up-regulated genes with these pathways and diseases.
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5.4 Discussion
The presence of MRD in acute leukaemia patients has been strongly 
correlated with treatment success and clinical outcome. Therefore, the 
detection of MRD in AML is prognostically highly relevant at diagnosis, 
following treatment and as an early detection method for the reappearance 
of leukaemic clones in the case of relapse (San Miguel et al, 
1997;Coustan-Smith et al, 1998;van der Velden et al, 2003). Targets for 
detection of MRD by nested PCR or real-time quantitative RT-PCR (RQ- 
PCR) include fusion-gene transcripts, gene mutations and aberrantly 
expressed genes (Kern et al, 2008). However, approximately 45% of 
patients diagnosed with de novo AML have no underlying chromosomal 
aberrations (Mrozek et al, 2004) and therefore no fusion-gene transcripts 
to monitor MRD by RQ-PCR. Mutations in exon 12 of the NPM1 gene have 
been reported as the most frequent genetic aberration occurring in normal 
karyotype AML at diagnosis but its long-term stability has led to a 
questioning of its potential as an MRD marker (Falini et at, 2007;Papadaki 
et al, 2009). A possible tool for identifying genes with an aberrant level of 
expression in specific conditions for the purpose of MRD monitoring in 
these patients is gene expression profiling. The potential of gene 
expression profiling has grown from a tool for class prediction and 
comparison (Golub et al, 1999) to predicting response to therapeutic 
treatments (Raponi et al, 2007). Therefore gene expression profiling could 
provide a means to identify genes differentially expressed between healthy
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normal donors and normal karyotype AML patients, which can then be 
further monitored by quantitative PCR assays in patient follow-up samples 
to observe significant changes in gene expression levels, monitor MRD 
levels and thereby predict early relapse. Various groups have investigated 
the ability of gene expression profiling to identify potential MRD markers 
but studies have been limited to paediatric patients, particularly in acute 
lymphoblastic leukaemia (ALL). Chen et al (2001) used cDNA arrays to 
identify several genes over-expressed for MRD in a small cohort of ALL 
patients. They identified 64 genes that were over-expressed in three ALL 
patients and validated the expression of 7 proteins encoded by these 
genes by flow cytometry (Chen et al, 2001). Steinbach et al (2006) 
analysed five pools of 10 paediatric AML patient samples based on the 
hypothesis that for every useful MRD marker there would be at least 1 in 
10 patients expressing the gene at a high level. Using oligonucleotide 
arrays and real-time PCR, they identified 5 potential markers of MRD for 
paediatric AML (Steinbach et al, 2006). Although these data are 
encouraging, it is clear that further investigation into the identification of 
MRD markers in acute leukaemias through gene expression profiling is 
required in much larger patient cohorts for the genes identified to have a 
stronger statistical potential to act as markers for MRD in AML.
Using gene expression profiling to identify potential MRD markers for AML 
in this study, 25 probe sets were identified as upregulated in diagnostic
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normal karyotype AML samples compared to healthy donor samples, by a 
mean change of between 4.0 and 36.7 fold. Homeobox (HOX) genes and 
HOX-related genes were represented by 8/25 (32%) of the upregulated 
probe sets; HOXA5, HOXA9, HOXA10, HOXB2, HOXB6 and MEIS1, a 
TALE (three amino acid loop extension) subfamily member of non-HOX 
homeobox genes. The identification of this HOX expression pattern 
through gene expression profiling is strongly supported by a previous study 
by Debernardi et al (2003) in which AML patients with a normal karyotype 
were found to have a distinctive up-regulation of several HOXA and HOXB 
genes and HOX-related genes compared to AML patients with a 
favourable risk translocation through microarray-based gene expression 
analysis. Comparing the expression profiles of patients with either 
favourable risk translocations, rearrangements of the MLL gene or a 
normal karyotype, Debernardi et al (2003) found the normal karyotype 
patient group were characterised predominantly by elevated levels of 
HOXA5, HOXA9, HOXB2, HOXB6 and MEIS1’, these findings strongly 
support the analysis presented in this chapter. They also observed 
elevated levels of HOXA4, HOXB3, HOXB5, HOXB6 and PBX3 (pre-B-cell 
leukaemia transcription factor 3), another member of the TALE (three 
amino acid loop extension) gene family, in the normal karyotype patients; 
these genes were not found to be upregulated in this present study 
(Debernardi et al, 2003). Debernardi et al (2003) identified a strong link 
between expression patterns and karyotypic status that implied a common
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genetic lesion between these patients (Debernardi et al, 2003). Bullinger et 
al (2004) performed gene expression profiling on 116 adult samples to 
identify prognostic subgroups within AML and identified the 
characterisation of normal karyotype AML through the overexpression of 
HOX genes, including HOXA4, HOXA9, HOXA10 and MEIS1 (Bullinger et 
al, 2004). Genes containing a homeobox encode for transcription factors 
controlling pattern formation, differentiation and proliferation, particularly in 
haematopoiesis (Lawrence et al, 1996) and are expressed in a stage- and 
lineage-dependent manner. Various studies have seen higher expression 
levels of HOXA9, HOXA10 and MEIS1 in immature CD34+CD38‘ normal 
cell populations compared to more mature, differentiated populations of 
CD38' cells, where their expression levels have significantly decreased. In 
AML cells, the expression levels of these three genes do not decrease in 
the same manner in more differentiated cells, but have been reported to be 
significantly higher than in the CD34+CD38' normal cell population 
(Kawagoe et al, 1999;Lawrence et al, 1999). Findings like these strongly 
support the concept of HOX genes playing an important role in the 
regulation normal haematopoietic development and a disruption to their 
regulation results in the development of myeloid leukaemia. This 
contributes to the notion that certain HOX genes, for example HOXA9 and 
HOXA10, have the potential to act as markers of MRD in AML. If these 
HOX family members play a role in haematopoietic development in a 
stage-dependent manner, as patients achieve a “cure” their levels of
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expression should decrease as the immature leukaemic cells are removed 
and normal cell differentiation is resumed. Conversely, relapse should 
result in an increase in expression of these genes as the differentiation 
block is resumed and the cells accumulate in an immature stage of 
development. Monitoring the changes in their expression would allow for 
the commencement of any necessary treatment to avoid a haematological 
relapse from occurring. It is of great importance that genes used as MRD 
markers in AML show a significant difference in transcription levels 
between diagnosis and when remission is achieved and should clearly 
distinguish between the disease state and normal health. In this study the 
HOX genes were over-expressed in the normal karyotype diagnostic AML 
samples between 4.0 and 37.7 fold compared to the healthy donor 
samples. As previously mentioned, oligonucleotide microarrays 
underestimate the fold changes of genes compared to real-time 
quantitative PCR assays (Yuen et al, 2002;Yao et al, 2004). Therefore, 
despite some of these lower fold changes measured by the microarray 
analysis, several of the HOX genes identified may indeed exhibit a larger, 
and more significant, fold change when investigated by real-time 
quantitative PCR assays making them more desirable as markers of MRD.
Two of the upregulated probe sets identified in this analysis are already 
used as markers of MRD in AML; the fms-related tyrosine kinase 3 (FLT3) 
gene and the Wilms tumour (WT1) gene. In normal bone marrow cells
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FLT3 is preferentially expressed in early progenitors, including CD34+ cells 
and decreases in expression with increasing differentiation (Small et al, 
1994;Weisel et al, 2009). Whilst FLT3 plays an important role in 
haematopoiesis, mutations of the FLT3 gene lead to a pathogenic role in 
AML. An internal tandem duplication (ITD) of the FLT3 gene results in a 
constitutive activation of the FLT3 kinase protein and is associated with a 
poorer prognosis (Kiyoi et al, 1998;Kiyoi et al, 1999;Abu-Duhier et al, 
2000). ITD mutations have been reported to occur in approximately 20- 
30% of all AML cases and 80-90% of FLT3ATDs are found in normal 
karyotype AML (Kiyoi et al, 1999;Thiede et al, 2002;Beretta et al, 2004). 
The role FLT3 plays in both normal haematopoiesis and in AML and the 
incidence of FLT3-ITD activating mutations occurring in AML have led to 
various studies investigating the role of a FLT3-ITD as a marker of MRD. 
Beretta et al (2004) found FLT3-ITD monitoring in eight paediatric AML 
patients agreed with the clinical course of each patient suggesting the 
FLT3-ITD mutations have the potential to act as MRD markers (Beretta et 
al, 2004). The reappearance of FLT3-ITDs with relapse and, so its ability to 
act as an MRD marker, has been investigated by many groups with varying 
results; both Nakano et al (1999) and Kottaridis et al (2002) identified 
patients presenting with a FLT3-ITD at diagnosis but no mutation at 
relapse and vice versa (Nakano et al, 1999;Kottaridis et al, 2002). In a 
much larger cohort of patients, Shih et al (2002) found a prevalence of 
FLT3A1D at relapse than originally identified at diagnosis and a higher
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mutational level at relapse than at diagnosis (Shih et al, 2002). Despite 
these results the studies were able to show significant differences between 
the diagnostic and relapse samples suggesting the potential of FLT3-ITD 
as an MRD marker. In this particular study the FLT3 gene was identified as 
over-expressed in normal karyotype AML patients at diagnosis and the 
single study into the use of FLT3 expression as an MRD marker is not as 
positive as the studies into the use of FLT3 mutations. Kainz et al (2005) 
studied the expression levels of wild-type FLT3 in 85 AML patients and 
concluded FLT3 expression levels were of limited value for the monitoring 
of MRD. Higher levels of FLT3 expression were observed in patients with a 
FZ_ 73-ITD but this was not statistically significant (Kainz et al, 2005). These 
studies clearly highlight an involvement of the FLT3 gene in AML and when 
identifying MRD markers for normal karyotype AML, it may be necessary to 
take into account the FLT3 status of patients. A further step of gene 
expression profiling analysis between FLT3 wild-type and FL73-ITD 
patients may prove beneficial for identifying more specific and sensitive 
MRD markers for normal karyotype patients.
WT1 was identified as having a mean 14 fold higher expression in the 
normal karyotype diagnostic samples when compared with normal donor 
samples. WT1 was initially identified as a tumour suppressor gene involved 
in Wilms’ tumour, a childhood kidney malignancy (Coppes et al, 1993). 
However, recent studies have identified a potential role for WT1 as an
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oncogene due to its overexpression in a variety of cancers (Yang et al, 
2007). WT1 is preferentially expressed in developing genitourinary cells 
and haematopoietic cells (Ariyaratana & Loeb, 2007). Like the FLT3 gene, 
WT1 is expressed in haematopoietic CD34+ early progenitors and 
decreases in expression with increasing differentiation (Fraizer et al, 1995). 
Very low levels of WT1 gene expression are observed by RT-PCR in 
normal haematopoietic cells. In contrast, the expression levels of WT1 In 
leukaemias are often as much as ten times greater than those observed in 
normal bone marrow and progenitors (Inoue et al, 1994;lnoue et al, 1997). 
A recent gene expression profiling study by Stirewalt et al (2008) identified 
WT1 as being over expressed in AML blasts compared to normal 
haematopoietic cells (Stirewalt et al, 2008). Due to the significance of this 
over expression of WT1 in AML, it has been investigated as a potential 
marker of MRD in normal karyotype AML patients. In an early study by 
Gaiger et al (1998), AML patients with detectable WT1 mRNA at diagnosis 
and who went on to achieve complete remission following chemotherapy 
were monitored by PCR. No difference was observed in disease-free 
survival (DFS) and survival from remission between WT1-negative patients 
and WTf-positive patients in complete remission following chemotherapy. 
The authors therefore concluded that WT1 was of limited value in MRD 
monitoring (Gaiger et al, 1998). However, several other groups have more 
recently investigated WT1 as an MRD marker using real-time quantitative 
PCR (RQ-PCR) in order to improve sensitivity. They all agree that WT1
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does have the ability to act as an MRD marker in AML patients (Cilloni et 
al, 2002;0stergaard et al, 2004;Weisser et al, 2005).
Several of the genes identified as upregulated in the normal karyotype 
patient samples were found to interact with each other in biological 
pathway networks. GeneGO analysis further highlighted the interactions of 
several of these genes pointing to their potential contribution to the 
pathology of AML; of the 50 diseases identified by GeneGO, 19 (38%) 
were haematological malignancies. The statistically significant associations 
observed between the genes identified in this study and several 
haematological malignancies pave the way for further promising avenues 
of research into the identification of key biological processes that underpin 
the aetiology of AML.
The aim of this chapter was to identify potential MRD markers for normal 
karyotype AML patients using gene expression profiling. A list of 25 probe 
sets, relating to 20 genes, were identified as upregulated in the normal 
karyotype diagnostic AML patient samples compared to healthy donor 
samples. Using an independent dataset, the strength of the group of 
upregulated probe sets’ ability to classify between normal karyotype AML 
samples and healthy donor samples was tested and found to be very 
strong, indicating the robustness of gene expression profiling. Furthermore, 
previous studies have identified several of these genes, such as the
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homeobox and homeobox-related genes, as having some role in 
leukaemic transformation indicating their importance in AML. The studies 
by various groups highlighting the roles of these genes in AML, their 
involvement in particular networks and diseases and their expression 
levels observed in this current study suggest several may have the 
potential to act as markers of MRD, which further supports gene 
expression profiling as a tool for identifying markers of MRD in AML.
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Chapter 6
Monitoring MRD in Normal Karyotype AML
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6.1 Introduction
6.1.1 MRD Detection
Complete remission (CR) is achieved by 60-80% of AML patients 
undergoing intensive induction chemotherapy regimens (Kern et al, 
2005). Despite the relative success of these treatments and the addition 
of new “targeted” therapies, relapse remains a major obstacle in the 
fight against leukaemia, occurring in up to 70% of patients undergoing 
chemotherapy (Liu Yin, 2002b). The purpose of minimal residual 
disease (MRD) monitoring is to detect and quantify any persistent or 
relapsing leukaemic blasts, with the objective of eradicating them to 
prevent a haematological relapse (Chung et al, 2006). Knowing the 
level of MRD in a patient following induction treatment can provide 
useful information on the course of the disease and can also be used in 
decisions relating to treatment strategies following induction therapy 
(Kern et al, 2005). A patient’s disease can be monitored through 
conventional cytogenetics, fluorescence in situ hybridisation (FISH), 
multi-parameter flow cytometry (MFC) and PCR techniques. PCR 
approaches for MRD detection are very sensitive with methodologies 
capable of detecting one leukaemic cell in 104-106 normal cells 
(Campana & Pui, 1995;van Dongen et al, 1999;Liu Yin, 2002a). Early 
MRD studies used qualitative PCR methods. Assays generated either a 
positive or negative result that was dependent on the assay sensitivity; 
a negative result did not necessarily translate to an actual absence of 
residual disease but rather indicated that the threshold of detection of
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the assay had been reached (Liu Yin, 2002c). Real-time quantitative 
PCR (RQ-PCR) is a sensitive method of MRD detection quantifying the 
levels of PCR product produced as it accumulates rather than an 
estimate at the end-point of the reaction. Due to the high levels of 
sensitivity of RQ-PCR, great care must be taken to avoid false-positive 
resulting from contamination. As with qualitative PCR methods the 
results generated from RQ-PCR are dependent upon the sensitivity of 
the protocol (Liu Yin, 2002d).
6.1.2 HOX Genes and MRD
The HOX family of Homeobox genes (Class I) encode for DNA-binding 
transcription factors that act during development. In mammals there are 
39 HOX genes spread over four different chromosomes in four clusters; 
A, B, C and D (Argiropoulos & Humphries, 2007). The majority of HOX 
genes (clusters A-C) are preferentially expressed in haematopoietic 
stem cell-enriched sub-populations and in immature progenitor 
compartments. These genes are often down-regulated during 
differentiation and maturation, suggesting a key role in early 
haematopoietic cells (Sauvageau et al, 1994;Kawagoe et al, 1999). The 
observed down-regulation and up-regulation of some HOX genes in 
AML blasts compared to normal bone marrow cells has led to the 
suggestion that disruption of the normal HOX regulatory pathway is 
extremely important in leukaemogenesis (Lawrence et al, 
1999;Kawagoe et al, 1999;Thompson et al, 2003;Argiropoulos &
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Humphries, 2007). Expression of the HOXA9 gene is regularly altered 
in myelodysplastic syndromes and acute myeloid leukaemia. The 
t(7;11 )(p15;p15) chromosomal translocation results in the fusion of the 
NUP98 (nucleoporin, 98kDa) gene on chromosome 11 and the HOXA9 
gene on chromosome 7 (Reviewed by (Romana et al, 2006;Moore et al, 
2007). Kroon et al (2001) observed transplanting primary bone marrow 
cells transduced with a retrovirus expressing the NUP98-HOXA9 fusion 
gene induced myeloproliferative disease (MPD) in mice, which 
developed into AML following a latency period of at least 4 months 
(Kroon et al, 2001). Takeda et al (2006) observed impaired myeloid and 
erythroid differentiation and the induction of proliferation of primitive 
cells capable of long-term growth following an initial suppression in a 
population of human CD34+ haematopoietic progenitors transduced 
with a NUP98-HOXA9 retrovirus (Takeda et al, 2006). High levels of 
HOX gene expression have been observed intermediate risk AML 
patients and those with a normal karyotype leading to the suggestion of 
the use of HOX genes in the clinical management of AML patients 
(Drabkin et al, 2002;Debernardi et al, 2003;Roche et al, 2004). 
However, no further investigations into the use of HOX genes as 
markers of MRD have been carried out
6.1.3 WT1
As previously discussed in Chapter 4, WT1 was originally identified as a 
tumour suppressor gene in patients with Wilms’ tumours, a kidney 
neoplasm (Haber et al, 1990). Many groups have provided evidence
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that strongly supports the use of WT1 gene expression level as an 
alternative marker of MRD (Cilloni et al, 2002;0stergaard et al, 
2004;Candoni et al, 2009).
6.1.4 COL4A5
The COL4A5 gene, encoding for the a5 (IV) chain of type IV collagen, is 
co-localised at chromosome Xq22 with the COL4A6 gene (Sugimoto et 
al, 1994;Oohashi et al, 1994). Mutations in the COL4A5 gene result in 
Alport Syndrome; patients present with a progressive hereditary 
nephritis often combined with a sensorineural deafness. To date, 38 
large/medium-sized deletions and 138 small mutations have been 
identified in the COL4A5 gene (as reviewed by (Lemmink et al, 1997). 
Previous gene expression profiling studies have identified an over­
expression of COL4A5 in the yolk sac tumour elements of germ cell 
tumours (GCT) and in solitary fibrous tumours (SFT) but to date an 
over-expression of COL4A5 in a haematological malignancy has not 
been recorded (Juric et al, 2005;West et al, 2005).
The aim of this chapter was to use real-time quantitative PCR (RQ- 
PCR) to evaluate the candidate genes identified previously through 
gene expression profiling (GEP) (Chapter 5) in a group of normal 
karyotype diagnostic AML patients and normal healthy donors to 
validate the GEP analysis and monitor these genes in diagnostic and 
follow-up patient samples to assess their ability to act as markers of 
MRD.
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6.2 Materials and Methods
6.2.1 Patient and Donor samples
6.2.1a Diagnostic Screening of Candidate Genes 
Cell lysates and RNA from bone marrow aspirates of 15 healthy donors 
and 52 normal karyotype AML patients at diagnosis were obtained from 
the School of Medicine, Cardiff University (Table 1). Mononuclear cells 
were isolated from the bone marrow aspirates as described in section
2.3.3 (Chapter 2) and RNA was extracted using TRIzol reagent or the 
Qiagen RNeasy Mini Kit as described in section 2.4.1 (Chapter 2).
6.2.1b MRD Monitoring by RQ-PCR
Diagnostic and follow-up RNA from 6 normal karyotype AML patients 
entered into the AML15 trial were obtained from the School of Medicine, 
Cardiff University and processed for MRD monitoring by RQ-PCR 
(Table 2). The diagnostic and follow-up RNA samples were processed 
as described above.
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Characteristic Value
Sex - no. (%)
Male 27 (51.9)
Female 25 (48.1)
Not determined 0 (0)
Age group -  no. (%)
<30 years 4 (7.7)
30-60 years 19 (36.5)
>60 years 29 (55.8)
Age -  years
Median 54
Range 12-78
French-American British Classification - no. (%)
MO 2 (3-8)
M1 6 (11.5)
M2 14 (26.9)
M3 0 (0)
M4 7 (13.5)
M5 9 (17.4)
M6 2 (3.8)
M7 0 (0)
Other 2 (3.8)
Not determined 10 (19.3)
Molecular Abnormalities -  no. (%)
Mutation
FLT3 Internal tandem 19 (36.5)
duplication
FLT3 Tyrosine kinase 3 (5.8)
domain
NPM1 20 (38.5)
ITD+/NPM1 + 10 (19.2)
ITD+/NPM1- 6 (11.5)
ITD7NPM1 + 9 (17.3)
ITD7NPM1" 14 (26.9)
Table 1. The frequencies and percentages of the clinical and molecular 
characteristics of the 52 patients diagnosed with normal karyotype AML in the 
sample set for RQ-PCR gene expression validation.
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Characteristic Value
Sex - no. (%)
Male 3 (50.0)
Female 3 (50.0)
Not determined 0 (0)
Age group -  no. (%)
<30 years 1 (16.7)
30-60 years 5 (88.3)
>60 years 0 (0)
Age -  years
Median 42
Range 17-47
French-American British Classification - no. (%)
MO 0 (0)
M1 3 (50.0)
M2 2 (33.3)
M3 0 (0)
M4 1 (16.7)
M5 0 (0)
M6 0 (0)
M7 0 (0)
Other 0 (0)
Not determined 0 (16.7)
Molecular Abnormalities -  no. (%)
Mutation
FLT3 Internal tandem 4 (66.7)
duplication
FLT3 Tyrosine kinase 0 (0)
domain
FLT3 Not determined 0 (0)
NPM1 Mutant 4 (66.7)
NPM1 Not determined 1 (16.7)
Table 2. The frequencies and percentages of the clinical and molecular 
characteristics of the 6 normal karyotype AML patients in the sample set for 
MRD detection.
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6.2.2 Quantitative Real-Time PCR
6.2.2a Gene Expression Validation
RQ-PCR was performed using the Roche LightCycler system as 
described in section 2.5 (Chapter 2). Each sample was run in duplicate 
and a duplicate “no-RNA” cDNA control sample and “no-cDNA” control 
sample was included. The Abelson (ABL) gene was used as the control 
house-keeping gene to evaluate the quality and quantity of the starting 
RNA and correct for any variations in expression arising from this 
between samples. ABL is a proto-oncogene that encodes for a nuclear 
and cytoplasmic tyrosine kinase protein. In the “A Europe Against 
Cancer” Programme, the ABL gene transcript was found to be a reliable 
control gene for the comparison of diagnostic and MRD samples; a 
similar expression of the ABL gene transcript was seen in both the 
normal and the diagnostic samples. The correlation between the ABL 
gene expression and the expression of the candidate genes were the 
highest observed amongst the fourteen control genes tested (Beillard et 
al, 2003;Gabert et al, 2003).
6.2.2b MRD Monitoring
RQ-PCR was performed on cDNA generated from AML diagnostic 
samples and healthy donor samples to monitor expression of the 
candidate genes in the patient samples. As with the diagnostic 
screening, the Ct values generated (see Chapter 2, Section 2.5.3) for 
the candidate genes were normalised to the Ct values of the control
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gene ABL. Samples with Ct values greater than 40 cycles were deemed 
as “not determined”; i.e. “negative”.
6.3 Results
6.3.1 Validation of Identified Genes by RQ-PCR
Previously, gene expression analysis was applied to a dataset of 
normal karyotype AML diagnostic samples and healthy donor samples 
to identify differentially expressed genes between the two groups. From 
this analysis 25 probe sets relating to 20 genes were identified as up- 
regulated in the normal karyotype AML diagnostic samples compared to 
the normal healthy donor samples (Chapter 5). In order to establish if 
these genes have the potential to act as markers of MRD in normal 
karyotype AML, RQ-PCR was performed to screen selected genes 
across a panel of normal karyotype AML diagnostic patient samples 
and healthy donor samples. Probe sets with a greater level of 
expression (>10 fold) in the normal karyotype AML samples compared 
to the healthy donor samples were selected for gene expression 
screening in patient samples at diagnosis. The probe sets related to five 
genes; HOXA5, HOXA9, HOXB6, WT1 and COL4A5 (Chapter 5, Table 
3).
6.3.1a Diagnostic Screening of Candidate Genes
Expression of the candidate gene transcripts was measured in
diagnostic normal karyotype AML patient samples and compared to
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levels measured in healthy normal donor samples. Initially primer sets 
were designed for the amplification of the five candidate genes as 
described in the Materials and Methods section 2.5.1 (Chapter 2) and 
using serial dilutions of cDNA, their amplification efficiencies were 
compared to that of the control gene, ABL (Figure 1). The amplification 
curves generated from the cell line cDNA for the five candidate genes 
were similar to those generated for the control gene ABL across the 
dynamic range of the cDNA template dilutions used. Therefore ABL was 
considered suitable as the normalising control gene (Figure 1).
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Figure 1. The amplification curves of the primer sets used for HOXA5 (a), HOXA9 (b), HOXB6 (c), WT1 (d) and COL4A5 (e) and of the control gene, ABL, 
generated from serial dilutions of cell line cDNA to compare their amplification efficiencies.
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The levels of expression of the five genes were measured in 52 AML 
diagnostic normal karyotype patient samples and compared to their 
levels of expression in 15 normal healthy bone marrow donor samples 
to observe any significant difference in the expression of the five genes 
between the two conditions that could point towards a potential MRD 
marker (Figure 2). Using a f-test analysis, highly significant differences 
were observed between the mean normalised Ct values of the 
candidate genes in the diagnostic normal karyotype AML patient 
samples and mean normalised Ct values of the candidate genes in the 
healthy normal donor samples (Table 3).
Internal tandem duplications (ITD) of the FLT3 gene have been 
identified as an independent poor prognostic factor for overall survival, 
disease-free survival and event-free survival in AML patients (Kiyoi et 
al, 2005). To identify any significant association between the presence 
of a FLT3 ITD and the expression of the genes of interest, the mean 
normalised Ct values of the five candidate genes were measured in the 
24 patient samples exhibiting a wild-type FLT3 gene at diagnosis and 
the 19 patient samples exhibiting FLT3 ITD at diagnosis (Figure 3). 
There was no significant difference in expression observed for four of 
the candidate genes between the wild-type FLT3 patient group and the 
FLT3-MD patient group (Table 4), suggesting the expression of these 
genes identified as specific to normal karyotype AML through 
microarray analysis were not influenced by the presence of a FLT3 ITD. 
However, the expression of HOXA9 appeared to be associated with the
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presence of FLT3 ITD. This finding requires further investigation in a 
larger cohort of normal karyotype AML samples.
Mutation of the NPM1 gene in normal karyotype AML patients is 
associated with a favourable outcome both in terms of event-free 
survival and overall survival (Chen et al, 2006). To identify any 
significant associations between the mutational status of NPM1 and the 
expression of the candidate genes, the mean normalised Ct values of 
the five candidate genes were also measured in the 20 patient samples 
exhibiting a wild-type NPM1 gene at diagnosis and 19 patient samples 
exhibiting an NPM1 mutation at diagnosis (Figure 4). There was no 
significant difference observed between the wild-type NPM1 patient 
group and the mutated NPM1 patient group for WT1 and COL4A5. 
However, a significant difference between the NPM1 wild-type and 
mutant samples was observed for HOXA5, HOXA9 and HOXB6 (Table 
5) implying that the expression of these genes may be modulated by 
NPM1 status. Once again, this potentially interesting finding would need 
to be examined prospectively in a larger cohort of patients.
279
10- HOXA5
-1 0 J
10-
§ 5 '
> 0- 5
|  - *  
f  -10-
z
-15-
■■
m
■■ ■ 
■
■ ®
• ■■hfl 
■ 
■ 
■ ■ 
■
I ■■
Donors Normal Karyotype
Means significantly different (p<0.0001) 
WT1
Donors Normal Karyotype
M eans significantly different (p<0.0001)
10-i
§ 5
1 
C o-
-5-
- 10-
5-i
HOXA9
^ 0- 
C
I *
-1 0 J
m r
Donors Normal Karyotype
Means significantly different (p<0.0001)
COL4A5
Donors Normal Karyotype
Means significantly different (p=0.0007)
10-j
j j  5-
£c 0
HOXB6
|  -5- 
1 - 10-  
-15-1 Donors Normal Karyotype
Means significantly different (p<0.0001)
Figure 2. Scatter plots of the spread of the normalised Ct values of the candidate genes measured in the normal karyotype AML diagnostic patient 
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HOXA5 HOXA9 HOXB6 WT1 COL4A5
P Value <0.0001 <0.0001 <0.0001 <0.0001 0.0007
Are the means
significantly Yes Yes Yes Yes Yes
different (p<0.05)
Donors mean value -3.070 -3.130 -7.104 -10.770 -5.266
Donors 95% Cl -3.64 to -2.50
-3.86 to 
-2.40
-7.51 to 
-6.69
-11.3 to 
-10.2
-6.38 to 
-4.15
Donors Expression -4.35 to -5.12 to -8.89 to -11.89 -7.46 to
Range -0.56 -0.82 -6.05 to -9.47 -2.57
NK mean value 0.820 1.907 -1.056 -2.749 -1.785
NK 95% Cl -0.05 to 0.99 to -2.04 to -3.83 to -2.74 to1.69 2.82 -0.08 -1.67 -0.83
NK Expression -5.77 to -8.71 to -10.24 -10.07 -7.55 to
Range 8.64 8.71 to 6.01 to 5.41 4.28
Table 3. The statistical significance of the mean Ct values, normalised to the Ct 
values of ABL, of the candidate genes measured in the 52 normal karyotype (NK) 
AML diagnostic patient samples and the 15 healthy normal donor samples. Cl = 
confidence interval.
HOXA5 HOXA9 HOXB6 WT1 COL4A5
P Value 
Are the means
0.1823 0.0356 0.0637 0.1226 0.1372
significantly 
different (p<0.05)
No Yes No No No
ITD +ve mean 
value 1.644 3.226 0.196 -1.719 -1.068
ITD +ve 95% Cl 0.32 to 3.51 2.213
-0.69 to 
1.56
-3.13 to 
0.42
-1.94 to 
0.73
ITD +ve -5.58 to -1.19 to -3.89 to -9.14 to -7.55 to
Expression Range 8.64 8.71 -6.01 5.41 2.61
ITD -ve mean 
value 0.6021 1.457 -1.045 -3.303 -1.846
ITD -ve 95% Cl -0.96 to -0.47 to -2.90 to -5.25 to -3.91 to1.97 2.99 0.18 -1.38 -0.42
ITD -ve -5.77 to -8.71 to -7.72 to -10.07 -6.87 to
Expression Range 8.58 7.35 4.34 to 0.65 5.13
Table 4. The statistical significance of the mean Ct values, normalised to the Ct 
values of ABL, of the candidate genes measured in the 19 FLT3-ITD positive NK AML 
diagnostic patient samples (ITD +ve) and the 25 FL73-ITD negative NK AML 
diagnostic patient samples (ITD -ve). Cl = confidence interval.
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HOXA5 HOXA9 HOXB6 WT1 COL4A5
P Value
Are the means
significantly
different (p<0.05)
Mutant mean
value
Mutant 95% Cl
Mutant Expression 
Range
Wild-type mean 
value
Wild-type 95% Cl
Wild-type 
Expression Range
0.0283
Yes
2.425
1.55 to 
3.30 
0.77 to 
5.34
0.1270
-1.75 to 
2.01 
-5.77 to 
8.634
0.0409
Yes
3.447
2.69 to 
4.20 
1.34 to 
6.80
1.243
-0.86 to 
3.03 
-8.71 to 
8.71
0.0173
Yes
0.6705
-0.19 to 
1.53 
-1.77 to 
4.34
-1.652
-3.49 to 
0.19 
-7.72 to 
6.01
0.7967
No
-2.129
-3.46 
to-0.80 
-7.06 to 
0.45
-2.450
-4.74 to 
-0.16 
-9.14 to 
5.41
0.1041
No
-0.664
-1.74 to 
0.41 
-4.58 to 
2.61
-2.434
-4.63 to 
-0.24 
-7.33 to 
4.28
Table 5. The statistical significance of the mean Ct values, normalised to the Ct 
values of ABL, of the candidate genes measured in the 19 mutant NPM1 NK AML 
diagnostic patient samples (Mutant) and the 20 wild-type NPM1 NK AML diagnostic 
patient samples (Wild-type). Cl = confidence interval.
Based on these findings, the expression levels of these five genes were 
monitored in AML patient diagnostic and follow-up samples to identify 
whether any had the potential to act as a marker of MRD for normal 
karyotype AML.
6.3.1b Candidate Genes as MRD Markers
The transcript expression levels of the five genes were monitored in the 
diagnostic sample and follow-up samples of six AML patients with a 
normal karyotype.
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The fold change of gene transcript expression levels relative to ABL 
were calculated as described in Chapter 3 and compared to the upper 
fold change in expression observed in the healthy normal donor 
samples (Figure 5). The MRD values (MRDv) of the genes in the patient 
samples were calculated as described in Chapter 3 and compared to 
the level of transcript at diagnosis (Figure 6). Patients 1 to 4 achieved 
and remained in complete remission. Patient 5 relapsed at 252 days 
following diagnosis and patient 6 relapsed at 125 days following 
diagnosis.
/'. HOX Genes
The fold changes in expression of the three HOX genes relative to ABL 
displayed inconsistent changes following induction therapy to what 
would be expected from the status of six patients of complete remission 
(CR) or relapse; both increases and decreases in fold changes in 
expression of the three genes were detected following induction therapy 
in the four patients achieving complete remission and in the two that 
relapsed. These fold changes in expression were within two logs of that 
detected diagnosis bar for HOXA9 in one patient; an increase by 
approximately three logs following induction therapy in a patient that 
achieved complete remission. The level of expression of the three 
genes in the two patients that relapsed remained above the upper 
levels detected in healthy normal donors for the disease length. Again, 
inconsistency was observed for the four patients achieving CR in
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regards to their gene levels relative to the upper levels detected in 
healthy normal donors (Figure 5a, 5b and 5c).
//. WT1
Expression data was only available for three normal karyotype patients 
that achieved CR and one normal karyotype patient that relapsed.
The levels of WT1 expression of all four patients at diagnosis was 
between one and two logs higher than the upper level of WT1 
expression detected in healthy normal donor samples. Following 
induction therapy the fold change in expression of WT1 in the three CR 
patients decreased and continued so for the remainder of their disease. 
The fold change in expression of WT1 in the patient that relapsed 
displayed an expected behaviour of decreasing following the start of 
induction therapy before increasing 90 days prior to a haematological 
relapse by more than 1 log (Figure 5d).
///. COL4A5
The fold change in COL4A5 expression relative to ABL of the four 
patients that achieved CR displayed similar expression patterns as the 
three HOX genes in these patients; inconsistent fold changes in the 
level of expression following the start of therapy by approximately one 
log from the levels detected at diagnosis. Again, inconsistent fold 
changes in expression following diagnosis and the start of therapy were 
detected in the two patients that relapsed (5 and 6). All four patients
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that achieved CR displayed expression levels below the upper level 
measured in the healthy donor samples (Figure 5e).
WT1 was the only candidate gene to display a fall in its level of 
transcription in all patients monitored; increases and decreases in 
levels of HOXA5, HOXA9, HOXB6 and COL4A5 from their transcript 
level at diagnosis were observed in both the patients that achieved CR 
and the patients that relapsed. WT1 also displayed the largest increase 
in transcript level following the initial decrease following induction 
therapy in the patient that relapsed; 2.5 logs compared to the one log 
increase observed for the three HOX genes (Figure 6).
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Figure 5. Longitudinal monitoring of HOXA5 (a), HOXA9 (b), HOXB6 (c), WT1 (d) and COL4A5 (e) in six normal karyotype AML patients. The graphs 
show the fold change values generated for respective genes in each sample, relative to the ABL gene. Only four patient sample sets were available for 
monitoring of WT1. Red lines - patients who relapsed. Green lines - patients who remained in complete remission (CR). The blue dashed line represents 
the upper limit of gene expression in the healthy normal donor samples. Patient 5 relapsed at 252 days following diagnosis; patient 6 relapsed at 125 
days following diagnosis.
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Figure 6. Longitudinal monitoring of HOXA5 (a), HOXA9 (b), HOXB6 (c), WT1 (d) and COL4A5 (e) in six normal karyotype AML patients. The graphs 
show the MRD values calculated for the genes in each sample. Only four patient sample sets were available for monitoring of WT1. Red lines - patients 
who relapsed. Green lines - patients who remained in complete remission (CR). Patient 5 relapsed at 252 days following diagnosis; patient 6 relapsed at 
125 days following diagnosis.
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6.4 Discussion
Despite improvements in the treatment of AML, up to 70% of patients 
undergoing chemotherapy ultimately relapse (Liu Yin, 2002e). 
Monitoring levels of residual disease in patients can help to provide 
useful information about the course of the disease and inform the 
clinician if any intervention is required to prevent a haematological 
relapse (Kern et al, 2005;Chung et al, 2006). Current MRD markers are 
generally limited to those patients with a fusion-gene product resulting 
from a “favourable-risk” translocation; 50% of the AML population are 
classed as having a “normal” karyotype and so have no underlying 
detectable chromosomal abnormalities that could provide markers for 
MRD monitoring. However, normal karyotype AML is not a 
homogeneous sub-group and some genetic alterations in specific genes 
have been detected that may serve as markers of MRD. For example, 
approximately 30% of normal karyotype AML patients present with an 
internal tandem duplication in the FLT3 gene (Whitman et al, 
2001;Thiede etal, 2002;Frohling et al, 2002;Schnittger et al, 2005;Bienz 
et al, 2005). The FL 73-length mutation (FLT3- LM) in the 
juxtamembrane (JM) domain-coding sequence caused by the internal 
tandem duplication (ITD) has been proposed as a marker of MRD in 
normal karyotype AML. Investigation of FLT3 gene ITDs as an MRD 
marker has been performed with promising results but there are 
limitations to the FLT3 ITD MRD assay, for example, patient-specific 
primers need to be developed and optimised to account for the ITD 
length for each patient (Stirewalt et al, 2001 ;Schnittger et al,
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2002;Scholl et al, 2005). The NPM1 (nucleophosmin 1) gene is partner 
to many other genes in translocations occurring in leukaemias and 
lymphomas, including the ALK (anaplastic lymphoma receptor tyrosine 
kinase) gene, the RARa (retinoic acid receptor alpha) gene and the 
MLF1 (myeloid leukaemia factor 1) gene (Morris et al, 1994;Redner et 
al, 1996;Yoneda-Kato et al, 1999). Normally shuttling between the 
nucleus and the cytoplasm, the NPM1 protein aberrantly localises in the 
cytoplasm when a mutation occurs in the NPM1 gene (Quentmeier et 
al, 2005;Wang et al, 2005). Many groups have revealed NPM1 
mutations in AML patients especially in those with a normal karyotype 
and therefore, NPM1 gene mutations have been predicted to be an 
ideal marker for MRD (Falini et al, 2005;Schnittger et al, 2005;Boissel et 
al, 2005;Verhaak et al, 2005;Dohner et al, 2005). Gorello et al (2006) 
developed an RQ-PCR assay for both RNA and DNA to monitor NPM1 
mutations in normal karyotype AML adult patients. In 13 patients 
carrying mutations in exon 12 of the NPM1 gene, the number of NPM1 
type A-mutated transcripts closely correlated with tumour burden at 
diagnosis and with response to induction therapy (Gorello et al, 2006). 
Due to the small patient cohort in this study further validation of the 
NPM1 gene was indicated. Chou et al (2007) performed RQ-PCR on 
samples from 38 AML patients bearing an NPM1 gene mutation and 
observed more mutant copies of the NPM1 gene transcript in samples 
taken at the first morphological CR from the patients with subsequent 
clinical relapse than those from the patients without subsequent relapse 
(Chou et al, 2007). Whilst the use of the type A mutation in the NPM1
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gene as an MRD marker for normal karyotype AML is promising, an 
NPM1 mutation is detected in only approximately 50% of patients with a 
normal karyotype (Falini et al, 2005;Boissel et al, 2005;Schnittger et al, 
2005;Dohner et al, 2005;Thiede et al, 2006). The association of an 
NPM1 mutation with a favourable outcome may also influence its ability 
as a reliable marker of MRD (Chen et al, 2006).
Previously gene expression profiling was used to identify potential 
markers of MRD in AML patients with a normal karyotype (Chapter 5). 
Twenty genes were identified as being highly expressed in the normal 
karyotype patients compared to healthy normal donors; five genes, 
represented by probe sets, with a greater expression in the normal 
karyotype AML samples than the healthy donor samples by more than 
10 fold. Initially the HOXA5, HOXA9, HOXB6, WT1 and COL4A5 genes 
were screened in 52 diagnostic normal karyotype AML patient samples 
and 15 healthy normal donor samples to identify their potential to act as 
markers of MRD. A statistically significant difference was observed for 
the increase in mean normalised expression levels for all five genes in 
the diagnostic normal karyotype AML samples compared to the healthy 
normal donor samples; the largest difference in mean expression level 
between the two groups was observed for the WT1 gene. Whilst not 
solely restricted to the study of normal karyotype AML, many previous 
studies have shown an aberrant expression of the WT1 gene and the 
HOX genes in AML patients lacking a specific fusion gene. A recent 
study by Stirewalt et al (2008), in which Affymetrix HG-U133A gene
292
chips were initially used to identify AML-specific gene expression 
changes, identified the WT1 gene as AML-specific. Validating their data 
with quantitative RT-PCR, a significant increase in WT1 expression was 
observed in AML patients compared to normal hematopoietic cell 
donors (Stirewalt et al, 2008) corroborating earlier studies by Inoue et al 
(1997) where it was also observed the WT1 expression levels in 
leukaemic cells were at least one log higher than in normal 
hematopoietic progenitor cells (Inoue et al, 1997). Qin et at (2009) went 
a step further to investigate the expression levels of WT1, along with 
the FRAME gene (previously mentioned in chapter 4), in patients 
lacking a specific fusion gene. They found that WT1 was detected at 
minimal levels in normal bone marrow samples but was detected at its 
highest levels in those patients lacking a specific fusion gene compared 
to patients with a specific fusion gene (Qin et al, 2009). In support of the 
significant increase in the expression of HOXA5, HOXA9 and HOXB6 in 
normal karyotype patients in this study, a study by Roche et al (2004) 
used Q-RT/PCR with SYBR-green to group AML patients into clusters 
marked by the expression of low, intermediate and high HOX 
expression. They identified 94% of the patients in the high HOX 
expression group as belonging to the intermediate cytogenetic group 
i.e. no specific fusion genes (Roche et al, 2004). In particular, 
Giampaolo et al (2002) observed absent HOXB6 expression in almost 
all AML samples with fusion genes resulting to the commonest 
translocations compared to the AML samples lacking chromosomal 
translocations that were HOXB6* (Giampaolo et al, 2002). Whilst these
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studies were not specifically investigating normal karyotype AML, 
patients with a normal karyotype are placed in the intermediate 
cytogenetics/risk group and therefore the results of these studies do 
bear some significance with and support the findings in this particular 
section; the WT1, HOXA5, HOXA9 and HOXB6 genes are significantly 
increased in expression in diagnostic normal karyotype AML patients 
compared to their healthy normal counterparts. To date there is no 
literature on COL4A5 expression in AML. In order to identify the true 
potential of COL4A5 as a marker of MRD or just an over-expression 
with no clinical relevance, the expression of the COL4A5 gene needs to 
be followed in longitudinal patient samples.
In agreement with previous studies, 36.5% of the 52 normal karyotype 
AML samples presented with a FL 73-ITD whilst the incidence of an 
NPM1 mutation in these patients at diagnosis (38.5%) was slightly 
lower than the incidences of approximately 50% previously reported by 
other groups (Whitman et al, 2001;Frohling et al, 2002;Dohner et al, 
2005;Falini et al, 2005;Boissel et al, 2005;Schnittger et al, 2005). Using 
f-tests, no statistically significant difference in the mean normalised 
expression levels of the genes between the FL 73-ITD normal karyotype 
patient samples and the wild-type FLT3 normal karyotype patient 
samples was observed for 4 of the genes; only a small correlation was 
observed for HOXA9 (p=0.0356). Unfortunately the FLT3 results 
disagree with the study by Roche et al (2004) in which approximately 
twice the number of FLT3 mutations occurred in high HOX expression
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AML cases compared to low or intermediate HOX expression AML 
cases (Roche et al, 2004). However, these findings were not found to 
be statistically significant and were extrapolated from AML cases across 
the sub-group spectrum rather than just those with intermediate 
cytogenetics. However, a statistically significant difference in the 
normalised mean expression levels of HOXA5, HOXA9 and HOXB6 
was observed between the mutant NPM1 normal karyotype patients 
and the wild-type NPM1 normal karyotype patients. Previous microarray 
studies have demonstrated distinct expression patterns of homeobox 
genes in normal karyotype AML displaying NPM1 mutations. Verhaak et 
al (2005) identified a positive correlation between AML normal 
karyotype and mutations of NPM1 from the analysis of 275 primary 
AML cases. From a cohort of 58 patients presenting with aberrant 
cytoplasmic NPM1 localization (NPMc+), Alcalay et al (2005) identified 
52 patients exhibiting both a normal karyotype and an NPM1 mutation. 
Microarray analysis of this patient group demonstrated a striking gene 
expression pattern highlighting the up-regulation of several 
homeodomain-containing genes, including the HOXA9 and HOXB6 
genes selected for further investigation this current study (Alcalay et al, 
2005). In a later study, Andreeff et al (2008) went on to use quantitative 
RT-PCR to analyse 42 genes, including 39 homeodomain genes, in 119 
newly diagnosed AML samples. They detected low levels of HOXA and 
HOXB gene expression in favourable risk AML yet a marked over­
expression of these genes was observed in AML cases with 
intermediate cytogenetics and NPM1 mutations (Andreeff et al, 2008).
295
After identifying the significant difference in expression of the five genes 
in normal karyotype AML patients at diagnosis compared to the healthy 
normal bone marrow samples, the genes were monitored in six normal 
karyotype AML patients to observe their ability to monitor the disease. 
The expression levels of the HOXA5, HOXA9, HOXB6 and COL4A5 
transcripts displayed no consistent correlation with the patients’ disease 
status. Following diagnosis and the start of treatment the expression 
levels of the four gene transcripts decreased in two of the four of the 
patients remaining in complete remission (CR) but increased in the 
remaining two CR patients. An increase in gene transcript level of the 
three HOX genes was observed in one of the two patients that 
relapsed, but the increase seen was less than one log; not significant 
enough to predict a potential molecular relapse. From their studies in 
CBF leukaemias, Lane et al (2008) suggested that a £1 log™ rise in 
RQ-PCR transcript levels observed in serial remission bone marrow 
samples is a clinically useful definition of and reliably predicts a 
morphologic relapse (Lane et al, 2008). Currently there has been little 
investigation into the monitoring of HOX gene expression as a marker 
of MRD in haematological malignancies. Riedt et al (2009) investigated 
the caudal (CDX) family of the homeobox genes specifically in acute 
lymphoblastic leukaemia (ALL). They observed an expression of the 
CDX2 (caudal type homeobox 2) gene in the mononuclear cells of 9 out 
of 10 AML patients compared to no expression detected in healthy 
donor bone marrow and peripheral blood cells. They also identified low 
or negative CDX2 expression in only 16% of paediatric ALL patient
296
samples comparable to levels in healthy donors. Measuring the 
expression of CDX2 at diagnosis and at two subsequent time points in 
ALL patients led to the suggestion that the expression levels of CDX2 at 
the manifestation of the disease may be used to foresee the response 
to treatment of patients that are MRD-positive at day 33 following 
diagnosis (Riedt et al, 2009). Scholl et al (2007) detected CDX2 
expression in 90% of their AML patient cohort yet no expression in 
haematopoietic stem and progenitor cells from healthy normal donors; 
the second highest levels of CDX2 expression identified in patients with 
a normal karyotype. They found that the level of CDX2 expression in 2 
patients over the course of their disease correlated with the disease 
burden (Scholl et al, 2007a). CDX2 regulates expression of HOX genes 
during embryogenesis and developmental haematopoiesis (Deschamps 
et al, 1999;Abramovich & Humphries, 2005;Scholl et al, 2007b). Whilst 
it is apparent that HOX genes and their regulators have a prominent 
role in leukaemogenesis, the HOX genes in this study do not appear to 
have the potential to act as MRD markers despite their increased 
expression levels at diagnosis. It may be the answer lies within other 
HOX family members. From the original analysis, probe sets 
representing HOXA10, HOXB2 and MEIS1 were also identified as being 
highly expressed in normal karyotype AML compared to healthy normal 
donors. Further investigation into these HOX genes and co-factors may 
identify a candidate for monitoring MRD. It may also prove more 
informative if the expression of several HOX genes and co-factors were 
monitored simultaneously to gain a more reliable insight into the
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directional progression of a patient’s disease rather than using just one 
HOX genes as a marker. Various studies have demonstrated the 
differential pattern of the HOX genes during the stages of 
haematopoiesis and that the HOX genes are switched on and off in 
blocks (Magli etal, 1991;Sauvageau et al, 1994;Magli et al, 1997).
In the four normal karyotype patients in which WT1 was monitored a 
consistent pattern in WT1 expression could be seen with the 
remission/relapse status of the patients. The expression levels of WT1 
in the patient that relapsed never decreased below the upper level of 
expression detected in the healthy donor samples. After the initial 
decrease in WT1 MRD by 1.5 logs from the transcript levels detected at 
diagnosis, an increase in MRD by 2.5 logs over three serial bone 
marrow samples was observed. This strongly suggests a molecular 
relapse supported by the study by Lane et al (2008) in which a 1 log 
rise in transcript level in serial bone marrow remission samples is 
enough to reliably predict a morphological relapse. The levels of WT1 
MRD in the three patients that achieved complete remission decreased 
from the level of transcript detected at diagnosis. It was unfortunate 
further remission samples were unavailable for these patients as it 
would be insightful to know if the level of WT1 expression continued to 
decrease to below the upper level detected in the healthy normal donor 
samples and remained below this level. WT1 expression has been 
evaluated for MRD monitoring in AML in many previous studies (Inoue 
et al, 1996;Cilloni et al, 2002;Barragan et al, 2004;0stergaard et al, 
2004;Weisser et al, 2005;0mmen et al, 2008). These studies all agree
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that WT1 is useful as a marker of MRD, particularly in those patients 
without markers but others have reported background levels of WT1 
during remission and following bone marrow or peripheral blood stem 
cell transplantation and therefore argue that WT1 is only useful to those 
patients without an alternative marker (Gaiger et al, 1998;Elmaagacli et 
al, 2000;Hamalainen et al, 2008).
The mean +/-95% confidence intervals generated for the three HOX 
genes, WT1 and COL4A5 in the diagnostic normal karyotype AML 
patient samples displayed no overlap with the mean +/-95% confidence 
intervals generated for the genes in the healthy normal donor samples 
supporting their selection for further longitudinal MRD studies in section 
6.3.1b. However, from the longitudinal studies it was clear that only 
WT1 had the ability to monitor the disease and predict relapse in normal 
karyotype patients. This could have possibly been predicted at the 
diagnostic screening stage. The largest difference observed in the +/- 
95% confidence interval between patients and the healthy normal 
donors was for the WT1 gene suggesting that this particular gene would 
go on to act as a useful MRD marker. However, whilst still no overlap 
was observed, a significantly smaller gap was observed for the mean 
+/-95% confidence intervals between patients and healthy normal 
donors for the COL4A5 gene highlighting an insufficient difference in 
transcription between the patients and the healthy normal donors to be 
confident that the gene could be used as MRD markers.
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A limitation of this investigation lies within the number of follow-up 
samples and the relatively small number of monitoring time points 
available for this study. Patient 5 relapsed 252 days following diagnosis 
but in this study we were only able to follow their disease up to 159 
days following diagnosis, approximately 3 months prior to relapse. 
Therefore an increase in transcript level would not necessarily be 
expected within this time-frame, instead a molecular relapse might have 
been observed after 159 days. Innate noise within the system also 
provides a problem for MRD monitoring and the reliability of increases 
and decreases in transcript levels detected. As previously mentioned 
Lane et al (2008) suggested that a £1 log™ rise in RQ-PCR transcript 
levels observed in serial remission bone marrow samples is a clinically 
useful definition of and reliably predicts a morphologic relapse (Lane et 
al, 2008). Lane et al (2008 were monitoring fusion gene products 
generated from t(8;21) and inv(16) in CBF AML patients. In this current 
study fluctuations of more than 1 log were observed in some of the CR 
patients for the HOX genes over two follow-up samples. These 
fluctuations may have been due to the methodology, for example the 
normalisation approach used, or due to biological causes, for example a 
natural innate variation in the genes of interest. Events like this need to 
be take into account when analysing transcript levels for relapse 
prediction. An important caveat to this study is the sample size. Further 
investigations of a larger normal karyotype patient cohort and serial 
bone marrow samples following diagnosis is required to support the 
findings of this particular study. However, these samples are incredibly
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difficult to source and realistically would only be made available through 
a prospectively designed clinical trial.
HOXA5, HOXA9, HOXB6, COL4A5 and WT1 were identified through 
gene expression profiling as being more highly expressed in normal 
karyotype AML patients compared to healthy normal donors. Their over­
expression was validated in diagnostic normal karyotype patient 
samples by RQ-PCR and compared to the expression levels detected in 
healthy normal donor samples. A statistically significant difference in 
mean expression was observed between the two sample groups 
indicating the potential of all five genes to act as markers of MRD in 
normal karyotype AML. Further longitudinal monitoring highlighted the 
ability of the WT1 gene to act as a marker of MRD but the three HOX 
genes and COL4A5 failed to fill such a role. Supported by previous 
studies, WT1 appears to be a strong candidate for a marker of MRD. 
Whilst there is some contradicting evidence in regards to the expression 
of WT1 in healthy bone marrow samples and its level of sensitivity in 
comparison to markers currently used, in terms of normal karyotype 
AML where there are currently no markers, WT1 may provide useful 
and reliable clinical information in regards to prognosis and predicting a 
molecular relapse. WT1 has effectively worked as a positive control in 
this study demonstrating the ability of gene expression profiling using 
the Affymetrix platform to identify potential markers of MRD in normal 
karyotype AML. As WT1 has been previously identified as an MRD 
marker in several investigations (Cilloni et al, 2002;0gawa et al,
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2003;Weisser et al, 2005), its identification here suggests that the 
present study was sufficiently sensitive to reiterate what has been 
shown previously. In this context, the inability to identify any novel MRD 
markers suggests that a more sensitive microarray platform may be 
required in future studies. Alternatively, we may have to concede that 
global gene expression profiling may be incapable of identifying better 
MRD markers in the context of NK AML.
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Chapter 7
The treatment of AML cell lines with differentiation 
agents and gene-specific inhibitors
303
7.1 Introduction
In the previous chapters, gene expression profiling was used to identify 
genes over-expressed in specific AML subgroups. Comparing minimal 
residual disease (MRD) data for the identified genes in patient 
diagnostic and follow-up samples revealed a strong correlation between 
these genes and the markers currently in use for MRD evaluation. 
Several of the genes identified have previously been shown to play 
important roles in the development of leukaemia and so represent 
potentially very interesting alternative biomarkers of response to 
therapy.
7.1.1 Hepatocyte growth factor (HG F)
HGF was identified as being over-expressed specifically in AML 
patients with a t(15;17) and showed a very strong correlation with the 
markers currently used, PML-RARa and RARa-PML (Chapter 3). HGF 
was originally identified as a mitogen in primary cultured adult rat 
hepatocytes and plays an important role in the regeneration of hepatic 
cells (Hino et al, 1996). Evarts et al (1993) observed increased levels of 
both HGF and transforming growth factor a (TGF-a) following a partial 
hepatectomy suggesting a role of HGF in proliferation and 
differentiation of hepatic cells (Evarts et al, 1993). Several studies have 
identified HGF as a multi-functional cytokine. The induction of tubule 
formation by MDCK (Madin-Darby canine kidney) cells showed that 
HGF was produced by fibroblasts (Rubin et al, 1991) whilst HGF, or a
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molecule biologically and immunologically related to HGF, could induce 
tubule formation (Montesano et al, 1991). The motogenic properties of 
HGF were identified in a study by Stoker and Perryman (1985). A 
motility factor was identified that was able to affect the motility of 
epithelial cells; its presence caused the expansion of epithelial colonies 
and cells to be scattered, resulting in its name of “Scatter factor” (Stoker 
& Perryman, 1985;Stoker et al, 1987). Subsequent analysis of the 
biological activity and comparative immunology, partial protein analysis 
and cDNA sequences identified scatter factor and HGF as the same 
molecule (Weidner et al, 1991). HGF has been demonstrated to 
regulate haematopoiesis in mouse foetal liver and adult bone marrow 
(Nishino et al, 1995) and various studies have observed an increased 
level of plasma HGF in AML and CML patients compared to healthy 
samples, yet low levels in ALL patients, suggesting a role in myeloid 
leukaemias (Hino et al, 1996;Nakamura et al, 1994). HGF was also 
found to stimulate the proliferation or colony formation and affect the 
migration of myeloid leukaemia cells in bone marrow or peripheral blood 
samples (Weimar et al, 1998). The receptor for HGF is a tyrosine 
kinase protein encoded by the proto-oncogene c-Met (Park et al, 1986). 
The binding of the HGF ligand to its receptor c-Met results in 
autophosphorylation of c-Met, which results in constitutive downstream 
signalling. Simultaneous expression of HGF and c-Met has not been 
seen to occur in normal cells but concomitant expression has been 
observed in myeloma cells (Borset et al, 1996a;Borset et al, 1996b)
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7.1.2 Preferentially expressed antigen in melanoma (P R A M E )
PRAME (preferentially expressed antigen in melanoma) was identified 
as being over-expressed specifically in t(8;21) AML patients and a 
correlation was observed with WT1 and t(8;21), the markers currently 
used in the assessment of MRD (Chapter 4). PRAME was originally 
identified as a tumour antigen in malignant melanoma (Ikeda et al, 
1997). However, several studies have shown over-expression of 
PRAME in AML samples (van Baren et al, 1998) and have suggested 
that PRAME could be a potential MRD monitoring candidate 
(Matsushita etal, 2001;Paydas etal, 2005).
7.1.3 Meningioma 1 (M N1)
MN1 (meningioma 1) was identified as being over-expressed 
specifically in inv(16) AML patients and its expression correlated with 
WT1 and CBFp-MYH11 MRD (Chapter 4). MN1 was first identified as a 
target of a t(4;22) in a patient with meningioma (Lekanne Deprez et al, 
1991). MN1 acts as a transcriptional co-activator by stimulating retinoic 
acid receptor/retinoid X receptor (RAR-RXR)-mediated transcription 
through the recruitment of co-activators p300 and RAC3 (retinoic acid 
receptor interacting protein 3) (Buijs et al, 2000;van Wely et al, 2003). 
MN1 is also a target in the chromosome translocation t(12;22) resulting 
in the fusion gene product MN1-TEL. MN1-TEL is only associated with 
myeloid diseases and acts as an oncogene repressing transcription 
(Buijs et al, 2000;Kawagoe & Grosveld, 2005). As well as forming part 
of an oncogene in myeloid diseases, an overexpression of MN1 has
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been observed in inv(16) AML patients in several gene expression 
profiling studies and in QRT-PCR studies (Carella et al, 2007;Ichikawa 
et al, 2006).
7.1.4 H O X A 1
HOXA1 was identified as being over-expressed specifically in normal 
karyotype AML patients and its expression was strongly correlated with 
WT1 MRD data. HOXA1 is a member of the homeodomain containing 
transcription factor family involved in cell differentiation and growth. Low 
levels of HOXA1 expression is seen in human mammary glands during 
normal growth and differentiation but higher levels of expression has 
been observed in a variety of breast cancer lesions (Chariot & 
Castronovo, 1996) and enhances the proliferation and survival of the 
cells observed in oncogenesis (Zhang et al, 2003).
7.1.5 All-frans retinoic acid (ATRA)
Several studies identified the ability of retinoids to induce differentiation 
in HL-60 cells and in promyelocytes from acute promyelocytic 
leukaemia (APL) patients (Breitman et al, 1980;Breitman et al, 1981). 
All-trans retinoic acid (ATRA) is a natural isoform of retinoic acid 
successfully used in for the treatment of APL (Huang et al, 1988). ATRA 
induces a terminal differentiation followed by apoptosis of malignant 
cells (Huang et al, 1988). When APL cells are treated with 
pharmacological doses of ATRA (>1 pM) co-repressors that bind to the
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PML-RARa fusion product and result in a negative control of 
transcription are released, allowing the expression of genes involved in 
myeloid cell differentiation (Barber et al, 2008).
7.1.6 NK4
NK4 is a small molecule containing the N-terminal domain and the 4 
kringle domains of HGF and is an antagonist of HGF. The kringle 
domains are required for receptor binding and therefore necessary for 
the biological function of HGF (Chirgadze et al, 1998). NK4 binds to c- 
Met without activating the autophosphorylation that normally occurs 
when c-Met is bound to HGF and inhibits any downstream mitogenic, 
motogenic and morphogenic activities (Date et al, 1997). NK4 has also 
been observed to inhibit angiogenesis in human lung-derived 
endothelial cells (Kuba et al, 2000). Due to the important role of HGF in 
cancer progression, NK4 has been suggested as a potential therapeutic 
and several studies have observed a suppression of tumour 
angiogenesis, growth and metastasis in colon cancer cells, cervical 
carcinoma cells and multiple myeloma cells (Date et al, 1998;Kuba et 
al, 2000;Wen et al, 2007;Du etal, 2007).
7.1.7 siRNA
RNA interference (RNAi) is a sequence-specific, post-transcriptional 
process for gene silencing. Double stranded RNA molecules are 
recognised by the cell as foreign and cleaved into short fragments
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called small interfering RNA (siRNA) by a ribonuclease Ill-type protein, 
dicer RNase III (Elbashir et al, 2001). The resulting siRNA molecules 
are 21-23 nucleotides long and contain 3'-overhanging ends 2-3 
nucleotides long (Zamore et al, 2000). A nuclease-containing complex 
called the RNA-induced silencing complex (RISC) incorporates the 
siRNAs, which are unwound by an RNA helicase. The RISC complex is 
activated and guided to the complementary mRNA strand by the siRNA 
(Elbashir et al, 2001). The siRNA hybridises to the mRNA causing the 
RISC complex to catalyse cleavage of the mRNA within the target site 
producing unprotected ends and resulting in degradation of the mRNA 
(Zamore et al, 2000). The RISC complex is recovered allowing further 
binding and cleavage to occur, resulting in a decreased expression of 
the target gene.
7.1.8 Cell surface markers
Currently it is standard practice to carry out immunophenotyping of 
blasts from bone marrow and peripheral blood samples of AML patients 
at diagnosis. A variety of differentiation markers characterise the 
leukaemic blasts and are associated with their commitment to the 
myeloid lineage and their level of maturation. The identification of 
markers that are not normally associated with the myeloid lineage can 
be used for diagnostic purposes and for the detection of minimal 
residual disease (Mason et al, 2006). CD11b is such a marker 
associated with the myeloid lineage. It is expressed as a heterodimer 
with CD18 and has been observed on mature monocytes and
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macrophages. A study by Drayson et al (2001) identified monocytes 
and neutrophils as expressing CD11b whereas HL-60 did not express 
CD11 b until treatment with the differentiating agent ATRA (Drayson et 
al, 2001). CD38 is a transmembrane glycoprotein and is expressed 
during the early stages of myeloid differentiation during normal 
haematopoiesis cells (Drach et al, 1994). Expression of CD38 is highly 
regulated by retinoids and in HL-60 cells ATRA was identified as a 
potent inducer of CD38 expression (Drach et al, 1993;Drach et al, 
1994).
Many genes have previously been identified as being specific to various 
sub-groups of AML but their relevance to and how they function in the 
development leukaemogenesis is not fully known. Selecting a gene 
identified as specific from each sub-group, the aim of this chapter was 
to treat AML cell lines with differentiating agents and gene-specific 
inhibitors and observe their effects on the cells and the expression of 
the identified genes.
7.2 Materials and Methods
7.2.1 The effect of ATRA upon HGF expression in AML Cells
To determine the effect of ATRA on the expression of HGF in AML, 
three cell lines; NB4 (a t(15:17) AML cell line), HL-60 (an APL cell line) 
and Me-1 (an inv(16) AML cell line), were treated with ATRA at a 
concentration of 10‘7M over 4 days. The cells were treated at day 0 only
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or treated every 24 hours from day 0. Cells were harvested at the start 
of treatment and at 1, 2, 3 and 4 days after treatment. The cells were 
snap-frozen and subsequently RNA was extracted as previously 
described (Chapter 2). The expression levels of the four genes 
identified as being specific to either one of the three favourable 
translocations or to a normal karyotype were monitored in three AML 
cell lines to observe the affects of ATRA upon their expression. Real­
time PCR was performed using 1pg of RNA reverse transcribed into 
cDNA (Chapter 2).
7.2.2 The effect of NK4 upon HGF expression in AML cell lines
To observe the effects of the HGF-antagonist NK4 in leukaemic cells, 
NB4 cells were treated with NK4 (supplied by Dr Gaynor Davies and Dr 
Christian Parr, Department of Surgery, Cardiff University) over a period 
of 72 hours. To determine the concentration of NK4 required for the 
treatment of NB4 cells, the level of HGF protein was quantified using 
the Quantikine® HGF ELISA kit (Section 2.5.2). A standard curve was 
generated using HGF standards and the HGF concentration in NB4 
cells was calculated. The amount of NK4 required for inhibitory effects 
was ten times the amount of HGF present. NB4 cells were set at a 
density of 1 x1 05 cells/ml and initially treated with 0.8pg/ml of NK4 and 
left to grow for 72 hours. Cell counts and viability counts were 
performed at 0, 3, 6, 9, 15 24, 48 and 72 hours. The experiment was 
performed in triplicate. The cells were pelleted and resuspended in 1x 
phosphate buffered saline (PBS) for immunophenotyping to observe the
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effects of NK4 upon the expression of surface markers in these cells 
(Chapter 2).
7.2.3 The effect of RNA interference upon the expression of genes 
identified as being specific to AML sub-groups in AML cell lines.
To observe the effect of RNA interference on the expression levels of 
selected genes in NB4 cells, cells were transfected with siRNA 
designed to silence with the expression of HGF, HOXA1, MN1 and 
PRAME. In parallel experiments a negative control scrambled siRNA 
was used. The protocol for the transfection of siRNA and the efficiency 
of transfection is described in chapter 2.
7.3 Results
7.3.1 The effect of ATRA on the growth of AML cells and the 
expression of selected genes
The AML cell lines NB4, HL-60 and Me-1 were treated with 10'7 ATRA 
over a period of 4 days to monitor its effects upon cell growth, viability 
and expression of the genes HGF, PRAME, MN1 and HOXA1. These 
genes were selected for investigation to compare a potential ATRA 
responsive gene (HGF) to genes identified from ATRA non-responsive 
leukaemias; t(8;21), inv(16) and normal karyotype.
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a. Cell growth and viability
The results shown in Figure 1 indicate an inhibition of growth by day 2 
of the treatment when compared to untreated cells in all three cell lines 
cells treated with ATRA. The greatest effect was seen in the NB4 cells 
and the HL-60 cells. There was no significant difference in the rate of 
growth between those cells treated with ATRA on day 0 or those treated 
with ATRA on day 0, 1, 2 and 3. Further, despite the inhibition of 
growth, there was no significant change in cell viability between the 
ATRA-treated and untreated cells.
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Figure 1. The effect of ATRA on the growth (a) and viability (b) of NB4 cells over 
72 hours when treated with 10'7M ATRA at day 0 only and when treated at day 0, 
1, 2 and 3 compared to untreated cells.
313
b. Gene expression
The level of expression of the HOXA1 gene appeared to increase in all 
three cell lines following treatment with ATRA over 4 days compared to 
the levels observed in the untreated cells, which remained constant 
over the 4 days (Figures 2, 3 and 4). No significance difference in the 
level of expression of PRAME was observed between the ATRA treated 
cells and the untreated cells in any of the 3 cell lines (Figures 2, 3 and 
4). There appeared to be no difference in level of expression of MN1 
between the treated and untreated NB4 cells (Figures 2 and 3). In 
contrast, the level of MN1 expression in the HL-60 and Me-1 cell lines 
increased by day 1 following treatment with ATRA compared to the 
untreated cells but then decreased for the remainder of the treatment 
(Figure 4). The levels of HGF expression decreased in NB4 cells 
following treatment with ATRA compared to the levels in the untreated 
cells, which remained constant for the 4 days (Figure 2). No difference 
was observed in HGF expression levels in the ATRA treated Me-1 cells 
whilst an increase in HGF expression was observed in the untreated 
cells over the 4 days (Figure 6.4). No data for HGF expression was 
available for the HL-60 cells.
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Figure 2. The effect of 10‘7M ATRA on the expression of HOXA1, PRAME, MN1 
and HGF in NB4, the t(15;17) cell line, cells over 72 hours when treated only at day 
0 and when treated at day 0, 1, 2 and 3 compared to untreated cells.
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Figure 3. The effect of ATRA on the expression of HOXA1, PRAME, MN1 and HGF 
in HL-60, the promyelocytic cell line, cells over 72 hours when treated only at day 0 
and when treated at day 0, 1, 2 and 3 compared to untreated cells.
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Figure 4. The effect of ATRA on the expression of HOXA1, PRAME, MN1 and 
HGF in Me-1, the inv(16) cell line, cells over 72 hours when treated only at day 0 
and when treated at day O, 1, 2 and 3 compared to untreated cells.
7.3.2 The effect of the HGF-antagonist NK4 on NB4 cells
NB4 cells were treated with 0.8|jg/ml NK4, an HGF antagonist, for a 
period of 72 hours to observe its effect upon cell growth, viability and 
the expression of the cell surface markers CD11 b and CD38
a. Cell growth and viability
The results shown in Figure 5 indicate that the growth of NB4 cells was 
inhibited for a period of 24 hours when treated with NK4 at 0 hours only 
than when left untreated, but begin to grow after this time as the effects 
of NK4 ceased. No significant change in cell viability between treated 
and untreated cells was observed. When the NB4 cells were treated 
with NK4 at 0 hours and at 24 hours after the initial treatment, the
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growth of cells was inhibited until 48 hours after initial treatment, when 
cell growth resumed (Figure 6.6). Again, cell viability was unaffected by 
treatment with NK4.
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Figure 5. The effect of NK4 on growth (a) and viability (b) of NB4 cells over 72 
hours when treated with 0.8|jg/ml of NK4 at 0 hours and at 24 hours after initial 
treatment. Experiments were performed in triplicate and the error bars represent 
+/- one standard deviation from the mean.
b. Cell surface markers
As seen in Figure 6, no consistent change in expression of CD38 was 
observed in the NK4-treated NB4 cells compared to the untreated cells. 
A slight increase in expression of CD11b was observed at 48 hours 
after treatment compared to the untreated cells but due to the lack of 
replicates the significance of this data is inconclusive.
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Figure 6. The effect of 0.8pg/ml NK4 on the expression of cell surface markers of 
NB4 cells over 72 hours when treated at 0 hours and 24 hours after initial 
treatment. Experiments were performed once due to a lack of the NK4 inhibitor.
7.3.3 Measurement of transfection efficiency of FAM-labelled 
siRNA against selected genes in NB4 cells
NB4 cells were transfected with 50nM and 100nM siRNA designed to 
silence HGF, MN1, PRAME and HOXA1 and with a scrambled siRNA to 
act as a negative control. The efficiency of siRNA transfection into the 
NB4 cells was determined by flow cytometry on day 2 following 
transfection so that any changes in cell growth or gene expression in 
the cells could be correctly attributed to the actions of the siRNA. There 
was no significant difference in the level of fluorescence between the 
transfected and non-transfected cells suggesting inadequate 
transfection of the siRNA. It was decided due to time restraints not carry 
out any further investigation into the effect of siRNA on gene 
expression.
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7.4 Discussion
Gene expression profiling has identified several genes specific to 
certain AML subgroups (Chapters 3-5). Several of the genes identified, 
for example HGF, are already recognised as playing an important role 
in the development of leukaemia. To investigate the 
relevance/importance of these genes in AML, several genes were 
selected for further investigation. AML cell lines were treated with the 
differentiation agent ATRA, with the HGF antagonist NK4 and were 
transfected with siRNA designed to silence the expression of HGF, 
MN1, PRAME and HOXA1 in order to examine the effects upon cell 
growth, viability, gene expression and cell-surface marker expression.
When treated with 10'7M ATRA, a decrease in growth was observed in 
the AML cell lines NB4, HL60 and Me-1 after approximately 2 days 
following treatment. No significant change in cell viability was observed 
in any of the cell lines. This data is supported by a study by Ozeki et al 
(2008) in which a growth arrest in HL-60 cells was observed 1-2 days 
following treatment with ATRA and <15% early apoptotic cells were 
observed throughout the 5-day treatment (Ozeki & Shively, 2008). The 
growth inhibition observed was much greater in the promyelocytic cell 
lines compared to the Me-1 cells, the cell line harbouring an inv(16) 
translocation. Previously a gene identified as specific to inv(16) patients 
was MN1 (Chapter 4). The MN1 protein has been identified as 
functioning as a transcription co-activator for the retinoic acid receptor 
(van Wely et al, 2007). Heuser et al (2007) later observed that MN1
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greatly increases the resistance of cells to ATRA-induced differentiation 
and cell cycle arrest (Heuser et al, 2007). Therefore the lower growth 
inhibition observed in the Me-1 cells could be due to the presence of an 
inv(16) and the subsequent over-expression of MN1. Treatment with 
ATRA saw the level of HGF expression to decrease in NB4 cells, 
increase in HL-60 cells and remained unchanged in Me-1 cells over the 
4 days. The level of HOXA1 increased in all 3 cell lines treated with 
ATRA over 4 days whereas the level of PRAME expression remained 
unchanged in the cell lines. The expression levels of MN1 remained 
unchanged in the ATRA-treated NB4 cells, an increase in MN1 
expression was observed in the HL-60 cells and the Me-1 cells at 24 
hours following treatment, but then decreased for the remainder of the 
treatment. NB4 is a promyelocytic cell line and HL-60 cells, derived 
from an AML FAB type M2 patient, display a myeloblastic/promyelocytic 
morphology but the t(15;17) translocation is only expressed in the NB4 
cells (Birnie, 1988). HGF was previously identified as being specific to 
t(15;17) AML patients (Chapter 3). Whilst the effect of ATRA on the 
expression of HGF has not been investigated in haematological 
malignancies, a study using a human malignant astrocytoma cell line, 
U87, did observe a decrease in the expression upon treatment with 
ATRA in a time- and concentration-dependent manner (Chattopadhyay 
et al, 2001). Despite NB4 cells being promyelocytic and HL-60 
displaying a promyelocytic morphology, the difference in effect on HGF 
expression between the HL-60 cells and the NB4 cells could be due to 
the absence of the t(15;17) translocation in HL-60 cells but this can only
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be speculative due to the lack of confirmatory experimental data. The 
lack of change in HGF expression in the Me-1 cells could again be due 
to an over-expression of MN1 resulting resistance to ATRA, or HGF not 
having as a significant role in inv(16) AML than in t(15;17) AML. 
PRAME was identified as being specific to t(8;21) patients and no 
change in it’s expression was observed in the 3 cell lines suggesting 
that PRAME is not regulated by retinoids in these cell lines. 
Unfortunately these results are not conclusive due to the lack of 
replicates. It would also be interesting to include a t(8;21) AML cell line, 
such as Kasumi, in the study to observe the effect of ATRA upon all the 
genes selected in their specific sub-group.
When treated with NK4, the NB4 cells exhibited an inhibition of growth 
for 24 hours following treatment. No significant change in cell viability 
was observed. No change in expression of CD38 was observed upon 
treatment with NK4 but a slight increase in CD11 b was observed at 48 
hours following treatment. The significance of the CD11b cannot be 
determined due to the lack of replicates. The expression of both CD11 b 
and CD38 has been observed to increase in HL-60 cells upon treatment 
with the differentiating agent ATRA (Drach et al, 1993;Drayson et al, 
2001). The lack of significant increase of both surface antigens in this 
study suggests that NK4 does inhibit the growth of cells but does not 
cause them to differentiate. HGF has been observed as a 
multifunctional protein that promotes tumour cell growth, which is 
inhibited by NK4 (Du et al, 2007). The cell surface marker assays need
321
to be repeated in order to determine their statistical significance. It 
would have also been interesting to follow the effect of NK4 in a wider 
panel of AML cell lines and look at the expression levels of HGF, MN1 
and HOXA1 in the treated cells but unfortunately a problem with the 
supply of the NK4 meant this and further immunoassays were not 
possible.
Inhibition of the selected genes by siRNA was attempted but 
transfection of the AML cell lines was unsuccessful. Further 
investigation into the silencing of genes identified as specific to AML 
sub-groups could provide useful information, potentially leading to the 
validation of new therapeutic targets.
ATRA is currently used to induce differentiation in acute promyelocytic 
leukaemia patients and the ability of NK4 to down-regulate HGF and 
inhibit tumour growth has already been recognised in several cancers. 
However the observation of growth inhibition of AML cell lines would 
suggest that NK4 has the potential as a therapeutic treatment for AML 
and should be investigated further. This investigation into possible novel 
markers of MRD has also highlighted that the AML sub-group-specific 
genes may have the potential to identify new therapeutic targets.
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Chapter 8
Discussion
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Despite improved survival rates over the past decade, relapse still 
remains a major obstacle to the cure of leukaemia (Chung et al, 2006). 
One strategy to combat relapse is the early detection and treatment of 
minimal residual disease (MRD) in order to reduce the risk of a potential 
relapse. Therefore, MRD markers can be used to tailor treatment by 
identifying patients who need further therapy (MRD positive) and those 
who do not require further intervention (MRD negative). However, these 
MRD markers need to be tested prospectively and must meet exacting 
sensitivity and specificity criteria. Real-time PCR (RQ-PCR) is already 
routinely used to quantitate fusion gene products resulting from 
common translocations occurring in AML; PML-RARa, AML1-ETO and 
CBFp-MYH11. Unfortunately patients presenting with these 
chromosomal abnormalities only account for approximately 20% of the 
adult AML cases and approximately 50% of AML cases have no 
detectable aberrations. The use of microarrays as a tool for disease 
classification was first explored by Golub et al (1999) using class 
discovery and class prediction to distinguish between ALL and AML 
samples (Golub et al, 1999). The predictive power of gene expression 
profiling was further utilised to identify distinct gene expression profiles 
for AML-specific genetic alterations and later with specific gene 
mutations and aberrant gene expressions within AML. Using these 
profiles, markers have been identified that can help diagnose individual 
patients and predict prognosis. Reports such as these have prompted 
investigations into the suitability of gene expression profiling to identify
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new therapeutic targets and predict therapeutic outcome and patient 
responses.
With the need for novel MRD markers in AML clearly evident and the 
potential of gene expression profiling to identify such markers, the aim 
of this study was to use gene expression profiling to identify new 
markers of MRD specific to AML sub-groups.
As a “proof-of-principle”, gene expression profiling was initially applied 
to a cohort of AML patients to identify potential markers of MRD specific 
to AML bearing the t(15;17) translocation (Chapter 3). Statistical 
analysis and filtering tools identified a list of probe sets specific to this 
AML sub-group. Several probe sets identified as significantly over­
expressed in t(15;17) patients in comparison to non-t(15;17) patients, 
including the two probe sets with the greatest fold change in 
expression, represented the hepatocyte growth factor (HGF) gene. This 
is consistent with previous gene expression profiling studies of APL. 
Valk et al (2004) identified the HGF gene as specific to a cluster of 
patients, all of whom were diagnosed with APL and as the best 
predictor for the t(15;17) aberration in AML whilst Gutierrez et al (2005) 
identified HGF as significantly over-expressed in APL patients and as 
the second most over-expressed gene in APL patients when compared 
to non-APL patients. The observation of a statistically significant 
difference in expression of HGF and IGFBP2 between t(15;17) AML 
diagnostic patient samples and healthy normal bone marrow samples 
led to longitudinal monitoring of these genes in three t(15;17) patients
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that achieved complete remission. The candidate genes displayed 
similar expression patterns to the genes currently used as MRD 
markers, PML-RARa and RARa-PML, and remained lower than the 
upper levels detected in healthy normal donor bone marrow samples. 
However, only a two log decrease in HGF and IGFBP2 transcripts 
levels from diagnosis and induction therapy to complete remission was 
observed compared to the six log decrease observed for the PML- 
RARa and RARa-PML transcripts. This relatively small change in 
transcript levels probably limits the usefulness of these markers in the 
MRD setting but they may still be biologically important in the context of 
remission and disease relapse.
Using the same principle for the core binding factor leukaemias, gene 
expression profiling was applied to the cohort of AML patients to identify 
potential markers of MRD specific to AML bearing the t(8;21) 
translocation or inversion of chromosome 16 (Chapter 4). Many genes 
identified in this study as over-expressed in either t(8;21) or in(16) AML 
have previously been identified in other investigations. Confirming the 
results of the current study, Valk et al (2004) identified the ETO gene as 
the most discriminating genes for a cluster containing all patients 
exhibiting a t(8;21), whilst Gutierrez et al (2005) observed an elevated 
MYH11 expression in inv(16) AML patients. In further agreement with 
this study, Bullinger et al (2007) identified the POU4F1 (POU domain, 
class 4, transcription factor 1), CAV1 (caveolin 1), HSPG2 (heparan 
sulphate proteoglycan 2) and TRH (Thyrotropin-releasing hormone)
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genes as defining the t(8;21) patients and the NT5E (5-nucleotidase, 
ecto (CD73)) and SPARC (secreted protein, acidic, cysteine-rich) genes 
defining the inv(16) patients. Diagnostic monitoring of several genes, 
selected on the basis of their level of expression in the gene expression 
profiling analysis and current literature, from each CBF groups in CBF 
patients and in healthy normal bone marrow demonstrated promising 
results but longitudinal studies demonstrated a similar problem seen for 
the t(15;17) monitoring -  much smaller changes in transcript levels for 
the candidate compared to the markers currently used and therefore, 
the relevance of their change in expression can be questioned. 
However, in agreement with earlier studies of Matsushita et al (2001) 
and Tajeddine et al (2006), promising results were seen for the PRAME 
gene, identified as over-expressed in t(8;21) AML, and the monitoring of 
residual disease in several t(8;21) patients.
The potential of gene expression profiling to identify candidate MRD 
makers demonstrated in the favourable AML sub-groups led the 
investigation to identify potential markers for normal karyotype AML 
(Chapter 5). From a core dataset of normal karyotype AML patients and 
healthy normal donors, 25 probe sets were identified as up-regulated in 
the normal karyotype AML patients and correctly clustered samples as 
normal karyotype AML or healthy normal bone marrow in an 
independent dataset. Similar to the investigation by Debernardi et a! 
(2003), a number of HOX gene and HOX-related genes were up- 
regulated in the normal karyotype AML samples. Selected on the basis
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of their level in expression in the normal karyotype AML samples from 
the gene profiling analysis, several HOX genes, COL4A5 and WT1, the 
gene currently used as an MRD marker, were monitored in diagnostic 
normal karyotype AML samples and healthy bone marrow (Chapter 6). 
Whilst all displaying statistically significant differences in mean 
expression levels between the normal karyotype AML samples and the 
healthy normal bone marrow samples, the lack of spread of expression 
levels of WT1 between the two groups indicated WT1 had the greatest 
potential from the group of genes to discriminate between residual 
disease indicating a relapse and background levels similar to those 
detected in healthy normal samples. This was confirmed from 
longitudinal monitoring of the genes in normal karyotype AML patients. 
A decrease in WT1 expression levels following induction therapy was 
observed in all patients. In those patients achieving complete remission, 
WT1 expression levels remained at this lower level whereas an 
increase in WT1 expression was observed approximately three months 
prior to relapse in the patient that relapsed at 125 days following 
diagnosis. The three HOX genes and COL4A5 displayed patterns of 
expression that would not be expected of a marker displaying either 
remission or relapse and of unknown relevance to their disease. WT1 
has a long history of investigation as a potential marker of MRD in AML 
(Inoue et al, 1996;Cilloni et al, 2002;Trka et al, 2002;0gawa et al, 
2003;Weisser et al, 2005;Candoni et al, 2009). The identification of 
WT1 in the current study, and its validation as a marker, confirms the 
ability of gene expression profiling to identify new markers of MRD for
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AML. The lack of other genes confirmed as suitable MRD markers may 
be due to a lack of sensitivity of the Affymetrix platform to identify 
further markers or that gene expression profiling is simply not a method 
suitable for identifying markers better than those already in use.
One possible limitation to this study may be the time-frame of patient 
follow-up samples that were available for analysis. The follow-up 
samples used for monitoring all the patients in the current study were 
not always available to the point of relapse. As a consequence, 
potentially important changes of gene expression relating to relapse 
were not observed as samples close enough to the point of relapse 
were not always available. Fluctuations in gene expression, possibly 
due to methodology and/or biological reasons, were regularly detected 
without a change in the patient’s disease status. Following the rule of 
Lane et al (2008); the requirement for a greater than one log rise in RQ- 
PCR transcript levels detected in serial bone marrow samples, most of 
the fluctuations could be ignored as innate noise.
The use of hybridisation probes to detect the transcript levels of the 
candidate genes would improve the sensitivity of the detection during 
longitudinal monitoring and assess the potential relevance of any 
changes in expression detected. In the current study a SYBR green 
method with primers was utilised for the detection of transcripts by RQ- 
PCR. A disadvantage of this method is the reduced specificity of the 
primers compared to hybridisation probes resulting in the non-specific 
amplification of PCR products and primer dimers. To account for this
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problem in the current study a melting curve analysis was performed to 
identify any non-specific amplification. However, this does not eliminate 
non-specific amplification and reduces the specificity and sensitivity of 
the amplification.
The small size of the sample populations monitored within this study 
precludes the drawing of definitive conclusions and further 
investigations of a larger normal karyotype patient cohort and serial 
bone marrow samples following diagnosis is required to corroborate the 
findings. However, it should be noted that these samples are very 
difficult to source and realistically would only be made available through 
a prospectively designed clinical trial.
This study identified a series of sub-group specific genes which were 
compared to existing MRD markers. A few of these genes correlated 
with the expression of existing markers and further validation in larger 
MRD studies could prove their usefulness in the clinical environment. 
Unfortunately, the majority of the candidate markers identified failed to 
meet all of the necessary suitability criteria for use as MRD markers. 
However, this does not invalidate gene expression profiling as a method 
of identifying potential MRD markers, it merely highlights the complexity 
of the problem and points to the need for a large-scale studies to 
minimise false discovery rates and positively identify important 
candidates. The identification and validation of a gene currently used as 
an MRD marker, WT1, demonstrates the ability of gene expression
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profiling to identify potentially significant genes for AML sub-groups that 
may ultimately be used as markers of MRD.
Possible future work;
■ Re-evaluate the current genes identified as specific to AML sub­
groups to assess other potential MRD marker candidates 
previously over-looked.
■ Apply gene expression profiling to identify genes specific to 
normal karyotype AML patients bearing significant prognostic 
markers, for example NPM1, FLT3, CEBPA, MN1
■ Validate the potential MRD markers in a larger sample group and 
observe their behaviour in patients from other AML sub-groups.
■ Use the standardised MRD protocols for monitoring the 
candidate markers.
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Appendix II: Gene Lists 
t(15;17)-Specific Genes
Genes identified as over-expressed in t(15;17) AML through filtering on 
fold-change, ANOVA and SAM analysis of probe sets classified as 
“present in at least 1 sample” and as “present and changing” (Chapter
3).
Probe Set GeneSymbol Gene Title
Fold
Change
1 210794_s_at MEG3 Maternally expressed 3 (non-protein coding) 3.002
2 208581_x_at MT1X Metallothionein 1X 3.149
3 209686_at SIOOB S100 calcium binding protein B 3.184
4 203074_at ANXA8 Annexin A8 3.387
5 221898_at PDPN Podoplanin 3.689
6 205047_s_at ASNS Asparagine synthetase 3.706
7 *204879_at PDPN Podoplanin 3.739
8 219837_s_at CYTL1 Cytokine-like 1 3.838
9 207076_s_at ASS1 Argininosuccinate synthetase 1 3.874
10 211663_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 3.961
11 203068_at KLHL21 Kelch-like 21 (Drosophila) 3.970
12 209960_at HGF Hepatocyte growth factor 4.796
13 202718_at IGFBP2 Insulin-like growth factor binding protein 2 4.800
14 210755_at HGF Hepatocyte growth factor 5.263
15 212187_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 6.344
16 211748_x_at PTGDS Prostaglandin D2 synthase 21 kDa (brain) 6.950
17 210998_s_at HGF Hepatocyte growth factor 7.367
18 210997_at HGF Hepatocyte growth factor 8.958
t(8;21)-Specific Genes
Genes identified as over-expressed in t(8;21) AML through filtering on 
fold-change, ANOVA and SAM analysis of probe sets classified as 
“present in at least 1 sample” and as “present and changing” (Chapter
4).
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Probe Set Gene Gene Title FoldSymbol Change
1 218825_at EGFL7 EGF-like-domain, multiple 7 3.004
2 209728_at HLA-DRB4
Major histocompatibility complex, class II, DR 
beta 4 3.008
3 202242_at TSPAN7 Tetraspanin 7 3.010
4 207550_at MPL Myeloproliferative leukemia virus oncogene 3.029
5 208178_x_at TRIO Triple functional domain (PTPRF interacting) 3.033
6 206187_at PTGIR Prostaglandin 12 (prostacyclin) receptor (IP) 3.082
7 210997_at HGF Hepatocyte growth factor 3.102
8 222222_s_at HOMER3 Homer homolog 3 (Drosophila) 3.189
9 207030_s_at CSRP2 Cysteine and glycine-rich protein 2 3.229
10 209560 s at DLK1 delta-like 1 homolog (Drosophila) 3.242
11 204548_at STAR Steroidogenic acute regulatory protein 3.244
12 211140_s_at CASP2 Caspase 2, apoptosis-related cysteine peptidase 3.247
13 212671_s_at HLA-DQA1
Major histocompatibility complex, class II, DQ 
alpha 1 3.276
14 207496_at MS4A2
Membrane-spanning 4-domains, subfamily A, 
member 2 3.293
15 219790_s_at NPR3
Natriuretic peptide receptor C/guanylate cyclase 
C 3.424
16 211549_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 3.439
17 212013_at PXDN Peroxidasin homolog (Drosophila) 3.533
18 210012_s_at EWSR1 Ewing sarcoma breakpoint region 1 3.537
19 209543_s_at CD34 CD34 molecule 3.542
20 219090_at SLC24A3 Solute carrier family 24 (sodium/potassium /calcium exchanger), member 3 3.590
21 204990_s_at ITGB4 Integrin, beta 4 3.614
22 202760_s_at
PALM2-
AKAP2 PALM2-AKAP2 readthrough transcript 3.653
23 209013_x_at TRIO Triple functional domain (PTPRF interacting) 3.671
24 219837_s_at CYTL1 Cytokine-like 1 3.731
25 204811_s_at CACNA2D2
Calcium channel, voltage-dependent, alpha 
2/delta subunit 2 3.787
26 204073_s_at C11orf9 Chromosome 11 open reading frame 9 3.843
27 201015_s_at JUP Junction plakoglobin 3.932
28 214183_s_at TKTL1 Transketolase-like 1 3.938
29 201621_at NBL1 Neuroblastoma, suppression of tumorigenicity 1 3.986
30 200671 _s_at SPTBN1 Spectrin, beta, non-erythrocytic 1 4.171
31 203913_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 4.220
32 203065_s_at CAV1 Caveolin 1, caveolae protein, 22kDa 4.439
33 204468_s_at TIE1
Tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 4.551
34 219686_at STK32B Serine/threonine kinase 32B 4.716
35 204885_s_at MSLN Mesothelin 5.182
36 209170_s_at GPM6B Glycoprotein M6B 5.236
37 218876_at TPPP3 Tubulin polymerization-promoting protein family member 3 5.312
38 208534_s_at RASA4 RAS p21 protein activator 4 5.353
39 209010_s_at TRIO Triple functional domain (PTPRF interacting) 5.453
40 209167_at GPM6B Glycoprotein M6B 6.328
41 206726_at PGDS Prostaglandin D2 synthase, hematopoietic 6.844
42 206940_s_at POU4F1 POU class 4 homeobox 1 7.522
43 212097_at CAV1 Caveolin 1, caveolae protein, 22kDa 8.016
44 213194_at ROBOI Roundabout, axon guidance receptor, homolog 1 8.209
45 207741_x_at TBSAB1 Tryptase alpha/beta 1 8.355
46 204086_at PRAME Preferentially expressed antigen in melanoma 8.990
47 207134 x at TPSB2 Tryptase beta 2 9.150
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48 201655_s_at HSPG2 Heparan sulfate proteoglycan 2 9.649
49 205683_x_at TPSAB1 Tryptase alpha/beta 1 10.01
50 216474_x_at TPSAB1 Tryptase alpha/beta 1 12.06
51 216831_s_at RUNX1T1 Runt-related transcription factor 1 13.09
52 205529_s_at RUNX1T1 Runt-related transcription factor 1 13.25
53 215382_x_at TPSAB1 Tryptase alpha/beta 1 13.61
54 217023_x_at TPSB2 Tryptase alpha/beta 1 14.81
55 210744_s_at IL5RA Interleukin 5 receptor, alpha 16.56
56 205528_s_at RUNX1T1 Runt-related transcription factor 1 18.12
57 210084_x_at TPSAB1 Tryptase alpha/beta 1 21.71
58 211517_s_at IL5RA Interleukin 5 receptor, alpha 25.35
59 211341_at POU4F1 POU class 4 homeobox 1 39.08
60 206622_at TRH Thyrotropin-releasing hormone 39.27
inv(16)-Specific Genes
Genes identified as over-expressed in inv(16) AML through filtering on 
fold-change, ANOVA and SAM analysis of probe sets classified as 
“present in at least 1 sample” and as “present and changing” (Chapter
4).
Probe Set
Gene
Symbol Gene Title
Fold
Change
1 216953_s_at WT1 Wilms tumor 1
Serpin peptidase inhibitor, clade E (nexin,
3.007
2 202627_s_at SERPINE1 plasminogen activator inhibitor type 1), member 1 3.042
3 209013_x_at TRIO Triple functional domain (PTPRF intera 3.068
4 219901_at FGD6 FYVE, RhoGEF and PH domain conta 3.097
5 219051_x_at METRN Meteorin, glial cell differentiation regul 3.112
6 205081_at CRIP1 Cysteine-rich protein 1 (intestinal) 3.114
7 201841_s_at HSPB1 Heat shock 27kDa protein 1 
Neurotrophic tyrosine kinase, receptor, type
3.116
8 208605_s_at NTRK1 1 3.135
9 203329_at PTPRM Protein tyrosine phosphatase, receptor type, M 3.14
10 203407_at PPL Periplakin 3.173
11 215111_s_at TSC22D1 TSC22 domain family, member 1 
Solute carrier family 6 (neurotransmitter
3.185
12 211030_s_at SLC6A6 transporter, taurine), member 6
Major histocompatibility complex, class II, DQ beta
3.191
13 212998_x_at HLA-DRB4 1 3.235
14 210090_at ARC Activity-regulated cytoskeleton-associated protein 3.238
15 202291 _s_at MGP Matrix Gla protein 3.264
16 202827_s_at MMP14 Matrix metallopeptidase 14 (membrane-inserted) 3.296
17 203973_s_at CEBPD CCAAT/enhancer binding protein (C/EBP), delta 3.343
18 204134_at PDE2A Phosphodiesterase 2A, 3.36
19 202145_at LY6E Lymphocyte antigen 6 complex, locus E 3.363
20 219308_s_at AK5 Adenylate kinase 5 3.364
21 211182 x at RUNX1 Runt-related transcription factor 1 3.392
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22 207075_at CIAS1 NLR family, pyrin domain containing 3.414
23 47553_at DFNB31 Deafness, autosomal recessive 31 3.435
24 213895_at EMP1 Epithelial membrane protein 1 3.445
25 208456_s_at RRAS2 Related RAS viral (r-ras) oncogene homolog 2 
BCL2-interacting killer (apoptosis-
3.456
26 205780_at BIK inducing) 3.474
27 206067_s_at WT1 Wilms tumor 1 3.475
28 212803_at NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 3.487
29 201667_at GJA1 Gap junction protein, alpha 1, 43kDa 3.518
30 201015_s_at JUP Junction plakoglobin 3.528
31 200951_s_at CCND2 Cyclin D2 3.541
32 218825_at EGFL7 EGF-like-domain, multiple 7 3.549
33 202746_at ITM2A Integral membrane protein 2A 
Cytochrome P450, family 2, subfamily E,
3.575
34 209975_at CYP2E1 polypeptide 3.588
35 202016_at MEST Mesoderm specific transcript homolog (mouse) 3.593
36 201739_at SGK Serum/glucocorticoid regulated kinase 1 3.71
37 209386_at TM4SF1 Transmembrane 4 L six family member 1 3.717
38 217388_s_at KYNU Kynureninase (L-kynurenine hydrolase) 3.722
39 202628_s_at SERPINE1 Serpin peptidase inhibitor, 3.778
40 205157_s_at KRT17 Keratin 17 3.8
41 215034_s_at TM4SF1 Transmembrane 4 L six family member 1 3.847
42 204787_at VSIG4 V-set and immunoglobulin domain containing 4 3.917
43 204011_at SPRY2 Sprouty homolog 2 (Drosophila) 3.919
44 203913_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 3.934
45 216016_at NLRP3 NLR family, pyrin domain containing 3 3.953
46 205819_at MARCO Macrophage receptor with collagenous structure 3.958
47 204794_at DUSP2 Dual specificity phosphatase 2 
Solute carrier family 2 (facilitated glucose
4.008
48 220091_at SLC2A6 transporter), member 6 4.01
49 202340_x_at NR4A1 Nuclear receptor subfamily 4, group A, member 1 4.026
50 212667_at SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 4.035
51 207741_x_at TPSAB1 Tryptase alpha/beta 1 4.139
52 210997_at HGF Hepatocyte growth factor
Guanine nucleotide binding protein (G protein),
4.16
53 209576_at GNAI1 alpha inhibiting activity 4.232
54 207134_x_at TPSB2 Tryptase beta 2 4.239
55 217849_s_at BPB CDC42 binding protein kinase beta (DMPK-like) 4.358
56 216442_x_at FN1 Fibronectin 1 4.399
57 209487_at RBPMS RNA binding protein with multiple splicing 4.432
58 202007_at NID1 Nidogen 1 4.45
59 212464_s_at FN1 Fibronectin 1 4.563
60 205683_x_at TPSAB1 Tryptase alpha/beta 1 4.612
61 210202_s_at BIN1 Bridging integrator 1 4.63
62 214020_x_at ITGB5 Integrin, beta 5 4.64
63 216474_x_at TPSAB1 Tryptase alpha/beta 1 4.712
64 206682_at CLEC10A C-type lectin domain family 10, member A 4.764
65 202747_s_at ITM2A Integral membrane protein 2A 
Serpin peptidase inhibitor, clade F (alpha-2
4.771
66 202283_at SERPINF1 antiplasmin, pigmen 4.84
67 217023_x_at TPSB2 Tryptase alpha/beta 1 4.935
68 211719_x_at FN1 Fibronectin 4.945
69 201496_x_at MYH11 Myosin, heavy chain 11, smooth muscle 4.967
71 208450_at LGALS2 Lectin, galactoside-binding, soluble, 2 5.059
70 34210_at CD52 CD52 molecule 4.977
71 208450_at LGALS2 Lectin, galactoside-binding, soluble, 2 5.059
72 204163 at EMILIN1 Elastin microfibril interfacer 1 5.24
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73 210139_s_at PMP22 Peripheral myelin protein 22 5.296
74 215382_x_at TPSAB1 Tryptase alpha/beta 1 5.322
75 214390_s_at BCAT1 Branched chain aminotransferase 1, cytosolic 5.524
76 215666_at HLA-DRB4
Major histocompatibility complex, class II, OR beta 
4 5.615
77 206622_at TRH Thyrotropin-releasing hormone 5.722
78 201005_at CD9 CD9 molecule 5.828
79 205239_at AREG Amphiregulin 5.858
80 210495_x_at FN1 Fibronectin 1 5.859
81 200665_s_at SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 5.889
82 210084_x_at TPSAB1 Tryptase alpha/beta 1 5.904
83 204661_at CD52 CD52 molecule 5.964
84 221914_at SYN1 Synapsin I 6.055
85 208978_at CRIP2 Cysteine-rich protein 2 6.491
86 213479_at NPTX2 Neuronal pentraxin II 6.53
87 203036_s_at MTSS1 Metastasis suppressor 1 6.634
88 209387_s_at TM4SF1 Transmembrane 4 L six family member 1 6.767
89 201324_at EMP1 Epithelial membrane protein 1 6.792
90 205987_at CD1C CD1c molecule 7.03
91 205330_at MN1 Meningioma (disrupted in balanced translocation) 1 7.947
92 203939_at NT5E 5'-nucleotidase, ecto (CD73) 8.023
93 208789_at PTRF polymerase I and transcript release factor 8.23
94 201325_s_at EMP1 Epithelial membrane protein 1 8.544
95 209488_s_at RBPMS RNA binding protein with multiple splicing 8.791
96 212358_at CLIP3 CAP-GLY domain containing linker protein 3 9.902
97 201497_x_at MYH11 Myosin, heavy chain 11, smooth muscle 10.32
98 218876_at TPPP3
Tubulin polymerization-promoting protein family 
member 3 10.81
99 204885_s_at MSLN Mesothelin 15.47
100 206135_at ST18
Suppression of tumorigenicity 18 (breast 
carcinoma) (zinc finger protein) 26.59
Normal Karyotype AML
Genes identified as over-expressed in normal karyotype AML through
filtering on fold-change and Bayesian f-testing (Chapter 5).
Probe set GeneSymbol Gene Title
Fold
Change
1 213147_at HOXA10 Homeobox A10
Pleckstrin homology-like domain, family A, member
4.030
2 218000 s at PHLDA1 1 4.084
3 212803 at NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 4.141
4 214488 at RAP2B RAP2B, member of RAS oncogene family 4.171
5 209983 s at NRXN2 Neurexin 2 4.195
6 201243 s at ATP1B1 ATPase, Na+/K+ 4.252
7 206532 at - Human Ini1 mRNA, complete cds 4.296
8 204069 at MEIS1 Meis homeobox 1 4.446
9 206674 at FLT3 fms-related tyrosine kinase 3 4.584
10 205453_at HOXB2 Homeobox B2 4.621
11 214880_x_at CALD1 Caldesmon 1
Cholinergic receptor, nicotinic, alpha 1
4.988
12 211039 at CHRNA1 (muscle) 5.538
13 219908 at DKK2 Dickkopf homolog 2 (Xenopus laevis 5.705
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14 213150_at HOXA10 Homeobox A10 5.737
211125 x at GRIN1
Glutamate receptor, ionotropic, N-methyl D-
15 aspartate 1 6.637
16 215441 at - Human clone 23842 mRNA sequence 7.490
17 216011 at SLC39A9 Solute carrier family 39 (zinc transporter), member 9 7.594
18 206310 at SPINK2 Serine peptidase inhibitor, Kazal type 2 8.029
19 213110 s at COL4A5 Collagen, type IV, alpha 5 10.59
20 214651 s at HOXA9 Homeobox A9 11.04
21 213844 at HOXA5 Homeobox A5 11.27
22 206067 s at WT1 Wilms tumor 1 14.05
23 217698 at - /DB_XREF=AV651668 /CLONE=GLCCSC04 16.94
24 209905 at HOXA9 Homeobox A9 17.45
25 205366 s at HOXB6 Homeobox B6 36.73
Appendix III: Cel Files
See attached DVD
The image files (Cel files) used for the favourable AML gene expression 
profiling analysis (Master Experiment) (Chapter 3, 4).
The image files (Cel files) used for the normal karyotype AML gene 
expression profiling analysis (Master Experiment, MILE and GEO) 
(Chapter 5).
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